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ABSTRACT
Protein-protein interactions are important for almost all cellular functions. Knowing
which proteins interact with one another is important for understanding protein function as well
as for being able to disrupt their interactions. The basic leucine-zipper transcription factors
(bZIPs) are a class of eukaryotic transcription factors that form either homodimers or
heterodimers that bind to DNA in a site-specific manner. bZIPs are similar in sequence and
structure, yet bZIP protein-protein interactions are specific, and this specificity is important for
determining which DNA sites are bound. bZIP proteins have a simple structure that makes them
experimentally tractable and well suited for developing models of interaction specificity. While
current models perform well at being able to distinguish interactions from non-interactions, they
are not fully accurate or able to predict interaction affinity.
Our current understanding of protein interaction specificity is limited by the small
number of large, high-quality interaction data sets that can be analyzed. For my thesis work I
took a biophysical approach to experimentally measure the interactions of many native and
designed bZIP and bZIP-like proteins in a high-throughput manner. The first method I used
involved protein arrays containing small spots of bZIP-derived peptides immobilized on glass
slides, which were probed with fluorescently labeled candidate protein partners. To improve
upon this technique, I developed a solution-based FRET assay. In this experiment, two different
dye-labeled versions of each protein are purified and mixed together at multiple concentrations
to generate binding curves that quantify the affinity of each pair-wise interaction.
Using the array assay, I identified novel interactions between human proteins and virally
encoded bZIPs, characterized peptides designed to bind specifically to native bZIPs, and
measured the interactions of a large set of synthetic bZIP-like coiled coils. Using the solution-
based FRET assay, I quantified the bZIP interaction networks of five metazoan species and
observed conservation as well as rewiring of interactions throughout evolution. Together, these
studies have identified new interactions, created peptide reagents, identified sequence
determinants of interaction specificity, and generated large amounts of interaction data that will
help in the further understanding of bZIP protein interaction specificity.
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Title: Associate Professor of Biology
ACKNOWLEDGEMENTS
I would like to thank the following people that helped make this work possible:
My advisor, Amy Keating, for giving me the freedom to be able to go in the directions I found
most interesting and providing advice, guidance, and support along the way. She has also been
instrumental in helping me improve my ability to both perform and communicate science.
My thesis committee members, Rick Young and Dennis Kim, for providing advice and forcing
me to think how my work fits into a larger picture. Marian Walhout for coming to the defense.
Members of the Keating lab, past and present, for always being helpful, providing advice, and
creating a fun environment in which to do experiments. Gevorg Grigoryan, Scott Chen, Judy
Baek, and Orr Ashenberg who were a pleasure to collaborate with. Jen Kaplan for reading my
thesis.
Bob Grant for teaching me what I know about X-ray crystallography.
Members of the Baker, Kim, Laub, Sauer, and Schwartz for being generous with both equipment
and advice.
Ted Powers for having me in his lab as an undergraduate and teaching me how to be a scientist.
Karen Wedaman for showing me there is more fun to be had in lab than just washing dishes.
Friends and classmates for providing ample reasons to take a break from lab.
My family for their support and encouragement.
Steph, for being my cohort.
TABLE OF CONTENTS
PREFATORY MATERIAL
Title Page ....................................................................................................................................... 1
Abstract .......................................................................................................................................... 2
Acknowledgem ents ........................................................................................................................ 3
Table of Contents ........................................................................................................................... 4
List of Figures and Tables........................................................................................................ 8
CHAPTER 1:
An introduction to the study of protein-protein interactions ............................................... 12
Proteom e-wide m ethods for the study of protein interactions ................................................. 14
Domain-based approaches for studying protein interaction specificity...................................19
bZIPs as a m odel class of protein-protein interaction............................................................. 26
Identification and initial characterization of bZIPs ................................................................. 27
Specificity determ inants of bZIP protein-protein interactions............................................... 29
M odeling of bZIP protein-protein interactions ........................................................................ 30
Design of synthetic bZIPs............................................................................................................32
Research approach ....................................................................................................................... 33
REFEREN CES ............................................................................................................................ 34
CHAPTER 2:
Identification of bZIP interaction partners of viral proteins HBZ, MEQ, BZLF1, and K-
bZIP using coiled-coil arrays ................................................................................................. 47
ABSTRACT.................................................................................................................................48
INTRODUCTION ....................................................................................................................... 49
EXPERIM EN TAL M ETHOD S............................................................................................... 52
Plasm id construction, protein expression and purification................................................. 52
Coiled-coil arrays......................................................................................................................53
Circular dichroism .................................................................................................................... 54
Phylogenetic analysis................................................................................................................54
Gel-shift assay ........................................................................................................................... 54
Com putational design of anti-M EQ ...................................................................................... 54
RESULTS.....................................................................................................................................55
Four unique bZIPs are encoded by viral genom es............................................................... 55
Detection of viral-hum an bZIP interactions......................................................................... 58
Validation of novel interactions of HBZ and M EQ in solution ............................................ 62
Characterization of HBZ interactions with human proteins in the presence of DNA .......... 64
Characterization of M EQ and N FIL3 binding to DNA ........................................................ 67
Generation of a specific inhibitor of M EQ dim erization...................................................... 69
DISCUSSION .............................................................................................................................. 75
ACKN OW LEDGEM ENTS ...................................................................................................... 79
4
A BBREV IATION S ..................................................................................................................... 79
REFEREN CES ............................................................................................................................ 81
CHAPTER 3:
Design of protein-interaction specificity gives selective bZIP-binding peptides................89
ABSTRA CT.................................................................................................................................90
IN TROD U CTION ....................................................................................................................... 91
RESU LTS.....................................................................................................................................93
Com putational design of specificity ...................................................................................... 93
D esign of anti-bZIP peptides ............................................................................................... 96
Testing of anti-bZIP designs ................................................................................................. 97
Properties of the anti-bZIP designs.........................................................................................103
DISCU SSION ............................................................................................................................ 104
M ETH OD S SU M M A RY ........................................................................................................... 105
M ETH OD S ............................................................................................................................... 107
M odeling bZIP leucine-zipper interactions.............................................................................107
Cluster expansion....................................................................................................................108
M ulti-state design optim ization .............................................................................................. 108
Choosing 33 representative hum an bZIPs .............................................................................. 110
Plasmid construction and peptide expression, purification and labeling................................110
Preparation and probing of arrays...........................................................................................111
A CKN O W LED GEM EN TS ....................................................................................................... 112
REFEREN CES .......................................................................................................................... 113
CHAPTER 4:
A synthetic coiled-coil interactome provides heterospecific modules for molecular
engineering ................................................................................................................................. 117
ABSTRA CT ............................................................................................................................... 118
INTROD U CTION ..................................................................................................................... 119
RESU LTS AN D D ISCU SSION ................................................................................................. 120
M ETH O DS AN D M ATERIALS ............................................................................................... 128
Plasm id construction, protein expression and purification ..................................................... 128
Coiled-coil array assay............................................................................................................129
D ata analysis...........................................................................................................................129
Circular dichroism .................................................................................................................. 130
Crystallography ....................................................................................................................... 130
Pull dow n assay.......................................................................................................................131
Sequence analysis...................................................................................................................132
A CKN O W LED GEM EN TS.........................................................................................................132
REFEREN CES ............................................................................................................................ 134
CHAPTER 5:
Conservation and rewiring of bZIP protein-protein interaction networks..........................138
ABSTRA CT ............................................................................................................................... 139
IN TRODUCTION ..................................................................................................................... 139
RESULTS ................................................................................................................................... 141
M easurem ent of bZIP protein-protein interactions.................................................................141
Properties of bZIP interaction networks ................................................................................. 144
Conservation and rew iring of bZIP interaction networks.......................................................151
Evolution of bZIP interaction profiles .................................................................................... 155
D ISCU SSION............................................................................................................................165
M ETHO DS ................................................................................................................................ 166
bZIP identification .................................................................................................................. 166
Cloning, expression, purification, and labeling ...................................................................... 167
Interaction m easurem ents ....................................................................................................... 168
Fitting equilibrium disassociation constants...........................................................................169
Interaction data analysis..........................................................................................................170
A CKN OW LEDGEM EN TS.......................................................................................................171
REFEREN CES .......................................................................................................................... 172
TABLES ..................................................................................................................................... 175
CHAPTER 6:
Conclusions and future directions............................................................................................225
Com parison to previously generated data...............................................................................226
Com parison of assays used to m easure bZIP interactions ...................................................... 226
Biological im plications...........................................................................................................227
Increasing the throughput of quantitative in vitro binding assays..........................................229
Additional interactions to m easure ......................................................................................... 231
Im proving bZIP binding m odels ............................................................................................ 232
Applications of m ore accurate m odels....................................................................................232
M easuring DN A binding specificity of bZIPs ........................................................................ 233
Final conclusions ................................................... ............................................... 235
REFEREN CES .......................................................................................................................... 236
APPENDIX A:
Supplementary Information for "Identification of bZIP interaction partners of viral
proteins HBZ, MEQ, BZLF1, and K-bZIP using coiled-coil arrays"...................................240
SUPPLEM EN TARY EXPERIM EN TS ..................................................................................... 241
APPENDIX B:
Supplementary Information for "Design of protein-interaction specificity affords selective
bZIP-binding peptides".............................................................................................................256
SUPPLEM EN TARY M ETHODS .............................................................................................. 257
Overview of anti-bZIP design using classy ............................................................................ 257
Theory of cluster expansion....................................................................................................257
bZIP m odels ............................................................................................................................ 258
Integer linear program m ing ................................................................................................... 260
PSSM constraint...................................................................................................................... 262
Choosing b, c and f positions..................................................................................................263
Uncovering specificity-encoding features .............................................................................. 264
Dividing human bZIPs into 20 families..................................................................................265
How many unique anti-bZIP profiles are there?.....................................................................266
A picture of multi-state energy phase space ............................................................................ 268
Jun fam ily constructs .............................................................................................................. 270
D ata analysis ........................................................................................................................... 270
Interaction-profile clustering .................................................................................................. 272
C ircular dichroism .................................................................................................................. 272
Comparing CD and array-based stability ordering ................................................................. 273
Array results were highly reproducible...................................................................................274
SUPPLEMENTARY DISSCUSION ......................................................................................... 274
Beyond bzips: requirements for applying classy to other systems ......................................... 274
Classy introduces negative design using familiar bzip features ............................................. 279
Off-target interactions may form via structures that were not modeled ............... 280
SUPPLEMENTARY EXPERIMENTS ..................................................................................... 283
R E F E R E N C E S .......................................................................................................................... 34 1
APPENDIX C:
Supplementary Information for "A synthetic coiled-coil interactome provides heterospecific
modules for molecular engineering"................. .... .... ..... 347
SUPPLEMENTARY EXPERIMENTS .................................................................................... 348
R E FE R E N C E S ........................................................................................................................ 384
APPENDIX D:
Design of peptide inhibitors that bind the bZIP domain of Epstein-Barr virus protein
BZLF1.............................................................................. ............................................... 386
A B ST R A C T ...................................... ....................................................................................... 387
IN TR O D U C TIO N ............................................................ ............................................... 387
R E SU LT S ................................................................................................................................... 39 1
Computational design of a peptide to bind the N-terminal part of the BZLF 1 coiled coil.....391
Designs with weaker self-association..................................................................................395
BDec and BZLF1 form a heterodimer .......................................... 399
Testing designs in the full-length BZLF 1 dimerization domain..........................400
Specificity of BD,, against human bZIPs .............................................................................. 402
Enhancing design performance with an N-terminal acidic extension...................................404
Inhibiting DNA binding by BZLF 1........................................405
D ISC U S SIO N ............................................................................................................................ 407
Applying CLASSY to BZLF1..............................................................................................407
Features contributing to the stability and specificity of the designs ..................................... 408
The influence of the distal CT region ................................................................................... 410
Specificity against human bZIPs ........................................................................................... 411
Improving inhibitor potency using an N-terminal acidic extension ....................................... 412
Analysis of inhibitor potency ............................................. 413
CONCLUSION: IMPLICATIONS FOR PROTEIN DESIGN ................................................. 416
MATERIALS AND METHODS ......................................................................................... 417
Cloning, protein expression and purification ......................................................................... 417
Computational protein design using CLASSY ....................................................................... 418
Predicting interactions between BDec and human bZIPs........................................................419
Circular dichroism spectroscopy ............................................................................................ 419
A nalytical ultracentrifugation ................................................................................................ 420
Electrophoretic mobility shift assay (EMSA) ........................................................................ 420
Simulating the impact of affinity and specificity on designed peptide behaviors ................. 421
A CK N O W LED G EM EN TS ...................................................................................................... 422
R E FE R E N C E S .......................................................................................................................... 423
LIST OF FIGURES AND TABLES
CHAPTER 1:
An introduction to the study of protein-protein interactions
Figure 1.1. Proteome-wide methods for measuring protein-protein interactions ................. 16
Figure 1.2. Structures of peptide-binding domains...............................................................22
Figure 1.3. Structure of a bZIP coiled-coil .......................................................................... 27
CHAPTER 2:
Identification of bZIP interaction partners of viral proteins HBZ, MEQ, BZLF1, and K-
bZIP using coiled-coil arrays
Figure 2.1. Sequence properties of human and viral bZIPs................................................. 56
Figure 2.2. Identification of viral bZIP interactions using peptide microarrays...................60
Figure 2.3. Solution measurements of novel interactions for HBZ and MEQ ................... 63
Figure 2.4. Binding of HBZ and human bZIPs to specific DNA sites assessed by gel-shifts
................................................................................................................................................... 6 6
Figure 2.5. MEQ and NFIL3 interact and have different but overlapping DNA-binding
sp ecificities ............................................................................................................................... 6 9
Figure 2.6. Anti-MEQ binds MEQ with high affinity and specificity................................. 71
Figure 2.7. Anti-MEQ prevents MEQ from binding DNA.......................................................74
CHAPTER 3:
Identification of bZIP interaction partners of viral proteins HBZ, MEQ, BZLF1, and K-
bZIP using coiled-coil arrays
Figure 3.1. Designing specific peptides using CLASSY......................................................98
Figure 3.2. Experimental testing of anti-bZIP designs ........................................................... 101
Figure 3.3. Properties of designed peptides compared to human bZIP leucine-zippers.........103
CHAPTER 4:
A synthetic coiled-coil interactome provides heterospecific modules for molecular
engineering
Figure 4.1. Array data describing the interactions of 26 peptides that form specific interaction
p airs ......................................................................................................................................... 12 1
Figure 4.2. SYNZIP coiled coils form specific interaction subnetworks .............. 123
8
Figure 4.3. Interaction geometries for three heterospecific SYNZIP pairs ............................ 125
Figure 4.4. Biotin pull-down assay demonstrating specific interactions in each orthogonal set
................................................................................................................................................. 12 7
CHAPTER 5:
Conservation and rewiring of bZIP protein-protein interaction networks
Figure 5.1. Characteristics of bZIP protein-protein interaction networks from 7 species ........... 142
Figure 5.2. The bZIP family repertoire of each species...............................................................143
Figure 5.3. Reproducibility of measured bZIP interactions.........................................................144
Figure 5.4. Human bZIP interaction network .............................................................................. 145
Figure 5.5. C. intestinalis bZIP interaction network....................................................................146
Figure 5.6. D. melanogaster bZIP interaction network ............................................................... 147
Figure 5.7. C. elegans bZIP interaction network ......................................................................... 148
Figure 5.8. N. vectensis bZIP interaction network.......................................................................149
Figure 5.9. Monosiga brevicollis bZIP interaction network ........................................................ 150
Figure 5.10. S. cerevisiae bZIP interaction network....................................................................150
Figure 5.11. Comparison of interaction networks between species.............................................151
Figure 5.12. Rewiring of metazoan bZIP interactions networks ................................................. 153
Figure 5.13. Interactions of CEBPG and CEBP families following the CEBPG-CEBP duplication
...................................................................................................................................................... 15 4
Figure 5.14. Interactions of novel bZIP families show extensive connections to conserved
fam ilies.........................................................................................................................................15 5
Figure 5.15. Origins of interactions in extant bZIP interaction networks....................................155
Figure 5.16. C. intestinalis and Human interspecies bZIP interaction network .......................... 157
Figure 5.17 ATF4 family interaction specificity..........................................................................158
Figure 5.18. Characteristics of the Human, C. intestinalis, and interspecies interaction networks
...................................................................................................................................................... 15 9
Figure 5.19. Sequence identity at the coiled-coil interface vs. interaction similarity of paralogs
...................................................................................................................................................... 16 0
Figure 5.20. Sequence identity at the coiled-coil interface vs. interaction similarity of orthologs
...................................................................................................................................................... 16 0
Figure 5.21. Switching interaction profiles between bZIP paralogs............................................162
Figure 5.22. PAR family mutants in D. melanogaster.................................................................163
Figure 5.23. Mutants of Human and C. intestinalis orthologs.....................................................163
Table 5.1. List of bZIP sequences used in this study ................................................................... 175
Table 5.2. Equilibrium dissociation constants ............................................................................. 195
APPENDIX A:
Supplementary Information for "Identification of bZIP interaction partners of viral
proteins HBZ, MEQ, BZLF1, and K-bZIP using coiled-coil arrays"
Figure A.S1 - Comparison of Human and Chicken bZIPs......................................................241
Figure A.S2 - Complete interaction matrix of 33 human bZIPs and 4 viral bZIPs ................ 242
Figure A.S3 - Neither the BZLF1 leucine zipper nor BZLF1 with additional C-terminal
residues binds strongly to any human bZIP............................................................................243
Figure A.S4 - Gel shifts showing MEQ and NFIL3 directly binding to variants of the MDV
D N A site................................................................................................................................244
Table A.S1 - Protein sequences used in this study.................................................................245
Table A.S2 - Average background-corrected fluorescence values from the array experiments
................................................................................................................................................. 2 4 8
APPENDIX B:
Supplementary Information for "Design of protein-interaction specificity affords selective
bZIP-binding peptides"
Figure B.S 1. Array measurements characterizing all 48 designs................................................283
Figure B.S2. A global view of specificity sweeps with each human bZIP coiled coil as a target
...................................................................................................................................................... 2 8 7
Figure B.S3. Solution characterization of anti-ATF2 by CD ...................................................... 288
Figure B.S4. Solution characterization of anti-ATF4 by CD ...................................................... 288
Figure B.S5. Solution characterization of anti-LMAF by CD .................................................... 289
Figure B.S6. Solution characterization of anti-JUN by CD ........................................................ 289
Figure B.S7. Solution characterization of anti-FOS by CD ........................................................ 290
Figure B.S8. Solution characterization of anti-ZF by CD ......................................................... 290
Figure B .S9. Specificity sw eeps .................................................................................................. 291
Figure B.S 10. Adjusting the 9 a-position point ECI in model HP/S/Cv.....................................292
Figure B.S 11. The performance of cluster-expanded versions of models HP/S/Ca and HP/S/Cv
...................................................................................................................................................... 2 9 3
Figure B.S 12. 2D energy histograms of two states ..................................................................... 294
Figure B.S 13. Phylogentic tree constructed using the leucine-zipper regions of all human bZIP
p rotein s.........................................................................................................................................2 9 5
Figure B.S 14. Reproducibility of protein-microarray measurements ......................................... 295
Figure B.S 15. Common specificity mechanisms in successful designed peptides......................296
Figure B.S16. Helical-wheel diagrams for anti-SMAF-2 complexes with ATF-4 and MafG
...................................................................................................................................................... 2 9 7
Figure B.S17. Helical-wheel diagrams of the anti-BACH-2 homodimer complex....................297
Table B.Sl. All designed sequences tested.................................................................................298
Table B .S2. Melting temperature (Tm) values estimated by fitting to CD-monitored melting
cu rv es ........................................................................................................................................... 3 02
Table B.S3. Average background-corrected fluorescence values and Sarray values from
round 1 of array m easurem ents...................................................................................................303
Table B .S4. Average background-corrected fluorescence values and Sarray values from
round 2 of array m easurem ents...................................................................................................310
Table B .S5. Average background-corrected fluorescence values and Sarray values from
round 3 of array m easurem ents...................................................................................................323
Table B.S6. Calculated Sarray scores for the complete set of 33 human bZIP measurements
...................................................................................................................................................... 3 3 7
APPENDIX C:
Supplementary Information for "A synthetic coiled-coil interactome provides heterospecific
modules for molecular engineering"
Figure C.S1. Sequences and sequence features of the 55 peptides measured ........................ 349
Figure C.S2. Array measurements for all 55 peptides ............................................................ 350
Figure C.S3. Reproducibility of the array experiments .......................................................... 351
Figure C.S4. CD spectra for heterospecific pair SYNZIP6 + SYNZIP5................................352
Figure C.S5. CD-monitored thermal melts of peptide pairs that form orthogonal sets .......... 353
Figure C.S6. CD spectra characterizing an orthogonal set consisting of FOS:SYNZIP9 and
SY N Z IP3:SY N Z IP4 ............................................................................................................... 354
Figure C.S7. Electron density maps of SYNZIP5:SYNZIP6 and SYNZIP2:SYNZIP1 ........ 355
Table C.S 1. Protein and DNA sequences used in this study ................................................... 356
Table C.S2. Average background-corrected fluorescence values from the array experiment
................................................................................................................................................. 3 6 7
Table C.S3. List of the proteins composing each of the subnetworks identified....................380
Table C.S4. Crystallographic data collection and refinement statistics..................................384
APPENDIX D:
Design of peptide inhibitors that bind the bZIP domain of Epstein-Barr virus protein
BZLF1
Figure D. 1 Sequence and structure of the BZLF 1 bZIP domain ............................................ 392
Figure D .2 D esigned inhibitors...............................................................................................393
Figure D.3 Melting curves for targets, designs and complexes monitored by mean residue
ellipticity at 222 nm ..................................................................................................................... 398
Figure D.4 Representative analytical ultracentrifugation data for BD' + BZLFI (left) and
B D (right) ................................................................................................................................. 4 00
Figure D.5 Specificity of design against human bZIPs .......................................................... 403
Figure D.6 Peptide inhibition of B-3ZLF1" binding to DNA..............................................406
Figure D.7 Inhibition of DNA binding as a function of the affinity and anti-homodimer
specificity of the inhibitor............................................................................................................416
Table D. 1 Sequences and melting temperatures ('C) for BZLF 1 and design constructs.......396
Table D.2 Melting temperatures (*C) for different BZLF 1/design hetero-interactions..........397
Chapter 1
An introduction to the study of protein-protein interactions
Protein-protein interactions are essential for most cellular functions. Thus understanding
which proteins interact with each other is necessary for understanding how cells work. The
problem of how each protein is able to interact with a specific set of partners is complex. It is
estimated that 74,000-200,000 interactions occur among the -25,000 proteins encoded by the
human genome (Venkatesan, et al. 2009). This huge amount of interactions is further
complicated by the fact that protein-protein interactions have a diverse set of properties.
Interaction interfaces are structurally varied in nature and can either be mediated through
domain-domain interactions or by domains binding to short peptide regions. While some
interactions are stable, many interactions are dynamic and of lower affinity. Some proteins
interact with few partners, but some interact with many (Han, et al. 2004). All of these factors
combine to make it difficult to know which proteins interact with each other.
There are many goals in studying protein-protein interactions. The first is to identify
which interactions occur. This is often a first step in understanding the function of a protein,
because knowing which proteins it interacts with gives insight into a protein's functional role.
Large data sets of interactions can also be used to determine interaction network structure (Han,
et al. 2004). As this is a critical goal, a number of techniques have been developed for measuring
interactions on a large scale. A second goal in studying protein-protein interactions is to identify
the functional significance of the interactions. This is often attempted by knocking out or
knocking down a gene of interest for one or both partners and assaying the phenotypic effect.
Unfortunately this removes all interactions of the knocked out gene. A more focused approach is
to generate mutants that specifically disrupt an interaction without compromising the entire
function of the protein (Dreze, et al. 2009).
In addition to identifying interactions and determining their functions, there is a need to
understand biophysically how proteins interact. This understanding is important for being able to
generate models that describe the relationship between sequence and interaction properties.
There are several practical uses of such models. Models can be used to predict interactions from
protein sequence alone (Chen, et al. 2008). This can be useful for identifying unknown
interactions important for human biology, and also for predicting interactions from the
increasingly large number of genomes being sequenced. Models that could predict what effect
mutations have on binding affinity and specificity would be useful, especially for understanding
the basis of disease. An ability to accurately model interactions could also support the design of
proteins with specific interaction properties, such as peptides designed to specifically disrupt
interactions (Grigoryan, et al. 2009).
Two general approaches exist for measuring protein-protein interactions on a large scale.
One involves measurements that are done using full-length proteins, either in vivo in the
organism of interest or in yeast. These approaches have the advantage of being able to be applied
on a proteome-wide scale. A complementary set of approaches are those that rely on domain-
based in vitro measurement techniques. In these approaches, large domain families are selected
and representative domains are cloned. These domains are then expressed, purified, and tested
against a number of potential interaction partners using a variety of different experimental
techniques. These methods can quantify large numbers of similar interactions, generating the
type of data that is the most useful for modeling interactions. The most widely used techniques
and the advantages and disadvantages of each approach are discussed below.
Proteome-wide methods for the study ofprotein interactions
Three main experimental techniques have been shown to be useful on a proteome-wide
scale for measuring protein-protein interactions (Figure 1.1). 1) In the yeast two-hybrid (Y2H)
assay, one protein is fused to an activator domain and the other to a DNA-binding domain. Yeast
expressing both constructs display transcriptional reporter activity if the two proteins interact.
Several versions of the assay exist, but the most common relies on the GAL4 transcription factor
driving a variety of selectable reporter genes (Rajagopala and Uetz. 2011). 2) Protein fragment
complementation assays (PCA) involve a reporter protein that is split into two fragments, with
the N-terminal fragment fused to one of the proteins being tested and the C-terminal fragment
fused to the other. When a pair of proteins interacts, the protein activity of the split reporter is
reconstituted. The most commonly used split protein in yeast is a mutant version of dihydrofolate
reductase, which allows for selection using the drug methotrexate (Michnick, et al. 2011). 3)
Affinity purifications followed by mass spectrometry (AP/MS) involves fusing each protein to an
affinity tag that is then used to purify the protein along with any other proteins that are associated
with it. Isolated protein complexes are then digested into peptides using proteases such as
trypsin, and the identity of the peptides is determined using MS/MS. Many different tags exist
for doing purification, with the most common being tandem affinity purification tags that allow
for two rounds of purification to eliminate background binding (Gavin, et al. 2011).
Yeast two-hybrid Protein-fragment Affinity purifications/(Y2H) complementation assay mass spectrometry
(PCA) (AP/MS)
Prey Bait Prey Copurified
Bait proteins
Reconstituted
enzyme Bait
Figure 1.1. Proteome-wide methods for measuring protein-protein interactions. Modified
from (Jensen and Bork. 2008).
The first attempts to map interactions on a proteome-wide scale were done using Y2H
applied first to T7 bacteriophage, followed by other viruses as well as partial attempts in H.
pylori, S. cerevisiae, C. elegans, and D.melanogaster (McCraith, et al. 2000, Uetz, et al. 2000,
Rain, et al. 2001, Flajolet, et al. 2000, Ito, et al. 2001, Ito, et al. 2000, Giot, et al. 2003, Li, et al.
2004, Walhout, et al. 2000). These initial studies were followed by an improvement in the
methodology and throughput of the assay, which was subsequently applied to several bacteria,
more complex organisms such as human and Arabidopsis, and higher-coverage versions of the
C. elegans and yeast interaction maps (Stelzl, et al. 2005, Titz, et al. 2008, Rual, et al. 2005,
Parrish, et al. 2007, Simonis, et al. 2009, Yu, et al. 2008). Y2H was the first technology that
allowed interactions to be measured on a large scale, and this approach revealed the size and
connectedness of interaction networks. Y2H suffers from a high false negative rate, however,
with as few as 10% of true interactions being detected; this resulted in little overlap of
interactions in initial studies (Yu, et al. 2008). Low assay sensitivity in Y2H has been addressed
both by measuring every potential interaction in an array format, using all possible combinations
of N-terminal and C-terminal fusion constructs, and by measuring protein fragments in addition
to full-length proteins (Xin, et al. 2009, Boxem, et al. 2008, Chen, et al. 2010). Even when using
multiple Y2H versions in an array format, 20% of a gold set of interactions still could not be
detected, likely because of the requirement for proteins to be expressed and localized and to
interact as fusion proteins in the yeast nucleus (Chen, et al. 2010). While much effort has been
made to prevent assay false positives, interactions can nevertheless be detected between proteins
that may never interact physiologically, due to never being co-expressed or co-localized.
PCA was first used on a proteome-wide scale to map interactions in S. cerevisiae
(Tarassov, et al. 2008). While so far less used than Y2H, PCA has several advantages.
Interactions can be measured under the endogenous promoter with native localization in living
cells. The data generated also provide some topological information, as the maximum distance
the two fused halves can be from one another is 80 A. A drawback is that only the interactions
that occur under the cellular conditions measured can be observed. In the study by Tarassov et
al., measurements were done under only one condition and thus likely missed interactions from
proteins that were not expressed or differentially localized. False positives can arise in PCA due
to the split fragments bringing proteins together that otherwise wouldn't interact. Additional
versions of PCA based on fluorescence or luminescence have the potential to detect interactions
in vivo as well as to provide cellular and subcellular localization information (Michnick, et al.
2011).
AP/MS was first applied on a proteome-wide scale to map interactions in yeast. In two
pilot studies and then in two subsequent studies, the vast majority of the -6,000 yeast proteins
were tagged and over 1/3 of purifications were successful (Ho, et al. 2002, Krogan, et al. 2006,
Gavin, et al. 2002, Gavin, et al. 2006). This technique has also been applied to E. coli, M
pneumonia, D. melanogaster, and human interactions (Malovannaya, et al. 2011, Guruharsha, et
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al. 2011, Kuhner, et al. 2009, Hu, et al. 2009, Arifuzzaman, et al. 2006, Butland, et al. 2005).
AP/MS, like PCA, has the advantage of being able to detect interactions in vivo, but suffers from
only detecting interactions under the conditions they are assayed under. Quantitative approaches
hold promise for comparing between different conditions and cell states (Bantscheff, et al. 2007).
The AP/MS approach suffers from potential false negatives, including interactions that are
transient, have fast off rates, or are lost during the isolation and washing procedure. False
positives are also a problem, and these can arise both from highly expressed non-specifically
binding proteins, as well from disruption of cellular substructure that can allow differentially
sublocalized proteins to interact.
A main difficulty in this approach is engineering organisms to express the tagged proteins
of interest. Proteins fused to an affinity tag under an endogenous promoter are preferred because
overexpression of a protein can lead to false positive interactions (Ho, et al. 2002). Only in yeast
and recently in E. coli has endogenous tagging been possible. Recent methods for cloning large
amounts of DNA including regulatory regions will allow for greater coverage in systems such as
human cell lines (Poser, et al. 2008, Hutchins, et al. 2010). Antibodies provide a potential way to
circumvent using engineered strains. A recent study using a large number of antibodies in human
cells identified specific interactions by constraining interactions to be present in reciprocal
isolations (Malovannaya, et al. 2011). Making the large numbers of antibodies required to bind
to every protein is difficult, though affinity reagents based on other scaffolds hold promise
(Boersma and Pluckthun. 2011).
All of these proteome-wide methods are not yet comprehensive. Even in yeast, where all
three approaches have been used, there is not yet complete coverage. Y2H applied to yeast has
only mapped ~20% of the estimated total interactions (Yu, et al. 2008). PCA was able to test
93% of genes, but the sensitivity of the assay is not known (Tarassov, et al. 2008). In the two
large yeast AP/MS studies, 60% of the proteome was detected, but only 18% of the interactions
observed are shared between the two studies (Goll and Uetz. 2006). This lack of complete
coverage is due both to the number of proteins that were assayed as well as the sensitivity of the
assays. There is also little overlap in the interactions detected by these three methods because
each method has biases towards different classes of proteins (Jensen and Bork. 2008). Further
improvement to these assays, combined with other potential high-throughput approaches, should
allow for even more complete maps of interactions to emerge (Snider, et al. 2010, Kung and
Snyder. 2006, Lievens, et al. 2009, Miller, et al. 2009, Petschnigg, et al. 2011).
A major drawback of these approaches is they typically give little structural information
on how the interactions occur. In the case of Y2H and PCA, it is likely that the pair of fused
proteins is directly mediating the interaction. In the case of AP/MS, complexes of interacting
proteins are isolated, and it is typically not known what the direct physical interactions that occur
are. Additionally, these methods don't provide information on the regions of proteins mediating
the interactions. This type of information could be gained by using Y2H with protein fragments
to map minimal interacting domains, or by using AP/MS with crosslinkers of defined length to
provide spatial constraints to the regions of proteins that interact (Boxem, et al. 2008, Stengel, et
al. 2011).
Domain-based approaches for studying protein interaction specificity
As an alternative to mapping interactions of full-length proteins on a proteome-wide
scale, much effort has been made to measure the interactions of individual domain families.
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Proteins are composed of many different domains, of which at least 70 are known to mediate
protein-protein interactions (Letunic, et al. 2012, Pawson and Nash. 2003). Domains can interact
with other structured domains or with short peptide regions, and these interactions can be
influenced by post-translational modifications such as phosphorylation (Pawson and Nash.
2003). There are several advantages of focusing on domains. Domains alone have been shown to
be sufficient to bind to partners independent of the rest of the protein. In fact, proteins often have
regulatory regions that can inhibit interactions in the context of the full-length protein. Domains
often behave better in vitro than full-length proteins. Finally, focusing on domains reduces the
complexity of determining where the partner binds.
A collection of different techniques has been shown to be useful for measuring the
specificity of protein domains in vitro. Several of the most widely used methods are described
below. Selection-based techniques such as phage display, yeast display, and ribosome display all
work by expressing a protein or peptide that is linked to its genetically encoded message. A large
number of different library members, 107 to 1014, can be expressed at a time, and interactions can
be identified by pulling down with the domain of interest or through cell sorting. The selected
sequences can then be determined by sequencing the DNA of the binding population. A large
advantage of this approach is that only one partner needs to be purified and a very large number
of potential binders can be assayed at a time. The drawback of this approach is that it typically
only identifies high-affinity binders, missing weak interactions and non-interactions that could be
important for understanding binding specificity and function (Shao, et al. 2011, Liu, et al. 2010).
Also, libraries are often biased as to which sequences are expressed.
Protein arrays involve printing proteins onto a solid surface. Arrays can be prepared in a
96-well format, where each well contains an identical subarray containing several hundred
proteins. The arrays can then be probed with a fluorescently-labeled partner, allowing for many
interactions to be measured in parallel. If done at multiple concentrations, quantitative binding
affinities can be determined (Jones, et al. 2006). Arrays can also be prepared by synthesizing
peptides on cellulose membranes, known as SPOT arrays (Briant, et al. 2009). Both protein and
peptide arrays have the advantage that binders from a range of different affinities as well as non-
binders can be measured at the same time. Disadvantages include potential artifacts resulting
from measuring interactions on a surface, as well as the technical nature of preparing protein
arrays.
Solution measurements of protein interactions can be done in high-throughput in 384-
well plates using either fluorescence polarization or FRET (Stiffler, et al. 2006). This approach
has the advantage of being able to quantify interactions without the issue of potential surface
artifacts. The main drawback to this type of approach is that these experiments are often time
consuming and costly, which limits the number of potential interactions that can be assayed.
High-throughput data processing and curve-fitting is also challenging. Solution methods, protein
arrays, and display methods are complementary to one another, and often multiple techniques are
used on a domain family to gain a deeper understanding of the determinants of binding
specificity, as discussed below.
The binding specificity of several domain families has been investigated in detail. Three
of the largest domain families are the PDZ, SH2, and SH3 domains, which have all been studied
extensively using high-throughput approaches (Figure 1.2). These families contain many
members, and the individual domains are small in size and experimentally tractable. These
domains also all bind short peptides, which can be expressed as random libraries, synthesized on
surfaces, or fluorescently labeled. Work on these domains has demonstrated that peptide-binding
domains can display a high degree of specificity. This has also to led to the idea that although
interactions in vivo can be influenced by many cellular effects, such as expression and
localization, binding specificity can also be hardwired in protein sequence (Liu, et al. 2010,
Stiffler, et al. 2007, Tonikian, et al. 2009).
A B C
Figure 1.2. Structures of peptide-binding domains in complex with peptides. A) SH3 domain
(PDB: lABO). B) SH2 domain (PDB: lD4W). C) PDZ domain (PDB: 1MFG). Figures
generated using PyMOL (DeLano Scientific, Palo Alto, CA).
SH3 domains are involved in signaling by binding mainly to multi-proline-containing
peptides. The domains consist of-80 amino-acid residues, and there are 400 SH3 domains in
humans and 27 in yeast (Castagnoli, et al. 2004). They were originally divided into two classes,
binding either the consensus motif +XXPXXP or PXXPX+ (where X is any residue and + is
either arginine or lysine). Cesareni and coworkers expanded on previous studies by measuring
the interaction specificity of 25 yeast SH3 domains using phage display, peptide arrays, and Y2H
(Tonikian, et al. 2009, Landgraf, et al. 2004, Tong, et al. 2002). These three experimental data
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sets were combined into a single model that showed better prediction than any single technique.
This demonstrated the usefulness of applying different measurement technologies to the same
problem. These experiments also revealed that although the majority of domains did fall into the
two specificity classes, within these classes there are many distinct specificities. Further,
positions outside of the core binding motif were shown to be important for binding.
SH2 domains are composed of-100 amino-acid residues and bind to phosphotyrosine-
containing peptides. There are 120 SH2 domains in humans, and they are involved in signaling
downstream from protein-tyrosine kinases (Liu, et al. 2006). As it is difficult to express
phosphorylated peptides, most work on SH2 binding specificity has been performed using
protein and peptide arrays. MacBeath and coworkers measured the binding of about 90 SH2
domains against 61 phosphtyrosine peptides { {71 Jones,R.B. 2006}}. The authors printed
domains on the surface of glass slides and generated binding curves using fluorescently-labeled
peptides. This was the first large scale quantitative affinity study of any binding domain and
showed that proteins arrays could be used not just for detecting interactions but for quantifying
the strength of the interactions. In another study the specificity of 76 SH2 domains was
determined using a version of SPOT arrays where each position was fixed to one amino acid at a
time while all other positions except the phosphotyrosine were randomized. These experiments
suggested that there were only a limited number of specificity-determining residues on the
peptides that were recognized by each domain (Huang, et al. 2008). In an alternative approach,
50 SH2 domains were measured against 192 phosphotyrosine peptides derived from native
proteins using SPOT arrays. This revealed that SH2 domains displayed specificity with respect to
these peptides and were more specific than previously anticipated. This suggested that
permissive residues alone are not enough to determine binding specificities, and non-permissive
residues can be important (Liu, et al. 2010).
PDZ domains are composed of~80 amino-acid residues and typically bind to short, C-
terminal peptides. They are present in all domains of life (-250 domains in human) and are
involved in many different cellular signaling processes (Tonikian, et al. 2008). Many different
high-throughput experimental approaches have been used to measure their interaction specificity,
including protein arrays, SPOT arrays, phage display, Y2H, and fluorescence polarization
(Stiffler, et al. 2007, Tonikian, et al. 2008, Wiedemann, et al. 2004, Lenfant, et al. 2010). Two
groups have recently measured a large number of interactions using different approaches.
MacBeath and coworkers measured the interactions of 85 murine PDZ domains with over 200
peptides. They used a two-stage strategy that involved identifying positive and negative
interactions on arrays presenting PDZ domains, and then quantifying the affinity for the positives
using fluorescence polarization (Stiffler, et al. 2006, Stiffler, et al. 2007). Sidhu and coworkers
profiled binding specificity using phage display with a peptide library that had at least 7
positions randomized. They measured the binding specificity of 82 native PDZ domains from
human and C. elegans, 83 synthetic domains, and 91 single point mutants (Tonikian, et al. 2008,
Ernst, et al. 2009, Ernst, et al. 2010). While initial studies suggested that PDZ domains could be
grouped into three different classes of broad specificity, these newer and much more expansive
studies have shown PDZ domains to be much more selective and have identified at least 23
distinct specificity clusters. While they do display specificity, each PDZ domain is predicted to
interact with ~250 proteins on average (Stiffler, et al. 2007). PDZ domains are also known to
interact with internal peptides, as well as to form dimers with other PDZ domains using a distinct
interface (Im, et al. 2003). Recently, 157 domains were measured against each other using
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protein arrays, and 30% of domains were shown to interact with each other (Chang, et al. 2011).
Interpretation of these interactions is difficult, as it is unclear which interface of the PDZ domain
is used in mediating the interactions.
The data for PDZ domain binding have been a rich source for development of models to
predict binding specificity. Computational modeling was used to predict the binding specificity
of 17 PDZ domains analyzed by phage display. On average, half of the positions bound by each
domain were predicted well (Smith and Kortemme. 2010). Two groups also developed models of
PDZ domain binding using the MacBeath data set of quantitative interactions and non-
interactions. Chen et al. trained a novel model on the data and were able to predict new
interactions with ~50% accuracy (Chen, et al. 2008). A different machine learning approach on
the same data set was able to predict the affinity of a set of single point mutants with a
correlation of 0.92 (Shao, et al. 2011). These results indicate clear progress, but while there is
now an enormous amount of data, the problem of predicting interactions with high accuracy
based on sequence and structure is far from solved.
In summary, domain-based in vitro assays provide a reductionist approach that allows for
the decoupling of cellular influences, such as expression and localization, and focusing on
measuring all interactions that can physically occur. Systematic data sets of both interactions and
non-binders can be generated that are useful for developing models of binding specificity.
Binding models are useful for predicting interactions in each domain family, as well as for
uncovering general principles that govern protein-binding specificity. The domain-based
approach is complementary to the proteome-wide approach. Having a deep understanding of the
binding specificity of a large number of domains would allow mapping of domain interactions to
the larger proteome-wide datasets. Domain interactions can also be inferred from proteome-wide
data sets, which could potentially identify domain interactions that can be interrogated in vitro
(Deng, et al. 2002).
bZIPs as a model class ofprotein-protein interaction
The basic leucine-zipper transcription factors (bZIPs) are an evolutionally conserved
family of eukaryotic transcription factors that are ideal for studying protein-protein interaction
specificity. bZIPs bind to DNA site specifically via a basic region. Immediately C-terminal to the
DNA-binding residues is a coiled coil that mediates the formation of either homodimers or
heterodimers (Figure 1.3A). The bZIP proteins are involved in many different cellular processes
and can act as both activators and repressors of transcription (Hirai S, Bourachot B,Yaniv M.
1990, Lai and Ting. 1999). The protein partnering specificity is important, as it can dictate which
DNA sites are bound (Hai and Curran. 1991). There are several features that make bZIPs an ideal
domain to study protein-protein interaction specificity. They have a simple interaction interface
of two alpha helices forming a parallel dimeric coiled coil. Further simplifying the interaction is
the repeating-heptad structure, where each position in the heptad can be designated with a letter
abcdefg. The bZIP coiled coils are thought to interact exclusively with one another, which limits
the number of potential interactions to be tested. There are a number of bZIPs in both human and
other species, which provides a large collection of sequences for which to map the specificity
(Amoutzias, et al. 2007). The coiled coils in bZIPs are typically ~35-50 amino acids long,
making them very experimentally tractable. bZIPs are also a model system for understanding
coiled-coil interaction specificity more broadly, which is important because coiled coils are
predicated to occur in ~10% of proteins in eukaryotic genomes (Liu and Rost. 2001). What is
known about how bZIPs interact, and what the specificity determining features are, is the result
of the work of many laboratories and is summarized below.
Coiled coil
Basic region
Figure 1.3. Structure of a bZIP coiled coil. A). Crystal structure of a quaternary complex of JUN
and FOS bound to double-stranded DNA (PDB: IFOS). B). Helical wheel diagram of JUN and
FOS. Hydrophobic residues, black. Polar residues, yellow. Positively charged residues, blue.
Negatively charged residues, red. Attractive g-e' electrostatics, blue-dashed lines. Repulsive g-e'
electrostatics, red-dashed lines. Crystal structure figure created using PyMOL (DeLano
Scientific, Palo Alto, CA). Helical wheel diagram generated using DrawCoil 1.0.
http://www.gevorggrigoryan.com/drawcoil/)
Identification and initial characterization of bZIPs
The founding members of the bZIP family were first discovered and characterized by
converging work on oncogenic viruses, yeast transcriptional regulation, and viral enhancer
binding proteins. FOS and JUN were both identified first in oncogenic retroviruses and then
cloned from human cells (Curran, et al. 1982, van Straaten, et al. 1983, Maki, et al. 1987). GCN4
was identified in yeast as being a positive regulator of amino-acid biosynthesis (Hinnebusch and
Fink. 1983). CEBPA was identified from rat livers as a protein that bound to viral enhancers
(Landschulz, et al. 1989). Molecular work on these four bZIPs led to a detailed, mechanistic
understanding of how bZIPs function. The functional region of GCN4 responsible for DNA
binding was narrowed to a 60 amino-acid region (Hope and Struhl. 1986). GCN4 was then
shown to bind to palindromic DNA sites as a dimer and form stable complexes even without
DNA present (Hope and Struhl. 1987). FOS and JUN were shown to form heterodimers, and it
was demonstrated that this association depends on the leucine-zipper domain (Sassone-Corsi, et
al. 1988, Turner and Tjian. 1989, Gentz, et al. 1989).
McKnight and coworkers first observed that these four proteins shared a common
structural feature that was termed a "leucine zipper," and suggested that these leucine zippers
associated as dimers in an antiparallel fashion (Landschulz, et al. 1988). Shortly thereafter
disulfide exchange experiments on GCN4 showed that the association was that of a parallel
dimer, and the interaction was suggestive of a coiled coil (O'Shea, et al. 1989). Using CEBPA, it
was shown that mutations to the leucine zipper prevented both dimerization and DNA binding
whereas mutations in the basic region disrupted only DNA binding (Landschulz, et al. 1989).
Several groups also made chimeras between different leucine zippers and basic regions. These
chimera experiments demonstrated that the leucine zipper was responsible for dimerization, the
basic region bound to DNA, and these functions were separable (Agre, et al. 1989, Sellers and
Struhl. 1989, Kouzarides and Ziff. 1989). Going even further, two groups showed that that the
native leucine zipper could be replaced with either an idealized coiled coil, or a disulfide bond,
demonstrating that a dimerized basic region is sufficient for binding to DNA (Talanian, et al.
1990, O'Neil, et al. 1990). Structural models were developed that consisted of bZIPs forming
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parallel dimers via the coiled-coil domain, with the basic regions forming a continuous helix that
interacted with DNA (O'Neil, et al. 1990, Vinson, et al. 1989). Crystal structures of a homodimer
of GCN4 and a heterodimer of JUN and FOS, both bound to DNA, provided experimental
evidence in excellent agreement with these models (Ellenberger, et al. 1992, Glover and
Harrison. 1995).
Specificity determinants of bZIP protein-protein interactions
Two major findings from these studies were that the leucine zipper controlled
dimerization specificity and that only certain homodimers and heterodimers could interact
(Sellers and Struhl. 1989, Kouzarides and Ziff. 1989). Understanding this specificity became a
major research focus. O'Shea and Kim made chimeras of the bcf positions (the outside of the
helix) and the adeg positions (the inside of the helix) between GCN4, FOS and JUN. This
experiment showed that specificity was largely influenced by the adeg positions. They further
showed that just the eg positions were sufficient to explain the specificity between these bZIPs,
and placing the 8 residues in these positions from FOS and from JUN into GCN4 was sufficient
for the specific formation of heterodimers (Figure 1.3B) (O'Shea, et al. 1992). To test the
principals of g-e' electrostatics, two peptides were designed, one that had glutamates at all eg
positions and another that had all lysines at these positions. These peptides, termed peptide
"Velcro," were show to form very weak homodimers, but when mixed together formed strong
heterodimers. (O'Shea, et al. 1993). Using these same principals Vinson and coworkers predicted
native bZIPs that would and would not form heterodimers and validated these predications
experimentally (Vinson, et al. 1993).
It was later shown that asparagines at a positions could also impart specificity, in that
they could pair with asparagines at an a position on the opposite helix, but not with hydrophobic
amino acids such as isoleucine, valine, or leucine (Zeng, et al. 1997, Acharya, et al. 2006,
Acharya, et al. 2002). The a position has also been observed to be involved in imparting
structural specificity, as mutating an asparagine at an a position to a hydrophobic amino acid can
lead to the formation of oligomers and/or loss of orientation specificity (Harbury, et al. 1993,
Lumb and Kim. 1995). Leucine, which is the most common amino acid at d positions in native
bZIPs, was shown to be the most stabilizing homotypic interaction at the d position (Moitra, et
al. 1997). Coupling energies of electrostatics of g-e' interactions were measured using double
mutant alanine thermodynamic cycle analysis (Krylov, et al. 1994). Coupling energies of all
pairwise interactions amongst the 10 most common amino acids at the a position were also
measured (Acharya, et al. 2006). This confirmed the preference for asparagines not to pair with
hydrophobic amino acids at a-a', with asparagine-isoleucine destabilizing the interaction 1000-
fold. In contrast, these measurements showed that a-a' interactions with polar amino acids such
as lysine or arginine paired with asparagine were favorable. The combination of these rules has
been used to predict specificity on a genome-wide basis (Vinson, et al. 2002, Fassler, et al. 2002,
Deppmann, et al. 2004). Additionally, a-g' and d-e' electrostatic interactions have been shown to
be important in determining specificity (Grigoryan, et al. 2009, Reinke, et al. 2010).
Modeling of bZIP protein-protein interactions
To develop a deeper understating of bZIP interaction specificity, it is necessary to
measure a large number of interactions and develop models that can predict them. Using a
protein array assay, the majority of human bZIPs were measured against one another, which
demonstrated that bZIPs do indeed display interaction specificity (Newman and Keating. 2003).
A large number of GCN4 single and double point mutants were also measured using SPOT
arrays, though this data is difficult to interpret due to the structural ambiguity of these interacting
complexes (Portwich, et al. 2007).
There have been several efforts to develop models that can accurately predict the binding
specificity of bZIPs. Using simple rules based on g-e' electrostatics or quantitative coupling
energies is only partially able to describe this specificity (Newman and Keating. 2003, Fong, et
al. 2004). Using a machine learning approach to derive weights from a database of known
coiled-coil interactions, 70% of true strong interactions could be predicted at an 8% false
negative rate (Fong, et al. 2004). Arndt and coworkers developed a model based on the Vinson
coupling energies and trained it on a set of melting temperatures for FOS and JUN family bZIPs
and coiled coils selected to bind to either JUN or FOS. This model also included a term for helix
propensity, and slightly outperformed the previous models in predicting the array interactions
(Mason, et al. 2006). A structural modeling approach that also included helix stability and
machine learning weights for a-a'and d-d' interactions also performed quite well (Grigoryan and
Keating. 2006). While these models perform well in discriminating strong interactions from non-
binders, they are not fully accurate at this task. Further, they are unable to perform more
challenging tasks such as predicting the affinity of interactions. To improve models it would be
useful to have a large, quantitative, and diverse data set. This additional data would be useful
both to further benchmark models based on structure, as well as to train machine-learning based
approaches.
Design of synthetic bZIPs
There has been a long standing interest in designing synthetic coiled coils that can bind to
native bZIPs or be used as molecular parts. Vinson and coworkers generated dominant negative
inhibitors of bZIPs by appending an acidic extension to a native leucine zipper (A-ZIPs) (Krylov,
et al. 1995). They showed that these A-ZIPs would target bZIPs with the same specificity of the
fused leucine zipper but with increased affinity. Several studies have demonstrated that A-ZIPs
can prevent bZIPs from binding DNA and are useful in vivo (Krylov, et al. 1995, Ahn, et al.
1998, Gerdes, et al. 2006, Acharya, et al. 2006, Oh, et al. 2007). Since most human bZIPs
interact with at least several other bZIPs, most human bZIPs cannot be targeted specifically
using this approach (Newman and Keating. 2003). To attempt to design more stable and specific
leucine zippers against either FOS or JUN, PCA in bacteria was used to select synthetic binders
out of peptides libraries. While these selected peptides did bind with greater affinity than their
native counterparts, they were not very specific for binding to JUN vs. FOS vs. themselves
(Mason, et al. 2006). By expressing a competitive off-target peptide, the authors were able to
adapt the selections to generate slightly more specific binders (Mason, et al. 2007). It is unclear
how useful this approach is, since if the number of potential off-targets is large it would be
difficult to apply this to more than several competitors.
The first attempt to reengineer bZIPs with defined specificities for use as molecular parts
was that of peptide 'Velcro' (O'Shea, et al. 1993). Additional work has generated pairs of
peptides that have a range of affinities as well as pairs that are orthogonal to one another (Moll,
et al. 2001, Lai, et al. 2004, Bromley, et al. 2009, Diss and Kennan. 2008a, Diss and Kennan.
2008b). Native and designed synthetic coiled coils have been useful for making artificial
transcription factors, rewiring cellular pathways, and assembling nano-scale fibers (Mapp, et al.
2000, Wolfe, et al. 2003, McAllister, et al. 2008, Bashor, et al. 2008).
Research approach
In my thesis work I focused on understanding the specificity of interactions of native and
designed bZIP coiled coils using high-throughput measurement techniques. In chapter 2, I
describe the measurement of interactions between viral and host bZIPs. Four bZIPs, each
encoded by an oncogenic virus, were measured against a representative panel of 33 human
bZIPs. Most previously reported interactions were observed and several novel interactions were
identified. Two of the viral bZIPs, MEQ and HBZ, interact with multiple human partners and
have unique interaction profiles compared to any human bZIP, whereas the other two viral
bZIPs, K-bZIP and BZLF1, display homo-specificity. In chapter 2 and appendix D, I describe
experimental characterization of inhibitors that can prevent the viral bZIPs MEQ and bZLF1
from binding to DNA. In chapter 3, a novel computational method was used by my collaborator
to design peptides that would specifically bind to target human bZIP proteins, yet not interact
with other human bZIPs or self-associate. I tested 48 of these designs for their ability to interact
specifically with the intended target. Of the 20 human bZIP families targeted, designs for 8 of the
families bound the target more tightly than they bound to any other family. This represents the
first large-scale computational design and testing of peptides that interact specifically with native
targets. In chapter 4 I describe the measured interactions of 48 designed synthetic peptides as
well as 7 human bZIPs to generate a 55-member synthetic protein interactome. This interaction
network contains many sub-networks consisting of 3 to 6 protein nodes. Of special interest are
pairs of interactions that act orthogonally to one another, as these could have many applications
in molecular engineering. I characterized two such sets of orthogonal heterodimers using
solution assays and x-ray crystallography. In chapter 5, I quantitatively measured bZIP protein-
protein interaction networks for 7 species (five metazoans and two single-cell organisms) using a
high-throughput FRET assay. The 5 metazoan species contain a core set of interactions that is
invariantly conserved. Interestingly, while all the networks contain this set of core interactions,
each species network is diversified, both through rewiring of interactions between conserved
proteins as well as the addition of new proteins and interactions. To understand the sequence
changes that lead to changes in interactions, several examples of paralogs with different
interaction specificities were identified. Mutants containing a small number of sequence changes
were observed to largely switch interaction profiles between paralogs. Taken together, these
projects have identified many new interactions, generated specific peptide reagents, identified
sequence determinants of interaction specificity, and provided large data sets that will be useful
for further understanding the specificity of bZIP proteins.
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Identification of bZIP interaction partners of viral proteins HBZ,
MEQ, BZLF1, and K-bZIP using coiled-coil arrays
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ABSTRACT
Basic-region leucine-zipper transcription factors (bZIPs) contain a segment rich in basic
amino acids that can bind DNA, followed by a leucine zipper that can interact with other leucine
zippers to form coiled-coil homo- or heterodimers. Several viruses encode proteins containing
bZIP domains, including four that encode bZIPs lacking significant homology to any human
protein. We investigated the interaction specificity of these four viral bZIPs by using coiled-coil
arrays to assess self-associations as well as hetero-interactions with 33 representative human
bZIPs. The arrays recapitulated reported viral-human interactions and also uncovered new
associations. MEQ and HBZ interacted with multiple human partners and had unique interaction
profiles compared to any human bZIPs, whereas K-bZIP and BZLF1 displayed homo-specificity.
New interactions detected included HBZ with MAFB, MAFG, ATF2, CEBPG, and CREBZF,
and MEQ with NFIL3. These were confirmed in solution using circular dichroism. HBZ can
hetero-associate with MAFB and MAFG in the presence of MARE-site DNA, and this
interaction is dependent on the basic region of HBZ. NFIL3 and MEQ have different yet
overlapping DNA-binding specificities and can form a heterocomplex with DNA. Computational
design considering both affinity for MEQ and specificity with respect to other undesired bZIP-
type interactions was used to generate a MEQ dimerization inhibitor. This peptide, anti-MEQ,
bound MEQ both stably and specifically, as assayed using coiled-coil arrays and circular
dichroism in solution. Anti-MEQ also inhibited MEQ binding to DNA. These studies can guide
further investigation of the function of viral and human bZIP complexes.
INTRODUCTION
Many viruses hijack cellular machinery by using viral proteins to interact with host
proteins. Viruses can incorporate host protein domains into their genomes for this purpose, as is
the case for several viruses that use BCL-2 homologs to prevent apoptosis. Viral host-derived
protein domains often make interactions similar to those of their homologues, although these can
occur in a misregulated manner (Hardwick and Bellows. 2003). Alternatively, host-derived
protein domains can diverge from their cellular counterparts, such that they retain little sequence
similarity. In such cases, virus-host protein interactions can be expected to differ markedly from
corresponding host-host complexes (Kvansakul, et al. 2008).
The bZIP transcription factors are a large class of proteins found in most eukaryotic
organisms. Named for their DNA-binding and dimerization domain, bZIP proteins interact with
DNA site-specifically via a region of conserved basic amino acids. Immediately C-terminal to
the basic region is the leucine zipper, a coiled coil that mediates the formation of homodimeric or
heterodimeric complexes. The dimerization specificity of the leucine zippers allows for
combinatorial interactions that can influence DNA binding and thus transcriptional regulation
(Daury, et al. 2001, Hai and Curran. 1991). Given the importance of protein partnering
specificity for the function of the bZIPs, a high-throughput protein array assay was used to
determine the global in vitro interaction profiles of most human bZIPs. The coiled-coil
microarray assay used for this purpose was shown to identify most reported interactions, and the
relative stabilities of interactions measured on the arrays were also shown to agree well with
solution measurements (Grigoryan, et al. 2009a, Newman and Keating. 2003).
Proteins containing bZIP domains have been identified in several viruses. Three human
bZIP proteins, JUN (cJun), FOS (cFos), and MAF (cMaf), occur in an altered form in oncogenic
avian and murine retroviruses. These homologous viral bZIPs maintain the protein dimerization
properties of the human proteins and are oncogenic because of altered regulation (van Straaten,
et al. 1983a, Bos, et al. 1989, Kataoka, et al. 1993). Four viral bZIPs that have little homology to
human bZIPs have also been identified, and although several interactions with host proteins have
been reported, global investigation of the interactions of these proteins with host bZIPs is
lacking.
Human T-cell leukemia virus type 1 is a retrovirus that causes adult T-cell leukemia; it
encodes the bZIP protein HBZ (reviewed in (Mesnard, et al. 2006)). HBZ has been shown to
repress both viral and cellular gene expression. A recent study suggests that in addition to the
role of the HBZ protein in disease progression, the mRNA of HBZ promotes proliferation
(Satou, et al. 2006). Interactions have been reported between HBZ and many human bZIPs both
in vivo and in vitro including ATF4, JUN, JUNB, JUND, CREB1, and ATF1 (Lemasson, et al.
2007, Thebault, et al. 2004, Basbous, et al. 2003, Gaudray, et al. 2002). HBZ has been shown to
form complexes with JUN, JUNB, CREB1, and ATF4 and to prevent these proteins from
binding DNA. In contrast, HBZ has been reported to increase the transcriptional activity of
JUND (Thebault, et al. 2004).
MEQ is encoded by Marek's disease virus (MDV), an oncogenic herpes virus that infects
chickens. The disease is estimated to cost the US poultry industry one billion dollars annually
(reviewed in (Nair. 2005)). MEQ has been demonstrated to be largely responsible for the
oncogenic properties of MDV (Suchodolski, et al. 2009, Levy, et al. 2005, Brown, et al. 2009).
MEQ can self-associate as well as interact with a variety of other bZIPs in vitro including: JUN,
JUNB, CREBI, ATF1, ATF2, ATF3, FOS, and BATF3 (Suchodolski, et al. 2009, Levy, et al.
2003, Qian, et al. 1996, Qian, et al. 1995). Additionally, MEQ has been shown to bind JUN in
vivo, and JUN is required for MEQ to transform cells (Levy, et al. 2005, Levy, et al. 2003).
Two gammaherpesviruses are reported to encode bZIP-containing proteins. These viruses
are implicated in several proliferative disorders in humans. Epstein-Barr virus encodes BZLF1
(ZEBRA, Zta, Z, EB1) and is associated with Burkitt's lymphoma, Hodgkin's disease, and
nasopharyngeal carcinoma. Kaposi's sarcoma-associated herpesvirus encodes K-bZIP (K8, RAP)
and is involved in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's
disease (reviewed in (Thomas. 2006, Kutok and Wang. 2006)). These two proteins are positional
homologs and also share low sequence similarity with one another (Lin, et al. 1999). BZLF1 is
responsible for triggering the switch from latent to lytic infection by binding sites within the viral
genome and causing transcriptional activation of many genes. It is also involved in viral
replication (Countryman, et al. 1987, Schepers, et al. 1996). Over-expression of K-bZIP does not
cause virus reactivation, but K-bZIP is necessary for viral replication as well as the repression
and activation of many genes within the viral genome, though not always through direct binding
to promoters (Rossetto, et al. 2009, Ellison, et al. 2009). BZLF1 and K-bZIP both interact with
many viral and cellular proteins including the human bZIP CEBPA (C/EBPa) (Sinclair. 2003).
Interestingly, the interaction with CEBPA for both BZLF1 and K-bZIP is proposed to involve
higher order oligomers rather than just dimers (Wu, et al. 2004, Wu, et al. 2003). Recently, the
crystal structure of BZLF1 was solved showing that a C-terminal region adjacent to the leucine
zipper folds back and stabilizes the coiled-coil structure, significantly stabilizing the homodimer
(Petosa, et al. 2006). K-bZIP has been shown to self associate through its leucine zipper, but this
homomeric interaction was reported to be one of higher order oligomers (Lin, et al. 1999, Wu, et
al. 2003).
Given the importance of both human and viral bZIPs to human health, several strategies
have been used to generate inhibitors that can prevent dimerization and/or DNA binding. One
approach is to use the leucine zipper of a homodimerizing bZIP as a dominant negative. The
utility of this approach has been demonstrated in the context of BZLF1. Using a peptide that
consisted of only the leucine zipper of BZLF 1, (Hicks, et al. 2003) showed that BZLF 1 could be
prevented from binding DNA. However, the EC50 for the peptide was high micromolar. A
possible disadvantage of using native leucine-zipper peptides as inhibitors is that these may
associate with bZIPs other than the desired target. Recently, we reported a computational design
method for obtaining peptides that interact specifically with leucine zippers and applied it to a
range of human targets. Out of the 20 human bZIP families, peptides were designed that
successfully interacted with 19. Of these 19, 8 designs bound to their target family stronger than
to any other family (Grigoryan, et al. 2009a).
Here we report all pair-wise interactions of four bZIP peptides derived from viral proteins
with 33 human bZIP proteins measured using peptide microarrays. We identified several new
interactions for both MEQ and HBZ, and these interactions were confirmed using circular
dichroism and gel-shift assays. Additionally, we designed a peptide, anti-MEQ, to serve as a
MEQ dimerization inhibitor. We demonstrate that this peptide binds specifically to MEQ and can
prevent MEQ from binding DNA.
EXPERIMENTAL METHODS
Plasmid construction, protein expression and purification
Human protein constructs used for array experiments have been previously described and
are listed in Table A.S 1 (Grigoryan, et al. 2009a, Newman and Keating. 2003). Synthetic genes
encoding the leucine zipper regions of HBZ, MEQ, BZLF 1, K-bZIP, anti-MEQ and the full bZIP
domains of MAFB, HBZ, and MEQ were synthesized using DNAWorks to design primers and a
two-step PCR method to anneal them (Hoover and Lubkowski. 2002). The bZIP domains of
CREBZF, ATF2 and JUND were cloned from plasmids acquired from Open Biosystems
(Gerhard, et al. 2004) and NFIL3, JUN, CEBPG and MAFG were cloned from plasmids obtained
from PlasmID (Witt, et al. 2006).These proteins were cloned into modified versions of a
pDEST17 vector. Proteins were expressed in RP3098 cells and purified under denaturing
conditions using Ni-NTA followed by reverse-phase HPLC as described previously (Newman
and Keating. 2003, Grigoryan, et al. 2009b). A tagless version of anti-MEQ used for gel-shift
and CD studies was constructed by cloning into pSV282 (Vanderbilt University Medical Center,
Center for Structural Biology). The 6XHIS-MBP-anti-MEQ fusion protein was expressed in
RP3098 cells by growing a 1 L culture in LB at 37 'C and inducing at 0.5 OD by adding 1 mM
IPTG and growing for 4 hours. The fusion protein was purified under native conditions by
binding to Ni-NTA resin (Qiagen) and eluted by adding 8 ml buffer (300 mM imidazole, 20 mM
TRIS, 500 mM NaCl, 1 mM DTT, pH 7.9). The fusion protein was then dialyzed overnight into
TEV cleavage buffer (50 mM TRIS, 50 mM NaCl, 1 mM DTT, 0.5 mM EDTA, pH 7.5) and then
cleaved by adding 100 pl TEV protease (lmg/ml) for 3 hours at 18-22 'C. This mixture was then
added to Ni-NTA resin and the flow-through collected. The anti-MEQ peptide was further
purified using reverse-phase HPLC. The molecular weights of the peptides were confirmed by
mass spectrometry. Protein sequences generated for this study are listed in Table A.S 1.
Coiled-coil arrays
Array experiments were performed as described previously (Grigoryan, et al. 2009b). The
average background-corrected fluorescence values for all measurements are listed in Table A.S2.
Two measures used to report fluorescence intensities in the figures are Sarray and arrayscore.
These are defined in references (Grigoryan, et al. 2009b) and (Reinke, et al. 2010), respectively.
Circular dichroism
Circular dichroism experiments were performed as described previously (Grigoryan, et
al. 2009b). The concentrations used for each experiment are listed in the figure legends. Thermal
dentaturations were measured from 0 to 65 'C and all were reversible with all complexes having
differences in Tm of less than 3 'C upon refolding. The buffer for CD measurements of MEQ
was PBS (potassium phosphate (pH 7.4) and 150 mM KCl) with 1mM DTT. For measurements
of HBZ the buffer also included 200 mM GdnHCl and 0.25 mM EDTA.
Phylogenetic analysis
An unrooted phylogenetic tree was constructed using the neighbor-joining method for
the 53 human and 4 viral bZIP leucine-zipper regions as described previously (Grigoryan, et al.
2009b). For comparison of chicken and human sequences, each human bZIP was used to BLAST
the G. gallus genome and 41 chicken bZIPs were identified. Leucine-zipper regions were defined
as previously reported (Newman and Keating. 2003). Families were defined according to
evolutionary conservation and interaction profiles, as in (Newman and Keating. 2003,
Amoutzias, et al. 2007).
Gel-shift assay
DNA probes for the AP-1, TFIID, and NF-rB sites were obtained from Promega. Other probes
were based on literature-defined sequences (MARE (Kataoka, et al. 1994), CAAT (Acharya, et
al. 2006a), CRE1 (Levy, et al. 2003), CRE2 (Chen, et al. 1995), MDVORI (Levy, et al. 2003)),
ordered as PAGE-purified oligos (IDT) and then annealed. Probes were end labeled with [y-
32P]ATP using PNK (NEB). Proteins were incubated for 3 hours at 18-22 'C in gel-shift buffer
(50 mM KCl, 25 mM TRIS pH 8.0, 0.5 mM EDTA, 2.5 mM DTT, 1 mg/ml BSA, 10% (v/v)
glycerol, 0.1 mg/ml competitor DNA (Poly (I)-Poly (C) (GE)). Radiolabeled DNA was then
added and incubated for 1 hour at 18-22 *C. Radiolabeled DNA was at a final concentration of
0.7 nM, except for experiments in Figure A.S4 where the final concentration was 20 nM.
Protein/DNA mixtures were loaded on NOVEX DNA retardation gels (Invitrogen) using 0.5X
TBE buffer and run at 200-300V for 15-25 minutes. For complexes involving JUN proteins, the
buffer was pre-cooled to 4 'C to prevent complex dissociation. Gels were dried and imaged using
a phosphorimaging screen and a Typhoon 9400 imaging system.
Computational design of anti-MEQ
Anti-MEQ was designed using CLASSY with the HP/S/Ca energy function as
previously reported (Grigoryan, et al. 2009b). 46 human proteins and design homodimerization
were used as negative design states.
RESULTS
Four unique bZIPs are encoded by viral genomes
There are four bZIPs of viral origin described in the literature that are not closely related
to any human bZIP. These are MEQ, HBZ, BZLF 1, and K-bZIP. To compare these proteins to
the human bZIPs, a phylogenetic tree was constructed using the leucine- zipper regions of the
four viral proteins as well as 53 human bZIPs (Figure 2.1A). According to this analysis, all four
viral bZIPs are quite diverged from human bZIPs. The sequences of the 4 viral bZIPs are aligned
to several representative human sequences in Figure 2.1B. Human bZIPs have a highly
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Figure 2.1. Sequence properties of human and viral bZIPs. (A) A phylogenetic tree was inferred
by neighbor-joining using only the leucine-zipper region of each of the 53 human bZIPs and the
4 viral bZIPs. Viral sequences are boxed. Proteins used to measure interactions are indicated
with a black square. Family names are in bold. The scale bar refers to amino-acid changes per
position. (B) Multiple-sequence alignment of viral bZIPs with representative human bZIPs. The
following are underlined: Highly conserved basic-region asparagine and arginine residues and
conserved leucines in the leucine zippers.
conserved basic region consisting of the motif
(R/K)XX(R/K)N(R/K)XAAXX(S/C)RX(R/K)(R/K) (Adya, et al. 1994), and a striking feature of
the basic-region alignment is the presence of an invariant asparagine in almost all human bZIPs.
The only two human families that do not have this asparagine are CREBZF (ZF, Zhangfei) and
DDIT3 (CHOP), which are not known to bind DNA as homodimers but can bind as heterodimers
(Hogan, et al. 2006, Ubeda, et al. 1996). An arginine, separated by 8 residues from the conserved
asparagine, is strictly conserved in all human bZIPs. Both MEQ and BZLF 1 conform well to this
conserved motif and include the key asparagine and arginine residues. In contrast, the basic
regions from HBZ and K-bZIP poorly match the basic-region motif, and neither contains the key
conserved asparagine or arginine. The leucine-zipper regions of human bZIPs are 4-7 heptads
long and are characterized by strong conservation of leucine every 7 amino acids. MEQ, HBZ,
and to a lesser extent K-bZIP, have mostly canonical leucine-zipper regions. On the other hand,
BZLF 1 has a very short leucine zipper that is non-canonical, with only one coiled-coil d-position
leucine (coiled-coil residues are traditionally labeled a-f, with a and d largely buried in the core,
e and g on the periphery and b, c and f on the outside of the helical complex). BZLF 1 has also
been shown to be stabilized by an extended C-terminal region that makes contacts with the
coiled coil (Petosa, et al. 2006). These observations are consistent with reports of both MEQ and
BZLF1 binding DNA, whereas there is no direct evidence to support binding of DNA by HBZ
(Levy, et al. 2003, Petosa, et al. 2006, Hivin, et al. 2006). K-bZIP has been shown to directly
bind DNA, though it is not clear whether the bZIP domain is involved (Lefort, et al. 2007).
Unlike HBZ, K-bZIP and BZLF 1, which are found in viruses that infect humans, MEQ is
encoded by an avian oncovirus. Because of the availability of a large number of human, but not
avian, bZIP clones, we wanted to confirm that human bZIPs could be used as a reasonable
substitute for chicken bZIPs. MEQ has been previously reported to interact with both human and
mouse bZIP proteins (Levy, et al. 2003). We also compared human bZIP sequences to chicken
bZIP sequences and found them to be highly homologous (Figure A.S1). Considering just the
coiled-coil interface positions that are most responsible for interactions (adeg), 85% of direct
orthologues have greater than 90% identity. Additionally, all human bZIP families are conserved
between human and chicken, except DDIT3, which is specific to humans.
Detection of viral-human bZIP interactions
Interactions between human and viral bZIPs were measured using a previously described
protein microarray assay (Newman and Keating. 2003, Grigoryan, et al. 2009b). The leucine-
zipper regions of 33 representative human bZIPs were purified and printed onto aldehyde-
derivatized glass slides along with leucine zippers from the 4 viral proteins (Table A.S1). All
human bZIP families were represented on the arrays except for OASISb, which is very similar in
its protein sequences and interaction profiles to OASIS. Each protein was then individually
fluorescently labeled and used to probe the arrays at a concentration of ~160 nM, unless
otherwise indicated. A total of 8 spots on the surface were used for each measurement. The
fluorescence intensity of each spot was corrected for background, and the averages of the 8
values were converted into a score called San-ay, a Z-score like measure, as described previously
(Table A.S2) (Grigoryan, et al. 2009b).
As in prior studies using this technique, there were several indications that the data are of
good quality. First, interactions observed among human bZIPs (measured simultaneously with
the viral-human interaction data) were highly consistent with previously published data (Figure
A.S2) (Newman and Keating. 2003). Next, each heteromeric interaction was measured twice,
once when the first protein was on the surface and again when it was in solution. Most
interactions were observed in both directions. Further, interactions involving MEQ and HBZ
were measured over a large range of concentrations and gave rise to similar interaction profiles
(Figure 2.2B). Finally, many interactions observed between viral and human proteins were
consistent with prior reports, as discussed below.
Most previously reported interactions involving the viral bZIPs were observed on the
array and are indicated by green boxes in Figure 2.2A. Exceptions are boxed with green dotted
lines in Figure 2.2A and include the interaction of HBZ with ATF4 and the interaction of MEQ
with FOS. However, the HBZ-ATF4 interaction was reported to be weaker with just the
leucine-zipper region (as was measured on the arrays) than in context of the entire protein
(Gaudray, et al. 2002). Also, the interaction of MEQ with FOS has been shown to be weak
compared to other interactions of MEQ (Suchodolski, et al. 2009, Levy, et al. 2003). Several
interactions previously reported to not occur were also not observed to interact on the arrays.
These include HBZ self interaction, HBZ-FOS, BZLF1-FOS, and BZLF1-JUN (Basbous, et
al. 2003, Chang, et al. 1990, Matsumoto, et al. 2005). Both BZLF1 and K-bZIP have been
reported to interact with CEBPA, but not as heterodimers (see Discussion).
Many previously unreported interactions were detected for HBZ. New partners included:
MAF and MAFB, MAFG, ATF2 and ATF7, CEBPG (C/EBPy), CREBZF, and ATF3. MEQ was
found to interact with NFIL3 (E4BP4) and BACH 1. Meq was also found to interact with JUND
and ATF7, members of the JUN and ATF2 families that MEQ is known to interact with.
Interactions were also observed for MEQ with DDIT3 and NFE2, but these proteins are not
conserved between human and chickens. DDIT3 is a member of the one human bZIP family that
is not found in chickens. The NFE2 family is conserved in chickens but the human NFE2 protein
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Figure 2.2. Identification of viral bZIP interactions using peptide microarrays. Interactions are
displayed as a color map, as indicated by the scale at right. Family names are listed in the first
column and individual proteins are listed in the second column. (A) Interactions made by 4 viral
proteins, when in solution or on the surface, are shown in columns. The potential interaction
partners are in rows. Each heteromeric interaction is shown twice, corresponding to the two
different ways it could be measured. Observations in agreement with prior studies are boxed in
green; those interactions reported to be weak in the literature are indicated with dashed boxes.
Fluorescently labeled proteins were used at 160 nM in a phosphate buffer that included IM
guanidine hydrochloride (GdnHCl), except BZLF1 was used at a probe concentration of 1280
nM and K-bZIP was used at a probe concentration of 640 nM in 2.2 M GdnHCl. (B) MEQ and
HBZ interactions at concentrations of 1-1800 nM. (C) Interaction profiles for 6 human proteins
used as solution probes are shown for comparison to HBZ and MEQ solution profiles.
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does not have a direct ortholog, and the member of the family that does have a conserved
ortholog, NFE2L1, is not observed to interact with MEQ.
BZLF 1 was observed to self-associate strongly, but not to interact with any human bZIP
peptides (Figure 2.2A). A BZLF1 construct with the C-terminal extension (BZLFlCT) also did
not interact strongly with any human proteins. This construct gave greater fluorescence signal
when probed against itself than against the version containing just the leucine zipper. BZFL 1 CT
also showed strong signal at a lower concentration than BZLF1 with just the leucine zipper. This
result is consistent with previous reports documenting stabilities in solution, and further
demonstrates the ability of the arrays to accurately report relative affinities (Figure A.S3) (Hicks,
et al. 2003, Hicks, et al. 2001). K-bZIP interacted with itself stronger than with any other protein
on the arrays. Weak interactions were observed with ATF2 and ATF7 when K-bZIP was in
solution, but these interactions were not observed when K-bZIP was on the surface (Figure
2.2A).
A significant result of this experiment is that the leucine-zipper regions of MEQ and HBZ
participate in multiple interactions with different human bZIPs, while BZLF1 and K-bZIP
display almost exclusive homo-association (Figure 2.2A). Additionally, MEQ and HBZ each
interact with a unique combination of partners (Figure 2.2C). HBZ interacts with many of the
same proteins as ATF3 and FOS, but is distinguished by many other strong interactions that are
not made by these proteins, including interactions with both the small and large MAF families,
CEBPG, and CREBZF. MEQ also has a similar profile to human ATF3 and FOS, but
additionally interacts strongly with NFIL3.
Validation of novel interactions of HBZ and MEQ in solution
To validate novel interactions detected on the protein microarrays we tested associations
using circular dichroism (CD). Proteins consisting of the bZIP domain (basic region plus leucine
zipper) were used for these experiments (see Methods, Table A.S 1). For NFIL3, the chicken and
human proteins are identical in this region. For the MAF proteins, the extended homology region
that contains an auxiliary DNA binding domain was included (Kerppola and Curran. 1994). We
first tested JUN for interaction with HBZ and MEQ. JUN has been reported to interact with both
MEQ and HBZ and was also observed to interact with both on the arrays. HBZ and Jun each at
40 pM were mixed together and the CD spectrum was measured (Figure 2.3A). Spectra were
also recorded for each protein in isolation. The spectra of each individual protein, as well as the
mixture, had minima at 208 and 222 nm, which is characteristic of coiled coils. The observed
mean residue ellipticity at 222 nm ([0]222) is consistent with the expected helical content for these
peptides forming coiled coils, as the leucine zipper accounts for -50% of the sequence (Chen, et
al. 1974). The mixture also had increased signal compared to the sum of the individual proteins,
indicating a hetero-association. Similar results were observed for MEQ and JUN (Figure 2.3B).
We next tested HBZ against the newly identified partners ATF2, CEBPG, CREBZF,
MAFG, and MAFB. Thermal melts monitored by CD were performed with each protein at a
concentration of 4 ptM and the mixture at 8 pM. Thermal melts were also carried out for HBZ
with JUN (Figure 2.3, C-H). Over a large range of temperature all mixtures had increased signal
over the sum of the spectra for the individual proteins, confirming the interactions. We then
performed thermal melts of MEQ with NFIL3 and with JUN (Figure 2.31, J). Again the mixture
had increased signal over that expected for non-interacting proteins. Two pairs not observed to
interact on the arrays, HBZ with NFIL3 and MEQ with MAFB, also were not observed to
interact in solution (Figure 2.3K, L). Thus, all protein pairs tested in solution agreed well with
the results of the protein array assay.
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Figure 2.3. Solution measurements of novel interactions for HBZ and MEQ.
(A and B) CD spectra at 40 tM for each protein or 80 ptM for each mixture at 25 'C. (A) HBZ
(open triangles), JUN (open circles), mixture (dashed line). (B) MEQ (open triangles), JUN
(open circles), mixture (dashed line). (C-J) Thermal melts monitored by CD at 4 pM for each
protein or 8 pM for each mixture. All mixtures are shown in dashed lines. (C) HBZ (open
triangles), JUN (open circles). (D) HBZ (open triangle), MAFB (open circles). (E) HBZ (open
triangles), MAFG (open circles). (F) HBZ (open triangles), ATF2 (open circles). (G) HBZ (open
triangles), CEBPG (open circles). (H) HBZ (open triangles), CREBZF (open circles). (I) MEQ
(open triangles), JUN (open circles). (J) MEQ (open triangles), E4BP4 (open circles). (K) HBZ
(open triangles), NIFL3 (open circles). (L) MEQ (open triangles), MAFB (open circles).
Characterization of HBZ interactions with human proteins in the presence of DNA
We tested whether HBZ could prevent its human bZIP interaction partners from binding
DNA and/or whether heteromeric HBZ complexes could themselves bind DNA. MAFB and
MAFG were tested in a gel-shift assay using a MARE site (Kataoka, et al. 1994). Both bound
MARE DNA as homodimers at a concentration of 4 nM, but HBZ did not bind even at a 100-
fold higher concentration. Surprisingly, when HBZ at increasing concentrations was mixed with
a constant concentration of either MAFB or MAFG, an additional shifted band of greater
mobility appeared (Figure 2.4A). To determine whether the interaction was dependant on the
basic region of HBZ, a leucine-zipper-only version of HBZ, HBZLZ, was mixed with the MAF
proteins and the amount of MAF protein bound to DNA was decreased, though a higher
concentration of HBZLZ was required. No additional complex was formed (Figure 2.4B). Taken
together, this is the first evidence, to our knowledge, that suggests HBZ can directly bind to
DNA. We also tested whether ATF2 or CEBPG could bind DNA in complex with HBZ. Both
ATF2 and CEBPG at 20 nM were prevented from binding MARE DNA by HBZ, but no
additional band was formed (Figure 2.4C). CREBZF was not tested in complex with HBZ on
DNA as CREBZF is not known to bind DNA by itself (Hogan, et al. 2006).
MAFG also binds to the AP-l site and was tested for binding in combination with HBZ.
In contrast to the MARE site, HBZ decreased the binding of MAFG to the AP- 1 site without any
additional shifted bands (Figure 2.4D). Both the AP- 1 and the MARE sites contain the core
consensus binding site TGA(C/G)TCA. The MAF proteins have an auxiliary binding domain
that is responsible for binding flanking residues of the MARE site (Kerppola and Curran. 1994).
At the middle of the binding site, position 0, the MARE site we used has a C and the AP- 1 site
contains a G. To determine if this middle position can affect binding by HBZ:MAFG complexes,
the 0 position in MARE was changed to a G and the same position in AP-1 was changed to a C.
The mutant sites had similar binding properties to unchanged sites, suggesting that the middle
position is not the key element that influences HBZ-MAFG heteroassociation on AP-1 vs.
MARE (Figure 2.4E, F). This suggests that bases flanking the core site are important for HBZ
binding.
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Figure 2.4. Binding of HBZ and human bZIPs to specific DNA sites assessed by gel-shifts.
Homo- and hetero- complexes formed on DNA are indicated. (A) HBZ can form
heterocomplexes with MAFB or MAFG on MARE DNA sites. The concentration of MAFB was
4 nM, MAFG was 4 nM, and HBZ was 4, 40 or 400 nM. (B) A leucine-zipper-only version of
HBZ (HBZLZ) prevents MAFB and MAFG from binding MARE-site DNA. The concentration
of MAFB was 4 nM, MAFG was 4 nM, and HBZLZ was at 4, 40, 400, or 4000 nM. HBZLZ
incubated alone was at 4000 nM. (C) HBZ prevents ATF2 and CEBPG from binding MARE-site
DNA. The concentrations of ATF2 and CEBPG were 20 nM, and HBZ was at 40 or 400 nM. (D)
HBZ prevents MAFG from binding AP-1 DNA. The concentration of MAFG was 20 nM, and
HBZ was at 40 or 400 nM. (E) AP-1-site variant TGACTCA (GOC) was not sufficient for HBZ
to bind DNA with MAFG. The concentration of MAFG was 20 nM with AP-1 GOC and 4 nM
with MARE COG. The concentration of HBZ was 40 or 400 nM. (F) DNA sequences used in
gel-shift assays; the consensus site is underlined and position 0 is indicated.
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Characterization of MEQ and NFIL3 binding to DNA
To determine whether NFIL3 and MEQ could bind DNA as heterodimers we tested
several known bZIP-binding sites. AP-1, also known as TRE, is a site bound by JUN and by
FOS-JUN heterodimer (Rauscher Iii, et al. 1988). CAAT contains the consensus site for the
CEBP family of bZIPs (Oikarinen, et al. 1987). CRE1 and CRE2 are two CRE-like sites that
have been previously used in DNA binding studies with MEQ and NFIL3 and are each one
change away from the consensus CRE site TGACGTCA (Levy, et al. 2003, Chen, et al. 1995).
Also tested was the MDVORI site, which is derived from the origin of replication of Marek's
disease virus. MEQ has previously been shown to bind this site as a homodimer (Levy, et al.
2003). In a gel-shift assay neither MEQ nor NFIL3 bound strongly to the negative control sites
TFIID or NF-KB at 80 nM. Only MEQ bound strongly to the AP-1 site and only NFIL3 bound
strongly to the CAAT site. Both MEQ and NFIL3 bound the CRE1 and CRE2 sites, though
NFIL3 bound more strongly. For both of these sites there appeared to be some heterodimer
formation, but the predominant species was the NFIL3 homodimer. Interestingly, NFIL3 bound
to the MDVORI site, but weaker than MEQ did. The mixture on the MDVORI site was
composed of primarily MEQ homodimers (Figure 2.5A).
We also wanted to know if MEQ and NFIL3 could bind a DNA site predominantly as a
heterodimer. Previously it has been shown that heterodimer sites can be constructed by taking
consensus half-sites for each of two interacting bZIPs (Vinson, et al. 1993). A DNA site was
constructed that contains the consensus half-sites for MEQ (ACAC) and NFIL3 (GTAA),
referred to in Figure 2.5C and below as MEQ/NFIL3 (Levy, et al. 2003, Cowell, et al. 1992).
This site has only two changes from the MDVORI site, at positions +1 and +3. This hybrid site
was bound as a homodimer by both MEQ and NFIL3. NFIL3 bound tighter than MEQ, and when
both proteins were mixed, the predominant species bound to the site was the heterodimer, with
mobility between the two homodimers (Figure 2.5A).
The MDVORI probe used in Figure 2.5 was 30 base pairs long, and to further probe the
nature of a MEQ-NFIL3 interaction we tested whether NFIL3 bound at a similar location as
MEQ. Competition gel-shift experiments were performed to test this. MEQ and NFIL3 were
individually incubated with radiolabeled MDVORI site and with cold competitor DNA encoding
either the MDVORI site or a variant of it. Single-base substitutions were made at 10 consecutive
positions in the site. Additionally, 2 double substitutions and a triple-mutant site were
constructed. Changes that affected MEQ binding by at least 2-fold were localized toward the 5'
half of the MDVORI site (Figure 2.5B). Substitutions that weakened MEQ binding included -4C,
-3A, and -IA. The change of -2T strengthened MEQ binding. The double mutant of -3A:-lA
decreased binding more than either individual substitution. NFIL3 binding was decreased by the
changes -lA, +1C, +2G, and +4C. The substitutions -3A and +3A increased binding of NFIL3.
Combining -2T and + 1 C decreased binding further. The changes of - A and +2G decreased
binding individually, but when both were together in combination with -3A, the triple mutant had
no decrease in binding (Figure 2.5B). These 13 altered sites were also tested for direct binding to
MEQ and NFIL3 and the results were consistent with the competition binding experiments
(Figure A.S4). Additionally, significant heterodimer formation by MEQ and NFIL3 was
observed on the +3A site, consistent with results using the hybrid site in Figure 2.5A (Figure
A.S4). Several things are apparent from this experiment. First, mutations on the 5' side of the site
affect binding to MEQ, while those toward the 3' end, and at the last two positions of the left
half-site, affect binding to NFIL3. Second, most DNA base changes have differential effects on
the binding of MEQ and NFIL3, demonstrating they indeed have different binding specificities.
Third, MEQ and NFIL3 bind at a similar location on the MDVORI DNA site.
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Figure 2.5. MEQ and NFIL3 interact and have different but overlapping DNA-binding
specificities. (A) Gel-shift experiments with MEQ and NFIL3. The concentration of MEQ and
NFIL3 was 80 nM each or 160 nM total protein for mixtures. Each homodimer and heterodimer
is indicated. (B) Competition gel-shifi demonstrates that MEQ and NFIL3 bind to similar regions
of an MDV probe, but have differing specificities. Each protein was at 80 nM incubated with 0.7
nM radiolabeled MDVORI DNA. Above each lane is listed the mutation or mutations made in
cold competitor DNA (400 nM). Three individual experiments were quantified, and those
positions that gave > 2-fold changes are indicated (+/- indicate increase/decrease in binding). (C)
DNA sequences used in gel-shift assays; the consensus site is underlined. The positions of the
MDV site are numbered.
Generation of a specfic inhibitor of MEQ dimerization
Specific inhibitors of bZIP interactions could provide valuable tools for elucidating
function and could potentially serve to validate transcription factors as therapeutic targets. To
generate a specific peptide to bind MEQ, that could potentially act as a dominant-negative
inhibitor, we used a recently-published computational design method called CLASSY
(Grigoryan, et al. 2009b). CLASSY was used to automatically design a peptide sequence
MEQ -
NFIL3- NFIL3
predicted to bind MEQ but to have minimal binding to any human bZIP or to itself. The designed
42-residue anti-MEQ peptide was tested for its ability to bind MEQ using bZIP protein arrays
including anti-MEQ, MEQ, and a panel of 32 human bZIPs (these included all the human
peptides tested previously except DDIT3, which is specific to humans). Anti-MEQ bound MEQ
stronger than any human protein (Figure 2.6A). The other proteins that anti-MEQ bound
strongest are the ATF2 family proteins ATF2 and ATF7, followed by JUN and BATF3. Even at
the highest concentration tested, 2000 nM, anti-MEQ bound MEQ and the ATF2 family proteins
preferentially to other bZIPs. Anti-MEQ was not observed to interact with itself on the arrays.
These results demonstrate that anti-MEQ is specific for binding to MEQ.
To compare the stability of the anti-MEQ-MEQ complex with that of other MEQ interactions,
we probed MEQ against an array including MEQ, anti-MEQ, and the panel of 32 human
peptides. MEQ interacted with anti-MEQ as strongly as it interacted with JUN, which was
MEQ's strongest interaction partner observed on the array (Figure 2.6A). The three strongest off-
target interactions, ATF2, JUN, and BATF3, were also tested in solution against anti-MEQ.
ATF2 bound anti-MEQ strongly compared to its strongest interactions on the array. In contrast,
JUN and BATF had much weaker interactions with anti-MEQ. Overall these results suggest that
anti-MEQ has high affinity for, and is specific for, interaction with MEQ.
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Figure 2.6. Anti-MEQ binds MEQ with high affinity and specificity. (A) Designed peptide anti-
MEQ characterized using coiled-coil arrays. Color map of arrayscore is shown, with the colors
defined in the scale. Left, anti-MEQ at different concentrations (nM\) in solution is listed in
columns, with proteins printed on the surface in rows. Right, MEQ and 3 human bZIPs tested
against anti-MEQ and other proteins printed on the surface. (B) CD spectra at 40 gtM for each
protein or 80 [tM for the mixture taken at 25 'C. MEQ (open triangles), anti-MEQ (open circles),
and the mixture (dashed line). (C and D) Thermal melts monitored by CD at 4 giM for each
protein or 8 giM for the mixture. (C) MEQ (open triangles), anti-MEQ (open circles), and the
mixture (dashed line). (D)ATF2 (open triangles), anti-MEQ (open circles), and the mixture
(dashed line). (E) Helical wheel diagram predicted for the interaction of MEQ with anti-MEQ.
Interaction is depicted as a parallel dimer where d-d, a-a, e-g', and a-g' interactions in each
heptad potentially contribute to both stability and specificity. Hydrophobic residues are in black,
charged residues are in red/blue, and polar residues are in green. Potential attractive electrostatic
interactions are shown in dashed blue lines. Diagram created using DrawCoil 1.0.
(http://www.gevorggrigoryan.com/drawcoil/).
The interaction of MEQ and anti-MEQ in solution was studied using a tag-less version of
anti-MEQ (see' Methods). CD spectra showed that anti-MEQ is mostly unfolded at 40 1iM, and
when combined with 40 pM MEQ the mixture has more signal than either MEQ or anti-MEQ
alone, indicating an interaction. The mixture also has a spectrum characteristic of a coiled coil
(Figure 2.6B). Thermal melts of anti-MEQ mixed with both MEQ and ATF2 were performed at
4 pM of each protein and 8 pM total protein for the mixture (Figure 2.6C, D). The temperature
of half denaturation (Tm) for anti-MEQ was 12.8 'C, for MEQ was 35.2 'C, and for ATF2 was
36.7 'C. The Tm for anti-MEQ in complex with MEQ was 40.5 'C, and thus the hetero-
association is more stable than either the homo-association of MEQ or anti-MEQ. The Tm of
ATF2 in complex with MEQ was 31.8 'C. JUN, a strong interaction partner for MEQ, has a Tm
in complex with MEQ of 41.3 'C. These results are consistent with the array data. A helical
wheel diagram depicting the predicted interaction geometry of MEQ and anti-MEQ is shown in
Figure 2.6E. The design has leucine residues at 5 consecutive d-positions, imparting stability to
the complex (Moitra, et al. 1997). It also introduces a complementary asparagine residue to
interact with an asparagine at an a-position in MEQ; this interaction is known to favor parallel
dimer formation (Harbury, et al. 1993). The e- and g-positions of anti-MEQ are complementary
to those in MEQ, and two rather uncommon cysteine residues at a positions are predicted to lie
across from designed alanine and lysine residues. Lysine at core a positions also favors dimer
formation (Campbell, et al. 2002). Two lysines at a positions are complementary to glutamate
residues at g position on the opposite helix. These a-g' interactions have previously been shown
to make important contributions to specificity (Grigoryan, et al. 2009b, Reinke, et al. 2010).
To test whether anti-MEQ could prevent MEQ from binding DNA, 20 nM MEQ was
incubated with increasing amounts of anti-MEQ and then radiolabeled MDVORI DNA was
added to the reactions. Anti-MEQ prevented MEQ binding of DNA, with an IC50 of less than 500
nM (Figure 2.7A). Binding of MEQ to AP-1 DNA was also inhibited by anti-MEQ (data not
shown). The experiment was repeated with 20 nM JUN and the AP-1 DNA site. No decrease in
JUN binding was observed even at 12.5 pM anti-MEQ (Figure 2.7B). The strongest off-target
interaction for anti-MEQ, ATF2, was also tested. At 20 nM ATF2 no decrease in binding was
observed when incubated with anti-MEQ (Figure 2.7C). At 4 nM ATF2, anti-MEQ decreased
ATF2 binding, but at higher concentrations than required for preventing MEQ binding (Figure
2.7D). These results show that anti-MEQ can prevent MEQ from binding DNA at a lower
concentration than it inhibits its strongest off-target interaction.
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Figure 2.7. Anti-MEQ prevents MEQ from binding DNA. Competition gel-shifts with a constant
amount of the indicated protein bound to DNA were titrated with increasing amounts of anti-
MEQ. Concentrations of competitor peptide were 0.02, 0.1, 0.5, 2.5, and 12.5 pM. Labeled DNA
was present at 0.7nM. (A) 20 nM MEQ with MDVORI DNA. (B) 20 nM JUN with AP-1 DNA.
(C) 20 nM ATF2 with CRE2 DNA. (D) 4 nM ATF2 with CRE2 DNA.
DISCUSSION
The bZIP transcription factors function by forming homodimers or heterodimers with
other bZIP proteins. In this context, viruses use bZIP proteins in a number of distinct ways that
are illuminated by the systematic study we present here. Several viral bZIPs that have high
sequence identity to host homologues maintain the interaction patterns of the host bZIPs.
Examples include v-FOS, v-JUN, and v-MAF (Bos, et al. 1989, Kataoka, et al. 1993, van
Straaten, et al. 1983b). The viral bZIPs HBZ and MEQ are not closely related to any other bZIPs,
and they have distinct interaction profiles compared to the human bZIPs. K-bZIP and BZLF1 are
also not highly conserved, but these two viral proteins primarily self-associate.
For MEQ and HBZ, we have uncovered new interactions that suggest possible
mechanisms of action of these proteins. The mechanism of HBZ protein function has been
somewhat of a mystery. The non-canonical basic region of this protein argues against direct
DNA binding, yet HBZ was shown previously to have a strong activation domain, suggesting
that it might function to regulate transcription when complexed with human bZIP proteins and
DNA (Nair. 2005, Kuhlmann, et al. 2007). Additionally, HBZ has been shown to stimulate the
transcriptional activity of JUND. However, data so far have not supported a direct interaction of
HBZ itself with DNA. Here we present the first evidence that HBZ can directly bind DNA. HBZ
can bind a MARE DNA site with MAFB or MAFG. This binding of DNA is specific and is
dependent both on the HBZ basic region and on DNA that flanks the central binding site. While
most bZIPs bind a 4-5 base pair half site, different flanking regions around an AP-1 site have
previously been shown to have different affinities for binding to JUN/FOS heterodimers (Ryseck
and Bravo. 1991). The HBZ ternary complex that we observed on DNA with either MAFB or
MAFG was weaker than MAF-DNA complexes. Also the HBZ-MAF complexes occurred at
higher concentrations of HBZ relative to MAF protein. Because the sequence of the HBZ basic
region is unique, it may have a distinct DNA-binding specificity, and it remains a possibility that
higher affinity sites for HBZ in association with MAF proteins exist.
The MAF proteins belong to two classes: the four large MAF proteins, which contain a
transcriptional activation domain, and the three small MAF proteins that don't. The small MAFs
interact with the NFE2 and BACH families of bZIPs and play a major role in the response to
oxidative stress (Katsuoka, et al. 2005). The large MAF proteins are similar to the JUN proteins
in that both are involved in cell growth and proliferation, both are proto-oncogenes and can cause
cellular transformation, and both have retroviral homologues (Vogt. 2001, Pouponnot, et al.
2005). They also have been reported to share similar downstream targets in inducing cellular
transformation (Kataoka, et al. 2001).
Other proteins we confirmed to interact with HBZ in vitro are CEBPG, ATF2, and ZF.
The CEBP family of bZIPs is involved in cell growth and differentiation. CEBPG forms
heterodimers with CEBP family proteins to repress their transcriptional activity (Parkin, et al.
2002). ATF2 has been shown to stimulate JUN-mediated cellular transformation (Huguier, et al.
1998). CREBZF was identified as having a role in herpes simplex virus gene expression (Lu and
Misra. 2000). CREBZF also interacts with ATF4, a known partner of HBZ (Gaudray, et al. 2002,
Hogan, et al. 2006). With ATF2 and CEBPG, it remains to be seen whether HBZ heterodimers
can bind DNA sites, or if HBZ functions primarily by preventing binding of these partners to
target sites. Neither HBZ nor CREBZF have been shown to bind DNA as homodimers,
suggesting that they have intrinsically weaker affinities for DNA and together would not be
likely to bind DNA as a heterodimer. These newly reported partners, along with other known
partners, suggest that HBZ has the potential to impact several different transcriptional pathways.
It was recently shown that MEQ homodimers alone are not sufficient to induce
transformation, suggesting that heterodimer formation with other bZIPs is necessary
(Suchodolski, et al. 2009). JUN has been shown to be an important MEQ partner, required for
cellular transformation mediated by MEQ, but it is likely that other interaction partners are also
functionally important. Here we identified a previously unreported bZIP partner, NFIL3, and
showed that it can form heterodimers with MEQ on DNA. NFIL3 was first identified as a
transcriptional repressor that bound the adenovirus E4 promoter, and was later shown to have an
activating role associated with anti-apoptotic activity. NFIL3 is also involved in regulating
circadian rhythms (Cowell, et al. 1992, Ikushima, et al. 1997, Doi, et al. 2001). NFIL3 was
further shown in the hepatitis B virus to both repress viral gene expression as well as viral
replication (Lai and Ting. 1999). In this context, it is interesting that NFIL3 can bind to the
MDVORI site as a homodimer. The MDVORI site from the origin of replication of MDV is also
situated between a bidirectional promoter that MEQ has been shown to repress as a homodimer
(Levy, et al. 2003, Qian, et al. 1996). There may exist functionally significant sites that MEQ and
NFIL3 can bind as a heterodimer with greater affinity than either homodimer. It will be
important to determine what role NFIL3 has on the MDV life cycle, both alone and in
combination with MEQ.
Other novel interactions with bZIP families detected on the arrays but not tested further
are HBZ with ATF3, and MEQ with BACH1. Based on the intensity of the fluorescence signal,
these interactions are likely to be weaker than the other interactions tested, but they may be
significant. Also, numerous interactions that we did not assay are highly likely to occur involving
paralogs of the proteins tested here. Although these interactions need to be confirmed
experimentally, most bZIP paralogs are highly similar to each other and have been shown to
share similar interaction profiles (Newman and Keating. 2003, Grigoryan, et al. 2009b,
Amoutzias, et al. 2007).
An interesting result is that the leucine-zipper regions of BZLF1 and K-bZIP
preferentially self-associate. Both proteins are reported to interact with CEBPA, but this pairing
was not observed in our array experiments. Basic residues were required for this interaction in
the case of BZLF1, and both proteins were observed to interact with CEBPA as higher-order
multimers and not as heterodimers (Wu, et al. 2004, Wu, et al. 2003). Our observation that the
leucine zippers are not sufficient for these interactions is consistent with those studies. It is not
surprising, given the unique structure of BZLF 1, that it does not form canonical interactions with
human BZIPs.
MDV is the first oncogenic virus for which a vaccine was made available to control the
disease, but increasing viral resistance is becoming a real concern to the poultry industry.
Further, MDV has proven valuable as a model oncogenic virus, and deletion and knockdown
experiments have demonstrated the necessity of MEQ for oncogenic transformation (Levy, et al.
2005). It has also been reported that a virus encoding a MEQ protein that cannot form
homodimers or heterodimers has a complete loss of oncogenicity, suggesting that the function of
MEQ could be inhibited by preventing MEQ from interacting with bZIPs (Brown, et al. 2009).
We showed that a computationally designed anti-MEQ peptide can prevent MEQ from binding
DNA in a specific manner, indicating that anti-MEQ could be a useful reagent for studying the
role of MEQ on the oncogenic properties of MDV. If necessary to achieve higher affinity, the
anti-MEQ peptide could potentially be further stabilized through the addition of an acidic peptide
extension that interacts with the basic region, as has been demonstrated for numerous other
coiled coils by the Vinson laboratory (Acharya, et al. 2006b).
In summary, we have shown that coiled-coil arrays are a powerful method for broadly
surveying the interaction properties of viral bZIP dimerization domains. Comprehensive testing
for in vitro interactions with all human bZIP families is an important step in exploring the
functions of these proteins. Further, we have validated that several newly discovered viral-host
complexes can bind to DNA, suggesting a mechanism by which viruses hijack cellular
transcriptional control. Determining which of the bZIPs that can associate in vitro also interact
with functional consequences in vivo will be an important next step.
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ABSTRACT
Interaction specificity is a required feature of biological networks and a necessary
characteristic of protein or small-molecule reagents and therapeutics. The ability to alter
or inhibit protein interactions selectively would advance basic and applied molecular
science. Assessing or modelling interaction specificity requires treating multiple
competing complexes, which presents computational and experimental challenges. Here
we present a computational framework for designing protein interaction specificity and
use it to identify specific peptide partners for human bZIP transcription factors. Protein
microarrays were used to characterize designed, synthetic ligands for all but one of 20
bZIP families. The bZIP proteins share strong sequence and structural similarities and
thus are challenging targets to bind specifically. Yet many of the designs, including
examples that bind the oncoproteins cJun, cFos and cMaf, were selective for their
targets over all 19 other families. Collectively, the designs exhibit a wide range of novel
interaction profiles, demonstrating that human bZIPs have only sparsely sampled the
possible interaction space accessible to them. Our computational method provides a way
to systematically analyze tradeoffs between stability and specificity and is suitable for
use with many types of structure-scoring functions; thus it may prove broadly useful as
a tool for protein design.
INTRODUCTION
Designing peptides, proteins, or small molecules that bind to native protein targets
is a promising route to new reagents and therapies. Yet dealing with the interaction
specificity problem - i.e. achieving designs that are selective for their intended targets
in preference to related alternatives - is difficult. Designing or assessing protein
interaction specificity in a comprehensive manner is impeded by the challenges and
costs inherent in modelling or measuring many competing complexes. Recent large-
scale experiments that have characterized interaction specificity for a handful of protein
families and/or domains represent significant progress in this area (Jones, et al. 2006,
Stiffler, et al. 2007, Wiedemann, et al. 2004, Newman and Keating. 2003, Landgraf, et
al. 2004, Skerker, et al. 2005). In particular, assays that provide a way to profile the
interactions of a protein with many candidate partners offer an opportunity to explore
how specificity can be introduced into proteins rationally, by design.
Computational design has led to remarkable advances in protein engineering over
the past decade, including the design of protein-protein interactions (Havranek and
Harbury. 2003, Kortemme, et al. 2004, Ali, et al. 2005, van der Sloot, et al. 2006, van
der Sloot, et al. 2006, Reina, et al. 2002, Shifman and Mayo. 2003, Fu, et al. 2007,
Bolon, et al. 2005). Introducing considerations of specificity into protein-design
calculations raises interesting theoretical challenges that have been addressed in a few
prior studies (Havranek and Harbury. 2003, Kangas and Tidor. 2000, Deutsch and
Kurosky. 1996) and/or treated on a case-by-case basis in several applications (Havranek
and Harbury. 2003, Kortemme, et al. 2004, Ali, et al. 2005, van der Sloot, et al. 2006,
Bolon, et al. 2005). Most often, however, specificity is simply ignored in computational
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protein design. Several proteins or peptides that were optimized solely for binding to a
native target were shown aposteriori to be specific for their intended interaction partner
over a few related alternatives (Reina, et al. 2002, Shifman and Mayo. 2003, Fu, et al.
2007, Yin, et al. 2007). However, focusing only on the stability of the desired complex
led to a lack of specificity, both in computational design and experimental selections, in
other examples (Bolon, et al. 2005, Deutsch and Kurosky. 1996, Mason, et al. 2006).
Strategies that can simultaneously consider affinity and multi-state specificity in the
design process are therefore highly desirable (Havranek and Harbury. 2003).
The basic-region leucine-zipper (bZIP) transcription factors provide an exciting
but highly challenging opportunity to test strategies for interaction specificity design.
The bZIPs homo- and/or heterodimerize by forming a parallel coiled coil (a "leucine
zipper") and bind DNA using a region rich in basic amino acids (Vinson, et al. 2006).
Approximately 53 human bZIP proteins that make up 20 families participate in a wide
range of important biological processes and pose attractive targets for selective
inhibition. Interest in inhibiting bZIPs dates to 1995, when Vinson and co-workers
showed that heterodimers containing one bZIP subunit and one subunit with an acidic
region replacing the basic region (A-ZIPs) are inactive. A-ZIPs have proven very useful
for applications both in vitro and in vivo (Gerdes, et al. 2006, Krylov, et al. 1995).
However, these inhibitors mimic the interaction preferences of the proteins from which
they are derived and typically associate with multiple bZIP families. Extensive sequence
similarity among the leucine-zipper domains hampers efforts to make specific peptides
that could provide more selective A-ZIPs or other inhibitors. For example, strong
undesirable off-target interactions were observed when experimentally selecting
synthetic partners for the cFos and cJun bZIP coiled coils out of peptide libraries
(Mason, et al. 2006).
The bZlPs are also attractive design targets because experiments have probed
sequence features that influence both structural and interaction specificity (Vinson, et al.
2006, Acharya, et al. 2006, Krylov, et al. 1998, Lupas and Gruber. 2005). Building upon
these insights and taking advantage of large experimental data sets, computational
models that provide useful predictions of bZIP interaction preferences have been
developed (Newman and Keating. 2003, Mason, et al. 2006, Fong, et al. 2004,
Grigoryan and Keating. 2006). These prior studies afford a relatively mature
understanding of bZIP partnering and provide the potential for specificity design.
RESULTS
Computational design of specificity
We have developed a strategy for addressing specificity in protein-design
calculations that rests on the trade-off between maximizing affinity and introducing
specificity. The stability/specificity trade-off has been discussed previously(Havranek
and Harbury. 2003, Bolon, et al. 2005, Kangas and Tidor. 2000, Deutsch and Kurosky.
1996), and has motivated the successful design of heterospecific coiled-coil pairs
(Havranek and Harbury. 2003). For our work, we note that a protein designed to bind
optimally to a native target may also bind strongly to one or more undesired
competitors, indicating that the difference in energy between forming undesired
complexes and the design-target complex is not sufficiently large. New designs can be
sought that increase this gap and are thus more selective for the target, but these will
necessarily have reduced target affinities relative to the design that is optimal for target
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binding. The computational method presented here formalizes this trade-off by
identifying sequences that minimize the stability sacrifice required to achieve increasing
energy gaps from competing complexes. Such sequences posses the important property
that they cannot simultaneously be improved both in predicted affinity and specificity.
Our framework, CLASSY (Cluster expansion and Linear programming-based
Analysis of Specificity and Stability), makes use of two computational techniques to
implement the above idea. The first is integer linear programming (ILP), an
optimization method that has been applied to the energy-minimization problem in
protein design (Kingsford, et al. 2005). The second is cluster expansion (CE), which we
use to convert a structure-based interaction model into a sequence-based scoring
function that is very fast to evaluate (Grigoryan, et al. 2006, Zhou, et al. 2005).
Importantly, CE allows us to apply ILP at the sequence level, rather than at the structure
level. This makes it possible to impose constraints on the energies of design-undesired
partner interactions during optimization of the design-target energy, which is the
keystone of the CLASSY approach. The power of CE and ILP mean that arbitrary
numbers of desired and undesired states and relationships between them can be included
in CLASSY designs. Thus, CLASSY can deal with problems beyond the scope of
traditional design methods, making it an appropriate approach for designing specific
anti-bZIP peptides.
As one example of how CLASSY can be used, we implemented a procedure
called a specificity sweep to identify sequences of optimal stability that satisfy
increasing requirements on specificity. For this purpose, the quantity A was defined as
the energy gap between the lowest-energy undesired state and the desired target state
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(Figure 3. 1A). A specificity sweep begins by using ILP to find the sequence with the
highest binding affinity for the target, ignoring specificity. An initial value for the
quantity A is then computed by predicting the energies of all possible complexes
involving this design. The ILP optimization is repeated, this time designing a protein
that optimizes binding with the target subject to the constraint that all undesired states
have energy gaps to the designed state that are larger than A plus a small increment.
This is repeated, gradually increasing the value of A, until it is no longer possible to find
design sequences that satisfy the constraints. Although CLASSY can be run with any
value assigned to A, one advantage of the specificity sweep exploring a broad range of A
values is that no assumption of how much stability or specificity is "enough" need be
made prior to the calculation.
Candidate designs from a specificity sweep list may be selected for testing by a
user, after considering predicted stability:specificity tradeoffs and the sequence changes
that bring these about. Other considerations may be included, as CLASSY provides the
ability to restrict arbitrary linear functions of sequence. In our application, a bias for the
bZIP coiled-coil fold was imposed by constraining designs to be leucine-zipper like
according to a position-specific scoring matrix (PSSM). Similar constraints could also
be used, for example, to place requirements on predicted solubility. Such
considerations, which are often included in designs in an ad hoc manner or by
employing manual post-evaluation and filtering, can be naturally incorporated into the
CLASSY procedure.
Design of anti-bZIP peptides
We applied CLASSY to design partners for nearly all human bZIPs and used our
computational results to assess the difficulty of the bZIP interaction specificity design
problem. We sought anti-bZIP designs predicted to bind their targets and yet interact
minimally with themselves and with members of the 19 non-target bZIP families.
Because of the extremely high sequence similarity within families, we did not require
that the designs discriminate between siblings in the target family. The desired
design-target heteromeric complex, as well as undesired design-design and design-off-
target complexes, were modelled as coiled-coil dimers on a fixed-backbone template
and evaluated using energy functions similar to that of reference (Grigoryan and
Keating. 2006), which was shown previously to give good performance predicting
native bZIP interaction preferences (Grigoryan and Keating. 2006) (also see appendix
B).
Specificity sweeps were computed for the 46 bZIPs in reference (Newman and
Keating. 2003). These calculations predicted that specificity will arise only rarely
among bZIP partners optimized for stability alone. Such designs are almost all predicted
to form strong homodimers, regardless of the family they are targeted against (Figure
B.S2). Negative design is also required to disfavour complexes with undesired bZIP
competitors. Approximately 65% of 46 designs optimized for affinity alone were judged
to face significant competition from non-target families; this can be addressed in
CLASSY by sacrificing stability, as shown in Figure B.S2. We carried out additional
computational analyses to estimate how candidate bZIP partners are distributed in
stability-specificity space (Figure B.S 12). Even when the design-design homodimer is
the only undesired state, the vast majority of sequence space is predicted to be non-
96
specific. Thus, addressing specificity is critical, but the drastic reduction this imposes on
acceptable sequences makes the design problem challenging.
Testing of anti-bZIP designs
We next tested 48 peptides designed to bind representative targets from all 20
bZIP families, using a protein microarray assay that has been validated for measuring
interaction preferences for bZIPs (Newman and Keating. 2003). Sequences to be tested
were selected from the specificity sweeps by hand, considering the magnitude of A, the
amount of stability lost relative to the most stable design, and sequence features such as
excessive loss of hydrophobic interactions in the core (see Figure 3.1 C for the example
of anti-SMAF; Table B.Sl provides detailed descriptions of the origin of each design).
In a few of the cases where we designed more than one peptide against a given target,
experimental results for initial designs were incorporated to guide the CLASSY design
procedure. For example, anti-ZF was designed using a modified specificity sweep that
up-weighted the influence of XBP-1 in determining A, after this protein was
experimentally determined to be a problematic competitor. The ability to easily
incorporate information about known competitors is one advantage of CLASSY.
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Figure 3. 1. Designing specific peptides using CLASSY. A) Specificity sweep scheme.
A sequence (black) is sought that binds a target (red) but not several undesired partners
(gray) or itself. Panels from left to right illustrate iterations of the CLASSY procedure,
during which the specificity gap A is increased. B) and C) A specificity sweep with
MafG as the target and all other human bZIP coiled coils (except MafK, in the same
family as MatG) and the design homodimer as undesired complexes. The plot in B
corresponds to the cartoon in A. Red dots, black bars and gray bars represent energies of
the design-target, design-design, and design-other bZIP complexes, respectively. C
plots design-target complex stability vs. specificity (A). Portions of several designed
complexes are shown using helical wheels (orange highlights amino-acid changes from
the previously shown sequence). The rightmost solution is anti-SM4AF.
In total, 48 peptides designed against 20 targets were tested for interaction with 33
representative human bZIP coiled coils and for self-association. Fluorescence intensities
measured on bZIP arrays have previously been shown to reflect relative interaction
strengths measured in solution (Newman and Keating. 2003). Each peptide in turn (both
designed and native) was labelled with the fluorescent dye Cy-3 and used to probe
aldehyde-derivatized slides printed with potential partners. Of the 48 designs tested, 40
bound to their intended target, as assessed by fluorescence signal above background
(Figure B.S1). The probability of this occurring by chance, given the distribution of
design-human interaction signals from the arrays, was ~10-* Self-association of the
designs was also evaluated. Only 40% of the designs showed detectable self-interactions
using the same criterion, and all but 6 interacted with a human bZIP more strongly than
they interacted with themselves (Figure 3.2A and Figure B.S 1).
To determine the interaction specificity of the designed molecules, we used Cy-3
labelled designed peptides and compared the array signal for interaction with the target
to that for interaction with non-target competitors. Results for the most specific design
identified for each of the 20 families are shown in Figure 3.2A. These designs are
named using the target family name. For 10 designs, the strongest interaction observed
was with the intended target. Strikingly, 8 of these designs bound their targets with
array signals distinctly greater than for any other non-target-family partner (targets: ZF,
cFos, MafG, ATF-2, cJun, cMaf, XBP- 1, ATF-4, leftmost in the Specificity panel of
Figure 3.2A). This indicates measurable interaction specificity on the arrays. For 2 more
designs, fluorescence signal for interaction with the target was only marginally greater
than that for interaction with 1-2 other proteins (targets: ATF-3, C/EBPy). Nine other
designs bound their targets, but less strongly than they bound to members of other
families. For one target family (PAR), the designed peptide did not show detectable
binding above background.
To assess the stability of each design-target interaction, we labelled each native
bZIP target with Cy-3 and probed an array containing 33 representative human bZIP
peptides as well as the anti-target design. This experiment assayed design-target
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stability relative to interactions of the target with its native partner(s). The strongest
signal was often from the design-target complex, indicating that many designs can be
expected to out-compete native partners of the targets, using modest concentrations
(summarized in Figure 3.2A, complete data in appendix B). Less stable designs can
likely be improved through generic strategies such as the addition of acidic extensions,
as for the A-ZIPs (Gerdes, et al. 2006).
To validate the array assay, 28 mixtures involving the 7 best designs were characterized
in solution using thermal denaturation monitored by circular dichroism. Each designed
peptide was tested for interaction with (1) its target, (2) its next-best interaction partner,
as reported by the array, (3) a protein closely related by sequence to the target, and (4)
itself. We monitored whether the mixtures showed an increase in the temperature of
denaturation (Tm) compared to that expected from the average of the signals of the
individual components (Figs 2B-E and Figure B.S3-8). In all cases, the Tm studies
supported binding of each design to its intended target. For the 21 undesired complexes
tested, 18 either showed no evidence for interaction or a Tm that was clearly lower than
that of the design-target complex. For the remaining 3 undesired complexes, formation
of mixtures complicated the analyses, although these are probably also weaker than the
corresponding design-target complexes (Figure B.S4- 6). Solution data were also
examined for consistency with the array measurements and supported the same relative
ordering of stabilities for 35 of 41 comparable cases (see appendix B).
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Figure 3.2. Experimental testing of anti-bZIP designs. A) Peptide array results for the
most specific design identified for each human bZIP family. Columns show experiments
using the indicated protein to probe an array. For the Specificity panel (left), designs in
solution were used to probe human bZIPs and designs on the surface. In the Relative
Stability panel (right), human bZIP targets were used to probe an array containing the
cognate design of each target and 33 human bZIPs. Data are plotted as -log(F/Fmax),
with F the fluorescence signal on the array, such that the strongest interaction has a
value of zero. Values of -log(F/Fmax) above 1.0 were set to 1.0. Thick red circles -
design-target; thin red circles - design interactions with siblings in the target family;
grey squares - interactions with other human bZIPs; black squares - design-design.
Designs are named using the family of their target. B) Solution testing of anti-SMAF
complexes assayed using circular dichroism. In each panel, anti-SMAF alone is shown
with dashed lines, the partner being tested with a solid line, the numerical average of
these two signals with open circles (o) and the mixture of the two peptides with closed
circles (e). (B, C) Anti-SMAF interacts with target MafG (Tm ~ 38 *C). (D) Anti-SMAF
interacts, at most, very weakly with cJun, the closest competitor according to
microarray data. (E) There is no evidence for anti-SMAF interacting with MafB, a
sequence closely related to the target. CD spectra in (B) were collected at 25 *C. Anti-
SMAF unfolds with Tm -12 *C. Similar data for other complexes are included in
Figures B.S3-8.
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Three of our best designs target cJun, cFos, and ATF-2. These proteins are
constituents of the AP- 1 transcription factor complexes involved in cell proliferation
and oncogenesis. The cJun-cJun, cJun-cFos, and cJun-ATF-2 dimers are involved in
these important processes in ways that have not been fully elucidated. Complexes
involving cJun have previously been targeted for disruption using a dominant-negative
A-ZIP version of cFos (Gerdes, et al. 2006). But because cFos also binds ATF-2 and its
family members (Newman and Keating. 2003), the A-ZIP strategy is not as specific as
might be desired. The same is true for cJun and ATF-2: native partners of these targets
also bind to additional families. Attempts to identify new partners for cFos and cJun
using experimental selection strategies gave peptides that strongly self-associated and
also bound bZIPs non-specifically (i.e. the intended anti-cFos and anti-Jun peptides
bound both FOS and JUN family members tightly) (Mason, et al. 2006, Mason, et al.
2007). Our designed peptides provide a way to introduce specificity, e.g. to disrupt
cJun-cFos but not cJun-cJun or cJun-ATF-2, using anti-FOS.
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Figure 3.3. Properties of designed peptides compared to human bZIP leucine-
zippers. A) Hierarchical clustering of interaction profiles for 33 human peptides and 48
designs; an interaction profile consists of the array signals for interactions with 33
surface-bound human peptides. Proteins on the surface are in columns and those in
solution are in rows, with designed proteins and their interaction profiles in blue and
human bZIP interaction profiles in yellow. B), C) Sequence logos for a, d, e, and g
positions from the first 5 heptads of the 33 human bZIP leucine zippers in B) and the 48
designed peptides in C) (http://weblogo.berkeley.edu).
Properties of the anti-bZIP designs
Figure 3.3A shows the interaction profiles of native bZIP leucine zippers and the
designed anti-bZIP peptides. The native proteins exhibit diverse interaction properties,
despite their limited sequence variability (Figure 3.3B)4. The designed peptides are even
more limited in sequence diversity, yet they encode many additional, novel specificity
profiles, suggesting that bZIP-like coiled-coil interaction space is only sparsely sampled
by the human proteins (Figure 3.3C). Based on the frequency of success of our
interaction prediction model, and results from CLASSY analysis, we conservatively
estimate that >1,900 very distinct interaction profiles can be encoded using the
restricted sequence space employed in our designs. This may prove useful for
applications in synthetic biology (see appendix B).
CLASSY designs exhibited canonical bZIP specificity determinants, such as a
preference for Asn residues at a positions to pair across helices, and charge
complementarity at g-to-e' pairs (see Figure 3.1 C for coiled-coil heptad positions; a
prime indicates a residue on the opposite helix, see Figure B.S 15) (Vinson, et al. 2006,
Lupas and Gruber. 2005). Interestingly, g-to-a' pairs were predicted to make a
comparable, if not larger, contribution to specificity than g-to-e' pairs. Other
unanticipated specificity patterns also emerged, involving steric interactions between a
and d' sites (see appendix B for a fuller discussion). The significance of such
interactions has not been broadly recognized in parallel coiled coils, although recent
studies suggest their importance in anti-parallel dimers (Hadley, et al. 2008).
DISCUSSION
CLASSY provides a way to analyze and optimize stability/specificity tradeoffs in
protein design. The CE/ILP procedure imposes few formal requirements on the type of
scoring function that can be used or the type of specificity problem that can be
addressed. However, measuring and predicting interaction specificity for proteins
generally remains challenging. Here, the bZIPs provided several advantages. The bZIP
microarray assay benefits from reversible folding of short coiled coils, and data from
prior array measurements of many bZIP transcription factor pairs were critical for
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developing predictive models (Newman and Keating. 2003, Fong, et al. 2004, Grigoryan
and Keating. 2006). Experimental helix propensities contributed to the quality of these
models, and knowledge of particular specificity determinants (e.g. the special role of
Asn pairs) improved predictions and also disfavoured the formation of higher-order
oligomers (Vinson, et al. 2006). Finally, symmetric fixed-backbone models proved
adequate for this application (Grigoryan and Keating. 2006). This facilitated both
structural modelling and cluster-expansion training, although CE can also be used for
asymmetric structures and with flexible backbones (Apgar, et al. 2009). Further details
about features specific to bZIP modelling are in Methods and appendix B.
Determinants of protein interaction specificity are not yet as well understood for
other complexes, but significant progress in this area is evident. Zinc-finger/DNA,
SH2/peptide and PDZ/peptide complexes have been extensively studied, and both
assays and interaction models have been developed that make these good candidates for
design using CLASSY (see appendix B) (Jones, et al. 2006, Wiedemann, et al. 2004,
Reina, et al. 2002, Sanchez, et al. 2008, Kaplan, et al. 2005). Large-scale interaction
experiments are becoming more common, and general-purpose models to describe
protein structures and energies are under development (Sanchez, et al. 2008, Boas and
Harbury. 2007, Das and Baker. 2008, Zhou and Zhou. 2002). Advances in these areas
will expand the problems that can be addressed using CLASSY. In the long term, we
hope this approach will help address how interaction crosstalk can be controlled in both
evolved and designed protein systems.
METHODS SUMMARY
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Structure-based modelling of coiled-coil interactions was done as previously
described, with modifications detailed in the Methods and appendix B (Grigoryan and
Keating. 2006). Using the technique of cluster expansion, structure-based models were
converted to functions of sequence that included constant, single-residue and residue-
pair terms. Training of the cluster expansion used 61,780 random bZIP-like sequences
that were modelled structurally (Grigoryan, et al. 2006, Zhou, et al. 2005). A limited
amino-acid alphabet was considered, which included the 10 residues most frequently
found at each coiled-coil heptad position in native bZIPs. Constrained optimization
employing integer linear programming (ILP) was used to design a, d, e and g sites. ILP
optimization minimized the energy of design-target complexes, subject to constraints on
the energy gap with respect to undesired complexes and the match of the design
sequence to a position-specific scoring matrix derived from 432 native bZIP leucine
zippers. Other positions in the coiled-coil repeat (b, c and f positions) were chosen to be
consistent with the designed interface a, d, e and g residues, using a probabilistic
framework. For each design target, the ILP optimization was repeated with increasing
values of the specificity gap parameter A, in a procedure termed a specificity sweep.
Sequences for experimental testing were selected manually from candidates generated
using the specificity sweeps.
For experimental testing, His6-tagged peptides were expressed in RP3098 cells
and purified by Ni-NTA followed by reverse-phase HPLC. Coiled-coil microarrays
were printed, processed and probed as described previously (Newman and Keating.
2003). Fluorescence signals from the arrays were processed to remove background and
normalized. Circular dichroism measurements were performed using standard
techniques to measure spectra between 195 and 280 nm at 25 'C or thermal stability by
monitoring ellipticity at 222 nm. Data were fit to appropriate thermodynamic equations
to obtain apparent Tms. Detailed descriptions of all procedures are included in Methods
and Appendix B.
Methods
Modelling bZIP leucine-zipper interactions
Two variants of the previously described energy function HP/S/C were used to
evaluate the relative stability of coiled-coil dimer structures (Grigoryan and Keating.
2006). Models were constructed using a single backbone, with rotameric sampling and
continuous relaxation used to position side chains. HP/S/Ca is the model as published
(Grigoryan and Keating. 2006), with scale factor s = 0 such that intra-chain interactions
in the folded structure do not directly contribute to stability (though there are indirect
contributions). HP/S/Ca replaces core a-a' and d-d' terms derived from structure-based
calculations with weights from a machine-learning algorithm (Grigoryan and Keating.
2006). In the variant model HP/S/Cv, structure-based a-a' interactions were replaced
with a-a' experimental coupling energies for 55 amino-acid combinations (Acharya, et
al. 2006) and the d-d' interaction for Leu-Leu was replaced with the empirical value -2
kcal/mol. Following cluster expansion (see below), a-position point contributions were
adjusted such that 100 folding free energies measured by (Acharya, et al. 2006) were
predicted optimally (in the least squares sense, see Figure B.S10). The following 10
amino acids were allowed: V, L, N, I, K, A, R, T, S, and E for a positions; L, V, I, M,
H, Y, T, A, K, and F for d positions; E, K, R, Q, L, S, T, A, V, and I for e positions; E,
K, Q, R, L, Y, T, D, A, and I for g positions. These are the 10 amino acids most
frequently encountered in the respective positions in bZIPs. Additionally, for the a
position, these are also the 10 amino acids for which Vinson and co-workers have
measured coupling energies (Acharya, et al. 2006).
Cluster expansion
Cluster expansion (CE) provides a way to express the energy of a sequence
adopting a particular backbone structure as an algebraic function of the sequence
itself2 8. The formal basis of the technique is described in the appendix B. In this study,
the desired and undesired structures had the same backbone, and thus one cluster
expansion (for parallel, coiled-coil dimers) was sufficient. CE calculations for both
HP/S/Ca and HP/S/Cv included single-residue and residue-pair terms. A training set
was built by randomly generating 61,780 coiled-coil sequences with heptad position-
specific amino-acid probabilities taken from a multi-species alignment of 432 bZIPs
(personal communication with Mona Singh, Princeton University). Gly and Pro were
not included. Pair contributions were included only for amino-acid pairs s 7 residues
apart, resulting in 9,929 possible effective cluster interactions (ECI): 1 constant, 68
point and 9,860 pair terms. After the fitting procedure, 2,544 and 2,470 ECI survived
the statistical significance test (e.g. lowered the cross-validated error (Grigoryan, et al.
2006)) for HP/S/Ca and HP/S/Cv, respectively. The performance of the resulting cluster
expansions on a similarly generated test set of 10,000 sequences not used in training is
shown in Figure B.S11.
Multi-state design optimization
Design sequences were optimized for interaction with the target using integer
linear programming (ILP), imposing constraints on the design interaction energy with
competitors and a degree of match to a bZIP position-specific scoring matrix (PSSM).
The ILP and PSSM are detailed in the appendix B. We performed two types of
CLASSY calculations. The first, a specificity sweep, starts by using ILP to identify the
design sequence that produces the provably lowest predicted binding energy to a target.
Given this sequence, energy gaps between the design-target dimer and all
design-competitor dimers, including design-design, are calculated as
gap= Edesign:competitor - Edesign:iarse,. The minimal gap (which may be negative) is defined
as A. In the next iteration of the specificity sweep, the design-target energy is re-
optimized, this time imposing constraints to require that all gaps be greater than A + 1
kcal/mol. In each round, A is updated and this procedure is repeated until no more
solutions exist (Figure 3.1A). Designs to be tested are chosen from this list of optimized
sequences, as discussed in the main text.
Anti-bZIP designs were tested in three rounds of microarray experiments. When
we sought to improve upon a previously tested design, we sometimes used experimental
results to formulate biased specificity sweeps. In these calculations, custom offsets were
applied to enhance or diminish the significance of some gaps relative to others; the
remainder of the procedure was identical to that for a standard specificity sweep. For
example, a biased specificity sweep was used to design anti-ZF after the first design
tested (named as anti-ZF-2) interacted with XBP- 1 more strongly than with ZF, contrary
to predictions of the model. This is illustrated and explained further in Figure B.S9.
Table B.S1 contains a list of all designs and the procedures by which they were
obtained, including the details of any biased specificity sweeps employed.
In all CLASSY procedures, except where noted in Table B.Sl, 46 human bZIPs
were considered (sequences take from (Fong, et al. 2004)), and the modelled states were
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as follows: the design-target complex was the only desired state; design-off-target bZIP
complexes for all bZIPs not in the family of the target bZIP were treated as undesired;
the design-design homodimer was also an undesired state.
Further details on the theory behind CLASSY, as well as other computational
analyses performed in this study, are in appendix B.
Choosing 33 representative human bZIPs
To avoid redundancy and conserve resources and time we used a representative
set of 33 human bZIPs that covered all 20 families (see Figure B.S13). Representatives
were chosen based on sequence similarity and reagent availability and described well
the distinct interaction profiles reported by Newman and Keating (Newman and
Keating. 2003). Computational design was nevertheless conducted with 46 human
bZIPs taken from (Newman and Keating. 2003).
Plasmid construction and peptide expression, purification and labelling
Synthetic genes encoding all designs were constructed using DNAWorks
(Hoover and Lubkowski. 2002) to design primers that contained flanking BamHI and
XhoI restriction sites. A two-step PCR method was used to assemble the primers and
the PCR products were digested with BamHI and XhoI and cloned into a modified
pDEST17 vector (Newman and Keating. 2003). All synthetic genes were confirmed to
be correct by sequencing. Plasmids encoding human leucine-zipper peptides have been
previously published in (Newman and Keating. 2003) with the exceptions of modified
Jun family constructs that are described in the appendix B.
Plasmids were transformed into RP3098 cells and 1 L cultures in LB were
grown to 0.4-0.6 OD and induced at 37 'C for 3-4 hours with addition of 1mM IPTG.
Peptides were purified under denaturing conditions (guanidine hydrochloride, GuHCl)
by binding to Ni-NTA resin and eluted with 60% acetonitrile/1% TFA. Following
reduction with 10 mM TCEP in 5% acetic acid for 3 minutes at 65 'C, peptides were
further purified using reverse-phase HPLC. The molecular weights of all designed
peptides were confirmed as correct to within 0.15% by mass spectrometry. To generate
dye labelled-peptides, 10 molar excess of Cy3 NHS ester in 6 M GuHCl/100 mM
phosphate (pH 7.5) was added to lyophilized aliquots of protein and incubated for 2
hours at room temperature. Free dye was removed using size-exclusion spin columns.
Labelled peptides were stored at -80 *C.
Preparation and probing of arrays
Lyophilized aliquots of protein were resuspended to a concentration of 40 gM in
6 M GuHCI/100 mM phosphate (pH 7.5)/0.04% Tween-20/10 pM Alexa Fluor 633
hydrazide. Proteins were printed on aldehyde-presenting glass slides (Thermo Fisher
Scientific) using a Microgrid TAS Arrayer. Twelve identical subarrays were printed on
each slide. Each protein was spotted twice, in two different print orders, for a total of
four spots for each protein per subarray. After printing, slides were divided into
subarrays by drawing a hydrophobic boundary (PAP pen, Electron Microscopy
Sciences). Slides were stored at -80 *C for up to 1 month.
Slides were prepared for probing by: (1) washing face up in -80 *C ethanol for
30 seconds; (2) transferring to 80% ethanol/10 mM NaOH and incubating with shaking
for 15 minutes; (3) washing in H20 for 15 seconds; (4) incubating in PB S/. 1% Tween-
20 for 15 minutes with shaking; (5) drying by centrifugation. Slides were then
immediately probed by diluting labelled peptide in 6 M GuHCl/100 mM phosphate (pH
7.5)/6 mM TCEP 6-fold into 1.2X Buffer (1.2% BSA, 1.2X PBS, 0.12% Tween-20).
The resulting solution was mixed and 35 l was immediately pipetted onto each
subarray. Each sample was probed in duplicate on adjacent subarrays, for a total of 8
spots used to detect each interaction. Slides were covered with a box and incubated for 1
hour. Slides were washed in PBS/0.1% Tween-20 for 15 seconds and then H20 for 15
seconds and were then dried by centrifugation. Slides were scanned using a DNA
Microarray Scanner (Agilent) at several photo-multiplier tube voltage levels. The
concentration of probe was 160 nM unless otherwise indicated.
Additional details on experimental techniques and data analysis are provided in
appendix B.
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CHAPTER 4
A synthetic coiled-coil interactome provides heterospecific
modules for molecular engineering
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ABSTRACT
The versatile coiled-coil protein motif is widely used to induce and control
macromolecular interactions in biology and materials science. Yet the types of interaction
patterns that can be constructed using known coiled coils are limited. Here we greatly
expand the coiled-coil toolkit by measuring the complete pair-wise interactions of 48
synthetic coiled coils and 7 human bZIP coiled coils using peptide microarrays. The
resulting 55-member protein 'interactome' includes 27 pairs of interacting peptides that
preferentially hetero-associate. The 27 pairs can be used in combinations to assemble sets
of 3 to 6 proteins that compose networks of varying topologies. Of special interest are
heterospecific peptide pairs that participate in mutually orthogonal interactions. Such
pairs provide the opportunity to dimerize two separate molecular systems without
undesired crosstalk. Solution and structural characterization of two such sets of
orthogonal heterodimers provide details of their interaction geometries. The orthogonal
pair, along with the many other network motifs discovered in our screen, provide new
capabilities for synthetic biology and other applications.
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INTRODUCTION
The coiled coil is a fundamental building block for molecular engineering. Its
simple structure, which consists of two or more alpha helices twisted into a supercoiled
rod-like bundle, is encoded in a seven amino-acid repeat designated [abcdefg]. Coiled
coils have been used to induce and stabilize protein oligomers, to promote protein-protein
interactions, to rewire cellular networks, to assemble functional scaffolds, to construct
hydrogel materials, and to self-assemble nano-scale fibers and/or recruit ligands to
nanopartices (Bashor, et al. 2008, Diehl, et al. 2006, Eckert, et al. 1999, Papapostolou, et
al. 2007, Takagi, et al. 2001, Wolfe, et al. 2003, Petka, et al. 1998, McAllister, et al.
2008, Mapp, et al. 2000). Important early advances in coiled-coil engineering included
demonstrating that leucine-zipper peptides, which are short coiled coils of -40 amino
acids, can fold to give stable structures composed of two to four helices, and that coiled
coils can be modified using charge patterning to encode heterospecificity and helix
orientation (Mason, et al. 2007). In particular, peptide "Velcro" is a designed
heterospecific coiled-coil dimer with glutamates at all interfacial e and g positions on one
helix and lysines at all e and g positions on the other; this heterodimer and variants of it
have been widely employed in bio-molecular engineering. Further experiments have
illustrated how residues at the hydrophobic interface, particularly those in a positions, can
be mutated to modulate interaction affinity and introduce additional specificity (Acharya,
et al. 2006). Prior studies not only generated reagents that have found many uses, but also
elucidated structural principles that control interaction selectivity (Arndt, et al. 2002,
Moll, et al. 2001, O'Shea, et al. 1993a).
Heterodimeric coiled-coil pairs have proven particularly useful for molecular
engineering (Arndt, et al. 2002, Moll, et al. 2001, O'Shea, et al. 1993c, Lai, et al. 2004,
Diss and Kennan. 2008, Bromley, et al. 2009, Mason, et al. 2006). Exciting recent
applications have included using coiled-coil heterodimers to modulate MAP kinase
signaling in yeast and inducing ordered structure via coiled coils in nano-scale fibers.
Notably, while coiled-coil reagents for inducing homo-oligomerization or hetero-
oligomerization of single complexes are widely used, the modern coiled-coil toolkit does
not provide access to more complex interaction patterns.
Lacking is a large set of coiled coils that participate in specific and defined interactions
with one another. Such reagents could be used to construct interaction networks
containing multiple associations in a logical manner. For example, when engineering
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cellular circuits it might be desirable to implement multiple parallel pathways, each using
coiled coils to direct assembly of signaling complexes without crosstalk. Likewise, to
engineer artificial transcription factors, heterodimers with specified cross-interactions
could provide access to combinatorial control of binding to different DNA sites. For
complex applications such as these, greater versatility is required than is currently
provided by characterized coiled-coil peptides.
RESULTS AND DISCUSSION
We recently reported the computational design of synthetic peptides that interact
with the coiled-coil regions of human bZIP transcription factors. These designed peptides
are 35-54 residues in length and share an amino-acid composition characteristic of bZIP
leucine zippers (Figure C.S 1, Table C.S 1). Homodimerization of the designed peptides
was disfavored by a variety of strategies, and experiments confirmed that most designs do
not form strong self-associations (Grigoryan, et al. 2009b). Speculating that this set of
heterospecific reagents might harbor interesting and useful interactions patterns, we
systematically measured all pair-wise interactions involving 48 designed peptides and 7
additional coiled coils from human bZIPs that do not strongly self-associate.
To identify new heterospecific coiled-coil interactions in a high-throughput
manner, we used a protein microarray assay. A complete 55 x 55 interaction matrix was
generated by spotting small amounts of each peptide onto aldehyde-derivatized slides
(Figure C.S2, Table C.S2). Each of the 55 proteins in turn was labeled with Cy3 dye and
used in solution to probe subarrays printed on the slides. This assay is highly
reproducible and shows good reciprocity with respect to which protein is immobilized
(Figures C.S2 and C.S3). The relative ordering of fluorescence intensities on the arrays
has also been shown to agree qualitatively with solution stability measurements
(Grigoryan, et al. 2009b, Newman and Keating. 2003).
To discover new pairs of hetero-associating coiled coils, the interaction matrix
was examined for peptides that: (1) did not show evidence of homo-association and (2)
made strong, reciprocal interactions with a partner. Interacting and non-interacting pairs
were chosen conservatively based on comparisons of prior array data with solution data.
A total of 27 heterospecific pairs involving 23 synthetic peptides (named SYNZIPs 1-23)
and 3 human bZIPs were selected for further analysis (Figure 4.1).
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Figure 4.1. Array data describing the interactions of 26 peptides that form specific
interaction pairs. Peptides printed on the surface are listed in rows, and fluorescently
labeled peptides in solution are listed in columns. Color indicates the strength of the array
fluorescence signal, given as arrayscore values (see Methods) according to the color bar
at right with 0 (black) indicating the strongest signal and >1 (white) indicating the
weakest. SYNZIP peptides 1-6, which are further described in Figures 4.2-4, are in the
top left corner, boxed in blue. The red diagonal highlights the absence of
homoassociation of peptides on the arrays. Interactions that showed arrayscore 5 0.2 in
both measurement directions are boxed in green. The number of strong, reciprocal
interactions formed by each peptide is listed at bottom of each column.
Coiled coils can vary in their oligomerization state, helix orientation and axial
helix alignment (Grigoryan and Keating. 2008). For the heterospecific pairs uncovered in
this assay to be maximally useful, knowledge of their interaction geometry is important.
The synthetic coil-coiled peptides were designed to interact with individual human bZIPs
as parallel dimers, and we hypothesize that most of the design-design and design-human
complexes detected on the arrays also form parallel dimers. Several lines of evidence
support this. First is the special role of paired a-position asparagines in leucine zippers.
Interaction of an asparagine residue with another asparagine on an opposing helix is
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common in coiled-coil dimers and is much more favorable than an interaction with a
hydrophobic residue (which we term an "Asn mismatch," unless the Asn occurs very
close to the end of the coiled coil) (Mason, et al. 2007, Acharya, et al. 2006). Paired
asparagines at a favor parallel dimer formation and are strongly conserved in the parallel,
dimeric leucine-zipper transcription factors (Mason, et al. 2007, Moll, et al. 2001,
Harbury, et al. 1993). Almost all (23 out of 26) peptides analyzed here contain at least
one Asn residue at a coiled-coil a position, and of the 27 heterospecific pairs considered,
24 can be aligned such that two a-position Asn residues are paired. All heterospecific
pairs can be aligned as parallel dimers without any Asn mismatches (Acharya, et al.
2006). In addition to the role of Asn residues, half of the 26 peptides also include a
charged residue in one or two non-terminal a positions. Lysine in a positions has been
reported to favor dimer formation over higher order oligomerization, presumably because
a positions in dimers are less buried (Mason, et al. 2007, Campbell, et al. 2002); this
likely applies for other charged side chains as well, as is supported by the lower
frequencies of Lys, Arg and Glu residues in a positions of parallel trimers compared to
parallel dimers (K. Gutwin and A. Keating, unpublished data). Additional indirect criteria
support parallel dimer formation. For example, when considered as parallel dimers, all
pairs can be aligned such that net g-e' electrostatic interactions are not unfavorable and
destabilizing (Mason, et al. 2007, O'Shea, et al. 1993b). Finally, none of the
heterospecific interactions encode a motif that has been reported to favor trimer
formation (Kammerer, et al. 2005).
Given 27 heterospecific pairs among 26 peptides that likely form parallel coiled-coil
dimers, we analyzed these to identify higher-order patterns of interaction and non-
interaction. Each of the 26 peptides participates in 1-7 interactions, suggesting that
subnetworks involving more than 2 peptides could be common in our data (Figure 4.1).
We searched exhaustively for all subnetworks containing 3-6 proteins and found
examples of the 10 topologies shown in Figure 4.2A (Table C.S3) (Wernicke and Rasche.
2006). In that figure, an edge indicates a high-confidence observation of an interaction on
the array and the absence of an edge indicates that an interaction was not observed. Most
networks are based on motifs we describe as "pair", "line", or "hub" structures. Many
networks are composed of smaller networks, such as the 4 node "orthogonal pair" (2
pairs with no cross-interactions), "orthogonal triplet" (3 pairs with no cross-interactions)
or the 5 node "pair + line" (similarly with no cross interactions). Interestingly, protein
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nodes in the networks are sparsely connected. It may be that features engineered to
diminish self-association also reduce interaction promiscuity more broadly.
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Figure 4.2. SYNZIP coiled coils form specific interaction subnetworks. (A) Graphical
representation of subnetworks detected in the coiled-coil array data. Edges indicate an
interaction and the absence of an edge between nodes indicates no interaction in the
microarray screen. The orthogonal pair motif is boxed in grey. (B, C) CD spectra for two
pairs of heterospecific coiled coils (4 pM of each protein and 8 pM total for mixtures, 25
*C). (B) SYNZIP2 (blue), SYNZIP1 (red), and SYNZIP2 + SYNZIPl (green). (C)
SYNZIP4 (blue), SYNZIP3 (red), and SYNZIP4 + SYNZIP3 (green). (D, E) Melting
temperatures (Tms) derived from fits to thermal melts of peptide mixtures. T. values for
the interacting pair mixtures are highlighted in green.
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Because of its immediate utility, e.g. for direct extension of existing applications,
we chose the orthogonal-pair motif for further characterization (Bashor, et al. 2008,
Diehl, et al. 2006, Wolfe, et al. 2003). Three coiled-coil pairs were selected that
participate in two sets of orthogonal interactions. All three pairs were evaluated in
solution using circular dichroism (Figure 4.2B and C, Figure C.S4). The six individual
peptides gave only weak helical signal in isolation. But mixing each peptide with its
appropriate partner gave a spectrum characteristic of a coiled coil, confirming
heterospecific interaction. The orthogonal sets that can be constructed from these three
pairs each consist of four peptides that participate in two interactions ('on' states) and
eight non-interactions ('off states). We measured the thermal stabilities of the ten
possible interactions for each set (Figure 4.2D and E, Figure C.S5). The 'on' states had
melting temperatures between 32 and 47 'C, at 8 pM total peptide concentration. For
[SYNZIP6:SYNZIP5, SYNZIPl:SYNZIP2] the difference between the weakest 'on'
state and the strongest 'off state was ~8 'C. For [SYNZIP4:SYNZIP3,
SYNZIPl:SYNZIP2] the difference was -18 'C. (See C.S6 for characterization of an
additional orthogonal set.) Previously published orthogonal coiled-coil pairs are either
much less stable than this, have the property that at least one 'off interactions is more
stable than one 'on' interaction, or incorporate non-natural amino acids (Lai, et al. 2004,
Diss and Kennan. 2008, Bromley, et al. 2009).
To confirm the interaction geometry of complexes composing the orthogonal
pairs, we solved the structures of SYNZIP6:SYNZIP5 and SYNZIPl:SYNZIP2 to 2.5
and 1.8 A, respectively (Figure C.S7, Table C.S4). Both complexes are parallel
heterodimers, as anticipated (Figure 4.3A and B). We were unable to obtain crystals of
SYNZIP4:SYNZIP3. While it is likely that this pair forms a parallel dimer (it includes a-
position Asn and Lys residues and highly charged e- and g-position residues), SYNZIP3
is shorter than SYNZIP4, and the precise axial alignment of its two helices is uncertain.
Either of two Asn residues in SYNZIP4 could be paired with the single a-position Asn in
SYNZIP3, while maintaining a similar extent of coiled-coil dimer. To experimentally
determine the alignment, two truncated versions of SYNZIP4 were generated. Each was
mixed with SYNZIP3, and the thermal stabilities of the resulting complexes were
measured by CD. The N-terminal SYNZIP4 truncation had very similar stability to the
full-length peptide, while the C-terminal truncation was markedly destabilized (Figure
4.3C). Thus, the two most N-terminal heptads of SYNZIP4 are dispensable for the
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interaction. Based on these experiments, helical wheel diagrams were generated for the
three heterospecific pairs (Figure 4.3 D-F).
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Figure 4.3. Interaction geometries for three heterospecific SYNZIP pairs. (A, B) Crystal
structures of SYNZIP5:SYNZIP6 (A) (grey:teal) and SYNZIP2:SYNZIP1 (B)
(orange:green) show that both complexes are parallel coiled-coil heterodimers. (C)
Determination of the axial alignment of SYNZIP4:SYNZIP3 using CD thermal melts.
SYNZIP4 1 54: SYNZIP3 (red), SYNZIP4 142: SYNZIP3, (blue), and SYNZIP415. 54:
SYNZIP3 (green). Each mixture was measured at 8 pM total peptide concentration, 4 p.M
of each peptide. (D-F) Helical wheel diagrams for SYNZIP5:SYNZIP6 (D),
SYNZIP2:SYNZIP1 (E), and SYNZIP3:SYNZIP4 (F). Charged residues are colored
red/blue, polar residues are in green, and hydrophobic residues are in black. Residues
shaded yellow in (D) and (E) correspond to those shown in panels (G) and (H),
respectively. (G) The fourth heptad of SYNZIP5 (residues 23-29):SYNZIP6 (residues 37-
43), and (H) the fourth heptad of SYNZIP2 (residues 23-29):SYNZIP1 (residues 23-29)
are shown in cross-section, as viewed from the N-terminus. A partially buried water
molecule is represented in purple. Crystal structure figures generated using PyMOL
(DeLano Scientific, Palo Alto, CA). Helical wheel diagrams created using DrawCoil 1.0.
(http://www.gevorggrigorvan.com/drawcoil/)
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These experiments suggested that portions of each complex were dispensable for
the formation of orthogonal pairs. To demonstrate that shorter experimentally determined
interaction regions interact specifically, truncated versions of SYNZIPs 1-6 (shown in
Figure 4.3 D-F) were cloned with an N-terminal cysteine. Each protein was labeled with
biotin. SYNZIPs 1 and 2 were also labeled with Alexa Fluor 546, and SYNZIPs 3, 4, 5,
and 6 were labeled with Alexa Fluor 488. For each orthogonal set, each biotinylated
protein was pre-mixed with the three other fluorescent proteins and then incubated with
NeutrAvidin coated beads. These pull-down experiments showed that each biotinylated
protein interacted specifically with its cognate partner (Figure 4.4A and B). Thus, the
shorter peptides are sufficient to form specific interactions in four-component mixtures.
The crystal structures of SYNZIP6:SYNZIP5 (PDB ID 3HE4) and
SYNZIPl:SYNZIP2 (PDB ID 3HE5) reveal interactions involving polar and charged
residues that likely play a role in encoding specificity. Both structures include paired
asparagines at a-a' positions that adopt conformations seen frequently in other parallel
coiled-coil dimers. Neither structure contains any asparagine mismatches at non-terminal
heptad positions, although both have mismatches at the extreme N-terminal heptad. At
that position, asparagine is paired with valine but remains largely solvent exposed due to
its location at the end of the helix. In the SYNZIP6:SYNZIP5 complex, in both the fourth
and fifth heptads, Lys at a across from Ile interacts with an aspartate at the proceeding g'
position (Figure 4.3G). In the SYNZIPl:SYNZIP2 complex, the fourth heptad contains a
complex polar network involving a partly buried water molecule. The water is
coordinated by SYNZIP1 residues Asn 24 at a and Lys 27 at d, as well as by SYNZIP2
residue Glu 24 at a'. In the 3 copies of the heterodimer in the asymmetric unit, Lys 23 at
g on SYNZIP1, as well as Gln 25 at b' and Glu 28 at e' on SYNZIP2, are involved to
varying degrees in this extended network (Figure 4.3H). These interactions suggest that
charged residues in coiled-coil core positions can contribute specificity in parallel dimers,
although such residues may be accommodated in ways that are difficult to anticipate, as
illustrated here by incorporation of a water molecule.
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A
Input Beads only Biotinylated protein:
1 2 3 4
1: + - - - - + + + - + + +
2:- + - - + - + + + - + +
3: + - + + - + + + - +
4: - + + + + - + + + -
546
4881 00*
B
Input Beads only Biotinylated protein:
1 2 5 6
1: + - - - - + + + - + + +
2: - + - - + - + + + - + +
5: + - + + - + + + - +
6: - + + + + - + + +
546
488
Figure 4.4. Biotin pull-down assay demonstrating specific interactions in each orthogonal
set. (A, B) SYNZIPs 1 and 2 were labeled with Alexa Fluor 546 and SYNZIPS 3, 4, 5,
and 6 were labeled with Alexa Fluor 488. Input lanes show each protein run individually.
The beads-only lanes shows mixtures of the indicated fluorescent proteins incubated with
NeutrAvidin beads. The biotinylated-protein lanes show mixtures of the 3 indicated
fluorescent proteins (4 pM each) mixed with the indicated biotinylated protein at 4 pM,
then incubated with NeutrAvidin beads. The two fluorescent channels 546 nm (top) and
488 nm (bottom) are indicated. (A) SYNZIP pairs 1-2 and 3-4. (B) SYNZIP pairs 1-2 and
5-6.
It is interesting to speculate about how specificity in the orthogonal sets is
determined. The simple ACID-BASE charge repulsion strategy used in peptide "Velcro"
is not sufficient to encode complex interaction patterns in coiled coils only -40 amino
acids long. How are so many different 'off states disfavored? Using a simple model, 5 of
the 14 'off pairs among the two orthogonal pair sets have net repulsive electrostatic
interactions at g-e' positions, when considered as parallel dimers. Unavoidable Asn
mismatches appear in an additional 2 pairs. In the remainder, charged residues at a and d
positions appear important, with a-position Lys and Glu residues disfavoring
homodimerization, and repulsive charges at g-a' and d-e' pairs disfavoring both homo-
and heterodimers (Acharya, et al. 2006). All of these interactions are implicated as useful
and important negative design features. In terms of improving specificity, if this is
required, we stress that the undesired complexes that form are weak and are not
necessarily parallel dimers.
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The orthogonal pairs introduced here dramatically increase the number of small,
heterospecific protein-protein interaction partners that can be used as modular
components for molecular engineering (Bromley, et al. 2008). The peptides can be over-
expressed in Escherichia coli, contain aromatic amino acids for quantification using
spectrometry and lack cysteines. While most of these peptides do partner with human
bZIPs, they are likely to be effective for applications in yeast or bacteria, where human
orthologs are absent, as well as in vitro and for materials applications. These reagents, or
molecular parts, are also likely to be useful when paired with other types of synthetic or
native interaction domains such as zinc fingers (Giesecke, et al. 2006). It is reasonable to
consider using them to design novel transcription factors that do not cross-interact, or to
elaborate molecular scaffolds (Bashor, et al. 2008, Wolfe, et al. 2003). Finally, the large
number of interactions measured in the course of characterizing these peptides will be
useful for testing computational models and further understanding the interaction
specificity of "simple" coiled coils.
METHODS AND MATERIALS
Plasmid construction, protein expression and purification
Proteins used in the array experiments were cloned, expressed and purified as
published previously (Grigoryan, et al. 2009a). For solution studies and crystallography,
genes were cloned into pSV282 (Vanderbilt University Medical Center, Center for
Structural Biology) using BamHI and XhoI restriction enzymes (NEB). For the pull-
down assays, synthetic genes for truncated peptides including an N-terminal cysteine and
a short linker (GSCGS) were cloned based on experimentally determined alignments.
SYNZIP6 was mutated at a c-position lysine to include a tyrosine for concentration
determination. Each plasmid was transformed into RP3098 cells and 1 L cultures in LB
were grown to 0.4-0.6 OD and induced at 37 'C for 3-4 hours with the addition of 1mM
IPTG. MBP fusion proteins with a His6 tag were purified under native conditions by
binding to Ni-NTA resin (Qiagen) and eluting with 8 ml elution buffer (300 mM
imidazole, 20 mM Tris, 500 mM NaCl, 1mM DTT, pH 7.9). Fusion proteins were then
dialyzed overnight at 4 'C in TEV cleavage buffer (50 mM Tris, 50 mM NaCl, 1 mM
DTT, 0.5 mM EDTA, pH 7.5). Peptides were cleaved from MBP by incubating with 100
pl TEV protease (1mg/ml) for 3 hours at room temp. After cleavage, the mixture was
added to Ni-NTA resin and the flow through was collected. In the case of SYNZIP2, the
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peptide bound the Ni-NTA resin after cleavage. SYNZIP2 was eluted from the resin with
6 M guanidine-HCl and the elute was then dialyzed into water. Peptides were additionally
purified using reverse-phase HPLC and lyophilized. The molecular weights of the
peptides were confirmed by mass spectrometry. Protein concentrations were determined
using the Edelhoch method (Edelhoch. 1967) of UV absorbance at 280 in 6 M guanidine-
HCl/100 mM sodium phosphate pH 7.4. Protein and DNA sequences are listed in Table
C.Sl.
Coiled-coil array assay
All array experiments were carried out as previously published (Grigoryan, et al.
2009b), with the exception that only two spots for each protein were printed per subarray,
for a total of 8 measurements of each heteromeric interaction. Briefly, lyophilized
proteins were resuspended to a concentration of 40 jM in 6 M guanidine-HCl/l 00 mM
sodium phosphate pH 7.5/0.04% Triton X-100/10 p.M Alexa Fluor 633 hydrazide.
Proteins were printed on aldehyde-derivatized glass slides and 12 identical subarrays per
slide were physically divided by drawing a hydrophobic boundary. Slides were blocked,
and then each subarray was probed with Cy3 -labeled proteins diluted six-fold from 6 M
guanidine-HCl/100 mM sodium phosphate pH 7.5/6 mM TCEP to a concentration of
-160 nM in 1.2X buffer (1.2% BSA, 1.2X PBS, 0.12% Tween-20). Slides were then
washed, dried, and scanned to obtain fluorescence values for each spot. Average
background-corrected fluorescence values are listed in Table C.S2.
Data analysis
For each peptide pair, fluorescence intensities for the 4 replicate spots
corresponding to the same surface/solution arrangement were corrected for background
and then averaged. Averages were corrected further by subtracting the median signal for
all proteins on the surface interacting with the same solution probe; this gave a value F.
The quantity arrayscore was calculated by taking -log(F/Fma) where Fm, was the
maximum F value for a given solution probe. To identify heterospecific pairs, a strict
criterion was employed by comparing arrayscore values to Tm measurements of
previously published data (Grigoryan, et al. 2009b). Non-interactions were required to
have arrayscore > 1, which corresponds to an average Tm of 14 'C (based on 13
comparisons). Interactions were required to have arrayscore < 0.2, which corresponds to
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an average Tm of 43 'C (based on 7 comparisons). These same criteria for interactions
and non-interactions were employed to identify subnetworks when using Fanmod
(Wernicke and Rasche. 2006) to search for all possible 3-6 node networks. Motifs are
listed in Table C.S3.
Circular dichroism
Circular dichroism spectra were measured on an AVIV 400 spectrometer in 12.5 mM
potassium phosphate (pH 7.4)/150 mM KCi. Individual measurements were made at 4
ptM peptide or 4 [.M of each peptide (8 p.M total peptide) for mixtures. All measurements
were made in a 1 cm cuvette. Mixtures of peptides were incubated for several hours at
room temperature before measurement. Spectra were measured at 25 'C. Wavelength
scans were monitored from 280 nm to 195 nm in 1 nm steps, averaging for 5 seconds at
each wavelength. Three scans for each sample were averaged. Thermal unfolding curves
were performed at 4 pM peptide for individual measurements or 4 p.M of each peptide (8
p.M total peptide) for mixtures and measured in a 1 cm cuvette with stirring. Melting
curves were determined by monitoring ellipticity at 222 nm with an averaging time of 30
seconds, an equilibration time of 1.5 minutes, and a scan rate of 2 'C/min. All samples
were measured from 0 to 85 'C. Tm values were estimated as reported previously
(Grigoryan, et al. 2009b). All thermal denaturations were reversible, with differences in
Tm values upon folding vs. unfolding of < 2*C for all but 2 weak complexes, and < 5 'C
in all cases.
For a third orthogonal set of coiled-coil heterodimers, a slightly modified CD
protocol was employed. The CD spectra in Figure 4.S6 were measured on an Aviv Model
202 spectrometer in 12.5 mM potassium phosphate (pH 7.4)/150 mM KCl. Individual
measurements were made at 40 p.M peptide and mixtures at 20 pM of each peptide, 40
p.M total peptide. Mixtures of peptides were incubated for several hours at room
temperature before measurement. Spectra were measured at 25 'C. Wavelength scans
were performed in a 0.1 cm cuvette and were monitored from 260 nm to 195 nm in 1 nm
steps averaging for 5 seconds at each wavelength.
Crystallography
Purified lyophilized protein was re-suspended in water to a concentration of 20
mg/ml and mixed to give 20 mg/ml of each complex. Crystals were grown by the hanging
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drop method at room temperature by mixing 1 pil protein solution with 1 il of reservoir
solution. SYNZIPl:SYNZIP2 was grown in 45% MPD, 100 mM Tris pH 8.0, and 160
mM ammonium acetate. SYNZIP6:SYNZIP5 was grown in 100 mM Tris pH 8.2 and
20% MPD. Crystals were frozen in LN2 without addition of any cryoprotectant.
Diffraction data were collected at 100K on a Rigaku MicroMax007-HF with VariMax-
HR optics and a RAXIS-IV detector (SYNZIPl: SYNZIP2) or at the NE-CAT 241D-E
beam line of the Advanced Photon Source (SYNZIP6:SYNZIP5) and processed using
HKL2000 (Otwinowski, et al. 1997). Both structures were solved by molecular
replacement using PHASER (McCoy, et al. 2005). In each case the search model was
derived from a single energy-minimized theoretical model selected from an ensemble of
models spanning the space of parameters of native parallel dimeric coiled-coil structures.
The ensemble was generated as previously described (Apgar, et al. 2008). The search
models had no overhangs and the side chains at all non-interfacial positions (b, c, and f)
were truncated to alanine. Model building was done using COOT (Emsley and Cowtan.
2004, Adams, et al. 2002) using twin law corrections for both structures (Table C.S4).
Non-crystallographic symmetry (NCS) restraints between the four copies of the
heterodimer in the asymmetric unit (ASU) of the SYNZIP6:SYNZIP5 crystals were used
to aid in the refinement of that structure. Geometry was checked using MOLPROBITY
(Davis, et al. 2007) and no outliers were identified (Table C.S4). Figures of structures
were generated using PyMol (DeLano Scientific, Palo Alto, CA).
Pull down assay
Proteins containing a unique N-terminal cysteine were labeled by mixing 100 piM protein
with 0.5 mM Alexa Fluor 488 or 546 maleimide (Invitrogen) or 2 mM maleimide-
PEG 1 -biotin (Thermo Scientific) in 100 mM potassium phosphate pH 7.0/150 mM
KCl/l mM TCEP. Solutions were incubated for three hours at 18-22 'C. Free dye or
biotin was removed using desalting spin columns (Thermo Scientific). Biotinylated
proteins were concentrated using centrifugal filter units (Millipore). The concentration of
unlabeled and biotinylated proteins was determined using the Edelhoch method. The
concentration of dye labeled proteins was estimated by assuming a 50% recovery after
desalting. Each dye labeled protein was mixed with the unlabeled version (at known
concentration) in a 1:10 ratio. 400 pmoles of ea.ch protein indicated in Figure 4.4 were
mixed in 75 pl binding buffer (12.5 mM potassium phosphate pH 7.4, 150 mM KCl, 1
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mM DTT, 1% BSA, 0.1% Tween-20). Protein mixtures were incubated for 1 hour at 18-
22 'C and then 50 pl of a 50% slurry of NeutrAvidin beads (Thermo Scientific) in
binding buffer was added. Mixtures were incubated for 2 hours at 18-22 'C with rotation.
Beads were then washed 3 times with 1 ml binding buffer at 4 'C and mixed with 100 pl
of loading buffer (10 % glycerol, 2% SDS, 100 mM DTT, 0.0 1% bromophenol blue, 100
mM Tris pH 6.8). Following heating at 65 'C for 15 minutes, 10 pl of each sample was
loaded onto an 18% Tris-glycine gel (Invitrogen). Gels were imaged on a Typhoon 9400
imager. Fluorsep software (Amersham Biosciences) was used to remove background
fluorescent overlap.
Sequence analysis
Positions a-g in the coiled-coil heptad repeat were assigned manually, as designed
previously (Grigoryan, et al. 2009b), based on conserved Leu residues and overall
hydrophobic/polar patterning. Each peptide contains 5-7 full heptads. The following
criteria were applied for sequence analysis. To predict the most probable alignments of
coiled-coil dimers, all possible helix alignments that overlapped by at least 5 full heptads
and did not contain an asparagine mismatch were considered. Asparagine mismatches
were defined as an Asn residue at a non-terminal a position across from isoleucine, valine
or leucine at a non-terminal a position. A terminal a position was defined as an a position
< 3 residues from the end of the coiled coil. For assessing g-e' electrostatics, the least
repulsive alignment of> 5 heptads that did not contain an asparagine mismatch was used.
For this purpose, each attractive g-e' interaction was scored as + 0.5 and each repulsive
g-e' interaction was scored as -0.5. Negatively charged glutamate and aspartate, and
positively charged lysine and arginine were considered during scoring. Note that Glu,
Lys, Arg and - to a lesser extent - Asp overwhelmingly predominate at g and e positions
of the 26 peptides considered (Table C.Sl).
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Chapter 5
Conservation and rewiring of bZIP protein-protein interaction
networks
A modified version of this chapter will be submitted for publication with Aaron W. Reinke, Judy
Baek, Orr Ashenberg and Amy E. Keating as authors.
Collaborator notes:
Judy Baek cloned genes, purified proteins, and measured interactions. Orr Ashenberg developed
ODE models for fitting binding curves to the data.
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ABSTRACT
Molecular functions such as protein-protein interactions are often conserved throughout
evolution, but it is unclear when and how frequently changes to interactions occur. Knowing how
protein-protein interaction specificity evolves is important for understanding how changes in
interactions can lead to changes in phenotype. To study the conservation of protein-protein
interaction networks, bZIP transcription factor protein-protein interaction networks were
measured for 5 metazoan and 2 single-cell species. The metazoan interaction networks displayed
broadly similar interaction properties that were distinct from the single cell species. A core
network of interactions was observed in the 5 metazoan species. This network was diversified in
each species, both through rewiring of interactions between conserved proteins as well as the
addition of new proteins and interactions. A cross-species interaction network including proteins
from C. intestinalis and human revealed that several proteins have highly conserved specificity
profiles, though for others, there are distinct changes in interactions. Minor sequence changes
were identified that could exert major changes on interaction profiles. These results indicate that
the bZIP interaction domain is flexible in its ability to evolve and rewire interactions.
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INTRODUCTION
Molecular changes drive phenotypic diversity throughout evolution. Differences in
transcriptional regulation have been shown to be major contributors to developmental and
cellular outcomes (Carroll. 2008). While much emphasis has been placed on changes to cis
regulatory elements, it is unclear what impact mutations in transcription factors can have on gene
regulation. Several recent studies suggest that changes to the molecular function of both protein-
DNA and protein-protein interactions are more common than previously assumed. For example,
the DNA-binding specificity of some transcription factors has been demonstrated to diverge
extensively, coevolving with cis regulatory elements (Kuo, et al. 2010, Baker, et al. 2011).
Different alleles of the human zinc finger protein PRDM9, which is involved in specifying
hotspots in meiotic recombination, have different DNA binding specificities (Baudat, et al.
2009). An interaction between the transcription factors HoxAl 1 and Foxola evolved regulatory
changes outside the interaction interface (Brayer, et al. 2011). Mutations to a phosphorylated
regulatory site of the bZIP transcription factor CEBPB are responsible for changing the protein
from a repressor to an activator upon phosphorylation (Lynch, et al. 2011). Some orthologs of
human and Caenorhabditis elegans PDZ domains also show differences in binding specificity
(Tonikian, et al. 2008). These studies suggest that biochemical functions of orthologous proteins
are not necessarily conserved (Dickinson, et al. 2011).
The basic-leucine zipper (bZIP) proteins are a large class of transcription factors present
in most eukaryotes. These proteins can form both homodimers and heterodimers, and the
complex that forms influences the DNA sites that can be bound. The bZIP proteins provide an
ideal system to study the evolution of interaction specificity. Fourteen bZIP families are
conserved as far back as cnidarians, and bZIPs form a closed interaction network, allowing
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potential partners to be identified by sequence (Amoutzias, et al. 2007). Interactions for the
human network have been previously reported and models have been developed that can predict
interactions with good, but limited accuracy (Grigoryan and Keating. 2006, Newman and
Keating. 2003).
Though families of bZIP proteins are conserved throughout metazoan evolution, it is
unclear if their interactions are. To address this question, we report quantitative in vitro
measurements of bZIP protein-protein interaction networks from 7 species. These networks
reveal that while a conserved set of interactions exists, extensive expansion and rewiring of the
bZIP protein-protein interaction network has occurred, especially in humans compared to simpler
metazoans.
RESULTS
Measurement of bZIP protein-protein interactions
We measured the bZIP protein-protein interaction networks of seven species. The species
were selected based on evolutionary position and their status as established or emerging model
organisms. They include 5 metazoan species: human, sea squirt (Ciona intestinalis), fruit fly
(Drosophila melanogaster), nematode (Caenorhabditis elegans), and sea anemone (Nematostella
vectensis). Also included were two single-cell organisms, choanoflagellates (Monosiga
brevicollis), the closest sister group of metazoans, and the yeast (Saccharomyces cerevisiae).
There are 21 bZIP families in humans. 18 of these families are conserved in C. intestinalis. 14 of
them occur in the last common ancestor of human and sea anemone. There are an additional 4
families that arose through duplication after the divergence of sea anemone. Both M brevicollis
and S. cerevisiae have only a few of the 14 metazoan ancestral families, indicating the majority
of the metazoan ancestral families appeared at the emergence of metazoans. Each species also
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has a number of novel families that are not conserved with any of the other species examined
(Figure 5.1A, Figure 5.2, and Table 5.1).
A Homo sapiens 53(18)
Ciona intestinalis 26(18)
Drosophila melanogaster 27(16)
Caenorhabditis elegans 26(13)
Nematostella vectensis 35(14)
Monosiga brevicollis 22(8)
Saccharomyces cerevisiae 15(4)
B
is
D E
Figure 5.1. Characteristics of bZIP protein-protein interaction networks from 7 species.
A, Evolutionary tree of studied species. After each species name the number of bZIPs in that species is
given, with the number of families in parentheses. B-D, Species abbreviations are as follows: HS,
Human; CI, C. intestinalis; DM, D. melanogaster; CE, C. elegans; NV, N. vectensis; MB, M brevicollis;
and SC, S. cerevisiae. B, Percentage of possible interactions observed with different affinities in each
network. C, Histogram of the connectedness of each network. D, Frequency of heterodimeric vs.
homodimeric interactions in each network. E, Relationship between conservation and interaction affinity.
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N. vectensis (14) C elegans (13) D. melanogaster (16) C intestinails (18) Human (18)
g.000
Figure 5.2. The bZIP family repertoire of each species.
The number of family in each species is indicated in parentheses. Circles represent bZIP families with the
name of each family given along with the number of family members. Green circles, ancestral families.
Blue circles, families conserved in at least 2 species. Red circles, novel families.
Interactions between bZIP proteins were quantified in vitro using a solution-based FRET
assay. Each protein was expressed, purified and labeled with a small molecule fluorophore. Two
versions of each bZIP were generated, either with an acceptor or donor fluorophore. Acceptor-
labeled proteins were titrated at - nM to 1 pM into 10 nM donor-labeled protein. Binding
curves were measured at 21 OC and equilibrium dissociation constants were determined (see
Methods). In humans there are 53 bZIPs, many of which are highly similar. 36 were selected that
represent all families and cover most of the human bZIP sequence diversity. For the remaining
species all possible pairwise interactions between bZIPs were measured. Each heteromeric
interaction was measured twice, as each donor-labeled protein was measured against each
acceptor-labeled protein; mostly similar affinities were observed for both measurements. The
data was also highly reproducible (Figures 5.3), and the data for human proteins compared well
to a previous array study (Newman and Keating. 2003).
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Figure 5.3. Reproducibility of measured bZIP interactions. Data are presented as a heat map with
the strength of interaction indicated by the scale at the bottom. A, B, Two independent
measurements of interactions among 21 human proteins.
Properties of bZIP interaction networks.
Interactions in each species were observed over a range of affinities, with the human
network the densest (Figure 5.1B, Figures 5.4-10, and Table 5.2). The human network also had
the most highly connected proteins, with choanoflagellates and yeast having the least connected
networks (Figure 5.1C). The majority of proteins in each network were capable of forming
homodimers and the majority of possible heterodimers were not observed. However, the number
of possible heterodimers in each network is much greater than the number of possible
homodimers. Thus, for the 5 metazoan species the interaction networks are composed of mostly
heterodimers. Interestingly, yeast shows the opposite composition, with the majority of the
network being composed of homodimers. The choanoflagellates network is composed of an
approximately equal number of homodimers and heterodimers (Figure 5.1D).
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For further analysis interactions were compared at the family level (see Methods). There
are three categories of interactions; those that are always conserved in all species, those that
interact in some organisms but not others, and those that occur in only one organism and thus are
not conserved. Interestingly, the majority of conserved interactions were of high affinity and the
majority of non-conserved interactions were of weaker affinity (Figure 5.1E). We compared how
conserved each metazoan network was with each other network, and the overlap of interactions
ranged from -25% to -75% (Figure 5.11).
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Figure 5.4. Human bZIP interaction network.
Data are presented as a heat map with the strength of interactions indicated by the scale at the
right.
145
Family
CEBPG
CEBP
CEBP
CEBP
CREB
OASISA
OASISB
,EP1
,BP1
XBP1
)BP1
ATF6
NFIL3
PAR
ATF2
JUN
FOS
FOS
ATF4
ATF3
SMAF
LMAF
NFE2
BACH 1
NOVE L
NOVEL
Protein
C11
C12
C13
C14
C15
C16cis
Ci7
Clo
C1111
C112
C113
C114
C115
C116
C118
Cit9
C120
C121
C122
C123
CM24
C125
Cl126
Figure 5.5. C. intestinalis bZIP interaction network.
Data are presented as a heat map with the strength of interactions indicated by the
right.
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Figure 5.6. D. melanogaster bZIP interaction network.
Data are presented as a heat map with the strength of interactions indicated by the scale at the
right.
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Figure 5.8. N. vectensis bZIP interaction network.
Data are presented as a heat map with the strength of interactions indicated by the scale at the
right.
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brevicollis bZIP interaction network.
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Figure 5.10. S. cerevisiae bZIP interaction network.
Data are presented as a heat map with the strength of interactions indicated by the scale at the
right.
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Figure 5.11. Comparison of interaction networks between species.
The percentage overlap of interactions between each pair of species (see methods).
Conservation and rewiring of bZIP interaction networks
Our data indicate that the extant bZIP interactions networks are the result of both
rewiring interactions among a set of ancestral families as well as the addition of new bZIP
families. To compare how metazoan interactions changed over time, we used considerations of
parsimony to infer a bZIP interaction network for the last common ancestor of metazoans (See
Methods). This network is composed of the 14 ancestral metazoan families and contains 10
homodimeric and 9 heterodimeric interactions (Figure 5.12A). Compared to this ancestral
network, several gains and losses occurred in N. vectensis and C. elegans, and a large number of
interactions were lost in D. melanogaster (Figure 5.12B-D). In the higher species, human and C.
intestinalis, a much larger number of changes occurred, and many new interactions were
introduced. Many of the gains of interactions were observed with the four-member XBP 1 family
in C. intestinalis and the two-member ATF4 family in human (Figure 5.12E, F). The 4 families
that arose from duplication of ancestral families (CEBPG-CEBP, PAR-NFIL3, FOS-ATF3, and
NFE2-BACH) also led to diversification of the networks by adding additional partners and
interactions. These duplicated families often maintained many of the same interactions, but also
changed to add additional partners (Figure 5.13). Finally, novel families arose that interact with
many of the conserved families (Figure 5.14). Taken together, rewiring of interactions among
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ancestral proteins, the addition of conserved duplicated families, and the introduction of novel
families has allowed each species to evolve a highly distinct bZIP interaction network (Figure
5.15).
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Figure 5.12. Rewiring of metazoan bZIP interactions networks.
A-F, Interactions involving proteins in the 14 ancestral families. Green circles, extant families.
Grey circles, lost families. Black lines, inferred ancestral interactions. Red lines, gained
interactions. Grey lines, lost interactions. A, Inferred ancestral network B, N. vectensis. C, C.
elegans. D, D. melanogaster. E, C. intestinalis. F, Human. Graphs created using Cytoscape
(http://www.cytoscape.org/).
153
04I
04I
NV CE
0
DM
0 C HS
0 0
* . 0
.0 0 0
Figure 5.13. Interactions of CEBPG and CEBP families following the CEBPG-CEBP
duplication.
Green circles represent ancestral families, blue circles show CEBP. Black lines are interactions
with CEBPG and red lines are interactions with CEBP. Species abbreviations are the same as in
Figure 5.1. Graphs created using Cytoscape (http://www.cytoscape.org/).
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Figure 5.14. Interactions of novel bZIP families show extensive connections to conserved
families.
Data are presented as in Figure 5.3.
NV DM
Figure 5.15. Origins of interactions in extant bZIP interaction networks.
Blue, ancestral interactions. Red other conserved or partially conserved interactions. Green, new
interactions. The total number of interactions that occur in each species between conserved
families is in the middle of each chart. Species abbreviations are the same as in Figure 5.1
Evolution of bZIP interaction profiles
When an interaction is gained or lost, it difficult to know which interaction partner was
responsible for the change. To pinpoint the mechanism of how interactions change between
orthologs, proteins must be profiled against a common set of partners. Towards this end, we
measured 32 human bZIPs against 24 C. intestinalis bZIPs. The resulting interspecies interaction
network revealed 5 families with highly similar interaction specificity profiles in each species
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(Figure 5.16). The remaining families showed differences in specificity to varying degrees.
These data allow identification of which partners change their specificity. For example, ATF4
from human interacts with ATF2 from both species, but C. intestinalis ATF4 doesn't interact
with either ATF2. This indicates that C. intestinalis ATF2 is competent to interact with ATF4,
but there are changes in the C. intestinalis version of ATF4 that prevent the interaction from
occurring (Figure 5.17). For roughly half the cases where differences of interaction occur
between the two species, there are changes in both partners, and for the rest there are changes in
just one partner (Figure 5.16). This suggests that there is flexibility in bZIPs to evolve their
interactions, by adding new partners while maintaining existing ones.
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Figure 5.16. C. intestinalis and Human interspecies bZIP interaction network.
32 Human bZIPs measured against 24 C. intestinalis bZIPs. Data presented as in Figure 5. 3.
Human proteins are in black and C. intestinalis are proteins in red.
Of particular interest is the ATF4 family, where a large number of interactions occur in
human but not in C. intestinalis. In humans there are two ATF4 family proteins ATF4 and ATF5;
ATF4 has a very promiscuous interaction profile while ATF5 is much more specific. The C.
intestinalis ATF4 is similar in interaction specificity to ATF5 but not ATF4 (Figure 5.17). We
also measured ATF4 from sea anemone and zebra fish (Danio rerio) against the human proteins.
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Zebra fish ATF4 has similar specificity to human, indicating that the change happened before the
last common ancestor of human and zebra fish. Sea anemone also is more similar in interaction
specificity to human ATF4 than to C. intestinalis, though many of the strong interactions are
with protein families that don't occur in N. vectensis. As a result N. vectensis ATF4 has more
interactions with human and C. intestinalis proteins than it has in its own species (Figure 5.17).
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Figure 5.17 ATF4 family interaction specificity.
ATF4 proteins from human, C. intestinalis, D. rerio, and N. vectensis were measured against proteins
from human and C. intestinalis. Data are presented as a heat map with the strength of interaction indicated
by the scale at the right. Human proteins are in black and C. intestinalis are proteins in red.
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Negative selection has been proposed by Lim and coworkers as an important means of
ensuring specificity in interaction networks (Zarrinpar, et al. 2003). They observed for SH3
ligand Pbs2 that intraspecies interactions were more specific while interspecies interactions were
more promiscuous. We do not observe the same trend in our data. Although there are interactions
in the human-C. intestinalis interspecies network that do not occur in either of the intraspecies
networks, the total number of interactions is less than in either intraspecies network (Figure
5.18). This could indicate that negative design is not a prominent force in shaping bZIP
interaction networks. Alternatively, negative design that reduces promiscuity in intraspecies
networks could work globally to reduce non-specific interactions.
Interaction network comparison
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Figure 5.18. Characteristics of the Human, C. intestinalis, and interspecies interaction networks.
Fraction of possible interactions of different affinities in each species' network. Blue, Human.
Red, C. intestinalis. Green, Human- C. intestinalis cross-species network. Purple, average of
Human and C. intestinalis interactions.
The relationship between sequence and interactions for bZIP paralogs is complex. There
are instances where small numbers of sequence changes lead to large differences in interaction
specificity, and conversely cases where large numbers of sequence changes do not significantly
alter interaction specificity. There is at best only a very weak correlation between sequence
identity and the conservation of an interaction (Figure 5.19). For orthologs, sequence
conservation >80% did correlate with higher conservation, but any trend at lower sequence
identity was very weak (Figure 5.20). Based on what is known about determinants of coiled-coil
interaction specificity (Vinson, et al. 2006), we investigated the detailed origins of certain
specificity changes.
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Figure 5.19. Sequence identity at the coiled-coil interface vs. interaction similarity of paralogs.
Each point is a comparison between paralogs in the same species (see Methods).
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Figure 5.20. Sequence identity at the coiled-coil interface vs. interaction similarity of orthologs.
Each point is the average percentage of conserved interactions in each sequence identity bin (see
Methods).
The PAR family in C. elegans contains several family members with different interaction
specificities (Figure 5.13). One member of the family, Y51H4A.4 contains an asparagine at an a
position where the others do not (Figure 5.21A). Asparagines at a positions have been shown to
be highly destabilizing when positioned across the interface from hydrophobic amino acids, but
not when pairs with asparagines (Acharya, et al. 2006). We mutated the asparagine in Y5 1 H4A.4
to alanine, which is the residue found at the same position in ces-2; we also made the reverse
alanine-to-asparagine mutation in the ces-2 protein. These changes led to a switch in specificity
(Figure 5.21B).
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A similar result was observed for PAR family proteins in D. melanogaster (Figure 5.22).
A second mechanism proposed to destabilize interactions is packing multiple amino acids
branched at the beta carbon (e.g. valine or isoleucine) into the core of the coiled-coil interface
(Grigoryan, et al. 2009). In humans, the ATF4 family member ATF5 has two consecutive d
position valines, which are leucines in ATF4. Both paralogs also have an isoleucine at the
following a position (Figure 5.21 A). To test whether these differences contribute to ATF5
having a much more specific interaction profile than ATF4, we mutated the valines to leucines in
ATF5, and made the reverse mutations in ATF4. This conferred an ATF-4 interaction profile on
ATF5, and the ATF4 mutant also became very ATF5 like (Figure 5.21C). Mutations were also
tested to switch specificity between orthologs of human and C. intestinalis. These either only
subtly changed interaction specificity or led to changes of specificity in one of the orthologs, but
not the other (Figure 5.23). Overall, these examples highlight the plasticity of the bZIP
interactome, which can be rewired with only modest sequence changes.
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Figure 5.21. Switching interaction profiles between bZIP paralogs.
A, Sequences of PAR family proteins in C. elegans (top) and ATF4 family proteins in human (bottom).
Interface positions are in blue and mutated residues are in red. B, C, Heat maps of interaction data, plotted
in the same way as in Figure 5.3. Columns one and three are the wild-type proteins. Column two is the
mutant version of column three, and column four is the mutant version of column one. Mutants are named
by wild-type residue at the heptad number and position followed by the mutant residue. B, PAR family
mutants in C. elegans C, ATF4 family mutants in human.
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Figure 5.22. PAR family mutants in D. melanogaster.
Data presented as in Figure 5.21. A, Sequences of PAR family proteins in D. melanogaster
B, PAR family mutants in D. melanogaster. Data are presented as a heat map.
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DISCUSSION
The biochemical measurements in this study uncover interactions that do not necessarily
occur in vivo. Further, interactions were assayed in the absence of DNA (preferred binding sites
for most bZIP pairs are not yet known), and the presence of DNA could stabilize certain
complexes not observed in our assay. Nonetheless, bZIP interactions that are conserved between
species are likely to be functionally relevant. Indeed, we have discovered a core set of
interactions that are conserved throughout metazoan evolution, and likely are involved in
essential processes. Additionally, because those interactions that are conserved are of higher
affinity, this suggests that the higher affinity interactions are also likely to be functionally
important. The converse argument that lack of conservation probably implies functional
irrelevance does not hold, however. One example is the interactions of JUN-FOS, JUN-ATF2,
and JUN-JUN. The JUN-FOS interaction is always conserved. JUN-ATF2 is not observed to
interact in C. elegans or D. melanogaster but does interact in the other three species. JUN-JUN
only interacts in human. They have different extents of conservation yet have all been reported to
be functionally important in humans (van Dam and Castellazzi. 2001).
A striking result is the number of interactions that change between networks. The bZIP
interaction interface allows for both drastically changing interaction profiles with small number
of changes, as well as being able to add or lose a small number of interactions while keeping
many interactions constant. This has been observed previously in designed bZIP interactions
(Grigoryan, et al. 2009), and some of the molecular mechanism that make this possible are
understood. Here we were able to use these principles to rationally alter the interaction profiles
of paralogous or orthologous proteins to make them more similar.
Our data can be used to inform research in several areas going forward. First, there is
considerable interest in using interactions measured in one species to annotate other organisms
165
(Yu, et al. 2004). Our results show some relationship between sequence identities and
interactions at high sequence identities as previously observed, but also suggest that annotation
based on homology alone for bZIPs is a poor indicator of which interactions occur (Yu, et al.
2004). This suggests a cautious and conservative approach to in inter-species interaction transfer.
Second, our data provide a very large number of quantitative interactions that can be used to test
and improve models for predicting bZIP interactions from sequence. Such improved models
could potentially be used to predict interactions in other species. Improved insight into more
general methods for modeling protein interaction specificity could also arise from computational
studies using these data. Third, this data can potentially be used predict which interactions occur
in various cell types using comprehensive expression data (Ravasi, et al. 2010). Finally, this
work provides a resource and starting to point to investigate the potential functional
consequences of rewiring of the bZIP interaction networks.
METHODS
bZIP identification.
Proteins containing bZIP domains were identified by searching with custom made HMM
models built using the program HMMER (Eddy. 1998). Initial models were constructed using 53
human bZIP domains. Additional versions of the model were generated using bZIPs identified
from other species. Genomes of each species were searched using multiple HMM models and
putative bZIP domains were manually inspected for the following features: highly conserved
basic residues, spacing between basic region and leucine zipper, and predominantly hydrophobic
coiled-coil core. Sequences were aligned using the previously described features. The N-terminal
domain boundary of each bZIP was defined as 10 amino acids beyond the end of the minimal
basic region (defined as the N-terminal end of the GCN4:DNA co-crystal structure) (Ellenberger,
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et al. 1992). For three N. vectensis proteins where the bZIP domain is at the extreme N-terminus,
the native N-terminal was used as the boundary instead. C-terminal boundaries were determined
by manual inspection for polar amino acids in core positions, glycines or prolines, or the native
C-terminal end of the protein. To determine ortholog assignments of each bZIP, phylogenetic
trees of bZIP domains built using the neighbor joining method were generated as described
previously (Grigoryan, et al. 2009) and reciprocal best hit databases were also used (Waterhouse,
et al. 2011, Ostlund, et al. 2010, Powell, et al. 2012, Chen, et al. 2006). In the few cases where
ortholog assignment was ambiguous, interaction profile similarities were used. bZIP family
names are consistent with (Amoutzias, et al. 2007).
Cloning, expression, purification, and labeling
C. elegans bZIP domains were cloned from cDNA. D. rerio ATF4 genes were cloned by
gene synthesis using the program DNAWorks to design primers, which were annealed using a
two-step PCR method (Hoover and Lubkowski. 2002). These genes were cloned as intein-chitin
binding domain fusions using a modified pTXB 1 (NEB) plasmid. Genes were cloned into the
plasmid using the SLIC method (Li and Elledge. 2007) or restriction digested with XhoI and
NsiI. The remaining genes were ordered synthesized from GENEWIZ. All clones were sequence
verified. Proteins were expressed in RP3098 cells by growing 1 L LB cultures at 37 'C to OD6 00
0.4-0.8 at which point expression was induced with 0.5 mM IPTG. Cultures were then incubated
for 3-4 hours and cells pelleted. For poorly expressing proteins an alternative protocol of
induction at 18 'C for 12-16 hours was used. Cells were resuspended in buffer (20 mM HEPES
pH 8.0, 500 mM NaCl, 2 mM EDTA, 1 M guanidine-HCl, 0.2 mM PMSF, and 0.1% Trition X-
100) and lysed using sonication. The lysate was then split and each half was pored over a column
containing 1 -ml chitin beads (NEB). The column was washed and then equilibrated with EPL
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buffer (50 mM HEPES pH 8.0, 500 mM NaCl, 200 mM MESNA, 1 M guanidine-HCl). To
cleave the intein and label the proteins with a fluorescent dye, the columns were incubated with
EPL buffer containing 1mg/ml of cysteine-lysine-dye where dye is either fluorescein or TAMRA
(CELTEK). Columns were capped and incubated for at least 16 hours. Cleaved and labeled
proteins were then eluted and diluted 5-fold into denaturing buffer (6 M guanidine-HCL, 5 mM
imidazole, 0.5 M NaCl, 20 mM TRIS ,1 mM DTT, pH 7.9). This solution was then flowed over
columns containing 1ml Ni-NTA resin. After washing, proteins were eluted with 60%
ACN/0. 1% TFA. Labeled proteins were lyophilized, resuspended, and desalted using spin-
columns (Bio-Rad). Proteins were stored in 10 mM potassium phosphate pH 4.5 at -80 'C.
Peptide concentrations were measured in 6 M guanidine-HCl/100 mM sodium phosphate pH 7.4
using the absorbance of the dye with an extinction coefficient of 68,000 M-1 cm-1 at 499 nm for
fluorescein and 86,000 M-1 cm-1 at 560 nm for TAMRA. To determine the accuracy of protein
concentration determination using dye absorbance, amino acid analysis was performed (UC
Davis proteomics core facility). Three fluorescein-labeled and three TAMRA-labeled proteins
were analyzed and all were less than 15% from the correct concentration. Molecular weights of
fluorescein-labeled C. elegans proteins were measured by mass spectrometry and were correct
within 0.15% and no evidence of unlabeled proteins was observed. Care was taken during the
purification process to protect the labeled proteins from photo damage.
Interaction measurements.
Fluorescein-labeled proteins were diluted to 80 nM in 1 mM TCEP in low protein
binding tubes (Eppendorf). Dilutions of fluorescein-labeled proteins were then transferred to an
entire row of a black 96-well non-binding surface plate (Coming). TAMRA-labeled proteins
were diluted to 2.67 p.M in 1 mM TCEP and 60 pl of each protein was transferred to a well in the
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first two columns of a black 384-well non-binding surface plate (Coming). The remaining wells
were filled with 30 tl of 1 mM TCEP. Each TAMRA labeled protein was serially diluted by
aspirating 30 pl of protein and mixing it in a well containing 30 pl of 1 mM TCEP. Ten 2-fold
dilutions of each protein were done, resulting in 11 concentrations of each TAMRA protein and a
well containing no TAMRA-labeled protein. 10 pl of each donor was then transferred from the
96-well plate to the 384-well plate and mixed. 40 pl of 2X binding buffer (100 mM potassium
phosphate pH 7.4, 300 mM KCl, 0.2% BSA, 0.2% Tween-20) was then added to each well and
mixed. All binding reactions were set up using a Tecan Freedom EVO liquid handling robot,
except for replicate experiments which were done using a multichannel pipette. Plates were then
incubated for 60-120 minutes at 37 'C. Following incubation, plates were read using a
fluorescence plate reader (Molecular Devices) with excitation at 480 nm and emission at 525 nm.
Plates were then transferred to 21 'C and incubated for 60-90 minutes and measured again.
Plates were then transferred to 4 'C and incubated for 60-90 minutes and measured again.
Fitting equilibrium disassociation constants.
Data were fit to the saturation binding equation Fobs=Fma-(( Fmax -
Fmin)/(2* [donor]))*((Kd+[donor]+[acceptor])-((Kd+x+[donor])A2-4* [acceptor] *. [donor] )A0.5)
where Fobs is the observed fluorescence of the donor and Fma and Fmin are the maximum and
minimum fluorescence intensity (Kohler and Schepartz. 2001). Using an ODE model that
accounted for homodimerization of donor and acceptor proteins gives similar, but improved
results (Ashenberg, et al. 2011). Curves were required to have a change of at least 20% between
Fmax and Fmin. Reported values are between 1 and 5000 nM. Interactions <1 nM or greater than
5000 nM were identified but could not be accurately quantified. For each heterodimer two
measurements were made and the lower value was used as the value for the interaction of the
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heterodimer, because this was judged to be the value least affected by not accounting for
competing homodimerization. Kd values are reported in Table 5.2.
Interaction data analysis
To determine conservation, interactions were analyzed at the family level. Two families
were considered to interact if at least one member of the family interacted with at least one
member of the other family and this interaction was tighter than 1000 nM. Interactions that
occurred in all species where both families were present were considered conserved, those that
occurred in at least 2, but not all, were considered partially conserved, and those that only
occurred in one species were considered not conserved.
Overlap of networks between species was determined by counting the number of
interactions between protein families that are shared by each pair of species. The number of
shared interactions for each pair of species was divided by the sum of all the interactions that
occurred in that pair of species.
The ancestral bZIP interaction network was inferred using parsimony. To be included in
the ancestral interaction network, an interaction had to occur in N. vectensis and in at least one of
the lower metazoans (C. elegans and D. melanogaster) or both chordates (C. intestinalis and
Human).
To determine the relationship between sequence identity and interaction properties for
paralogs, all possible pairs of paralogs from each species were used. The percent sequence
identity was calculated from the interface positions (adeg). The percent interaction similarity
was calculated using (shared interactions*2)/(interaction differences + shared interactions* 2).
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To determine sequence identity vs. interaction similarity of orthologs, all possible
interolog pairs were compared between species. The percent sequence identity was calculated
from the interface positions (adeg) using the combined sequences of each pair of orthologs.
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TABLES
Table 5.1: List of bZIP sequences used in this study
Species Family Name shorthand Protein sequence
Human DDIT3 DDIT3 LAQEEEEEDQGRTRKRKQSG
HSPARAGKQRMKEKEQENER
KVAQLAEENERLKQEIERLTR
EVEATRRALIDRMVNLHQA
Human CEBPG CEBPG KKSSPMDRNSDEYRQRRERN
NMAVKKSRLKSKQKAQDTL
QRVNQLKEENERLEAKIKLLT
KELSVLKDLFLEHLAHNLA
Human CEBP CEBPA KAKKSVDKNSNEYRVRRERN
NIAVRKSRDKAKQRNVETQQ
KVLELTSDNDRLRKRVEQLS
RELDTLRGIFRQL
Human CEBP CEBPE KGKKAVNKDSLEYRLRRERN
NIAVRKSRDKAKRRILETQQK
VLEYMAENERLRSRVEQLTQ
ELDTLRNLFRQI
Human CREB CREBI LPTQPAEEAARKREVRLMKN
REAARECRRKKKEYVKCLEN
RVAVLENQNKTLIEELKALK
DLYCHKSD
Human OASISA CREB3 LPLTKTEEQILKRVRRKIRNK
RSAQESRRKKKVYVGGLESR
VLKYTAQNMELQNKVQLLE
EQNLSLLDQLRKLQAMVIEIS
Human OASISA CREB3L3 LPLTKAEEKALKRVRRKIKN
KISAQESRRKKKEYVECLEK
KVETFTSENNELWKKVETLE
NANRTLLQQLQKLQTLVT
Human OASISB CREB3L1 LPTQLPLTKYEERVLKKIRRK
IRNKQSAQESRKKKKEYIDGL
ETRMSACTAQNQELQRKVLH
LEKQNLSLLEQLKKLQAIVV
175
Human CREBZ CREBZF GGGSGNDNNQAATKSPRKA
F AAAAARLNRLKKKEYVMGL
ESRVRGLAAENQELRAENRE
LGKRVQALQEESRYLRAVLA
Human XBP1 XBP1 RQRLTHLSPEEKALRRKLKN
RVAAQTARDRKKARMSELE
QQVVDLEEENQKLLLENQLL
REKTHGLVVENQELRQRL
Human ATF6 ATF6 MRNVGSDIAVLRRQQRMIKN
RESACQSRKKKKEYMLGLEA
RLKAALSENEQLKKENGTLK
RQLDEVVSENQRLKV
Human ATF6 ATF6B SCPPEVDAKLLKRQQRMIKN
RESACQSRRKKKEYLQGLEA
RLQAVLADNQQLRRENAALR
RRLEALLAENSELKL
Human NFIL3 NFIL3 REFIPDEKKDAMYWEKRRKN
NEAAKRSREKRRLNDLVLEN
KLIALGEENATLKAELLSLKL
KFGLISSTAY
Human PAR DBP KIQVPEEQKDEKYWSRRYKN
NEAAKRSRDARRLKENQISV
RAAFLEKENALLRQEVVAVR
QELSHYRAVLSRYQAQH
Human PAR HLF KVFIPDDLKDDKYWARRRKN
NMAAKRSRDARRLKENQIAI
RASFLEKENSALRQEVADLR
KELGKCKNILAKYEARH
Human ATF2 ATF2 RRRAANEDPDEKRRKFLERN
RAAASRCRQKRKVWVQSLE
KKAEDLSSLNGQLQSEVTLL
RNEVAQLKQLLLAHKD
Human JUN JUN SPIDMESQERIKAERKRMRNR
IAASKCRKRKLERIARLEEKV
KTLKAQNSELASTANMLREQ
VAQLKQKVMNHV
Human JUN JUNB SPINMEDQERIKVERKRLRNR
LAATKCRKRKLERIARLEDK
VKTLKAENAGLSSTAGLLRE
QVAQLKQKVMTHV
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Human FOS FOS KVEQLSPEEEEKRRIRRERNK
MAAAKCRNRRRELTDTLQAE
TDQLEDEKSALQTEIANLLKE
KEKLEFILAAHR
Human FOS FOSLI PCEQISPEEEERRRVRRERNK
LAAAKCRNRRKELTDFLQAE
TDKLEDEKSGLQREIEELQKQ
KERLELVLEAHR
Human ATF4 ATF4 VAAKVKGEKLDKKLKKMEQ
NKTAATRYRQKKRAEQEALT
GECKELEKKNEALKERADSL
AKEIQYLKDLIEEVRKAR
Human ATF4 ATF5 PYPHPATTRGDRKQKKRDQN
KSAALRYRQRKRAEGEALEG
ECQGLEARNRELKERAESVE
REIQYVKDLLIEVYKAR
Human ATF3 ATF3 TKAEVAPEEDERKKRRRERN
KIAAAKCRNKKKEKTECLQK
ESEKLESVNAELKAQIEELKN
EKQHLIYMLNLHR
Human BATF BATF PPGKQDSSDDVRRVQRREKN
RIAAQKSRQRQTQKADTLHL
ESEDLEKQNAALRKEIKQLTE
ELKYFTSVLNSHE
Human BATF BATF2 GLLTQTDPKEQQRQLKKQKN
RAAAQRSRQKHTDKADALH
QQHESLEKDNLALRKEIQSLQ
AELAWWSRTLHVHERLCP
Human BATF BATF3 QPQQQSPEDDDRKVRRREKN
RVAAQRSRKKQTQKADKLH
EEYESLEQENTMLRREIGKLT
EELKHLTEALKEHE
Human SMAF MAFF RGLSAEEVTRLKQRRRTLKN
RGYAASCRVKRVCQKEELQK
QKSELEREVDKLARENAAMR
LELDALRGKCEALQGFARSV
A
Human SMAF MAFG RGLSKEEIVQLKQRRRTLKNR
GYAASCRVKRVTQKEELEKQ
KAELQQEVEKLASENASMKL
ELDALRSKYEALQTFARTVA
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Human LMAF MAF RGVSKEEVIRLKQKRRTLKN
RGYAQSCRFKRVQQRHVLES
EKNQLLQQVDHLKQEISRLV
RERDAYKEKYEKLV
Human LMAF MAFB RGFTKDEVIRLKHKRRTLKN
RGYAQSCRYKRVQQKHHLE
NEKTQLIQQVEQLKQEVSRL
ARERDAYKVKCEKLA
Human NFE2 NFE2 YPLTESQLALVRDIRRRGKNK
VAAQNCRKRKLETIVQLERE
LERLTNERERLLRARGEADR
TLEVMRQQLTELYRDIFQHL
Human NFE2 NFE2L1 YQLSEAQLSLIRDIRRRGKNK
MAAQNCRKRKLDTILNLERD
VEDLQRDKARLLREKVEFLR
SLRQMKQKVQSLYQEVFGRL
Human NFE2 NFE2L2 EQFNEAQLALIRDIRRRGKNK
VAAQNCRKRKLENIVELEQD
LDHLKDEKEKLLKEKGENDK
SLHLLKKQLSTLYLEVFSML
Human NFE2 NFE2L3 YYLTDLQVSLIRDIRRRGKNK
VAAQNCRKRKLDIILNLEDD
VCNLQAKKETLKREQAQCN
KAINIMKQKLHDLYHDIFSRL
Human BACH BACHI HKLTPEQLDCIHDIRRRSKNRI
AAQRCRKRKLDCIQNLESEIE
KLQSEKESLLKERDHILSTLG
ETKQNLTGLCQKV
Human BACH BACH2 HKLTSEQLEFIHDVRRRSKNR
IAAQRCRKRKLDCIQNLECEI
RKLVCEKEKLLSERNQLKAC
MGELLDNFSCLSQEV
D. rerio ATF4 NP_001096662.1 DRE4A SASGSKVVVEKKKLKKMEQ
NKTAATRYRQKKRAEQETLL
SECAVLEERNQELAEKAESLT
KEIQYLKELMEEVKRAR
D. rerio ATF4 NP_998398.1 DRE4B VKTSSGAPKVEKKLKKMEQN
KTAATRYRQKKRVEQESLNS
ECSELEKKNRELSEKADSLSR
EIQYLRDLLEEMRTAK
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C. intestinalis CEBPG ENSCINP00000023749 CIlI IVKGELEGDQDDYVKRRQRN
NIAVKKSREKSREKSQITSERI
DQLKEENCVLENKVEVLNQE
LKVLKQVFMDHA
C. intestinalis CEBP ENSCINP00000023748 C12 KKTKILIKGSKEYVQKRERNN
VAVRRSRDKAKRKAAETQV
KVDQLQNENLKLHEKVAELT
HELTTLKNLLKAL
C. intestinalis CEBP ENSCINP00000023074 C13 DLTDAPSTSGVKVSRKRDRN
NAACRESRKKKKMKLVEAE
MEVVRLVEDNEVQRLKIARL
EVEVKETKALLLSKM
C. intestinalis CEBP ENSCINP00000002651 C14 NSLIPILHELDKIDRRRIRNNE
ACKKSRMRRKQRKMDKERE
AERLAAQNLHLKRKISMLQS
ECDKIRRQVLQAR
C. intestinalis CREB ENSCINP00000023419 C15 SPQQMAEEASRKRELRLMKN
REAAKECRRRKKEYVKCLET
RVAVLENQNKQLIDELKTLK
ELYVHKQN
C. intestinalis OASISA ENSCINP00000025439 C16 LPLTKYEERVLKKVRRKIRN
KKSAMASRQKKKDYIGGLEA
RVTKCTNLNQALSQRVKQLE
QQNFTLLEQLKQVHDAVK
C. intestinalis OASISB ENSCINPOOOOOO11026 C17 LPLTKSEEKSLKKVRRKIKNK
ISAQESRRKKKEYVETLEKR
MDVYNRENTELRHKLDSLES
SNRSLLSQLKSLQVLVA
C. intestinalis XBP1 ENSCINP00000024434 C18 QENIPLSAIEDKELRKKLRNR
QSALAARERKKARMMELEK
QVAELQETNRRMEDENQHLR
ARLDNII
C. intestinalis XBP1 ENSCINPOOOOOO10446 C19 RKRLTHLTTEEKVMRRKLKN
RVAAQTARDRKKVRMECLE
DNIQKVQQQAKELLDVNMQ
LLERAEALERENRELRVRL
C. intestinalis XBP1 ENSCINP00000021189 CIlI0 EQDDGYADVDEKELRKKLR
NRESAQRARDRQKARMQWL
EHEVSMLQVRNLTLTRENNL
LRNLLA
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C. intestinalis XBP1 ENSCINPOOOOOO15310 CIlII TPRKSFEHVTDKELRKKLKN
RESAQAARDRKKAKMLSLER
QISELLERNRIVETENQELRSR
IQRME
C. intestinalis ATF6 ENSCINP00000028986 Cl 2 LTIKDLDGRAMKRQQRMIKN
REAACQSRQRRKEYVSTLEQ
QMLECLDDNNKLRSMNQQL
RDKVMELENENTRLR
C. intestinalis NFIL3 ENSCINPOOOOOO16562 C1l3 PNSMCEDSKNKDYWVRRRK
NNEAARRSREKRRMNDLLLE
RRVLQLSEENKQLRAQLVAL
KIKYGDTE
C. intestinalis PAR ENSCINP00000004693 Cl 4 KVHVSSDSKDVKYWNRRNK
NNVAAKRSREARRIKENQIA
MRANFLEKENESLKMEVADL
RSELKRVMNTLRVYEKEII
C. intestinalis ATF2 ENSCINP00000005786 C15 GRQQQDVDPDIKRQRFLERN
RAAASRCRSKKKNWVVGLE
SKAKTLSQTNVMLQNEITQL
KDEIASLKQLLLSHR
C. intestinalis JUN ENSCINPOOOOOO18871 C116 SPINMDHQELIKSERKRLRNR
VAASKCRKRKLERISRLEDK
VNNLKNQNLELTSSANLLRQ
QVAELKSKVMTHV
C. intestinalis FOS 100130316 CI17 QDHELSPAEATKRHIRRERNK
IAAAKCRNRRRELTDRLQGE
TDHLEDHQSILHQEIMSLQQE
KEHLEFLLAAHS
C. intestinalis FOS ENSCINP00000007607 C1l8 DLDDLSDDERERMRVKRERN
RVAAAKCRNRRRELLERLEK
EAEQLEREQELLRESVKRLQS
QKRKLGVMLDEHE
C. intestinalis ATF4 ENSCINP00000022333 C1l9 GRKSKVTTTVERKQRKRDQN
KNAATRYRERKRLEFSKQES
EQRVLEEKNKSLHDNVNRVT
REIEYLKELMIEVYKIKGLIK
C. intestinalis ATF3 ENSCINP00000005786 C120 QNDEISPETLLKRERRRERNK
VAAAKCRFKKKILSEQLQEES
EHLENLNAKLKREIEKLQEER
QKLMYLLNGHK
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C. intestinalis SMAF ENSCINP00000002543 C121 RSLSPEESRRLKQRRRTLKNR
GYAASCRIKRLTQKDELDIER
IQLQNEVDRVTQENQRMKLE
LEAFQKKFHDLEQFAKSI
C. intestinalis LMAF ENSCINP00000002531 C122 RGLSKEDVMALKQRRRTLKN
RGYAQSCRTKRVMQRHILEK
EKDALQIQLNQVRDHLAAMS
KERDDYKTKFERLRKFFL
C. intestinalis NFE2 ENSCINP00000024999 C123 TPLTTAQQTLIKDIRRRGKNK
VAAQNCRKRKIETITTMEED
VDVLRGRKNDLEMEQDELE
ARKQNLKSQYNALYQQIF
C. intestinalis BACH ENSCINP00000026548 C124 PSLSPQQITAIHEIRRRGKNRI
AAQRCRKRKMDCIRSLQCQL
EQLREEHLNLMGERRTCQDK
SLKLAEMFQKRYEQVF
C. intestinalis NOVEL 100138308 C125 SLVAQLQNKDLQKFGDKS
RNAVLAKLNREKKKHKIA
LLETEVHHLRGKNNRLEK
MNQEFSTSILDLQHEVKYL
RGVIA
C. intestinalis NOVEL 100135870 C126 RHFVPNECKDEYYWRKRKK
NNEAARKSREKRKTIDSVLE
DKVLFLSQENLCLRNELYAL
KVNFT
D. melanogaster PAR CG17888-PE DM1 KQFVPDELKDDKYWARRRK
NNIAAKRSRDARRQKENQIA
MRARYLEKENATLHQEVEQL
KQENMDLRARLSKFQDV
D. melanogaster NOVEL CG15479-PA DM2 VNMVRKFPKKERSPKDQERR
NKNTIACRMSRRKKKFDDLQ
IEQQYKECSDEHLKIAEQSLR
ARVYLNHLKQLVK
D. melanogaster FOS CG33956-PD DM3 RSTNMTPEEEQKRAVRRERN
KQAAARCRKRRVDQTNELTE
EVEQLEKRGESMRKEIEVLTN
SKNQLEYLLATHRATCQKIRS
DMLSVVTCNGLIA
D. melanogaster OASISB CG7450-PB DM4 LPLTKAEEKSLKKIRRKIKNKI
SAQESRRKKKEYMDQLERRV
EILVTENHDYKKRLEGLEETN
ANLLSQLHKLQALVSKH4N
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D. melanogaster ATF2 CG30420-PC DM5 PPKAAKAKDRSRDEDCMERR
RAAASRYRNKMRNEHKDLIK
QNAQLQQENQELHERISRLE
KELQQHR
D. melanogaster ATF4 CG8669-PA DM6 RTRTYGRGVEDRKIRKKEQN
KNAATRYRQKKKLEMENVL
GEEHVLSKENEQLRRTLQER
HNEMRYLRQLIREFYHERK
D. melanogaster PAR CG7786-PA DM7 KRPIPEAQKDAKYFERRKRN
NEAAKRSRDARKIREDRIAFR
AALLEQENSILRAQVLALRDE
LQTVRQLL
D. melanogaster CEBP CG4354-PA DM8 HSNKHVDKGTDEYRRRRERN
NIAVRKSREKAKVRSREVEE
RVKSLLKEKDALIRQLGEMT
NELQLHKQIYMQLM
D. melanogaster CREB CG6103-PF DM9 DNSGIAEDQTRKREIRLQKNR
EAARECRRKKKEYIKCLENR
VAVLENQNKALIEELKSLKEL
YCQTKN
D. melanogaster CEBPG CG6272-PA DM10 DSPLSPHTDDPAYKEKRKKN
NEAVQRTREKTKKSAEERKK
RIDDLRKQNDALKVQIETSEK
HISTLRDLII
D. melanogaster ATF3 CG1 1405-PA DM11 QPKGLTPEDEDRRRRRRERN
KIAATKCRMKKRERTQNLIK
ESEVLDTQNVELKNQVRQLE
TERQKLVDMLKSH
D. melanogaster NFE2 CG17894-PC DM12 YDLSENQLSLIRDIRRRGKNK
VAAQNCRKRKLDQILTLEDE
VNAVVKRKTQLNQDRDHLE
SERKRISNKFAMLHRHVFQY
L
D. melanogaster LMAF CG10034-PA DM13 HGCPREEVVRLKQKRRTLKN
RGYAQNCRSKRLHQRHELEK
ANRVLNQDLHRLKLEYSRVC
QERDALMQRLQ
D. melanogaster JUN CG2275-PA DM14 NPIDMEAQEKIKLERKRQRN
RVAASKCRKRKLERISKLEDR
VKVLKGENVDLASIVKNLKD
HVAQLKQQVMEHI
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D. melanogaster ATF6 CG3136-PA DM15 TPSHTMDDKIYKKYQRMIKN
RESASLSRKKRKEYVVSLETR
INKLEKECDSLKAENITLRDQI
FLLA
D. melanogaster NFIL3 CG14029-PA DM16 REFTPDNKKDESYWDRRRRN
NEAAKRSREKRRYNDMVLE
QRVIELTKENHVLKAQLDAIR
DKFNISGENLVSVEKILASL
D. melanogaster PAR CG7952-PB DM17 GISSGSQVKDAAYYERRRKN
NAAAKKSRDRRRIKEDEIAIR
AAYLERQNIELLCQIDALKVQ
LAAFTSAKV
D. melanogaster XBP1 CG9415-PB DM18 KRRLDHLTWEEKVQRKKLK
NRVAAQTSRDRKKARMEEM
DYEIKELTDRTEILQNKCDSL
QAINESLLAKNHKLDSELELL
RQELAELK
D. melanogaster SMAF CG9954-PA DM19 RGLNREEIVRMKQRRRTLKN
RGYAASCRIKRIEQKDELETK
KSYEWTELEQMHEDNEQVR
REVSNWKNKYKALL
D. melanogaster NOVEL CG18619-PA DM20 KPGRKTSTEKLDMKAKLERS
RQSARECRARKKLRYQYLEE
LVADREKAVVALRTELERLI
QWNNQLSESNT
D. melanogaster PAR CG4575-PA DM21 GISSGSHVKDTAYYERRRKN
NAAAKKSRDRRRIKEDEIAIR
AAYLERQNIELLCRIDALEVQ
LAAITSAKV
D. melanogaster NOVEL CG33719 DM22 QKENERLQTEVQLMKQELDA
AEKAAISRAKKQAQIGELMQ
RIKELEEMQSSLEDEASELRE
QNELLEFRILELEDDSDKME
D. melanogaster NOVEL CG13624 DM23 MTPVSELPFNVRPKSRKEKN
KLASRACRLKKKAQHEANKI
KLFGLEIEHSEFNVKAVEIS
D. melanogaster NOVEL CG13624b DM24 MTPVSELPFNVRPKSRKEKN
KLASRACRLKKKAQHEANKI
KLFGLEIEHKRLMNGIAELKQ
ALV
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D. melanogaster NOVEL CG16813 DM26 RNHHKRRQRSPQEQLRRDRN
TLASLRHRRSQQQQQQLIEQ
QYLTSRIQHEANLQQQIRLSL
YYVRFL
D. melanogaster NOVEL CG16815 DM27 RRSNTNRQRSPKEQMkRDRN
TLACLLSRRAKQAQEEQVGQ
QYEQYRSHHAAMLEQQVRL
SLYYRHIL
D. melanogaster NOVEL CG17836 DM28 LMSSMKSEEERKAYQDRLKN
NEASRVSRRKTKVREEEEKR
AEDTLLAENLRLRARADEVA
SRERKFKKYLM
D. melanogaster NOVEL CG1641 DM29 DVKDAQRQRAESCRKSRYN
NKIKKAKLRFRHKFVSGQLK
KSAVMLDTMRDVIAQAERQL
L
D. melanogaster FOS CG33956-PD DM30 RSTNMTPEEEQKRAVRRERN
KQAAARCRKRRVDQTNELTE
EVEQLEKRGESMRKEIEVLTN
SKNQLEYLLATHR
C. elegans CEBPA D1005.3 CEl KLKADEEKAEPTYKLKRA
RNNDAVRKSRKKAKELQ
DKKEAEHDKMKRRIAELE
GLLQSERDARRRDQDTLE
QLLRNK
C. elegans NOVEL zip-2 CE2 KTSSVSSDSSSDYRHKRDK
NNLASQKSRQKRQAKIRE
SKEERERLEKRKVQLQAM
VLTLETQVEDYKRLVMMF
VKR
C. elegans PAR F17A9.3 CE3 LKRKKDQVKDVAYWERR
RKNNDAAKRSRDQRRMK
EDEMAHRATSLERENMLL
RVELDQLRAETDKLRALIL
C. elegans NFIL3 atf-2n CE4 NSVNESVIKDEHYWERRR
RNNDASRRSREKRRQNDL
AMEEKIMLLSAENERLKS
QL
C. elegans ATF2 atf-7 CE5 RSTTADMQPDERRNTILER
NKAAAVRYRKRKKEEHD
DMMGRVQAMEAEKNQLL
AIQTQNQVLRRELERVTAL
LTERESRCVCLK
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C. elegans XBP1 xbp-1 CE6 RERLNHLSQEEKMDRRKL
KNRVAAQNARDKKKERS
AKIEDVMRDLVEENRRLR
AENERLRRQNKNLMNQQ
N
C. elegans JUN jun-i CE7 CGMALDDQEKKKLERKR
ARNRQAATKCRQKKMDRI
KELEEQVLHEKHRGQRLD
AELLELNRALEHFRRTVEH
HS
C. elegans FOS fos-1 CE8 EEDNMEDDDDDKRLKRR
QRNKEAAARCRQRRIDLM
KELQDQVNDFKNSNDKK
MAECNNIRNKLNSLKNYL
ETHD
C. elegans CREB crh-1 CE9 GPLHGEDESNRKRQVRLL
KNREAAKECRRKKKEYV
KCLENRVSVLENQNKALIE
ELKTLKELYCRKEKD
C. elegans ATF6 atf-6 CE1O VDIKAEPQVFTSEQNRKIR
NRMYAQASRMRKKEADE
HMKMNLQELLQENEILRT
ENAALKQRLAFFEHEE
C. elegans ATF4 atf-5 CEl 1 EKSYHPYKTPEKKERKKA
QNRLAATRYREKKRREKE
EAMTCIEGLSVTNGKLKD
QVSELEREIRYFKKFMTEM
C. elegans PAR ces-2 CE12 SVPIPEEKKDSAYFERRRK
NNDAAKRSRDARRQKEEQ
IASKAHALERENMQLRGK
VSSLEQEAAQLRFLLFSKI
C. elegans OASISA let-607 CE13 FPLTKAEERDLKRIRRKIR
NKRSAQTSRKRKQDYIEQ
LEDRVSESTKENQALKQQI
ERLSSENQSVISQLKKLQA
QL
C. elegans PAR atf-2c CE14 EDHSNYSNKSPQYVDRRR
RNNEAAKRCRANRRAVFE
YRSRRVQLLEGENEDLRT
QIETLKAEIAHFKSVLAQR
ASVVTALH
C. elegans ATF4 zip-3 CE15 EGREEEESPEEILRRKRIQN
NLAAARYRKRQREARESA
ESELGDLTRRNDELRDQV
SRMEREIDRLKQAVL
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C. elegans NOVEL zip-5 CE16 TSCDEKLDLVSEDEKKRL
RNTEAARRCREKIKRKTD
DLETELTRLTARNEVMNQ
HRIRLLSQVEEQMRMLENI
KSRN
C. elegans NOVEL F23F12.9a CE17 DGSKIDPKRSPKYLEKRM
KNNEAAKKSRASRKHREQ
KNQTENELLKRKNAALEE
ELKQAKCELAQMQITIRD
MSIEREAYRRENEMLKMV
NNKFADSKF
C. elegans CEPBG C48E7.11 CE18 NTSEPREDDEDDYSTKRK
RNNEAVNRTRQKKRQEEN
DTAEKVDELKKENETLER
KVEQLQKELSFLKEMFMA
YA
C. elegans MAF F45H1 1.6 CE19 MGQDRNVVMQWKQKRR
TLKNRGYALNCRARRVNN
QVQLEADNMMLRNQIKTL
REALSEAQMRLHYYE
C. elegans ATF4 ZC376.7c CE20 RGVVLKPSVDEETDRRRM
LNRIAAVRYREKKRAEKK
GRKMEFQEVADRNRILLQ
KERQLKREINSMKKELRK
MGAIIQ
C. elegans OASISB C27D6.4 CE21 YPLTKSEEESLKIVRRKIKN
KLSAQESRRKRKEYIDALE
GRLHCFSEENKSLKKQVH
QLEASNRDLQQKLHQYE
C. elegans NOVEL W08E12.1 CE22 KKEGSSNDETKLLSRKRQ
QNKVAAARYRDKQKAKW
QDLLDQLEAEEDRNQRLK
LQAGHLEKEVAEMRQAFL
AKL
C. elegans PAR Y5 1 H4A.4 CE23 PVPVPENQKDEAYLDRRR
RNNEAARKSRESRKKVDQ
DNSVRVTYLERENQCLRV
YVQQLQLQNESMRQHLLL
QN
C. elegans CEBPA zip-4 CE24 NLKPDKEKVEPIYKLKRA
RNNDAVRKSRNKAKELQL
QKDEEYDEMKKRITQLEA
ELQSEREGRERDQQLIKQL
IREK
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C. elegans NOVEL R07H5.10 CE25 YEKVSEDQKDEKYSSKRE
KNNLAVKRCREKKKNEEK
YKKEAFENLIRSNLVKDQ
KIEQLNNLVQSGKQRENA
RIMEVQREKNILRQLKNEL
TRI
C. elegans NOVEL zip-I CE26 KAEMSRLTEKEKLERKKE
QNRANAKNCVKNRNNSK
EELKQTLEMLREKVQEAK
RQNEMQENGLLAAYETNI
C. elegans NOVEL Y116F11B.6 CE27 SQAAQSNIPSGKAKTKRER
NRIAAAKSRRLEKELMRK
TQAIYETKKITHEQLCAYN
NSNDSLFKTAVESVL
C. elegans NOVEL F17C11.17 CE28 PVSLVNLSDEEIAERKKQQ
NRAAALRYRQKLRESRVM
SVSVKETLTQRNAYLRDE
AERLSKECEVIRRLIFDKL
GKNA
C. elegans NOVEL Y17G7B.20 CE29 VKSPSSKRGRPSKVTSNSK
MANYARNYREQKKNEMS
TLQMHNSELEAELRLARE
ENAKMKKALAKASDEITQ
LKKVIDQDSQIARVV
C. elegans ATF2 atf-7 CE30 RSTTADMQPDERRNTILER
NKAAAVRYRKRKKEEHD
DMMGRVQAMEAEKNQLL
TQNQVLRRELERVTALLT
ERESRCVCLK
C. elegans NOVEL R07H5.10 CE31 YEKVSEDQKDEKYSSKREKN
NLAVKRCREKKKNEEKYKK
EAFENLIRSNLVKDQKIEQLN
NLVQ
N. vectensis PAR 165267 NV1 TEKHFNNNKDNKYWEKRQR
NNASAKRSRDARRVRELECQ
IRAEFLEEENHKYKVENEML
REENERLLKIIESFNNKQ
N. vectensis OASISB 28519 NV2 LPLTKVEERALKKVRRKIKN
KISAQESRRKKKEYMETLEK
RVETCSSENLELRKKLDSLEN
TNRNLIGQLQKLQALIS
187
N. vectensis FOS 233229 NV3 RKEQLTPEEEEKRRLRRERNK
QAANRCRKRKRDKIEMLERT
AQEIDDSNKALETDIANMRTE
LTELMSVLRSHDCVMRSRD
N. vectensis NOVEL 238168 NV4 LKPIHSLPLNARNKSRKEKNK
LASRACRLKKKAQHEANKLK
LHGLELEQQRLIHVIEKVRSEI
I
N. vectensis CEBPG 114346 NV5 DDEYIRKRERNNEAVRKSRK
KAKQRIQETQQRVTELSKEN
EELRSKVTLLQKELSVLRSLF
A
N. vectensis XBP1 211292 NV6 RRRLDNLTVEERALRRKLKN
RVAAQTARDRKKARMQDLE
EAVESLERENKRLREENKRL
NKSTESLAIENSELRVRL
N. vectensis FOS 246444 NV7 TPQPRPPEKPEVVEQRRRQNK
FAAMKSRKKRTERINRLRQK
TRKYEESIRKHGMVVKKLRE
EAEQLKQYLISHNCCKN
N. vectensis ATF2 34679 NV8 RRSQEELDPDERRRKFLERNR
AAATRCREKRKIWVQQLEKK
ADDLSNTNTQLQNEISLLRTE
VAQLKSLLLAHK
N. vectensis NOVEL 248021 NV9 FNEPLTEEELKDIEDKNKKNA
IAARENRAKKKKYMEDLEKT
VQDLKKENQELQTGHSKLQK
TVEALNDEVSYYKNVLA
N. vectensis PAR 241379 NV1O PSPSSSSGDSDKSEEKRKRNN
QASKKFRQARKGKQQALFA
KESELERENYSLKVQVEQLIR
ELNQLKAALH
N. vectensis CEBPG 104726 NVl 1 SKRNSMDKHSEEYRQKRERN
NVAVRKSRFKSKQKFIETQSR
VEELTEENERLHSRIDIITKEL
NALRSLFS
N. vectensis LMAF 118896 NV12 KGLSTEEQSRIKYRRRTLKNR
GYAHNCRIKRISQKKSLEETN
WELVQDLENLRKELEASKRE
RDMYKRKYENLYAMVM
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N. vectensis SMAF 99714 NV13 RGLPEDDVFKLKQRRRTLKN
RGYAQNSRTKRVRQREDLEY
ERQQLKDELFMVSKENEDLR
RERDEAKRKYDSLQKLLT
N. vectensis JUN 238589 NV14 PPIDLDLQEAVKNERKKLRN
RLAASKCRKRKLEKEAELED
KVKVLKDKNTKLVSEAQELR
RLVCELKEQVMNHV
N. vectensis JUN 95962 NV15 QPIDLEIQEVVKRERKKQRNR
IASSKCRKRKLEREARLENRV
KDLKERNIELNAVANALKQQ
VCDLKQRVMDHV
N. vectensis PAR 80243 NV16 AYGRDKDQKYIEKRMKNNL
AAKRSREAKRQREIEAMQKT
LTLEKENSDLNKEVNKLKKM
IARLENKLR
N. vectensis PAR 86952 NV17 RTSVPGEMKDQKYWERRLK
NNVAAKRSRDLKRQKEMTV
AKRAQNLEIENEKLRNEVTM
LKKRLQTLNGKLD
N. vectensis LMAF 242787 NV18 RGLPSTEIDTIRKRRRSLKNR
GYAMNCRTKREQENKELAK
MNKKLARDVVSMKEELRKIK
KERDAMKTKYDKMREVLNR
LC
N. vectensis CREB 243410 NV19 SNQQIAEEATRKREMRLMKN
REAAKECRRKKKEYVKCLEN
RVAVLENQNKTLIEELKALK
DLYCHKSE
N. vectensis NOVEL 127893 NV20 VSPTQLDMDRYVSDEGINRQ
AIMAKINREKKKQYVQELEG
SVEEYKSKNAVLQKDCEDM
KGLVKDLQMEIAYLKGVLA
N. vectensis NFE2 245260 NV21 EKLSDAQAKYVRDVRRRGK
NKEAARICRKRKMDAIETLD
DEITRLKQQRQSMFDERKDL
QQETAELKRKISELESSLF
N. vectensis ATF6 242270 NV22 QQPKVLDEKILRRQQRMIKN
RESACLSRKKKKEYLQSLET
QIKEVNLLNDKLSEENIKLKK
RVQELENENNILKAKN
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N. vectensis NOVEL 197394 NV23 SRDTKASTSIDKATERRIKNNI
ASRHTRAARRQREQELFEKE
EYLKKNNEELKQQIVELTKET
EILRKLVIQRLSSVN
N. vectensis PAR 243817 NV24 LSKAIADVKTEQYREKRRKN
NASAKRSREARKMREIHAQT
AAAYLQDENAKLRALVNVL
KEENVYLREIML
N. vectensis OASISA 244559 NV25 VSLTKAEERVLKKVRRKIKN
KQSAQESRKKKKDYVDGLE
MRVKVCTEKNTSLQKKVDN
LEKQNLTLMDQLKQLQAIVA
N. vectensis FOS 232694 NV26 FFCQLTPAEELKIIRRRQRNK
QAASRCREKRRQRLEELQRE
ATELEEQNAEVERDIATLRVE
YNELEALLTEHACVL
N. vectensis FOS 126097 NV27 KVEELSPAELEKRRIRRERNK
LAAFKCRQRRKEHIQELEIES
EGIEDSNKELEREISELHEQRQ
QLEEMLKTHSCKLS
N. vectensis JUN 150375 NV28 PPIDLELQEIVKRERKKQKNR
VAASKCRRKKLEREAQLEVR
VQQLKEKSIELNAVASALRQ
QVGELKQRVLEHV
N. vectensis PAR 29743 NV29 RKFVPDQEKDDRYWARRVK
NNVAARRSRDMRRQKEIEIS
MKWKQLEKENARLREELQQ
LKDRASELEKKLSEKQ
N. vectensis FOS 248713 NV30 LTPEEETRRKVRRQRNKVAA
SKCRLKRREHVKNLLKASEE
LESANSKLESDIACLNAEKEQ
LERMLDAHK
N. vectensis PAR 242269 NV31 TPVKVSKMDLQREAEKRRKN
NEASKRTREKRRNKEQELLK
EKEIKEKENKALRTQVEDLE
KQIKDIRSALDQRL
N. vectensis NOVEL 18367 NV33 GKKRGRKPSQIDLEAKLERSR
QSARECRARKKLRYKCLEDT
VTRKESEVSKLRQELDMYVR
WCKAIDQGVY
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N. vectensis LMAF 39846 NV34 RGLENSEIVRLRKRRRSLKNR
IYASVCKKKRVAEQKTYEVQ
NRILVKERNTLKMELEKVKT
ERDKIKEAYQTL
N. vectensis ATF4 sca_303 NV35 DTVSPKLKTPAQRQRKRVQN
KDAATRYRVKKKDEQSRLFD
EAEKLEKENNELKDEVGSLS
KEIEYLKNLMLEVYQTKQ
N. vectensis NOVEL 242703 NV36 SKDEQDLHRKLQEIQATQGD
MEEAQREIEKKKTEIEKIKAE
LEELQQKTVTLNRKRKSLSSE
CSQLQKKLHYCDSVLQVV
M brevicollis 37668 MB1 RASSVDPPIDERRLKHLERNR
AAATRCRERKKQWLQQLQQ
KAATLTTSNRQMHEELKRLR
DEVLNLKGNLV
M brevicollis 36000 MB2 DSEEAFSLAWQEWRSVRQKN
NAAVHKSRQKAKARRAVDR
HAAREKERKAAQLAMEAEM
LRKNVDVLIKAVR
M brevicollis 11417 MB3 DECTKHMKGMTPAQKKRLR
NKHASCVSRLKKKLYICNLV
RELDRAKETAAAFQDDMDA
LRARVTELEAENQHLR
M brevicollis 38819 MB4 DIKPDTTATAKRPSNKRASNR
ESARRFRQRRKEYIGQLEKK
VSRLISENQRLRALLTAHL
M brevicollis 32288 MB5 RRRRIADLAEADRARLRRLN
REAARKHRERSKWRDESAA
QDLQRLVLHHKQLASEAAAL
RTEVSTLREVVRTLY
M brevicollis 9939 MB6 DTEDEYQDAWQRWRAIRDH
NNESVKRSRENARHRKHQHE
AACRERERENSQLATEVDRL
KDQVVLLTKVLK
M brevicollis 30420 MB7 GLITQAQSRELKRMRRKVKN
KLSAKDSRRRRKEYVTQLEE
ENAQLRARLVTLHDQSMAR
Q
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M brevicollis 34232 MB8 PTSPASTVDSQLTDRTREFNRI
AALRHRQRAKMRRLELDQR
LLEASRHQQQLKMEMEELSK
KHHSLLELCFTLY
M brevicollis 32251 MB9 ELSGETTSKRAKTTDKKQLN
KQAADRYRRKKRQQFEELQS
QSSELADENKALSVKCERLE
NEVAYLKDLLM
M brevicollis 31571 MB10 KVAVAEHLKDEAYLAYREL
NNERARRCREKKREEKRQAS
RRLQTLDAENERLKDEMHRL
QDALKDLVQAMQARV
M brevicollis 31254 MB11 HSSDTHEDDDDHAGSTSNPN
KSAADRYRKKKREEFERLQH
DTEAMKAENLELKTRLSKLR
NEAEFLANMLQ
M brevicollis 38264 MB12 TKPSAGLSKAQLAEWRRDNN
RTAAKDLRDRKRQFEEDVSH
VVELAEAENAKLAARAQQLE
HHHATMRARLGAFMHTFNQ
VT
M brevicollis 31590 MB13 PANTPRGEDSNNYRIKRIRNN
EAVRRCRIKKKQEMEEKAMR
LELLEHKVSDLENCNRKLSEL
IVEQQKEIQRLRSERDTL
M brevicollis 24481 MB14 ATDDEYNLAWIKWRQSRDS
NNRSVKRSREKARERYQEIEI
QKDHLVQHNTELLNQLRQA
Q
M brevicollis 22289 MB15 LSPVELLEIKEKKERRMLKNR
ESASLSRKRKKEYLETLEHQL
HDAQQQLGRAQHQIQQLQN
DNHVLREQLANYHGFVN
M brevicollis 32766 MB16 RALTKAEEKELKKVRRKVKN
KISAQDSRKRRKEYLSQLEDK
VKSAMTNNRSLKTRVSSLER
QNSNLMEQINELHARLA
M brevicollis 33073 MB17 KRKLVADLNSSELEKMREVN
RIAAQRHRLIEKAKRRERQDR
FDSAIRLQKALQEEVVVLENE
LATLRRLVIELY
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M brevicollis 6968 MB18 AGLSKSEVADVKAKRRRLKN
RLSARLCSNKKREKCSELEDT
NRDLLAKLRQVAQENKTLKS
ETNRLKEANTALT
M brevicollis 38380 MB19 EHETSEQQAELRKRRRRTQN
RSAAKTSALRRKTNSLSTHA
KLAKFEEENRSLQQQLSLAR
QEKEDLLLANRILRAEIA
M brevicollis 10973 MB20 KALEAINTAGTDAARRKTRN
RLASAVSRARKKVFLHRLRS
ELLQLAARYQVSTIESQQFRL
QSLQAQRELWDLK
M brevicollis 31046 MB21 GSEEEYQLAWTKWRESRDN
NNESVKRSRMMAKKKREEQ
ERVHEEREAQNRKLETVVSS
MRDEVKFLNKVLK
M brevicollis 10034 MB22 LVDQLEARLETMTQHATEQN
KQLLRTTKKRQLEIDSELTSS
SEAIAKQIAQVQADLATLRRN
NKEIETKLR
S. cerevisiae YAP3 SCi SVAHNENVPDDSKAKKKAQ
NRAAQKAFRERKEARMKEL
QDKLLESERNRQSLLKEIEEL
RKANTEINAENRLLL
S. cerevisiae YAP5 SC2 HEDYETEENDEELQKKKRQN
RDAQRAYRERKNNKLQVLEE
TIESLSKVVKNYETKLNRLQN
ELQAKESENHALKQKLETLT
LKQASV
S. cerevisiae HAC1 SC3 KRAKTKEEKEQRRIERILRNR
RAAHQSREKKRLHLQYLERK
CSLLENLLNSVNLEKLADH
S. cerevisiae CST6 SC4 QGNPIPGTTAWKRARLLERN
RIAASKCRQRKKVAQLQLQK
EFNEIKDENRILLKKLNYYEK
LISKFKKFSKIHLREHEKLN
S. cerevisiae SKO1 SC5 VTLDENEEQERKRKEFLERN
RVAASKFRKRKKEYIKKIEND
LQFYESEYDDLTQVIGKLCGII
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S. cerevisiae ACA1 SC6 TAGLKDGAKAWKRARLLER
NRIAASKCRQRKKMSQLQLQ
REFDQISKENTMMKKKIENY
EKLVQKMKKISRLHM
S. cerevisiae CIN5 SC7 GQLIGKTGKPLRNTKRAAQN
RSAQKAFRQRREKYIKNLEE
KSKLFDGLMKENSELKKMIE
SLKSKLKE
S. cerevisiae YAPI SC8 KTSKKQDLDPETKQKRTAQN
RAAQRAFRERKERKMKELEK
KVQSLESIQQQNEVEATFLRD
QLITLVNELKKYR
S. cerevisiae MET28 SC9 APVSTSNELDKIKQERRRKNT
EASQRFRIRKKQKNFENMNK
LQNLNTQINKLRDRIEQLNKE
NEFWKAKLNDINEIKS
S. cerevisiae GCN4 Sc10 PLSPIVPESSDPAALKRARNTE
AARRSRARKLQRMKQLEDK
VEELLSKNYHLENEVARLKK
LV
S. cerevisiae CADI SCi1 GRPGRKRIDSEAKSRRTAQN
RAAQRAFRDRKEAKMKSLQ
ERVELLEQKDAQNKTTTDFL
LCSLKSLLSEITKYRAKNSDD
ERILAFLD
S. cerevisiae YAP7 SC12 GNGSGDENGVDSVEKRRRQ
NRDAQRAYRERRTTRIQVLE
EKVEMLHNLVDDWQRKYKL
LESEFSDTKENLQKSIALNNE
LQKAL
S. cerevisiae YAP6 SC13 TQLISSSGKTLRNTRRAAQNR
TAQKAFRQRKEKYIKNLEQK
SKIFDDLLAENNNFKSLNDSL
RNDNNILIAQHEAIRNAITML
RSEYD
S. cerevisiae ARRI SC14 RKGGRKPSLTPPKNKRAAQL
RASQNAFRKRKLERLEELEK
KEAQLTVTNDQIHILKKENEL
LHFMLRSLLT
S. cerevisiae MET4 SC15 HGFEKKQLIKKELGDDDEDL
LIQSKKSHQKKKLKEKELESS
IHELTEIAASLQKRIHTLETEN
KLLKNLVL
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Table 5.2: Equilibrium dissociation constants. Kd values, in nM, for each interaction measured.
NB, Non-binders.
Human bZIP interactions.
Family DDIT3 CEBPG CEBP CEBP CREB OASISA
Family Protein DDIT3 CEBPG CEBPA CEBPE CREBI CREB3
DDIT3 DDIT3 8.1 <1 <1 <1 NB 315.1
CEBPG CEBPG <1 2.0 <1 <1 NB 365.4
CEBP CEBPA <1 <1 7.9 19.0 NB NB
CEBP CEBPE <1 <1 19.0 <1 NB NB
CREB CREBI NB NB NB NB 20.7 NB
OASISA CREB3 315.1 365.4 NB NB NB 78.0
OASISA CREB3L3 >5000 NB NB NB NB 527.0
OASISB CREB3L1 600.9 4476.0 NB NB NB 355.5
CREBZF CREBZF NB NB NB NB NB NB
XBP1 XBP1 NB NB NB NB NB 3169.0
ATF6 ATF6 NB NB NB NB NB NB
ATF6 ATF6B NB NB NB NB NB 2693.4
NFIL3 NFIL3 219.0 4135.8 NB NB 2869.6 2144.8
PAR DBP 1.3 101.9 245.2 278.5 NB NB
PAR HLF 7.9 NB NB NB NB NB
ATF2 ATF2 14.8 80.8 1935.4 NB NB NB
JUN JUN 16.8 425.9 NB 3859.1 2566.9 NB
JUN JUNB 146.1 NB NB 2222.3 NB NB
FOS FOS 18.9 61.4 28.5 290.3 NB NB
FOS FOSLI 115.0 170.3 399.8 363.1 NB NB
ATF4 ATF4 <1 <1 <1 <1 NB 48.2
ATF4 ATF5 2261.4 <1 76.8 29.2 NB NB
ATF3 ATF3 <1 <1 29.2 63.8 NB 1535.9
BATF BATF <1 <1 24.0 69.2 NB 288.6
BATF BATF2 5.6 1.5 77.4 115.7 NB 352.3
BATF BATF3 <1 9.6 7.5 45.7 2453.2 542.1
SMAF MAFF 168.3 1156.8 NB NB NB NB
SMAF MAFG 447.5 NB NB NB NB NB
LMAF MAF NB NB NB NB NB NB
LMAF MAFB NB NB NB NB NB NB
NFE2 NFE2 3271.5 NB NB NB NB 2433.2
NFE2 NFE2L1 2898.0 1738.2 NB NB NB NB
NFE2 NFE2L2 NB 1637.0 NB 2368.5 NB 439.5
NFE2 NFE2L3 NB 1124.0 4696.3 NB NB 191.4
BACH BACHI 59.5 NB NB NB 3259.0 NB
BACH BACH2 79.2 2290.5 NB 2491.4 NB 2634.8
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Family OASISA OASISB CREBZF XBP1 ATF6 ATF6
Family Protein CREB3L3 CREB3L1 CREBZF XBP1 ATF6 ATF6B
DDIT3 DDIT3 >5000 600.9 NB NB NB NB
CEBPG CEBPG NB 4476.0 NB NB NB NB
CEBP CEBPA NB NB NB NB NB NB
CEBP CEBPE NB NB NB NB NB NB
CREB CREBI NB NB NB NB NB NB
OASISA CREB3 527.0 355.5 NB 3169.0 NB 2693.4
OASISA CREB3L3 5.1 96.1 NB NB NB NB
OASISB CREB3L1 96.1 8.9 NB NB NB NB
CREBZF CREBZF NB NB 1.9 <1 3864.7 3517.1
XBP1 XBP1 NB NB <1 6.2 <1 <1
ATF6 ATF6 NB NB 3864.7 <1 15.2 <1
ATF6 ATF6B NB NB 3517.1 <1 <1 1.1
NFIL3 NFIL3 NB 346.9 3666.6 NB NB NB
PAR DBP NB NB NB NB NB NB
PAR HLF NB NB NB NB NB NB
ATF2 ATF2 NB NB NB NB NB NB
JUN JUN NB NB NB NB NB NB
JUN JUNB NB NB NB NB NB NB
FOS FOS NB NB NB NB NB NB
FOS FOSLI NB NB NB NB NB NB
ATF4 ATF4 2883.8 >5000 35.9 NB NB NB
ATF4 ATF5 NB NB 2007.2 NB NB NB
ATF3 ATF3 NB NB NB NB NB NB
BATF BATF NB NB NB NB NB NB
BATF BATF2 NB >5000 NB NB NB NB
BATF BATF3 NB NB NB NB NB NB
SMAF MAFF NB NB NB NB NB NB
SMAF MAFG NB NB 4377.7 NB NB NB
LMAF MAF NB NB NB NB NB NB
LMAF MAFB NB NB NB >5000 NB NB
NFE2 NFE2 NB NB 167.2 2792.3 NB 2826.2
NFE2 NFE2L1 NB NB 33.8 1903.1 NB NB
NFE2 NFE2L2 NB 1675.7 86.3 NB NB NB
NFE2 NFE2L3 NB NB 1922.9 NB NB NB
BACH BACHI NB NB 2576.1 NB NB NB
BACH BACH2 NB NB 458.1 1887.3 NB 2313.7
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Family NFIL3 PAR PAR ATF2 JUN JUN
Family Protein NFIL3 DBP HLF ATF2 JUN JUNB
DDIT3 DDIT3 219.0 1.3 7.9 14.8 16.8 146.1
CEBPG CEBPG 4135.8 101.9 NB 80.8 425.9 NB
CEBP CEBPA NB 245.2 NB 1935.4 NB NB
CEBP CEBPE NB 278.5 NB NB 3859.1 2222.3
CREB CREBI 2869.6 NB NB NB 2566.9 NB
OASISA CREB3 2144.8 NB NB NB NB NB
OASISA CREB3L3 NB NB NB NB NB NB
OASISB CREB3L1 346.9 NB NB NB NB NB
CREBZF CREBZF 3666.6 NB NB NB NB NB
XBP1 XBP1 NB NB NB NB NB NB
ATF6 ATF6 NB NB NB NB NB NB
ATF6 ATF6B NB NB NB NB NB NB
NFIL3 NFIL3 52.1 3964.6 NB NB NB NB
PAR DBP 3964.6 6.5 <1 >5000 3768.2 3842.1
PAR HLF NB <1 2.9 NB NB 3616.8
ATF2 ATF2 NB >5000 NB 29.4 16.4 939.4
JUN JUN NB 3768.2 NB 16.4 185.9 2961.3
JUN JUNB NB 3842.1 3616.8 939.4 2961.3 NB
FOS FOS NB 2373.4 NB 6.7 <1 <1
FOS FOSLI NB NB NB 236.7 <1 2.4
ATF4 ATF4 NB NB 721.2 7.7 25.2 258.8
ATF4 ATF5 NB NB NB NB NB NB
ATF3 ATF3 NB 129.3 NB <1 <1 5.6
BATF BATF 262.9 117.3 28.8 18.2 <1 <1
BATF BATF2 1251.4 457.0 779.8 635.7 <1 2.1
BATF BATF3 184.0 43.3 92.1 28.2 <1 <1
SMAF MAFF 50.3 4403.3 NB NB NB >5000
SMAF MAFG 739.4 NB NB NB 4149.9 3624.5
LMAF MAF NB NB NB NB NB NB
LMAF MAFB NB NB NB NB NB NB
NFE2 NFE2 NB >5000 NB NB NB NB
NFE2 NFE2L1 1751.8 3953.2 NB NB NB NB
NFE2 NFE2L2 NB NB NB NB NB NB
NFE2 NFE2L3 1198.9 3278.5 NB NB NB NB
BACH BACH1 586.7 4238.2 NB 60.4 NB NB
BACH BACH2 2408.6 3457.4 NB 667.6 4461.0 NB
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Family FOS FOS ATF4 ATF4 ATF3 BATF
Family Protein FOS FOSLI ATF4 ATF5 ATF3 BATF
DDIT3 DDIT3 18.9 115.0 <1 2261.4 <1 <1
CEBPG CEBPG 61.4 170.3 <1 <1 <1 <1
CEBP CEBPA 28.5 399.8 <1 76.8 29.2 24.0
CEBP CEBPE 290.3 363.1 <1 29.2 63.8 69.2
CREB CREBI NB NB NB NB NB NB
OASISA CREB3 NB NB 48.2 NB 1535.9 288.6
OASISA CREB3L3 NB NB 2883.8 NB NB NB
OASISB CREB3L1 NB NB >5000 NB NB NB
CREBZF CREBZF NB NB 35.9 2007.2 NB NB
XBP1 XBP1 NB NB NB NB NB NB
ATF6 ATF6 NB NB NB NB NB NB
ATF6 ATF6B NB NB NB NB NB NB
NFIL3 NFIL3 NB NB NB NB NB 262.9
PAR DBP 2373.4 NB NB NB 129.3 117.3
PAR HLF NB NB 721.2 NB NB 28.8
ATF2 ATF2 6.7 236.7 7.7 NB <1 18.2
JUN JUN <1 <1 25.2 NB <1 <1
JUN JUNB <1 2.4 258.8 NB 5.6 <1
FOS FOS 386.3 604.5 1.5 NB 169.2 1001.3
FOS FOSLI 604.5 3739.7 42.6 NB 227.9 1996.2
ATF4 ATF4 1.5 42.6 186.0 NB <1 10.1
ATF4 ATF5 NB NB NB NB 3641.2 183.4
ATF3 ATF3 169.2 227.9 <1 3641.2 113.6 16.2
BATF BATF 1001.3 1996.2 10.1 183.4 16.2 104.6
BATF BATF2 4824.7 >5000 9.8 1601.0 568.2 164.5
BATF BATF3 382.0 381.9 1.3 383.3 2.0 42.2
SMAF MAFF 257.3 NB 192.9 NB 22.6 2493.7
SMAF MAFG 3608.1 NB 215.4 NB 120.5 NB
LMAF MAF 185.1 202.5 1.7 NB NB NB
LMAF MAFB 60.5 151.6 84.8 NB 485.1 611.8
NFE2 NFE2 NB NB 65.6 2900.8 NB NB
NFE2 NFE2L1 1917.5 2137.5 38.6 NB NB 2118.9
NFE2 NFE2L2 3977.2 NB 12.2 1717.7 NB NB
NFE2 NFE2L3 NB NB 34.4 NB NB NB
BACH BACHI 468.9 1224.3 160.4 NB 1866.6 114.6
BACH BACH2 363.9 1745.7 452.6 NB 3371.9 199.6
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Family BATF BATF SMAF SMAF LMAF LMAF
Family Protein BATF2 BATF3 MAFF MAFG MAF MAFB
DDIT3 DDIT3 5.6 <1 168.3 447.5 NB NB
CEBPG CEBPG 1.5 9.6 1156.8 NB NB NB
CEBP CEBPA 77.4 7.5 NB NB NB NB
CEBP CEBPE 115.7 45.7 NB NB NB NB
CREB CREBI NB 2453.2 NB NB NB NB
OASISA CREB3 352.3 542.1 NB NB NB NB
OASISA CREB3L3 NB NB NB NB NB NB
OASISB CREB3L1 >5000 NB NB NB NB NB
CREBZF CREBZF NB NB NB 4377.7 NB NB
XBP1 XBP1 NB NB NB NB NB >5000
ATF6 ATF6 NB NB NB NB NB NB
ATF6 ATF6B NB NB NB NB NB NB
NFIL3 NFIL3 1251.4 184.0 50.3 739.4 NB NB
PAR DBP 457.0 43.3 4403.3 NB NB NB
PAR HLF 779.8 92.1 NB NB NB NB
ATF2 ATF2 635.7 28.2 NB NB NB NB
JUN JUN <1 <1 NB 4149.9 NB NB
JUN JUNB 2.1 <1 >5000 3624.5 NB NB
FOS FOS 4824.7 382.0 257.3 3608.1 185.1 60.5
FOS FOSLI >5000 381.9 NB NB 202.5 151.6
ATF4 ATF4 9.8 1.3 192.9 215.4 1.7 84.8
ATF4 ATF5 1601.0 383.3 NB NB NB NB
ATF3 ATF3 568.2 2.0 22.6 120.5 NB 485.1
BATF BATF 164.5 42.2 2493.7 NB NB 611.8
BATF BATF2 2359.5 303.7 43.3 1039.6 NB NB
BATF BATF3 303.7 88.2 9.8 46.1 NB NB
SMAF MAFF 43.3 9.8 17.3 5.1 NB NB
SMAF MAFG 1039.6 46.1 5.1 13.7 NB NB
LMAF MAF NB NB NB NB <1 2.5
LMAF MAFB NB NB NB NB 2.5 39.4
NFE2 NFE2 NB NB 475.2 692.4 NB NB
NFE2 NFE2L1 109.6 3264.6 <1 <1 NB NB
NFE2 NFE2L2 NB NB 9.8 1.5 NB NB
NFE2 NFE2L3 4802.8 NB <1 <1 NB NB
BACH BACHI 26.9 37.9 1.3 <1 187.7 114.9
BACH BACH2 32.7 65.7 <1 <1 1307.1 371.6
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Family NFE2 NFE2 NFE2 NFE2 BACH BACH
Family Protein NFE2 NFE2L1 NFE2L2 NFE2L3 BACH1 BACH2
DDIT3 DDIT3 3271.5 2898.0 NB NB 59.5 79.2
CEBPG CEBPG NB 1738.2 1637.0 1124.0 NB 2290.5
CEBP CEBPA NB NB NB 4696.3 NB NB
CEBP CEBPE NB NB 2368.5 NB NB 2491.4
CREB CREBI NB NB NB NB 3259.0 NB
OASISA CREB3 2433.2 NB 439.5 191.4 NB 2634.8
OASISA CREB3L3 NB NB NB NB NB NB
OASISB CREB3L1 NB NB 1675.7 NB NB NB
CREBZF CREBZF 167.2 33.8 86.3 1922.9 2576.1 458.1
XBP1 XBP1 2792.3 1903.1 NB NB NB 1887.3
ATF6 ATF6 NB NB NB NB NB NB
ATF6 ATF6B 2826.2 NB NB NB NB 2313.7
NFIL3 NFIL3 NB 1751.8 NB 1198.9 586.7 2408.6
PAR DBP >5000 3953.2 NB 3278.5 4238.2 3457.4
PAR HLF NB NB NB NB NB NB
ATF2 ATF2 NB NB NB NB 60.4 667.6
JUN JUN NB NB NB NB NB 4461.0
JUN JUNB NB NB NB NB NB NB
FOS FOS NB 1917.5 3977.2 NB 468.9 363.9
FOS FOSLI NB 2137.5 NB NB 1224.3 1745.7
ATF4 ATF4 65.6 38.6 12.2 34.4 160.4 452.6
ATF4 ATF5 2900.8 NB 1717.7 NB NB NB
ATF3 ATF3 NB NB NB NB 1866.6 3371.9
BATF BATF NB 2118.9 NB NB 114.6 199.6
BATF BATF2 NB 109.6 NB 4802.8 26.9 32.7
BATF BATF3 NB 3264.6 NB NB 37.9 65.7
SMAF MAFF 475.2 <1 9.8 <1 1.3 <1
SMAF MAFG 692.4 <1 1.5 <1 <1 <1
LMAF MAF NB NB NB NB 187.7 1307.1
LMAF MAFB NB NB NB NB 114.9 371.6
NFE2 NFE2 212.4 2505.4 240.9 17.9 NB NB
NFE2 NFE2L1 2505.4 25.3 1466.9 64.7 NB 84.4
NFE2 NFE2L2 240.9 1466.9 2212.0 103.9 NB NB
NFE2 NFE2L3 17.9 64.7 103.9 10.9 NB 458.0
BACH BACHI NB NB NB NB NB NB
BACH BACH2 NB 84.4 NB 458.0 NB 548.8
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C. intestinalis bZIP interactions.
Family CEBPG CEBP CEBP CEBP CREB OASISA
Family Protein Cli C12 C13 C14 CI5 C16
CEBPG CIlI NB 37.5 >5000 7.2 NB NB
CEBP C12 37.5 <1 <1 <1 NB NB
CEBP C13 >5000 <1 2967.3 NB NB NB
CEBP C14 7.2 <1 NB NB NB NB
CREB C15 NB NB NB NB 10.9 NB
OASISA C16 NB NB NB NB NB 1476.3
OASISB C17 NB NB NB >5000 NB 359.1
XBP1 C18 NB NB NB NB NB NB
XBP1 C19 NB NB 33.1 NB NB 1243.0
XBP1 CIlo NB NB NB 19.4 NB 94.7
XBP1 Cill NB NB NB NB NB NB
ATF6 C112 NB NB NB NB NB NB
NFIL3 C113 NB NB NB 3171.0 NB NB
PAR C114 NB NB 1617.7 NB NB NB
ATF2 CI5 184.4 62.4 NB 97.9 NB NB
JUN C116 NB NB 3381.8 NB NB NB
FOS C117 NB NB NB 2816.3 NB NB
FOS C118 4964.7 NB NB 1726.3 NB 145.5
ATF4 C119 10.2 552.2 2283.9 NB NB NB
ATF3 C120 6.6 9.1 1852.8 23.2 NB NB
SMAF C121 NB NB NB NB NB NB
LMAF CI22 NB NB 1620.4 NB NB NB
NFE2 C123 NB NB NB NB NB NB
BACHI C124 NB NB 3706.2 NB NB NB
NOVEL C125 NB NB NB NB NB NB
NOVEL C126 NB NB NB NB NB NB
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Family OASISB XBP1 XBP1 XBP1 XBP1 ATF6
Family Protein C17 C18 C19 CIlo Ciil C112
CEBPG CIlI NB NB NB NB NB NB
CEBP C12 NB NB NB NB NB NB
CEBP C13 NB NB 33.1 NB NB NB
CEBP C14 >5000 NB NB 19.4 NB NB
CREB CI5 NB NB NB NB NB NB
OASISA C16 359.1 NB 1243.0 94.7 NB NB
OASISB C17 144.9 NB NB 556.2 NB NB
XBP1 C18 NB 74.5 NB 4.7 9.2 NB
XBP1 C19 NB NB 93.9 1481.2 NB 9.5
XBP1 CIlo 556.2 4.7 1481.2 4.9 812.9 3294.7
XBP1 Cli I NB 9.2 NB 812.9 16.4 NB
ATF6 C112 NB NB 9.5 3294.7 NB 7.9
NFIL3 C113 NB NB 3193.5 169.7 NB 3480.2
PAR C114 NB NB NB 47.6 NB >5000
ATF2 CIl5 NB NB NB 1030.7 NB NB
JUN C116 NB NB NB NB NB NB
FOS C117 NB NB 4386.6 NB NB NB
FOS C118 NB NB 31.3 NB 171.8 NB
ATF4 C119 NB NB NB 468.7 NB NB
ATF3 C120 2777.9 3247.4 71.7 NB NB 4368.6
SMAF C121 NB NB NB 266.2 NB NB
LMAF C122 NB NB NB 39.0 NB 4727.0
NFE2 C123 NB NB NB NB 4589.4 NB
BACHI C124 NB NB NB 97.3 NB NB
NOVEL C125 NB NB NB 968.3 NB NB
NOVEL C126 NB NB NB 1090.2 NB NB
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Family NFIL3 PAR ATF2 JUN FOS FOS
Family Protein C113 C114 C1l5 C116 C117 C118
CEBPG CIl NB NB 184.4 NB NB 4964.7
CEBP C12 NB NB 62.4 NB NB NB
CEBP C13 NB 1617.7 NB 3381.8 NB NB
CEBP C14 3171.0 NB 97.9 NB 2816.3 1726.3
CREB C15 NB NB NB NB NB NB
OASISA C16 NB NB NB NB NB 145.5
OASISB C17 NB NB NB NB NB NB
XBP1 C18 NB NB NB NB NB NB
XBP1 C19 3193.5 NB NB NB 4386.6 31.3
XBP1 CIlo 169.7 47.6 1030.7 NB NB NB
XBP1 CIl l NB NB NB NB NB 171.8
ATF6 C112 3480.2 >5000 NB NB NB NB
NFIL3 C113 29.7 110.9 NB NB 1443.4 2182.8
PAR C114 110.9 12.5 320.7 1120.6 NB 973.7
ATF2 CIl5 NB 320.7 22.3 52.3 25.0 41.1
JUN C116 NB 1120.6 52.3 NB 2301.4 76.8
FOS C117 1443.4 NB 25.0 2301.4 NB NB
FOS C118 2182.8 973.7 41.1 76.8 NB NB
ATF4 C119 NB NB 2342.7 NB NB NB
ATF3 C120 910.6 2482.5 <1 <1 NB 2591.0
SMAF C121 NB 102.6 NB NB NB NB
LMAF C122 NB NB NB NB NB NB
NFE2 C123 NB NB 1482.6 NB NB NB
BACHI CI24 NB 43.2 NB NB NB NB
NOVEL C125 3045.4 1977.1 NB NB NB NB
NOVEL C126 709.1 3330.4 NB NB NB NB
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Family ATF4 ATF3 SMAF LMAF NFE2 BACHI
Family Protein C119 C120 C121 C122 C123 C124
CEBPG CIlI 10.2 6.6 NB NB NB NB
CEBP C12 552.2 9.1 NB NB NB NB
CEBP C13 2283.9 1852.8 NB 1620.4 NB 3706.2
CEBP C14 NB 23.2 NB NB NB NB
CREB CI5 NB NB NB NB NB NB
OASISA C16 NB NB NB NB NB NB
OASISB C17 NB 2777.9 NB NB NB NB
XBP1 C18 NB 3247.4 NB NB NB NB
XBP1 C19 NB 71.7 NB NB NB NB
XBP1 CIlo 468.7 NB 266.2 39.0 NB 97.3
XBP1 Cli I NB NB NB NB 4589.4 NB
ATF6 C112 NB 4368.6 NB 4727.0 NB NB
NFIL3 C113 NB 910.6 NB NB NB NB
PAR C114 NB 2482.5 102.6 NB NB 43.2
ATF2 CIl5 2342.7 <1 NB NB 1482.6 NB
JUN C116 NB <1 NB NB NB NB
FOS C117 NB NB NB NB NB NB
FOS C118 NB 2591.0 NB NB NB NB
ATF4 C119 1487.2 238.1 NB NB NB NB
ATF3 C120 238.1 607.7 NB NB 2478.5 NB
SMAF C121 NB NB 111.9 NB 36.3 52.4
LMAF C122 NB NB NB 120.0 NB NB
NFE2 C123 NB 2478.5 36.3 NB NB >5000
BACH1 C124 NB NB 52.4 NB >5000 NB
NOVEL C125 NB NB NB NB NB NB
NOVEL C126 NB NB NB NB NB 1794.5
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Family NOVEL NOVEL
Family Protein C125 C126
CEBPG CIlI NB NB
CEBP C12 NB NB
CEBP C13 NB NB
CEBP C14 NB NB
CREB C15 NB NB
OASISA C16 NB NB
OASISB C17 NB NB
XBP1 C18 NB NB
XBP1 C19 NB NB
XBP1 CIlo 968.3 1090.2
XBP1 Cli I NB NB
ATF6 C112 NB NB
NFIL3 C113 3045.4 709.1
PAR C114 1977.1 3330.4
ATF2 C115 NB NB
JUN C116 NB NB
FOS C117 NB NB
FOS C118 NB NB
ATF4 C119 NB NB
ATF3 C120 NB NB
SMAF C121 NB NB
LMAF C122 NB NB
NFE2 C123 NB NB
BACHi C124 NB 1794.5
NOVEL C125 298.4 NB
NOVEL C126 NB 2782.5
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D. melanogaster bZIP interactions.
Family CEBPG CEBP CREB OASISB XBP1 ATF6
Family Protein DM10 DM8 DM9 DM4 DM18 DM15
CEBPG DM10 NB NB NB NB NB NB
CEBP DM8 NB 221.3 NB NB NB NB
CREB DM9 NB NB 5.8 NB NB NB
OASISB DM4 NB NB NB <1 NB NB
XBP1 DM18 NB NB NB NB 13.0 2346.0
ATF6 DM15 NB NB NB NB 2346.0 80.1
NFIL3 DM16 NB NB NB NB NB NB
PAR DM1 NB NB NB NB NB 3559.6
PAR DM7 NB <1 NB NB 2650.5 685.5
PAR DM17 NB NB 281.7 NB NB 2520.1
PAR DM21 NB NB NB NB NB 2157.1
ATF2 DM5 NB NB NB NB NB NB
JUN DM14 NB 2517.3 NB NB NB 1474.7
FOS DM3 NB NB NB NB NB 2326.5
ATF4 DM6 <1 1.2 NB NB 274.4 2591.1
ATF3 DM11 NB NB NB NB NB NB
SMAF DM19 NB NB NB NB NB 2860.4
LMAF DM13 NB NB NB NB 594.8 4511.8
NFE2 DM12 NB NB NB NB NB 1634.7
NOVEL DM28 227.0 NB NB NB NB NB
NOVEL DM20 NB 3063.6 NB NB NB 1642.9
NOVEL DM22 NB NB NB NB 254.7 1218.4
NOVEL DM29 NB NB NB NB NB >5000
NOVEL DM23 NB NB NB NB NB NB
NOVEL DM24 NB NB NB NB NB NB
NOVEL DM26 NB 2822.5 NB NB 810.1 392.6
NOVEL DM27 NB NB NB NB 3573.2 186.8
NOVEL DM2 NB NB NB NB NB NB
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Family NFIL3 PAR PAR PAR PAR ATF2
Family Protein DM16 DM1 DM7 DM17 DM21 DM5
CEBPG DM10 NB NB NB NB NB NB
CEBP DM8 NB NB <1 NB NB NB
CREB DM9 NB NB NB 281.7 NB NB
OASISB DM4 NB NB NB NB NB NB
XBP1 DM18 NB NB 2650.5 NB NB NB
ATF6 DM15 NB 3559.6 685.5 2520.1 2157.1 NB
NFIL3 DM16 35.7 NB NB NB NB NB
PAR DM1 NB 8.9 NB NB NB NB
PAR DM7 NB NB 34.8 1686.0 2964.4 NB
PAR DM17 NB NB 1686.0 59.5 528.0 NB
PAR DM21 NB NB 2964.4 528.0 264.2 NB
ATF2 DM5 NB NB NB NB NB 8.9
JUN DM14 NB NB 290.2 869.3 NB NB
FOS DM3 NB NB NB 2133.6 1213.1 NB
ATF4 DM6 NB NB NB 2307.7 2740.5 NB
ATF3 DM11 NB 4020.8 NB NB NB NB
SMAF DM19 NB NB 2474.6 NB NB NB
LMAF DM13 NB NB NB NB 4636.2 NB
NFE2 DM12 NB NB NB 2923.0 885.9 NB
NOVEL DM28 NB NB NB NB NB NB
NOVEL DM20 NB NB 1814.4 706.2 851.1 NB
NOVEL DM22 NB 3290.4 526.8 NB NB NB
NOVEL DM29 NB NB NB NB 2879.1 NB
NOVEL DM23 NB NB NB NB NB NB
NOVEL DM24 NB NB NB 1220.2 3044.2 NB
NOVEL DM26 105.5 NB 175.9 78.7 145.0 NB
NOVEL DM27 NB NB 313.1 506.0 428.0 NB
NOVEL DM2 NB NB NB NB NB NB
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Family JUN FOS ATF4 ATF3 SMAF LMAF
Family Protein DM14 DM3 DM6 DM11 DM19 DM13
CEBPG DM10 NB NB <1 NB NB NB
CEBP DM8 2517.3 NB 1.2 NB NB NB
CREB DM9 NB NB NB NB NB NB
OASISB DM4 NB NB NB NB NB NB
XBP1 DM18 NB NB 274.4 NB NB 594.8
ATF6 DM15 1474.7 2326.5 2591.1 NB 2860.4 4511.8
NFIL3 DM16 NB NB NB NB NB NB
PAR DM1 NB NB NB 4020.8 NB NB
PAR DM7 290.2 NB NB NB 2474.6 NB
PAR DM17 869.3 2133.6 2307.7 NB NB NB
PAR DM21 NB 1213.1 2740.5 NB NB 4636.2
ATF2 DM5 NB NB NB NB NB NB
JUN DM14 NB 8.4 NB 449.2 NB NB
FOS DM3 8.4 NB NB NB NB NB
ATF4 DM6 NB NB 3301.4 NB NB NB
ATF3 DM11 449.2 NB NB NB NB NB
SMAF DM19 NB NB NB NB NB NB
LMAF DM13 NB NB NB NB NB 54.8
NFE2 DM12 NB 3873.9 3059.8 NB 4159.7 NB
NOVEL DM28 NB NB NB NB NB NB
NOVEL DM20 NB 3575.1 2825.7 NB NB NB
NOVEL DM22 259.6 NB NB NB NB NB
NOVEL DM29 NB NB NB NB NB NB
NOVEL DM23 NB NB NB NB NB NB
NOVEL DM24 NB NB NB NB NB NB
NOVEL DM26 NB 152.8 2231.2 NB 1554.0 NB
NOVEL DM27 NB 1962.3 1871.4 NB 2547.5 NB
NOVEL DM2 NB NB NB NB NB NB
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Family NFE2 NOVEL NOVEL NOVEL NOVEL NOVEL
Family Protein DM12 DM28 DM20 DM22 DM29 DM23
CEBPG DM10 NB 227.0 NB NB NB NB
CEBP DM8 NB NB 3063.6 NB NB NB
CREB DM9 NB NB NB NB NB NB
OASISB DM4 NB NB NB NB NB NB
XBP1 DM18 NB NB NB 254.7 NB NB
ATF6 DM15 1634.7 NB 1642.9 1218.4 >5000 NB
NFIL3 DM16 NB NB NB NB NB NB
PAR DM1 NB NB NB 3290.4 NB NB
PAR DM7 NB NB 1814.4 526.8 NB NB
PAR DM17 2923.0 NB 706.2 NB NB NB
PAR DM21 885.9 NB 851.1 NB 2879.1 NB
ATF2 DM5 NB NB NB NB NB NB
JUN DM14 NB NB NB 259.6 NB NB
FOS DM3 3873.9 NB 3575.1 NB NB NB
ATF4 DM6 3059.8 NB 2825.7 NB NB NB
ATF3 DM11 NB NB NB NB NB NB
SMAF DM19 4159.7 NB NB NB NB NB
LMAF DM13 NB NB NB NB NB NB
NFE2 DM12 2659.8 NB 1344.4 NB NB NB
NOVEL DM28 NB NB NB NB NB NB
NOVEL DM20 1344.4 NB 1165.2 NB NB NB
NOVEL DM22 NB NB NB NB NB NB
NOVEL DM29 NB NB NB NB NB NB
NOVEL DM23 NB NB NB NB NB NB
NOVEL DM24 NB NB 1354.5 NB NB NB
NOVEL DM26 93.6 NB 390.0 132.9 33.4 70.2
NOVEL DM27 791.5 NB 847.0 803.9 3051.8 NB
NOVEL DM2 NB NB NB NB NB NB
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Family NOVEL NOVEL NOVEL NOVEL
Family Protein DM24 DM26 DM27 DM2
CEBPG DM10 NB NB NB NB
CEBP DM8 NB 2822.5 NB NB
CREB DM9 NB NB NB NB
OASISB DM4 NB NB NB NB
XBP1 DM18 NB 810.1 3573.2 NB
ATF6 DM15 NB 392.6 186.8 NB
NFIL3 DM16 NB 105.5 NB NB
PAR DM1 NB NB NB NB
PAR DM7 NB 175.9 313.1 NB
PAR DM17 1220.2 78.7 506.0 NB
PAR DM21 3044.2 145.0 428.0 NB
ATF2 DM5 NB NB NB NB
JUN DM14 NB NB NB NB
FOS DM3 NB 152.8 1962.3 NB
ATF4 DM6 NB 2231.2 1871.4 NB
ATF3 DM11 NB NB NB NB
SMAF DM19 NB 1554.0 2547.5 NB
LMAF DM13 NB NB NB NB
NFE2 DM12 NB 93.6 791.5 NB
NOVEL DM28 NB NB NB NB
NOVEL DM20 1354.5 390.0 847.0 NB
NOVEL DM22 NB 132.9 803.9 NB
NOVEL DM29 NB 33.4 3051.8 NB
NOVEL DM23 NB 70.2 NB NB
NOVEL DM24 NB 304.2 1861.9 NB
NOVEL DM26 304.2 14.4 25.9 NB
NOVEL DM27 1861.9 25.9 94.0 NB
NOVEL DM2 NB NB NB NB
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C. elegans bZIP interactions.
Family CEPBG CEBPA CEBPA CREB OASISA OASISB
Family Protein CE18 CEl CE24 CE9 CE13 CE21
CEPBG CE18 2.3 NB NB NB NB NB
CEBPA CEl NB 65.6 13.3 NB NB NB
CEBPA CE24 NB 13.3 18.2 NB NB NB
CREB CE9 NB NB NB 21.5 NB NB
OASISA CE13 NB NB NB NB 82.5 136.0
OASISB CE21 NB NB NB NB 136.0 62.1
XBP1 CE6 NB NB NB NB NB NB
ATF6 CE10 NB NB NB NB NB NB
PAR CE14 <1 NB NB NB NB 3307.1
PAR CE3 29.2 NB NB NB NB NB
PAR CE12 12.4 NB NB NB NB 330.9
PAR CE23 NB NB NB NB NB NB
ATF2 CE30 NB NB NB NB NB NB
ATF2 CE5 NB NB NB NB NB NB
JUN CE7 157.2 NB NB NB NB NB
FOS CE8 359.0 NB NB NB NB NB
ATF4 CEll <1 NB NB NB NB NB
ATF4 CE15 <1 NB NB NB NB NB
ATF4 CE20 <1 NB NB NB NB NB
MAF CE19 NB NB 2624.0 NB NB 3020.0
NOVEL CE2 <1 NB NB NB NB NB
NOVEL CE16 73.5 NB NB NB NB NB
NOVEL CE22 <1 NB NB NB NB NB
NOVEL CE28 <1 NB NB NB NB NB
NOVEL CE17 NB NB NB NB NB NB
NOVEL CE29 NB NB NB NB NB NB
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Family XBPl ATF6 PAR PAR PAR PAR
Family Protein CE6 CE10 CE14 CE3 CE12 CE23
CEPBG CE18 NB NB <1 29.2 12.4 NB
CEBPA CEl NB NB NB NB NB NB
CEBPA CE24 NB NB NB NB NB NB
CREB CE9 NB NB NB NB NB NB
OASISA CE13 NB NB NB NB NB NB
OASISB CE21 NB NB 3307.1 NB 330.9 NB
XBP1 CE6 7.1 407.3 NB NB NB NB
ATF6 CE10 407.3 18.2 NB NB NB NB
PAR CE14 NB NB 16.6 <1 2.2 85.3
PAR CE3 NB NB <1 13.4 69.0 41.5
PAR CE12 NB NB 2.2 69.0 156.9 5.6
PAR CE23 NB NB 85.3 41.5 5.6 160.5
ATF2 CE30 608.8 NB 1874.2 NB NB NB
ATF2 CE5 NB NB NB NB NB NB
JUN CE7 NB NB NB NB NB NB
FOS CE8 NB NB NB NB NB NB
ATF4 CEll NB NB 171.5 NB 79.6 NB
ATF4 CE15 NB NB 37.1 74.1 45.6 NB
ATF4 CE20 NB NB 1285.8 241.2 208.6 NB
MAF CE19 NB NB 79.1 NB NB NB
NOVEL CE2 NB NB 75.7 NB 182.7 NB
NOVEL CE16 NB NB NB 3697.4 NB NB
NOVEL CE22 NB NB 187.6 NB 317.6 NB
NOVEL CE28 NB NB 216.6 NB 1005.0 NB
NOVEL CE17 NB NB NB NB NB NB
NOVEL CE29 NB >5000 NB NB NB NB
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Family ATF2 ATF2 JUN FOS ATF4 ATF4
Family Protein CE30 CE5 CE7 CE8 CE 11 CE15
CEPBG CE18 NB NB 157.2 359.0 <1 <1
CEBPA CEl NB NB NB NB NB NB
CEBPA CE24 NB NB NB NB NB NB
CREB CE9 NB NB NB NB NB NB
OASISA CE13 NB NB NB NB NB NB
OASISB CE21 NB NB NB NB NB NB
XBP1 CE6 608.8 NB NB NB NB NB
ATF6 CE10 NB NB NB NB NB NB
PAR CE14 1874.2 NB NB NB 171.5 37.1
PAR CE3 NB NB NB NB NB 74.1
PAR CE12 NB NB NB NB 79.6 45.6
PAR CE23 NB NB NB NB NB NB
ATF2 CE30 63.4 131.7 NB NB NB NB
ATF2 CE5 131.7 730.1 NB NB NB NB
JUN CE7 NB NB NB 31.0 NB NB
FOS CE8 NB NB 31.0 NB NB NB
ATF4 CEll NB NB NB NB NB 545.3
ATF4 CE15 NB NB NB NB 545.3 601.1
ATF4 CE20 NB NB NB NB NB >5000
MAF CE19 NB 1773.3 NB NB NB NB
NOVEL CE2 NB NB NB NB 397.5 702.1
NOVEL CE16 NB NB 24.4 NB NB NB
NOVEL CE22 NB NB NB 1659.6 NB 400.8
NOVEL CE28 NB NB NB 1504.0 NB 2878.3
NOVEL CE17 NB NB NB NB NB NB
NOVEL CE29 517.1 NB NB NB NB 262.7
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Family ATF4 MAF NOVEL NOVEL NOVEL NOVEL
Family Protein CE20 CE19 CE2 CE16 CE22 CE28
CEPBG CE18 <1 NB <1 73.5 <1 <1
CEBPA CE1 NB NB NB NB NB NB
CEBPA CE24 NB 2624.0 NB NB NB NB
CREB CE9 NB NB NB NB NB NB
OASISA CE13 NB NB NB NB NB NB
OASISB CE21 NB 3020.0 NB NB NB NB
XBPl CE6 NB NB NB NB NB NB
ATF6 CE10 NB NB NB NB NB NB
PAR CE14 1285.8 79.1 75.7 NB 187.6 216.6
PAR CE3 241.2 NB NB 3697.4 NB NB
PAR CE12 208.6 NB 182.7 NB 317.6 1005.0
PAR CE23 NB NB NB NB NB NB
ATF2 CE30 NB NB NB NB NB NB
ATF2 CE5 NB 1773.3 NB NB NB NB
JUN CE7 NB NB NB 24.4 NB NB
FOS CE8 NB NB NB NB 1659.6 1504.0
ATF4 CEll NB NB 397.5 NB NB NB
ATF4 CE15 >5000 NB 702.1 NB 400.8 2878.3
ATF4 CE20 NB NB 916.4 NB NB NB
MAF CE19 NB 4.5 257.1 NB NB NB
NOVEL CE2 916.4 257.1 52.5 NB NB 1095.4
NOVEL CE16 NB NB NB NB NB NB
NOVEL CE22 NB NB NB NB NB NB
NOVEL CE28 NB NB 1095.4 NB NB NB
NOVEL CE17 NB NB NB NB NB NB
NOVEL CE29 NB NB NB NB NB NB
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Family NOVEL NOVEL
Family Protein CE17 CE29
CEPBG CE18 NB NB
CEBPA CEl NB NB
CEBPA CE24 NB NB
CREB CE9 NB NB
OASISA CE13 NB NB
OASISB CE21 NB NB
XBP1 CE6 NB NB
ATF6 CE10 NB >5000
PAR CE14 NB NB
PAR CE3 NB NB
PAR CE12 NB NB
PAR CE23 NB NB
ATF2 CE30 NB 517.1
ATF2 CE5 NB NB
JUN CE7 NB NB
FOS CE8 NB NB
ATF4 CE11 NB NB
ATF4 CE15 NB 262.7
ATF4 CE20 NB NB
MAF CE19 NB NB
NOVEL CE2 NB NB
NOVEL CE16 NB NB
NOVEL CE22 NB NB
NOVEL CE28 NB NB
NOVEL CE17 6.0 NB
NOVEL CE29 NB 36.9
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N. vectensis bZIP interactions.
Family CEBPG CEBPG CREB OASISA OASISB XBP1
Family Protein NV5 NV1 1 NV19 NV25 NV2 NV6
CEBPG NV5 2.8 18.2 NB NB NB NB
CEBPG NV11 18.2 4452.7 NB NB NB NB
CREB NV19 NB NB 14.0 NB NB NB
OASISA NV25 NB NB NB 57.1 104.6 NB
OASISB NV2 NB NB NB 104.6 16.7 NB
XBP1 NV6 NB NB NB NB NB 31.4
ATF6 NV22 NB NB NB NB NB NB
PAR NV1 NB NB NB NB NB 2543.4
PAR NV10 <1 NB NB NB NB NB
PAR NV16 201.4 1902.8 NB NB NB NB
PAR NV17 901.0 NB NB NB NB NB
PAR NV24 2095.9 NB NB NB NB 2768.2
PAR NV29 1679.4 NB NB NB NB NB
ATF2 NV8 890.8 704.4 NB NB NB NB
JUN NV14 1490.2 348.6 NB NB NB NB
JUN NV15 1567.0 318.6 NB NB NB NB
JUN NV28 4526.9 104.7 NB NB NB NB
FOS NV3 59.9 >5000 NB NB NB NB
FOS NV7 NB NB NB NB NB 2635.1
FOS NV26 546.9 4727.7 NB NB 419.9 571.4
FOS NV27 NB NB NB NB NB NB
FOS NV30 1290.8 NB NB NB NB NB
ATF4 NV35 <1 NB NB NB NB NB
SMAF NV13 NB NB NB NB NB NB
LMAF NV12 NB 241.3 NB NB NB 3116.3
LMAF NV18 NB NB NB NB NB NB
LMAF NV34 NB NB NB NB NB NB
NFE2 NV21 NB NB NB NB NB NB
NOVEL NV9 NB 797.8 NB NB NB NB
NOVEL NV20 1934.5 803.7 NB NB 2844.4 984.5
NOVEL NV23 <1 136.2 NB 1724.2 16.6 NB
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Family ATF6 PAR PAR PAR PAR PAR
Family Protein NV22 NV1 NVIO NV16 NV17 NV24
CEBPG NV5 NB NB <1 201.4 901.0 2095.9
CEBPG NV11 NB NB NB 1902.8 NB NB
CREB NV19 NB NB NB NB NB NB
OASISA NV25 NB NB NB NB NB NB
OASISB NV2 NB NB NB NB NB NB
XBP1 NV6 NB 2543.4 NB NB NB 2768.2
ATF6 NV22 <1 NB NB NB NB NB
PAR NV1 NB 6.9 NB NB NB 2665.2
PAR NV1O NB NB 9.9 23.7 187.2 485.5
PAR NV16 NB NB 23.7 61.2 <1 NB
PAR NV17 NB NB 187.2 <1 69.6 NB
PAR NV24 NB 2665.2 485.5 NB NB 25.7
PAR NV29 NB NB 877.6 <1 6.1 NB
ATF2 NV8 NB NB NB 4166.7 NB 2099.1
JUN NV14 NB NB 549.7 189.1 370.2 NB
JUN NV15 NB NB 104.9 436.3 1805.0 NB
JUN NV28 NB NB 112.0 1456.1 568.4 NB
FOS NV3 NB NB 3431.1 NB NB NB
FOS NV7 NB 433.8 307.8 NB 661.6 613.5
FOS NV26 NB 2488.2 NB 699.4 NB 324.5
FOS NV27 NB NB NB NB NB NB
FOS NV30 NB NB NB NB NB NB
ATF4 NV35 NB NB 14.9 198.9 98.2 NB
SMAF NV13 NB 375.5 NB >5000 NB NB
LMAF NV12 NB 627.0 NB NB NB 1771.8
LMAF NV18 NB NB NB NB NB NB
LMAF NV34 NB NB NB NB NB NB
NFE2 NV21 NB NB NB NB NB NB
NOVEL NV9 NB NB NB NB NB NB
NOVEL NV20 NB 1166.5 866.3 4629.3 NB 695.4
NOVEL NV23 NB NB <1 1.7 19.8 15.4
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Family PAR ATF2 JUN JUN JUN FOS
Family Protein NV29 NV8 NV14 NV15 NV28 NV3
CEBPG NV5 1679.4 890.8 1490.2 1567.0 4526.9 59.9
CEBPG NV11 NB 704.4 348.6 318.6 104.7 >5000
CREB NV19 NB NB NB NB NB NB
OASISA NV25 NB NB NB NB NB NB
OASISB NV2 NB NB NB NB NB NB
XBP1 NV6 NB NB NB NB NB NB
ATF6 NV22 NB NB NB NB NB NB
PAR NV1 NB NB NB NB NB NB
PAR NV1O 877.6 NB 549.7 104.9 112.0 3431.1
PAR NV16 <1 4166.7 189.1 436.3 1456.1 NB
PAR NV17 6.1 NB 370.2 1805.0 568.4 NB
PAR NV24 NB 2099.1 NB NB NB NB
PAR NV29 4.0 NB 842.4 NB NB 1657.0
ATF2 NV8 NB 1.1 85.3 112.9 11.0 NB
JUN NV14 842.4 85.3 3745.7 NB NB <1
JUN NV15 NB 112.9 NB NB NB <1
JUN NV28 NB 11.0 NB NB NB <1
FOS NV3 1657.0 NB <1 <1 <1 NB
FOS NV7 NB 73.2 17.0 1289.7 26.5 338.5
FOS NV26 286.6 1890.3 <1 2.5 <1 NB
FOS NV27 NB NB 2.0 15.7 6.4 NB
FOS NV30 >5000 2919.1 2.0 <1 3.2 NB
ATF4 NV35 37.8 2673.2 8.7 10.1 <1 NB
SMAF NV13 1130.1 NB NB NB NB NB
LMAF NV12 NB 2308.7 3786.3 NB NB NB
LMAF NV18 NB NB NB NB NB NB
LMAF NV34 NB NB NB NB NB NB
NFE2 NV21 293.3 NB NB NB NB NB
NOVEL NV9 NB NB NB NB NB NB
NOVEL NV20 856.4 4474.3 2245.3 2983.5 1443.9 NB
NOVEL NV23 9.5 90.0 18.8 18.9 51.0 1731.6
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Family FOS FOS FOS FOS ATF4 SMAF
Family Protein NV7 NV26 NV27 NV30 NV35 NV13
CEBPG NV5 NB 546.9 NB 1290.8 <1 NB
CEBPG NV1 1 NB 4727.7 NB NB NB NB
CREB NV19 NB NB NB NB NB NB
OASISA NV25 NB NB NB NB NB NB
OASISB NV2 NB 419.9 NB NB NB NB
XBP1 NV6 2635.1 571.4 NB NB NB NB
ATF6 NV22 NB NB NB NB NB NB
PAR NV1 433.8 2488.2 NB NB NB 375.5
PAR NV1O 307.8 NB NB NB 14.9 NB
PAR NV16 NB 699.4 NB NB 198.9 >5000
PAR NV17 661.6 NB NB NB 98.2 NB
PAR NV24 613.5 324.5 NB NB NB NB
PAR NV29 NB 286.6 NB >5000 37.8 1130.1
ATF2 NV8 73.2 1890.3 NB 2919.1 2673.2 NB
JUN NV14 17.0 <1 2.0 2.0 8.7 NB
JUN NV15 1289.7 2.5 15.7 <1 10.1 NB
JUN NV28 26.5 <1 6.4 3.2 <1 NB
FOS NV3 338.5 NB NB NB NB NB
FOS NV7 NB 1005.7 NB NB 2173.5 NB
FOS NV26 1005.7 2771.3 NB NB NB NB
FOS NV27 NB NB NB NB NB NB
FOS NV30 NB NB NB NB NB NB
ATF4 NV35 2173.5 NB NB NB 1994.5 NB
SMAF NV13 NB NB NB NB NB 279.0
LMAF NV12 NB 96.9 NB NB NB 69.9
LMAF NV18 NB 558.1 NB NB NB NB
LMAF NV34 NB 808.0 NB NB NB NB
NFE2 NV21 NB 1327.0 NB NB NB <1
NOVEL NV9 NB NB NB NB NB NB
NOVEL NV20 503.6 3124.7 NB NB NB NB
NOVEL NV23 228.8 2104.5 2492.2 499.7 15.2 292.0
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Family LMAF LMAF LMAF NFE2 NOVEL NOVEL NOVEL
Family Protein NV12 NV18 NV34 NV21 NV9 NV20 NV23
CEBPG NV5 NB NB NB NB NB 1934.5 <1
CEBPG NV11 241.3 NB NB NB 797.8 803.7 136.2
CREB NV19 NB NB NB NB NB NB NB
OASISA NV25 NB NB NB NB NB NB 1724.2
OASISB NV2 NB NB NB NB NB 2844.4 16.6
XBP1 NV6 3116.3 NB NB NB NB 984.5 NB
ATF6 NV22 NB NB NB NB NB NB NB
PAR NV1 627.0 NB NB NB NB 1166.5 NB
PAR NV1O NB NB NB NB NB 866.3 <1
PAR NV16 NB NB NB NB NB 4629.3 1.7
PAR NV17 NB NB NB NB NB NB 19.8
PAR NV24 1771.8 NB NB NB NB 695.4 15.4
PAR NV29 NB NB NB 293.3 NB 856.4 9.5
ATF2 NV8 2308.7 NB NB NB NB 4474.3 90.0
JUN NV14 3786.3 NB NB NB NB 2245.3 18.8
JUN NV15 NB NB NB NB NB 2983.5 18.9
JUN NV28 NB NB NB NB NB 1443.9 51.0
FOS NV3 NB NB NB NB NB NB 1731.6
FOS NV7 NB NB NB NB NB 503.6 228.8
FOS NV26 96.9 558.1 808.0 1327.0 NB 3124.7 2104.5
FOS NV27 NB NB NB NB NB NB 2492.2
FOS NV30 NB NB NB NB NB NB 499.7
ATF4 NV35 NB NB NB NB NB NB 15.2
SMAF NV13 69.9 NB NB <1 NB NB 292.0
LMAF NV12 1.5 NB NB 78.1 NB 126.3 NB
LMAF NV18 NB <1 NB NB NB 185.4 NB
LMAF NV34 NB NB NB NB NB 875.6 2675.0
NFE2 NV21 78.1 NB NB NB NB NB NB
NOVEL NV9 NB NB NB NB 204.9 3.6 NB
NOVEL NV20 126.3 185.4 875.6 NB 3.6 67.7 16.6
NOVEL NV23 NB NB 2675.0 NB NB 16.6 359.2
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M brevicollis bZIP interactions.
Protein MB2 MB13 MB16 MB7 MB3 MB15 MB1O MB1 MB9 MB11
MB2 NB NB NB NB NB NB 12.6 NB NB NB
MB13 NB 19.5 NB NB NB NB NB 1842.2 NB NB
MB16 NB NB 411.0 NB NB NB NB NB NB NB
MB7 NB NB NB 4072.3 NB NB NB NB NB NB
MB3 NB NB NB NB 178.5 19.2 NB NB NB NB
MB15 NB NB NB NB 19.2 20.3 NB NB NB NB
MB1O 12.6 NB NB NB NB NB 2558.4 160.3 NB >5000
MB1 NB 1842.2 NB NB NB NB 160.3 NB NB NB
MB9 NB NB NB NB NB NB NB NB 240.2 42.4
MB11 NB NB NB NB NB NB >5000 NB 42.4 NB
MB18 NB NB NB NB NB NB NB NB NB NB
MB4 NB NB NB NB NB NB NB NB NB NB
MB5 NB 2779.1 NB NB NB 2419.2 NB NB NB NB
MB6 NB NB NB NB NB NB 33.5 NB NB NB
MB8 1139.4 NB NB NB NB 4607.4 2874.9 NB NB NB
MB17 2797.3 NB NB NB NB NB 2114.4 NB 270.9 >5000
MB19 NB NB NB NB NB NB NB NB NB NB
MB20 1080.5 NB NB NB NB NB 1855.4 NB NB NB
MB21 NB NB NB NB NB NB NB NB NB NB
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Protein MB18 MB4 MB5 MB6 MB8 MB17 MB19 MB20 MB21
MB2 NB NB NB NB 1139.4 2797.3 NB 1080.5 NB
MB13 NB NB 2779.1 NB NB NB NB NB NB
MB16 NB NB NB NB NB NB NB NB NB
MB7 NB NB NB NB NB NB NB NB NB
MB3 NB NB NB NB NB NB NB NB NB
MB15 NB NB 2419.2 NB 4607.4 NB NB NB NB
MB1O NB NB NB 33.5 2874.9 2114.4 NB 1855.4 NB
MB1 NB NB NB NB NB NB NB NB NB
MB9 NB NB NB NB NB 270.9 NB NB NB
MB11 NB NB NB NB NB >5000 NB NB NB
MB18 NB NB NB NB NB NB NB NB NB
MB4 NB 21.6 NB NB 1706.3 NB NB NB NB
MB5 NB NB 32.3 3736.2 1402.2 428.6 NB NB NB
MB6 NB NB 3736.2 1432.9 NB 1086.0 NB NB NB
MB8 NB 1706.3 1402.2 NB 454.1 553.1 NB 211.2 NB
MB17 NB NB 428.6 1086.0 553.1 57.8 NB 41.9 52.3
MB19 NB NB NB NB NB NB 416.5 NB NB
MB20 NB NB NB NB 211.2 41.9 NB 70.2 NB
MB21 NB NB NB NB NB 52.3 NB NB NB
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S. cerevisiae bZIP interactions.
Protein SCi SC2 SC4 SC6 SC7 SC9 SC1O SCI1 SC12 SC14 SC15
SCl 515.7 NB NB NB NB NB NB NB NB NB NB
SC2 NB 2.8 NB NB NB 2531.3 NB NB NB NB NB
SC4 NB NB 71.4 127.8 NB NB NB NB NB 2001.3 NB
SC6 NB NB 127.8 158.8 NB NB NB NB NB NB NB
SC7 NB NB NB NB 109.9 NB NB NB NB NB NB
SC9 NB 2531.3 NB NB NB NB 704.4 NB NB NB 0.0
SC10 NB NB NB NB NB 704.4 18.7 NB NB NB NB
SCI1 NB NB NB NB NB NB NB 14.4 NB NB NB
SC12 NB NB NB NB NB NB NB NB 2.7 NB NB
SC14 NB NB 2001.3 NB NB NB NB NB NB 41.0 NB
SC15 NB NB NB NB NB 0.0 NB NB NB NB 21.9
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Chapter 6
Conclusions and future directions
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Comparison to previously generated data
While much progress has been made in understanding bZIP interaction specificity, no
model can, with very high accuracy, describe the relationship between protein sequence and the
energy of interaction. A useful experimental approach to this problem is one that increases both
the amount and the quality of experimental data available. When I started my thesis research, the
only large bZIP interaction data set consisted of most of the human and S. cerevisiae bZIPs,
measured using protein arrays. I have expanded upon this by using arrays to generate data for
viral bZIPs and designed coiled coils measured against human bZIPs, and designed bZIPs
measured against themselves. Additionally, using a quantitative FRET-based solution assay, I
quantified the bZIP interaction networks of human, S. cerevisiae, 5 additional species, cross-
species interactions between C. intestinalis and human, and a number of single and double point
mutants. Thus, I have measured -8,000 interactions and non-interactions, which is an increase in
the amount of available data of over 4 fold. Besides the increase in the amount of measured
interactions, the new data have a number of advantages. The data from additional species
represent a more diverse sequence space than that of the human bZIPs. The designed coiled-coil
data represent a more simplified interaction space, as the designed peptides are less diverse in
sequence than the human bZIPs. The data for bZIP point mutants are useful for looking at what
influence only one or two amino-acid changes can have on interaction profiles. Additionally, the
quantitative data set makes it possible to test predictions of affinity, rather than just
discriminating strong binders from non-binders.
Comparison of assays used to measure bZIP interactions
Two different techniques, arrays and FRET-based solution assays, were used to measure
bZIP interactions. The bZIP array assay involves expressing and purifying bZIPs both by Ni-
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NTA and then further by HPLC. These purified, reduced, and denatured peptides are then printed
onto aldehyde-presenting slides. Twelve identical subarrays of 56 proteins containing 4 spots
each can be printed on each slide. Each protein to be tested is fluorescently labeled with a CY3
NHS-ester, on one or more primary amine. The arrays are then blocked and incubated with the
fluorescently-labeled proteins. After washing, the arrays are imaged, and the fluorescence
intensity of each spot is determined. While the bZIP array assay can measure many interactions
in parallel, it does not allow for the quantification of interactions because the arrays are only
probed at a single concentration. There is also the potential for false negatives, due to semi-
specific chemical labeling as well as the measurement of interactions on a surface.
To improve upon the array assay, I developed a high-throughput solution-based FRET
assay. In this experiment, proteins are expressed as intein-chitin binding domain fusions and are
uniquely labeled at the C-terminus with a fluorescent dye using native chemical ligation. Two
versions of each protein are generated, one with an acceptor fluorophore and the other with a
donor fluorophore. The proteins are purified first over chitin beads and then over Ni-NTA. Donor
proteins are mixed with 12 different concentrations of acceptor labeled protein, and the
fluorescence emission of the donor is monitored. These binding curves can then be fit to
determine equilibrium disassociation constants. While the solution-based FRET assay is time
consuming and costly, it is superior to the array assay in that it provides high quality quantitative
data.
Biological implications
The in vitro interaction data that I have generated between native bZIPs represents the set
of interactions that can occur free from cellular influence. These measurements use a
standardized set of reagents and measurement techniques and as a result both the array and the
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FRET assay have low assay false positive and negative rates (defined as the differences in the
interactions that are observed to interact in vitro vs. interactions that occur in vitro measured by a
different technique). In contrast, this data will inevitably contain both biological false positives
and false negatives (defined as the differences in the interactions that occur in vivo vs. in vitro).
Biological false positives can occur if the proteins are not co-expressed or co-localized.
Additionally, a strong interaction partner for a bZIP might prevent interactions with weaker
partners. Biological false negatives can occur if the proteins are brought together by DNA, other
domains, or posttranslational modifications (Gaudray, et al. 2002, Lynch, et al. 2011). It is not
known how common either biological false positives or negatives will be for the bZIP interaction
data I have generated as there is not a comprehensive set of interactions detected in vivo to
compare to. Furthermore, it is challenging to measure interactions in vivo and these
measurements can also suffer from assay false positives and negatives. Also, it is difficult to
measure interactions in all cell types and conditions to rule out two proteins interacting under
any condition. Cellular complexity and difficulty in measuring interactions in vivo together make
it hard to identify biological relevant interactions (Walhout. 2011).
The bZIP interaction data, though measured in vitro, provide a resource to help elucidate
the functional significance of bZIP interactions when combined with other types of biological
data. One source of biological data is that of gene expression. A requirement for proteins to
interact is to be co-expressed, and bZIPS that interact in vitro could be compared to see if there is
any condition where both partners are expressed. There is now expression data available from
various tissues and developmental stages for humans, D. melanogaster, and C. elegans
(Malovannaya, et al. 2011, Ravasi, et al. 2010, Chintapalli, et al. 2007, Graveley, et al. 2011,
Spencer, et al. 2011). A drawback of this gene expression data is that levels of mRNA don't
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always correlate with protein concentration and the data doesn't have single-cell resolution or
contain information about subcellular localization. An alternative approach would be to fuse each
bZIP to a fluorescent protein at a single copy under the endogenous promoter, an approach that is
now possible in C. elegans (Frokjaer-Jensen, et al. 2008). This would allow for quantifying the
protein level of each bZIP in different cell types and subcellular locations, although this is an
enormous amount of work. Another type of biological data is phenotypic data from gene
knockouts or knockdowns, which exist for many genes in several species. Unfortunately, this
data is difficult to interpret as many bZIPs have more than one partner and their deletion could
result in pleotropic phenotypes. An approach that circumvents these issues is generating mutants
that only disrupt individual interactions instead of removing the function of the entire protein
(Dreze, et al. 2009). These mutations, when combined with compensatory mutations in the
partner that restored the interaction, would be useful for determining the biological significance
of interactions (See Applications of more accurate models). A third source of biological data is
that from CHIP experiments. In combination with information on bZIP DNA-binding specificity,
the interaction data could be used to infer which DNA sites are bound by which bZIP complexes.
Although the DNA-binding specificity of some bZIPs is known, for many bZIP this has not been
determined, especially for species other than human (See Measuring the DNA binding specificity
of bZIPs).
Increasing the throughput of quantitative in vitro binding assays
While both the work of others and the studies described in my thesis have generated a
large amount of data, there is likely a need for yet more data to fully understand the relationship
between sequence and binding energy in bZIPs. Thus, there is a need for further development of
assays that can quickly generate large amounts of quantitative data. The array assay I described
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could potentially be increased in throughput by performing it in a 96-well format (Jones, et al.
2006). This is unlikely to provide the high quality, quantitative data desired, however, due to the
issues mentioned above. The throughput of the FRET assay could be improved in several ways.
One possibility is to make bZIPs fused to fluorescent proteins and express the constructs using in
vitro extracts. Protein concentrations could then be estimated by fluorescence and the proteins
potentially used without purification. This would allow for a large increase in the number of
proteins that could be assayed, but it would need to be determined if the bZIPs function properly
fused to a much larger fluorescent protein, if bZIP fusion proteins are bright enough to measure
tight interactions, and if the proteins could be used without purification. The throughput of the
assay could be improved by using a two-stage approach, where initial measurements are made at
a single concentration, and then positive interactions are further quantified by making
measurements at multiple concentrations. The cutoff for interactions would have to be
determined to minimize false negatives as well as false positives. This approach would be
especially useful for measuring a sparse interaction space. These modifications together would
allow for a much larger number of interactions to be quantified.
Selection-based approaches are attractive since an extremely large number of sequences
can be measured simultaneously. Recently there has been excitement around using next
generation sequencing as a way to sample all binders, not just those of the highest affinity
(Jolma, et al. 2010, Hietpas, et al. 2011, Rockberg, et al. 2008, Ernst, et al. 2010, Fowler, et al.
2010). Combining selection-based approaches and deep sequencing with saturation binding
curves provides a potential way to generate a large amount of quantitative interaction data. Using
ribosome display, a large number of bZIP coiled-coil variants could be expressed. A biotin-
labeled bZIP could be used to isolate proteins that bind by pulling down with streptavidin beads.
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These pull downs could be done at multiple concentrations of the biotin-labeled bZIP. To isolate
expressing non-binders, displayed proteins could be fused to an epitope tag, incubated with a
saturating amount of biotin-labeled bZIP and streptavidin beads, and those proteins not
interacting with the biotin-labeled bZIP pulled down using antibody- conjugated beads. The
pools of binders at each concentration and non-binders could then be deep sequenced. By using
positive controls to calibrate the data, binding curves could be fit to determine Kds that covered
several magnitudes of affinity. Many conditions for this assay would have to be determined
including expression levels, washing, DNA amplification, sequencing, and data interpretation.
Nonetheless, the development of such an assay would allow the rapid quantification of an
extremely large number of interactions.
Additional interactions to measure
Plant bZIP networks are larger and have distinct sequences from the metazoans,
providing an interesting interaction space to measure. Plant bZIPs have been shown to be
involved in a number of diverse processes such as seed development, flower maturation, and
stress responses (Nijhawan, et al. 2008). 13 families of bZIPs that are conserved throughout plant
evolution are present in flowering plants (Correa, et al. 2008). The plant bZIPs represent a
separate origin, as only one bZIP family is shared with metazoa and fungi (Correa, et al. 2008).
Plant networks are also larger than in the metazoa, with 92 bZIPs in rice and 77 in Arabidopsis
thaliana (Nijhawan, et al. 2008, Correa, et al. 2008, Deppmann, et al. 2004). The bZIPs from
these two species contain bZIPs that are longer than those in human and have a larger number of
asparagines at a positions (Nijhawan, et al. 2008, Deppmann, et al. 2004). The plant bZIPs have
been suggested to primarily form homodimers and intrafamily heterodimers (Deppmann, et al.
2004). Which interactions actually occur is unclear, given the sequence differences between
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metazoan and plant bZIPs and little experimental data. A high-throughput FRET assay could
potentially be used to measure these interaction networks. Measurement of plant bZIP networks
would generate interaction data for a more diverse sequence space as well as provide a useful
resource to the plant research community.
Improving bZIP binding models
The quantitative interaction data generated from different species present a large and
diverse data set for improving bZIP-binding models. Several recent approaches that directly use
interaction data to derive predictive models have been applied to similar problems (Chen, et al.
2008, Shao, et al. 2011, AlQuraishi and McAdams. 2011, AlQuraishi and McAdams. 2011). Such
models can be tested in cross validation, by withholding protein families or portions of the
interaction data set when the model is derived. The devolvement of more accurate models could
guide the selection of additional experiments to perform, which would improve the models even
further. The solution-based FRET assay could be used to measure coupling energies for pairs of
interactions that the models do poorly on.
Applications of more accurate models
A useful application of improved binding models would be the design of proteins with
specific interaction properties. We previously showed that the CLASSY algorithm can be used to
design proteins that bind to one bZIP family but not others. A different design problem involves
eliminating one interaction, while maintaining all other interactions and non-interactions at the
same affinity. This problem is much harder, as it puts more stringent constraints on the designed
sequence. These types of mutants have been coined "edgetic" alleles and would be useful for
testing the function of individual interactions in vivo (Dreze, et al. 2009). A useful system to
apply this approach would be the C. elegans bZIP interaction network. This network has fewer
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proteins than the human network and also has a lower density of interactions. The development
of new techniques for introducing mutant alleles into C. elegans provides a convenient way to
test the phenotypic effect of the mutant alleles (Frokjaer-Jensen, et al. 2008). An additional use
of an improved model would be designing expanded synthetic networks. The synthetic networks
described in chapter 4 were not designed to include specific sub-networks and there are several
ways the existing networks could be improved. This could include the design of sub-networks
not previously observed, or improving existing sub-networks by increasing specificity and/or
affinity. These additional sub-networks could be added either to the existing SYNZIP network, or
created de novo.
Having a model that approaches experimental accuracy opens a number of interesting
opportunities to predict interactions. Almost all eukaryotic genomes contain bZIP proteins, and
the number of sequenced genomes is growing at an increasing rate. Prediction of interactions
would allow examination of interaction networks on a much larger scale than is accessible
experimentally. A much more detailed understanding of bZIP evolution could be achieved by
looking at which lineages and on what time scales different interactions were gained and lost.
Ancestral sequences could also be inferred, and the interaction properties of the resulting
networks predicted (Pinney, et al. 2007). It would also be interesting to see how bZIP interaction
network properties evolve by predicting interactions of non-metazoans and seeing whether all of
these networks are homodimeric and less connected, as was observed for S. cerevisiae and M.
brevicollis. Finally, the space of synthetic interactions could be interrogated, looking for example
at how many pairs of orthogonal bZIP-like coiled coils can exist in the same network.
Measuring the DNA binding specificity of bZIPs
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Knowing the DNA-binding specificity of transcription factors is important for
understanding which genes they regulate. While there has been much effort to map bZIP DNA-
binding specificity, there has not been a full accounting of which sites can be bound by each
homodimer and heterodimer. Recently several studies have shown that the DNA-binding
specificity of transcription factors can be measured rapidly using an approach known as SELEX-
SEQ (Jolma, et al. 2010, Zykovich, et al. 2009, Zhao, et al. 2009, Wong, et al. 2011, Slattery, et
al. 2011). We have applied this approach to map the DNA-binding specificity of the human bZIP
proteins (work in progress). First, a randomized DNA library is incubated with a biotin-labeled
bZIP. The bZIP proteins are then pulled down with streptavidin beads, and the bound DNA is
amplified and used in successive rounds of binding. After several rounds of enrichment, selected
DNA is barcoded with a unique DNA tag, combined with other selections, and subjected to deep
sequencing. Using a biotin-labeled bZIP in combination with an unlabeled bZIP partner, DNA-
binding specificity of heterodimers can be measured as well. In collaboration with the Ansari lab,
we have attempted to measure the DNA-binding specificity of 36 bZIP homodimers as well as a
number of heterodimers. Many questions can be addressed from this data, such as what is the
effect of protein-protein interactions on DNA binding and what is the space of DNA sequences
that are bound by heterodimers but not by homodimers. This specificity profiling approach will
also be useful for measuring the DNA-binding specificities of bZIPs from other species; the
clones described in chapter 5 can be biotin labeled using the same intein method used for
fluorescence labeling. Many of these proteins from other species have more diverse basic regions
and thus might have different DNA-binding specificities. Additionally, this data will be useful for
comparing how evolution of DNA-binding specificity compares with the evolution of protein-
protein interactions.
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Final conclusions
bZIPs are a great system for understanding both protein-protein and protein-DNA
interactions due to their structural simplicity and experimental tractability. Previous work as well
as the experiments described in my thesis help make bZIPs one of the best understood models of
molecular specificity. By taking advantage of the data already generated and developing new
techniques to measure even more interactions, it should be possible to understand in exquisite
molecular detail the binding specificity of bZIPs. This knowledge will then allow the prediction
of bZIP interaction specificity as well as the design of bZIPs with any specified properties.
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APPENDIX A
Supplementary Information for "Identification of bZIP
interaction partners of viral proteins HBZ, MEQ, BZLF1, and
K-bZIP using coiled-coil arrays"
Reproduced with permission from:
Reinke AW, Grigoryan G, Keating AE. Identification of bZIP interaction partners of viral
proteins HBZ, MEQ, BZLF 1, and K-bZIP using coiled-coil arrays. Biochemistry. 2010
Mar 9;49(9):1985-97.
Collaborator notes:
Gevorg Grigoryan computationally designed the anti-MEQ peptide.
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SUPPLEMENTARY EXPERIMENTS
Figure A.Sl. Comparison of Human and Chicken bZIPs. Tree is inferred by neighbor-joining
using the leucine-zipper sequence of each human bZIP and each G. galus bZIP as described in the
methods. Human sequences are in black and chicken sequences are in green. Family names are
listed in purple. The scale bar refers to amino-acid changes per position. Overall, the chicken
sequences are highly homologous to the human sequences, as judged by the short branch lengths
between orthologs. All families are conserved between chicken and human, except for DDIT3,
which is human specific.
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Figure A.S2. Complete interaction matrix of 33 human bZIPs and 4 viral bZIPs. Data are
displayed as in Figure 2.2. Solution probe proteins are in columns, and proteins on the surface are
in rows.
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HumanHumay Protein TFamily C
CE SPA
CEBP CEEPB
CE 0
CESPG CE PG
DDIT3 DDIT3
CISAT --
OAS CRX3
CREBZF cI~
XBP1 XBP1
PAR HLF
NFIL3 NFIL3
ATF2 ATF2ATF7
JUN
JUN JUNB
JUND
ATF3 ATF3-
ATF4 ATF4
FOS FOS
____FOSL2
BMTF BATFBATF3
SMAF MP
LMAF
NFE2 1 20
NFE2 NFE2L1 10-20
NFE2L3 10
BACH1 BACH1 2.5-5
BZLF1 0-2.5
BZLF1CT I <0
Figure A.S3. Neither the BZLF 1 leucine zipper nor BZLF 1 with additional C-terminal residues
binds strongly to any human bZIP. Fluorescently labeled BZLF1 at 1280 nM and BZLF1 with
the C-terminal region (BZLF ICT) at 160 nM in solution are listed in columns and potential
partners on the surface are listed in rows. Data are displayed as in Figure 2.2.
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1 3m"7IMAFB I
MDVORI
-6C
-5G
-4C
-3A
-2T
-1A
+1C
+2G
+3A
+4C
-3A: -1A
-2T:+1C
-3A: -1A:+2G
TGCTCATTTGCATACACATCACGTGATAGT
TGCTCATTTGCCTACACATCACGTGATAGT
TGCTCATTTGCAGACACATCCGTGATAGT
TGCTCATTTGCATCCACATCACGTGATAGT
TGCTCATTTGCATAAACATCACGTGATAGT
TGCTCATTTGCATACTCATLCACGTGATAGT
TGCTCATTTGCATACAAATCACGTGATAGT
TGCTCATTTGCATACACTCACGTGATAGT
TGCTCATTTGCATACACAGCACGTGATAGT
TGCTCATTTGCATACACATAACGTGATAGT
TGCTCATTTGCATACACATCCCGTGATAGT
TGCTCATTTGCATAAAAATCACGTGATAGT
TGCTCATTTGCATACTCC&CACGTGATAGT
TGCTCATTTGCATAAAAAGCACGTGATAGT
DNA MDVORI -6C -5G -4C -3A -2T -1A +1C
NFIL3 - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - +
MEQ - - + +- - + + - -+ - - + +- - + + - - + + - - + + - -+ +
MEQ-
NFIL3
MEQ-
NFIL3-
Free
Probe
DNA +2G +3A +4C -3A: -1A -2T: +1C -3A: -1A: +2G
NFIL3 - + - + - + - + - + - + - + - + - + - + - + - +
MEQ - - +4- -++ - - + + - - + - -++4 - + +
MEQ...
NFIL3- -MEQ-NFIL3
Free
Probe-
Figure A.S4. Gel shifts showing MEQ and NFIL3 directly binding to variants of the MDV DNA
site. (A) DNA sequences used in gel-shift assays. The putative binding site is underlined. (B) Gel-
shift experiments with MEQ and NFIL3 binding to different DNA sites. The concentration of
MEQ and NFIL3 was 80 nM each or 160 nM total protein for mixtures. Each lane had 20 nM
radiolabeled DNA. Each homodimer, heterodimer, and free probe is indicated at left. Strong
heterodimer formation is observed on the +3A site.
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Table A.S1. Protein sequences used in this study. Linker region of proteins is in bold.
Proteins used in array studies
Name Protein Source
CEBPA SYYUIHHHIILESTSLYKKAGSGSQRNVETQQKVLELTSDNDRLRKR Grigoryan, et al. 2009
VEOLSRELDTLRGIFROLLE
SYYHHHHHHLFSTSLYKKAGSEFSDEYKIRRERNNIAVRKSRDKAK
CEBPB MRNLETQHKVLELTAENERLQKKVEQLSRELSTLRNLFKQLPEPLLAS Newman, et al. 2003
SGHC
CEBPD SYYHHHHHHLESTSLYKKAGSGSRRNQEMQQKLVELSAENEKLHQ Newman, et al. 2003
RVEOLTRDLAGLROFFKOLLE
SYYHHHHHHLESTSLYKKAGSEFGERNNMAVKKSRLKSKQKAQDT
CEBPG LQRVNQLKEENERLEAKIKLLTKELSVLKDLFLEHAHNLADNVQSIST Newman, et al. 2003
ENTTADGLE
DDIT3 SYYHHHHHHLESTSLYKKAGSEFRMKEKEQENERKVAQLAEENERL Newman, et al. 2003
KOEIERLTREVEATRRAIJDRMVNLHQA
ATF1 SYYHHHHHHLESTSLYKKAGSEFDPQLKREIRLMKNREAARECRRK Newman, et al. 2003
_KKEYVKCLENRVAVLENQNKTUEELKTLKDLYSNKSV
CRBIu SYYHHHIHLESTSLYKKAGSGSKEAARKREVRLMKNREAARECR
RKKKEYVKCLENRVAVLENQNKTT ELKALKDLYCHKSD
CREB3L3 SYYHHHHHHLESTSLYKKAGSGSEYIDGLETRMSACTAQNQELQRK Newman, et al. 2003
VLHLEKONLSLLEOLKKLQAIVVQSTSLE
SYYHHHHHHLESTSLYKKAGSEFWRRKIRNKRSAQESRRKKKVYVG
CREB3 GLESRVLKYTAQNMELQNKVQLLEEQNLSLLDQLRKLQAMVIEISNK Newman, et al. 2003
TSSRE 
ATF6 SYYHHHHHLESTSLYKKAGSEFACQSRKKKKEYMLGLEARLKAA Newman, et al. 2003
LSENEOLKKENGTLKROLDEVVSENORLKVPSPKRRVLE
CREBZF SYYIIHIHHIHLESTSLYKKAGSEFCRLNRLKKKEYVMGLESRVRGLA Newman, et al. 2003
AENQELRAENRELGKRVQALQEESRYLRAVLANETGLE
SYYHHHHHHLESTTSLYKKAGSEFQTARDRKKARMSELEQQVVDLEE
XBP1 ENQKLLLENQLLREKTHGLVVENQELRQRLGMDALVAEEEAEAKGNE Newman, et al. 2003
VLE
HF SYYIHHHHHLESTSLYKKAGSGRLKENQIAIRASFLEKENSALRQEV Newman, et al. 2003
ADLRKELGKCKNILAKYEARHLE
NF SHL3 YYIIIIIIIIITESTSLYKKAGSEFEKRRLNDLVLENKLIALGEENATL Newman, et al. 2003
KAELLSLKLKFGLISSTAYAQEIOKLSNSTAVYFQDYQTSKSNVLE
SYYHHHiHESTSLYKKAGSEFDLERNRAAASRCRQKRKVWVQS
ATF2 LEKKAEDLSSLNGQLQSEVTLLRNEVAQLKQLLLAHKDCPVTAMQK Newman, et al. 2003
KSGFLE
ATF7 SYYIHEHIHIHLESTSLYKKAGSEFKRKLWVSSLEKKAEELTSQNIQLS Newman, et al. 2003
NEVTLLRNEVAQLKOLLLAHKDCPVrALKLE
SYYIHUHHIHLESTSLYKKAGSGSRKLERIARLEEKVKTLKAQNSEL Grigoryan, et al. 2009
ASTANMLREOVAOLKQKVMNHLE
SYYIHIHHHIIESTSLYKKAGSGSRKLERIARLEDKVKTLKAENACL Grigoryan, et al. 2009
SSTAGLLREOVAQLKOKVMNHLE
JUNm SYYHHHHHHLESTSLYKKAGSGSRKLERISRLEEKVKTLKSQNTELA Grigoryan, et al. 2009
STASLLREQVAOLKOKVMNHLE
SYYIHIHHHLESTSLYKKAGSGSCPEEDERKKRRRERNKIAAAKCR
ATF3 NKKKEKTECLQKESEKLESVNAELKAQIEELKNEKQHLIYMLNLHRPT Newman, et al. 2003
CIVRAONGRTPEDLE
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ATF4 SYYIHIHIIHLESTSLYKKAGSEFNKTAATRYRQKKRAEQEALTGE Newman, et al. 2003
____CKELEKKNEALKERADSLAKEIOYLKDLIEEVRKARCKKRVP 
______
S YYHHHHHH~Luh 1TSLYKKAGSEFNRKQKKRDQNKSAALRYRQRKR
ATF5 AEGEALEGECQGLEARNRELKERAESVEREJQYVKDLLLEWYKARSQRT Newman, et at. 2003
__ _ _R~sC 
_ _ _ _ _ _
S YYIHHHHHHLIIESTSLYKKAGSEFFRRERNKMAAAKCRNRRRELTD
FOS TLQAETDQLEDEKSALQTEJANLLKEKEKLEFLAAHRPACKIDDLG Newman, et al. 2003
____FPEEMSL,'E
FOSL2 SYYHfflU1HHFSTSLYK(AGSEFER4KLAAAKCR%duuRULTEKIQA Newman, et at. 2003
_____ TEEEEESGLOKEIAELQKEKEKLEFMLVAHGPVCKISPLE
BATF SYYIIHHHIHIITSLYKKAGSGSQKADTLHILESEDLEKQNAALRKENemneta.20
____IKOLTEELYYFTSVLNSIJELENemneta.20
BATF3 SYYHHHuhiLhESTSLYKKAGSEFRSRKKQTQKADKLHEEYESLEQE Newman, et at. 2003NTMLRREIGKLTEELKHLTEALKFEHEKm\CpLLLCpMNFVu1LE
SYIIIIIIIIIESTLYKKAGSEFGVQKEEEKQKAELQQEVEKLA
MAFG SENA SMKELDALRSKYEALQTFARTVARSPVAPARGPLAAGLGPLV Newman, et at. 2003
PCKVAATSVITIvKSKTDATiE
MAF SYYlllHH~lHIFSTSLYKKAGSEFQRVQQRHVLESEKNQLLQQVDHL Newman, et at. 2003
KOEISRLVRERDAYKEKYEKLVSSCFRENGSSSDNPSSPEFFM
MAFB SYYIHIIIIIHLISTSLYKKAGSEFQYKRVQQKHHLENEKTQLIQQVE Newman, et at. 2003
___OLKOEVSRLARERDAYKVKCEKLANSCFRFAGSTSDSPSSPEFFL
NFE SYYHHHHHLFSTSLYKKAGSEFQRKLETWQLERELERLTNERERLL Newman, et at. 2003
RARGEADRTLEVMROOLTELYRDIFOHLRDESGNS 
______
NFF2L1 SYllHRilIHI ETSLYKKAGSFfKLDTILNLERDVEDLQRDKARLLR Newman, et al. 2003EKVEFLRSLROMKOKVOSLYOEVFCRLRDENCRPYYLEII______
S YYHHHIIIIIIESTSLYKKAGSEFGDRRRGKNKVAAQNCRKRK-DII
NFF2L3 LNLEDDVCNLQAKKEJLKREQAQCNKAINIMKQKLHDLYHDWFSRLR Newman, et at. 2003
____DD0GRPVIE
BACHI SYYIHHUIHHLfESTSLYKKAGSEFGCRKRKLDCIQNLESEIEKLQSEKE Newman, et at. 2003
___SLLKERDHILSTLCETKONLTCLCOKVCKEAALSOEoNLE 
______
i-mZ SYYIIIUHHHESTSLYKKAGSGSMQELJDGYTRQLEGEVESLEAER Ti td
___RKLLOEKEDLMCEVNYWOCRLEAMWLX)hs td
MEQ SVYHHHHHLSTSLYKKAGSGSDYVDKLHEACEEQRANEHLRKE This study
____IRDLRTECTSLRVOLARHEP
BZLF1 S YY'llHlllH~LEhST'SLYKKAGSGSAKFKQLLQHYREVAAAKSSEND This study
RLRLLLKOMGGRDYKDDDDK
K-bZllP SYYHHH~llI-IL STSLYKKAGSGSVSSKAY7RQLQQALEEKDAQLCF This study
LAARLEAHKEOIIFLRDMLMRMCOOGGRDYKDDDDK
BLFICT 5 YYHHHHHBLIITEST'SLYKKAGSGSAKFKQLQHYREVVAAKSSEND This study
____RLRLLLKOMCPSL-DVDSIIPRTPDVLHEDLLNFLE_______
S YYHHHHHBLEh ST'SLYKKAGSGSNLLATLRSTAAVLENENHVLEKE This study
antiIMI
246
Proteins used in circular dichroism and gel-shift studies
Name Protein Source
UNJSHHHHGESKEYKKGSGSSPIDMESQERIKAERKRMRNRIAASKC This study
RKRKLERIARLEEKVKTLKAONSELASTANMLREOVAOLKOKVMNH
SHHHHHHGESKEYKKGSGSKKSSPMDRNSDEYRQRRERNNMAVKK
CEBPG SRLKSKQKAQDTLQRVNQLKEENERLEAKIKLLTKELSVLKDLFLEHA This study
HNLAD
SHHHHHHGESKEYKKGSGSGGGSGNDNNQAATKSPRKAAAAAAR
CREBZF LNRLKKKEYVMGLESRVRGLAAENQELRAENRELGKRVQALQEESRY This study
TLRAVLANETGL,
SHHHHHHGESKEYKKGSGSSDDQLVSMSVRELNRHLRGFTKDEVIRL
MAFB KQKRRTLKNRGYAQSCRYKRVQQKHHLENEKTQLIQQVEQLKQEVSR This study
LARERDAYKVKCEKLANSG
SHHHHHHGESKEYKKGSGSTDEELVTMSVRELNQHLRGLSKEEIVQL
MAFG KQRRRTLKNRGYAASCRVKRVTQKEELEKQKAELQQEVEKLASENA This study
SMKLELDALRSKYEALOTFARTVARS
NFEL SHHHHHHGESKEYKKGSGSREFIPDEKKDAMYWEKRRKNNEAAKR This study
SREKRRLNDLVLENKLIALGEENATLKAELLSLKLKIFGIS
S H1HtHH GFSKEYKKGSGSRRRAANEDPDEKRRKFLERNRAAASR
ATF2 CRQKRKVWVQSLEKKAEDLSSLNGQLQSEVTLLRNEVAQLKQLLLAH This study
_KDC
SHHHHHHGESKEYKKGSGSKAADVARRKQEEQERRERKWRQGAE
HBZ KAKQHSARKEKMQELGIDGYTRQLEGEVESLEAERRKLLQEKEDLMG This study
EVNYWOGRLEAMWLO
MEQ SHHHHGESKEYKKGSGSDGLSEEEKQKLERRRKRNRDAARRRRR This study
KOTDYVDKLHEACEELORANEHLRKEIRDLRTECTSLRVOLARHEP
HBZLZ SHHHHHHGESKEYKKGSGSMQELGIDGYT'RQLEGEVESLEAERRKL This study
OEKEDLMGEVNYWORLEAMWLQ
anti-Meq GSNLLATLRSTAAVLENENHVLEKEKEKLRKEKEQLLNKLEAYK This study
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Table A.S2. Average background-corrected fluorescence values from the array experiments. Peptides in solution are in columns and those on the
surface are in rows. Concentrations are in nM.
00
CEBPA CEBPB CEBPD CEBPG DDIT3 ATFI CREBI CREB3L3 CREB3 ATF6 CREBZF XBP1 HLF
CEBPA 16400.2 8465.3 27862.6 9709.6 15186.7 -506.3 -1345.1 39.0 854.9 447.3 -2210.8 602.6 721.7
CEBPB 7461.5 4130.7 8591.9 7753.9 26228.3 -908.5 -1663.9 -241.4 -715.6 625.3 -2029.1 1612.2 811.4
CEBPD 19228.3 10494.0 24816.0 13870.9 15487.3 -704.8 -1884.8 -909.6 3206.9 141.8 -3693.8 -82.5 2449.6
CEBPG 8%2.2 7403.8 27789.5 1671.9 13620.6 -174.0 542.7 -861.8 4113.4 1245.2 -1881.1 1262.3 4043.1
DDIT3 26600.9 20762.0 38960.3 32663.2 4609.1 602.1 1200.6 1171.1 9313.8 1412.0 1187.1 1250.8 39900.9
ATFI -2325.3 -752.7 -3890.6 -1944.6 -1049.1 7323.9 10884.8 -2272.6 -2677.4 540.4 -1896.8 2023.9 -631.4
CREBI -4412.3 -1331.3 -5543.4 -3011.3 -1302.8 12318.6 16312.6 8183.3 22.6 -1502.1 -5257.4 1707.9 -2266.8
CREB3L3 -2019.1 -547.3 -3228.1 -713.1 -1378.3 1139.9 2580.6 6710.3 10436.3 1545.3 -1101.1 1565.8 -1001.6
CREB3 40.0 75.4 387.8 -597.7 295.3 -503.5 -114.5 2829.3 4008.9 718.2 32.5 1099.8 170.5
ATF6 -3547.4 -593.4 -3227.4 -1915.9 -1391.2 -298.7 -14.1 -503.3 -2670.7 9418.6 841.3 7659.4 -1641.3
CREBZF -2999.2 -615.9 -5579.0 -1615.1 -1600.5 -594.1 -947.2 -306.9 -2843.9 1%9.0 17003.4 13108.1 -1889.5
XBP1 -6916.5 -547.2 -7262.9 -2792.9 -3011.3 754.8 2224.9 -768.8 -3298.7 13998.1 19643.8 20740.2 -2661.9
HLF -1301.0 256.9 -1111.6 -1468.2 2365.1 -154.1 -418.7 -161.4 -702.9 242.4 -75.2 1249.9 7040.4
NFIL3 -1599.6 74.3 -1199.6 -973.9 115.3 9223.2 13337.8 2318.7 8054.4 1508.5 -344.8 1191.6 1051.4
ATF2 1035.3 392.1 -2091.9 5852.3 2062.8 -529.5 -146.8 -1034.7 -718.0 611.7 -534.2 1981.5 868.6
ATF7 3827.6 2387.9 1705.9 8493.0 5268.9 -286.3 221.4 -355.9 864.9 928.9 919.6 1260.1 1360.1
JUN -1138.9 1104.1 1273.4 1133.4 1112.1 837.5 2531.1 -201.8 -41.4 912.5 -53.3 1307.4 4855.9
JUNB 329.0 328.1 333.1 -1054.5 859.6 -143.9 299.9 -2793.0 -2083.4 1165.6 210.2 884.7 2361.5
JUND -534.6 384.4 853.2 17.3 -17.2 33.8 534.7 -959.6 -902.1 1144.2 19.0 1101.1 3347.6
FOS 3174.7 262.3 1517.2 2895.8 3169.9 729.7 1007.3 97.1 1038.8 718.4 1801.2 1088.4 996.4
FOSL2 -2308.9 -751.7 -4357.6 -2292.1 777.8 441.7 1460.4 -1100.6 -1721.3 1350.8 158.9 1436.9 516.9
ATF3 2806.1 4267.3 2664.2 22753.4 9553.3 -106.5 -425.6 232.3 2208.9 1007.6 -972.4 2238.9 1037.1
ATF4 42648.7 7702.9 31696.6 37828.5 16336.9 -293.9 -469.8 764.2 1426.9 -389.4 11897.4 721.7 4694.9
ATF5 7171.6 416.8 7273.9 37753.9 -1748.5 -1494.4 -3841.6 -1762.7 -2506.3 -907.9 -3414.4 124.6 1124.4
BATF 3553.1 4548.5 5470.9 15419.5 11096.2 755.9 2427.5 -81.2 5270.6 1826.2 722.6 1111.6 13375.9
BATF3 2636.2 3614.8 9704.8 7478.2 15171.9 -562.1 278.1 787.2 9465.5 1012.4 1747.7 1144.1 12205.6
MAFG -1183.9 -63.0 -311.9 -622.7 1139.0 647.1 2002.4 -1726.7 1331.4 670.8 343.2 1756.7 159.6
MAF -2329.4 -339.8 -4658.0 -1457.8 -1166.8 225.1 1056.9 -785.8 -1984.5 934.9 -1061.8 767.5 -1173.0
MAFB -5483.4 -1013.9 -6333.9 -2140.1 -2616.7 221.3 1218.9 -920.0 -3630.9 915.3 705.4 1588.4 -1800.8
NFE2 -2821.6 -614.0 -4646.7 -1510.3 -920.4 -208.2 -396.0 -840.0 -545.9 1375.8 -576.6 1034.0 -2282.5
NFE2L1 -2720.7 -1318.3 -2439.9 -4630.6 -3339.6 1320.4 3225.5 -1003.4 571.8 620.9 21919.8 790.6 428.9
NFE2L3 -2135.3 -1394.6 -2950.1 -2078.8 -1473.6 -1587.1 -1765.9 -293.0 -1720.3 -930.3 -2797.8 216.3 -1946.4
BACHI -533.6 -139.6 -2345.4 946.1 415.6 3900.5 6874.6 -354.8 584.9 2954.9 3984.0 2655.3 2069.2
HBZ -972.4 1002.1 1611.6 3554.8 677.3 17760.8 25708.1 -493.2 1685.6 3201.4 16017.4 1463.7 3430.4
MEQ -2124.4 949.3 2242.4 64.4 853.4 5993.6 10513.8 310.9 4790.3 1837.4 1849.3 1700.5 1016.8
BZLF1 -2770.5 -769.1 -4329.3 -4146.8 -1388.7 379.9 2380.1 -1833.6 -2351.9 1376.9 -326.9 1404.2 -618.6
K-bZIP -2506.1 -261.5 -1129.1 -1520.8 -1119.4 90.3 1383.8 -83.6 659.2 693.1 -100.8 1560.6 -845.4
NFIL3 ATF2 ATF7 JUN JUNB JUND FOS FOSL2 ATF3 ATF4 ATF5 BATF BATF3
CEBPA 311.0 177.7 2142.6 443.3 161.8 167.2 1028.4 123.3 1594.4 10297.5 1135.1 1670.0 7982.9
CEBPB -975.4 -242.9 2616.4 131.1 411.6 -31.4 -336.8 176.7 2371.0 4304.3 215.2 3457.9 7326.8
CEBPD -42.6 -1858.2 -205.4 -22.1 -468.6 -785.9 142.3 220.8 2765.6 13044.8 699.1 3465.8 14516.9
CEBPG 1323.0 3834.6 7042.0 109.3 585.5 478.8 337.8 958.9 12723.0 18182.6 15097.3 8235.8 13138.5
DDIT3 9541.1 8325.1 10043.6 1175.8 2991.4 2757.3 9237.4 4533.2 15455.3 8893.6 -417.9 28971.3 28594.8
ATF1 3741.3 -1573.1 -700.9 -126.0 190.1 -350.2 -999.0 -169.2 -1237.6 -414.1 -246.6 -614.0 -1975.0
CREBI 3658.4 -5291.3 -1166.6 -782.3 -780.0 -1985.9 -2004.8 -770.9 -2966.8 -1935.2 -1794.8 -827.1 -5137.0
CREB3L3 4204.5 -261.5 -371.4 -138.6 388.7 -376.4 28.5 -55.8 90.6 -360.2 340.1 -731.8 1616.0
CREB3 57.3 -509.8 -516.1 87.5 -121.1 81.8 -581.9 -327.1 845.1 750.3 146.4 -573.1 3517.6
ATF6 -554.3 -2102.8 -1167.4 -720.4 -154.4 -564.4 -1550.1 -225.3 -1524.8 -427.6 -256.4 -860.6 -2381.9
CREBZF 218.9 -1429.3 632.1 468.1 1032.5 659.6 -202.6 72.6 -384.6 2317.1 -353.2 -950.6 1108.5
XBP1 -1162.3 -2233.0 -832.6 -171.3 458.9 236.1 -1021.7 -120.2 -1818.7 -990.6 -1059.9 -1572.4 -2693.0
ILF 710.3 -2027.1 -942.8 -291.2 597.9 -395.6 -1201.5 -259.3 -1568.9 307.9 -433.8 985.0 2552.6
NFIL3 36187.8 -2371.1 -1067.3 -13.9 221.2 -460.8 -1433.9 -113.6 129.3 -314.7 -1169.5 -1087.4 3450.6
ATF2 -2132.6 5073.2 5239.1 3518.8 3925.3 4649.3 5701.9 3343.9 7935.4 965.4 49.6 801.9 9572.6
ATF7 -536.4 6890.5 8203.3 8006.6 4837.2 7666.8 9036.9 6553.8 10295.4 2822.0 -847.1 511.3 11128.9
JUN -169.6 19776.8 19617.1 2428.2 1385.8 1262.9 45551.8 28676.3 17605.2 -405.3 -571.8 26673.3 21878.4
JUNB -1109.3 5917.8 7557.8 393.0 270.0 356.9 29611.2 14296.9 8909.2 83.7 67.6 16984.4 19485.6
JUND -866.3 10644.5 13456.1 513.0 367.0 107.1 37736.6 19249.6 12655.8 -394.1 -294.9 22249.5 20503.4
FOS 522.0 8367.4 10322.2 20367.8 19903.6 22831.6 3277.1 1276.4 2225.3 3989.1 497.0 -607.3 1681.9
FOSL2 -368.7 8843.4 8116.8 12360.6 13728.4 16881.4 3924.3 653.4 3644.9 715.6 -421.1 -2058.3 -918.3
ATF3 704.1 12564.9 14134.1 6003.6 8068.3 8131.3 3642.9 2656.0 454.6 5220.8 -504.4 1485.6 22269.8
ATF4 -1019.1 778.9 2882.3 -438.0 -336.2 -779.4 5731.6 588.9 5657.8 -837.6 -316.6 2929.7 11336.2
ATF5 -1773.8 -3627.9 -2386.1 -1661.9 -1547.1 -2013.1 -2763.5 -372.4 -2583.8 -736.8 -1240.7 223.8 5578.3
BATF 2610.4 4101.5 2571.9 11045.4 17121.3 18955.2 12.6 -526.9 3272.2 2899.7 1919.1 -225.9 5890.9
BATF3 2602.0 6868.8 6773.6 9549.0 12115.1 11855.2 571.1 353.1 10329.4 3567.6 908.1 1052.8 9517.6
MAFG 1850.6 764.4 1274.1 949.8 1946.8 1579.7 1644.1 -170.9 624.0 578.6 565.2 -894.4 6731.1
MAF -805.8 -294.3 -868.0 -13.8 1040.6 473.6 512.9 50.8 -81.9 3239.0 -101.0 -1018.1 -1526.8
MAFB -629.3 -618.8 -975.2 -318.8 837.3 744.2 3415.9 1257.3 -81.8 -448.7 -735.3 -789.6 -1361.7
NFE2 -783.9 -1479.1 -1312.3 -778.5 -422.6 -833.8 -1096.3 -216.4 -1347.9 188.1 -74.3 -1950.9 -2877.1
NFE2L1 -2427.6 345.8 1426.8 -1354.3 -264.5 -212.5 1023.4 282.4 -1609.1 3815.4 257.0 -1244.8 227.1
NFE2L3 -711.4 -3174.6 -1290.1 -1013.0 -980.9 -1452.3 -2584.0 -534.7 -2328.6 -128.6 -636.8 -897.5 -3180.9
BACHI 1005.3 4546.8 3102.4 245.8 1229.9 1290.2 2196.3 574.4 285.2 805.4 1171.4 367.3 3569.8
HBZ 839.8 16118.8 12402.9 26402.8 29515.8 18528.8 4509.8 912.4 5012.8 1663.2 665.7 -862.2 3634.7
MEQ 33263.3 17685.4 9372.8 13225.9 15470.0 14826.1 1461.8 569.2 4515.9 2899.0 257.3 -2883.2 7867.2
BZLF1 -779.3 -2752.1 -1963.9 -271.1 -384.6 -520.4 -1860.7 -202.9 -961.0 -785.6 -280.1 -2085.9 -1992.5
K-bZIP 254.7 2668.3 1509.1 -551.4 -126.1 -83.1 431.1 15.5 -102.3 -661.8 361.0 -382.6 -865.0
MAFG MAF MAFB NFE2 NFE2L1 NFE2L3 BACHI HBZ MEQ BZLF1 K-bZIP
CEBPA -575.3 -934.9 -293.4 -638.4 1073.9 -148.1 -368.5 1309.2 -708.9 -783.2 562.8
CEBPB -133.1 -727.9 105.6 -1147.5 -1948.4 -577.6 -910.1 -477.9 -298.4 -1051.2 625.0
CEBPD -297.1 -2206.0 -2014.8 -694.6 -242.4 -359.5 -1313.5 -1656.9 516.5 -2122.3 109.3
CEBPG 173.1 -852.9 231.3 -1149.2 -1961.5 -111.7 -702.4 12122.4 -628.9 -1955.2 644.0
DDIT3 1536.8 -1347.8 611.0 -417.8 -1159.9 -529.6 3344.6 2995.1 11570.3 -1620.2 1211.4
ATFI -104.4 -359.8 88.1 -1059.5 -1537.7 -694.8 1387.8 1919.3 1229.4 -952.4 470.0
CREBI -2140.3 -1584.5 -1828.8 -2132.1 -2342.7 -1817.6 1554.8 1390.1 308.1 -5005.3 -1437.0
CREB3L3 -118.4 -1526.3 -162.1 -442.7 -1033.6 -145.8 -1069.3 -1271.8 -1173.2 -477.1 707.3
CREB3 -11.4 -216.1 313.6 -403.4 -1329.1 -388.5 -680.3 -2641.1 -1215.8 -1004.0 1465.9
ATF6 -362.3 -3037.8 -1734.8 -1253.4 -5055.6 -1213.9 -1130.1 -3234.3 -1562.9 -1382.3 -253.3
CREBZF 319.6 -456.8 785.6 3389.6 28134.8 -319.6 1476.9 22064.3 -311.6 -446.1 665.6
XBP1 -184.6 -2038.6 -1934.4 -1843.4 -3647.8 -660.7 -998.4 -3391.2 -2531.2 -932.7 -703.3
HLF -979.3 -1756.4 -2103.1 -760.1 -1636.1 -497.4 -143.3 -1102.4 -862.1 -303.6 96.2
NFIL3 541.3 -1163.1 162.9 -1204.9 -2694.3 -336.3 119.2 -1272.2 23075.2 782.5 1249.1
ATF2 2%.9 403.2 1718.0 -658.4 2436.4 -564.0 3625.6 16538.5 23802.8 -927.8 3657.6
ATF7 587.5 -452.3 734.8 1374.6 6706.9 -1.9 5311.4 28123.2 19304.9 -774.6 3157.4
JUN -343.4 -127.4 422.3 -1870.0 -1487.1 -336.9 -122.0 48%3.6 39542.5 -1311.6 188.0
JUNB -801.1 15.2 344.4 -973.4 -2384.4 -387.2 225.1 40558.8 31224.1 -1748.8 21.7
JUND -66.3 -1469.6 107.6 -1095.0 -1442.8 -381.0 -292.0 41619.3 35094.7 -1585.0 -153.9
FOS 614.1 12%.3 7607.3 -800.9 5250.3 11.7 2734.4 -779.8 556.6 147.2 2752.4
FOSL2 308.5 -915.1 5471.6 -1209.8 581.1 -562.3 797.1 -1588.6 130.4 793.8 776.7
ATF3 678.7 60.3 4383.3 -979.4 -1967.0 -1035.5 -74.9 5899.5 9460.0 -2718.6 -105.5
ATF4 -221.5 6439.6 992.2 -332.4 19231.1 1636.9 104.1 -315.4 1530.2 -2728.5 1150.2
ATF5 -3506.4 -1479.8 -2058.9 151.6 -9.1 -1057.8 254.7 -2894.6 -2460.9 4593.2 284.1
BATF 279.3 -3082.1 697.3 -325.0 3975.8 277.4 2975.8 232.6 -1556.4 -379.3 1524.9
BATF3 2334.0 -995.0 1245.4 -1131.8 14.5 -516.3 1450.1 956.3 7311.6 218.6 724.1
MAFG 4335.0 -1075.3 879.1 10390.6 40099.8 25157.4 23867.6 19230.9 2409.8 294.1 702.3
MAF 15.8 19582.3 15441.3 -978.3 3799.9 46.8 3977.6 31679.4 -%7.6 -947.9 1099.2
MAFB -558.1 18881.3 9776.6 -676.4 5247.4 -326.2 7328.3 24522.3 -2220.7 -235.6 1006.9
NFE2 1434.5 -1266.4 21.4 18844.8 -1051.1 7592.4 -732.0 -2449.0 1464.1 -453.8 1604.1
NFE2L1 43009.4 453.8 2918.1 1124.9 4304.1 -92.3 -365.7 -1764.1 -1512.3 -788.9 1046.8
NFE2L3 52198.0 -959.1 -863.3 16419.4 -2762.6 37.6 -1337.8 -3129.1 -2098.4 -2208.9 -456.8
BACHI 20474.3 6783.8 12128.5 -886.4 323.8 -273.4 2255.3 -4121.1 1847.1 1551.6 2643.2
HBZ 11791.3 13803.1 30779.2 -1041.8 1528.9 -18.8 1256.8 -1720.9 17075.6 162.7 2144.6
MEQ 861.3 -279.1 1099.7 7238.4 2954.4 -84.3 3116.5 10837.1 6219.6 994.6 1391.5
BZLF1 -235.0 -705.2 122.9 -446.6 -2773.1 -448.3 -1377.4 -2226.8 -2414.6 9824.6 886.0
K-bZIP -391.5 -602.8 285.6 -1003.9 -634.6 -734.2 -95.6 -515.6 -627.4 1041.9 12707.8
MEQ1800 MEQ625 MEQ125 MEQ25 MEQ5 MEQI HBZ1800 HBZ625 HBZ125 HBZ25 HBZ5 HBZ1
CEBPA -1956.4 -1048.8 -1137.8 -41.9 6.6 11.7 2384.8 1231.9 -637.9 -104.5 3.9 9.2
CEBPB 2477.9 1657.6 -257.4 -7.1 23.5 25.1 849.8 -179.6 -826.4 -106.7 15.1 26.2
CEBPD 303.1 130.4 -549.8 -36.6 8.0 11.9 -3249.3 -4236.0 -1639.3 -215.2 -5.9 1.3
CEBPG 650.2 -220.2 -551.7 -19.9 9.4 14.6 36408.3 27983.8 6476.6 180.3 12.9 19.0
DDIT3 18879.9 14831.1 3871.3 148.0 55.4 30.9 7672.1 8868.3 1329.4 -41.3 -1.9 7.2
ATFI 7006.1 2915.6 -52.6 -0.3 23.6 24.3 10475.4 4560.9 115.9 -42.6 17.1 31.0
CREBI 6904.3 2468.8 -110.8 -3.6 67.1 74.4 13052.6 3906.6 -547.1 -149.2 45.4 66.3
CREB3L3 -1350.9 -1580.8 -1121.0 -37.2 4.8 6.9 -2274.8 -3930.3 -1141.3 -101.8 -0.9 7.1
CREB3 -132.6 -970.8 -359.2 -42.2 14.3 17.3 -1840.8 -1762.8 -1190.9 -71.9 6.6 16.1
ATF6 -2339.8 -2589.6 -1057.9 -43.7 9.1 20.0 -8566.8 -4360.4 -2222.2 -227.2 -29.6 -1.6
CREBZF 606.3 629.6 -69.9 -19.4 21.9 23.9 44116.1 43809.8 18047.3 742.3 124.8 87.2
XBP1 -2754.9 -2262.8 -954.5 -29.9 4.6 12.1 -3006.0 -5468.3 -3432.9 -202.6 -3.3 -0.8
HLF -1104.4 -552.6 -850.5 -33.6 2.9 12.9 -1963.8 -1077.0 -1917.5 -149.6 11.9 0.4
NFlIL3 34569.3 25897.4 9320.6 500.5 132.3 53.6 -787.4 -3668.9 -2195.8 -241.9 -18.3 5.9
ATF2 43809.1 34865.6 11030.8 489.5 164.9 54.7 49945.8 37822.1 7240.8 267.3 39.1 39.6
ATF7 33504.2 27277.8 10417.8 650.5 176.5 67.6 48362.3 49724.4 17226.0 1250.1 166.1 93.2
JUN 40956.9 35828.9 19746.9 1562.1 441.8 138.4 46284.6 48346.8 33404.8 4710.6 608.9 271.3
JUNB 38247.8 34017.6 14665.1 814.4 240.6 67.4 46897.5 49292.6 30957.0 2334.3 256.9 125.4
JUND 37200.4 35001.7 16522.2 1067.8 289.7 85.9 43240.8 45898.1 26671.4 2186.6 262.9 122.8
FOS 1533.3 1001.4 -315.8 -2.3 22.0 19.3 -1246.9 -806.4 -476.1 -65.4 10.9 16.6
FOSL2 2431.9 462.6 -4.6 7.8 17.2 21.2 -1947.4 -3642.8 -1629.8 -159.0 10.4 11.8
ATF3 26154.6 16520.2 3833.8 174.4 75.2 51.3 28222.4 15280.8 1322.2 35.1 40.9 43.4
ATF4 9900.7 4689.4 827.6 27.8 27.3 25.0 1286.8 -1658.2 -1008.5 -108.5 15.8 22.3
ATF5 -3566.5 -2411.4 -1035.8 -20.2 29.5 40.8 -4428.8 -1554.4 -853.5 -83.6 33.9 39.9
BATF -3492.7 -3787.8 -1855.7 -114.3 -13.1 2.6 882.6 -3269.1 -2850.0 -261.4 -22.4 -18.2
BATF3 19417.1 14058.3 4411.0 219.3 80.8 41.4 5455.3 65.9 -454.7 -120.3 3.9 26.9
MAFG 3525.3 984.3 -9.8 -21.8 15.9 16.0 43349.9 36152.3 11382.6 401.1 54.8 43.5
MAF -2530.1 -1860.8 -1105.5 -20.2 5.8 12.3 32799.1 28090.8 10693.6 816.9 104.6 51.8
MAFB -2983.1 -3317.3 -1134.9 -45.6 7.9 17.4 45207.9 33537.3 9535.5 349.5 42.8 53.8
NFE2 6121.4 3238.4 272.9 23.5 19.1 16.3 -2244.5 -3426.1 -1732.3 -145.9 -13.4 5.9
NFE2L1 -625.6 -1323.4 -740.9 -30.4 6.6 13.6 -4047.9 -1621.0 -1401.2 -66.3 5.0 11.4
NFE2L3 -3538.4 -3732.2 -1775.9 -93.2 4.6 19.9 -4985.8 -5444.1 -2290.4 -204.6 -6.1 22.6
BACHI 7620.1 4622.3 101.1 3.7 37.4 36.1 -3649.9 -2560.1 -1027.5 -132.0 8.4 27.5
HBZ 16059.6 14584.4 5662.5 382.9 120.4 51.4 -657.0 74.8 -461.1 -42.8 9.1 12.3
MEQ 12345.1 7763.5 2379.4 83.4 38.2 24.3 25434.4 23555.3 7755.9 406.1 55.3 35.4
BZLF1 BZLF1CT
CEBPA -918.0 -541.4
CEBPB -1035.4 -215.1
CEBPD -1303.9 -654.4
CEBPG -1356.1 -554.1
DDIT3 -673.9 -471.4
ATF1 -1020.0 -127.6
CREBI -1711.8 -347.5
CREB3L3 -1068.1 -575.7
CREB3 -905.4 -114.4
ATF6 -826.5 -62.1
CREBZF -884.4 -232.1
XBP1 -434.5 -29.5
HLF -553.8 225.8
NFL3 -56.1 -321.1
ATF2 -1065.1 -220.6
ATF7 -656.3 -103.8
JUN -1086.8 -451.1
JUNB -1094.2 -177.3
JUND -985.3 -473.9
FOS -472.6 16.3
FOSL2 -352.9 -25.4
ATF3 -1700.5 -290.6
ATF4 -1323.3 -101.4
ATF5 -1965.4 -703.5
BATF -716.5 -279.3
BATF3 -532.1 -396.4
MAFG 104.1 521.1
MAF -355.6 -199.3
MAFB -701.6 -67.6
NFE2 -381.4 -608.1
NFE2L1 -402.0 -371.4
NFE2L3 -2073.9 -552.9
BACHI -545.3 -451.0
BZLF1 3400.1 1743.3
BZLF1CT 8831.0 7053.4
anti-MEQ anti-MEQ2000 anti-MEQ1000 anti-MEQ500 MEQ ATF2 JUN BATF3
CEBPA -343.6 -981.7 -798.0 -1089.6 -1860.5 -1209.5 -220.3 2169.7
CEBPB -235.4 -520.4 -551.9 -195.6 -3720.1 -2318.1 -543.4 2156.1
CEBPD -502.5 -1077.4 -1297.4 -771.9 -2151.3 -3235.8 -540.0 2625.6
CEBPG 1982.6 1989.1 1100.7 509.0 -658.6 5155.8 345.5 5172.2
ATFI -211.4 -924.7 -499.9 -85.8 609.1 -1961.5 -947.1 -2072.6
CREBI -3510.3 -4096.5 -1946.2 -740.8 535.5 -6256.7 -1354.7 -3906.8
CREB3L3 -48.9 -808.8 -836.8 -345.1 -2395.3 -933.4 -830.6 -375.9
CREB3 -319.6 -1159.1 -1048.7 -580.3 -1330.6 -820.6 -279.0 438.1
ATF6 -751.9 -2121.8 -2701.0 -771.7 -1940.4 -3780.2 -1124.3 -2020.6
CREBZF 698.6 1197.8 769.6 510.6 2290.8 -789.8 296.4 1020.3
XBP1 -2030.7 -2413.3 -2652.4 -1757.5 -3871.8 -2048.6 -359.3 -1979.3
HLF -199.3 -605.1 -873.8 -71.1 -3105.3 -2699.3 -188.0 121.6
NFL3 -431.0 -878.9 -1388.9 -372.2 16377.4 -1942.6 -513.1 305.7
ATF2 15474.9 29845.1 18609.9 10084.3 29036.9 6994.6 4898.9 5202.8
ATF7 18632.6 27526.6 17875.0 12471.2 22867.0 9594.1 8099.6 7512.3
JUN 4410.5 7446.3 5109.8 3051.3 33011.3 14760.4 1997.3 11768.7
JUNB 1590.3 3779.5 2474.8 1351.5 29327.3 4758.5 449.4 9728.8
JUND 1680.8 6417.1 3982.6 1944.3 34845.1 9823.1 788.6 11304.0
FOS 237.5 -58.9 246.1 365.3 1014.5 13984.2 35014.5 703.8
FOSL2 -797.3 -78.6 -1304.8 -2507.3 -894.6 9788.4 19126.3 266.4
ATF3 985.6 2340.3 1654.7 949.5 11393.0 19928.4 12049.6 13952.3
ATF4 584.3 5432.9 1864.5 1157.2 3546.8 1728.8 -1060.4 14458.4
ATF5 -1081.3 -1536.0 -2095.3 -1318.5 -3394.4 -4831.8 -1941.1 3954.8
BATF 1095.1 950.3 811.1 -247.8 -5102.5 2149.7 13378.4 2425.2
BATF3 3505.8 7043.8 3208.4 1636.4 7014.1 9068.7 12668.4 5699.1
MAFG 434.1 -71.2 -514.9 -44.6 476.1 -253.8 268.3 2433.0
MAF -597.1 -1622.8 -869.6 -473.8 -2118.5 -253.3 92.8 -1080.9
MAFB 59.5 -1223.2 -483.7 -469.0 -2231.4 -733.8 -217.7 -935.9
NFE2 -754.6 -1774.4 -1274.8 -1921.6 -327.3 -2474.9 -544.6 -1826.8
NFE2L1 -784.6 -2374.6 -2141.1 -1102.9 -2314.9 98.8 -284.6 -769.6
NFE2L3 -486.8 -1242.3 -816.4 -297.1 -2088.4 -4486.5 -1628.7 -3341.4
BACHI 86.9 -1658.8 -247.4 -25.9 3391.9 6185.9 456.6 895.5
MEQ 29778.6 28393.8 23575.5 19969.3 3605.4 18790.1 11986.9 4714.5
anti-MEQ -109.4 -1402.1 -1635.9 -764.9 30928.2 23309.9 4148.3 2632.5
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Supplementary Information for "Design of protein-interaction
specificity gives selective bZIP-binding peptides"
Reproduced with permission from:
Grigoryan G, Reinke AW, Keating AE. Design of protein-interaction specificity gives selective
bZIP-binding peptides. Nature. 2009 Apr 16;458(7240):859-64.
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SUPPLEMENTARY METHODS
Overview ofAnti-bZIP Design Using CLASSY
CLASSY is a computational design procedure for optimizing the stability of a particular
structural state as a function of sequence, under an arbitrary number of constraints. It is
compatible with many types of potential functions. Any linear analytical function of sequence
variables can be constrained; examples include energy gaps towards other structures, or
properties such as amino-acid composition or hydrophobicity.
CLASSY is based on two components: cluster expansion (CE) and integer linear
programming (ILP) optimization. CE provides a way to express the energy of a sequence
adopting a particular backbone structure as an algebraic function of the sequence itself
(Grigoryan, et al. 2006). The formal basis of the technique is briefly described in the next
section, but two properties of a cluster expansion are important for CLASSY: (1) it makes the
evaluation of sequence energies many orders of magnitude faster than with direct structural
methods, and (2) its simple functional form renders a new set of computational approaches
applicable to protein design. We used CE in conjunction with ILP as a way to incorporate
information about undesired states into design calculations.
Theory of Cluster Expansion
We have previously shown that the conformational energy of a protein sequence in a
specified fold, defined numerically using structural calculations and optimization, can be
expressed as a direct function of sequence using the method of cluster expansion (Grigoryan, et
al. 2006, Zhou, et al. 2005). For completeness, we briefly describe this method here. Let Emin (a)
be the energy of sequence e in a given backbone fold (subscript min stands for minimization
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over side-chain degrees of freedom). Let C = { 0  N }, where o-, is a discrete variable
representing the amino acid at the i-th position of the sequence. For simplicity, and without loss
of generality, assume that in our design problem there are M amino-acid possibilities at each
position and a, can take on values from 0 to M-1. We can then express Emin (d ) as a cluster
expansion of the form:
N M-1 N-1 N M-1M-1
Emn ()= Jo + ii -p(si, i)+ J y -p(si, i). p9(sj, j)+...,
si=1 i=1 si=1 sj=si+l i=1 j=1
where p(si, i) is a binary function that evaluates as 1 if site si is occupied with amino-acid i and
zero otherwise. The summations are over sites and amino-acid identities. A collection of sites is
referred to as a cluster, and a cluster populated by a given set of amino acids is a cluster function
(CF). Terms J are the effective contributions of each cluster function to the overall energy
(effective cluster interactions, or EC). The three terms shown correspond to the constant, point
and pair cluster-function contributions. If the expansion is written out in its entirety (i.e. up to the
N-tuple cluster functions), then by virtue of having exactly the same number of ECI as possible
sequences (Mv), it is exact. If the expansion is truncated at a given point, an approximation of
Em can be derived by fitting the ECI to minimize the error between CE-estimated energies and
structure-derived energies for a training set of sequence-energy pairs. Once this procedure is
carried out, the process of estimating the energy of a sequence adopting the specified structure is
made many orders of magnitude more efficient (Grigoryan, et al. 2006).
bZIP Models
To model parallel dimeric coiled coils, we employed two variants of the energy function HP/S/C
that was previously shown to perform well in predicting human bZIP interaction specificity
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(Grigoryan and Keating. 2006). This function evaluates the relative stability of coiled-coil dimers
primarily as a function of the amino acids at a, d, e and g positions, based on predicted structures
of coiled-coil complexes. One of the key features of model HP/S/C is that core a-a' and d-d'
terms derived from structure-based calculations are replaced with statistical weights from a
machine-learning algorithm (Grigoryan and Keating. 2006). These terms can alternatively be
replaced by experimentally determined thermodynamic coupling energies. However, these were
only available for 15 amino-acid pairs at a-a' at the time of our earlier study (Acharya, et al.
2002), and using them gave inferior performance. Since then, Vinson and co-workers have
measured coupling energies for 55 amino-acid pairs at a-a' (Acharya, et al. 2006a). Additionally,
we recognized that almost all of the improvement upon replacing d-d' interactions with
statistical weights can be attributed to Leu-Leu pairs, which are modelled as only slightly
favourable in structure-based approaches, contrary to experimental data. As a result of these
findings, we developed model HP/S/Cv. Structure-based a-a' interactions were replaced with a-
a' coupling energies for 55 amino-acid combinations; the d-d' interaction for Leu-Leu was
replaced with -2 kcal/mol (no experimental value is available), and the resulting model was
expanded using CE. Because effective self contributions from our structural models and
experimental coupling energies may be on different scales, point ECI values for the a position
were adjusted such that 100 folding free energies measured by Acharya et al. were predicted
optimally (in the least squares sense) by the overall CE model - see Figure B.S 10.
As a way to account for pair-wise interactions in the reference state, both variant models
used in this study ignored the energy of intra-chain side-chain interactions in the final predicted
structure (see reference (Grigoryan and Keating. 2006)). Note, however, that because the process
of placing side chains for structure prediction does take into account all side-chain interactions,
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intra-chain interactions do make indirect contributions to the final energy, and corresponding
ECI do emerge in cluster expansion.
Integer Linear Programming
Kingsford et al. have shown that the problem of finding the lowest-energy rotamer-based
side-chain packing arrangement, in the context of protein design, can be expressed and solved as
an ILP (Kingsford, et al. 2005). Given that CE provides the energies of the desired and undesired
states as analytical functions of sequence, we introduced a similar approach for handling
specificity in design. With notation as in Kingsford et al., we represent the sequence space in our
problem of designing a peptide of length p as an undirected p-partite graph with node set
V = V u...u V,. Set V, contains one node for each amino-acid possibility at position i. For each
state S, each node u e V is assigned a weight Es corresponding to its contribution to the energy
of that state. If S is a heterodimer state (i.e. a state in which the design is complexed with a
protein of fixed sequence), this individual contribution is simply the sum of the point ECI
corresponding to u and pair ECI corresponding to pairs between u and all amino acids of the
partner sequence. If S is the design-design homodimer state, then E is the sum of point ECI
corresponding to u and pair ECI of u and its image on the opposite chain. The edges of the graph
D= tu,v): u e V andv e Vj,i w jj are assigned weights Es. If S is a heterodimer state, then
Es is the ECI of the corresponding intra-chain pair cluster function. If S is the design-design
homodimer state, then additional contributions to Es come from the ECI between u and the
image of v as well as v and the image of u. Given these definitions, the energy of the design
260
sequence in any state S can be expressed as 6s = I Ex + I Ex,, where binary variables
ueV u,veD
x. and x, determine which nodes and edges the sequence involves. Thus, the problem of
optimizing the energy of state S can be expressed as an ILP seeking to minimize cS, under the
constraint that the chosen nodes and edges correspond to one another. Further, because gaps
between different states are also linear functions of decision variables xu and xUV arbitrary gap
constraints can also be incorporated. Finally, any additional function of these decision variables,
such as a PSSM score, can also be incorporated. With T as the target state and U representing
undesired states, the ILP we used in this study is (where V\Vj stands for the set difference
between V and V):
Minimize :ET = T E' + I ETxu
ueV u,veD
subject to:
I xuu =1I for j =,.,p
ueV,
I xU = x, for j =1,...,p and v e V \V
U, _ T > gcl, wheresul =EEulxu + I Eixv
ueV u,veD
6 Uk T > gCk ,where EUk = Ekxu + I Ek xu
ueV U,VED
W u <pssmc
UEV
x. .e {,}
Here k is the number of undesired states, gc is the gap constraint for i-th state, pssmc is
the PSSM constraint and Wu is the PSSM weight corresponding to node u. We solved such ILPs
with the gipsol tool from the GNU Linear Programming Kit
(http://www.gnu.org/software/glpk/). Because of the simplicity of sequence-based expressions
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obtained through CE, solutions to these ILPs with as many as 46 undesired states were generally
obtained within 1-5 minutes on a single 2.7 GHz CPU.
Note that although everything was formulated in this instance for energy functions that
are pair-wise decomposable at the sequence level, in principle this approach can be easily
generalized for higher-order terms. Clearly, the CE methodology is already capable of taking
higher-order interactions into account, should there be a need (Grigoryan, et al. 2006). The ILP
formulation can be extended to handle higher-order terms by introducing additional decision
variables. For example, x. would be 1 if there is a triplet interaction between nodes u, v, and w.
Constraints for these new decision variables would also have to be imposed to ensure that
higher-order interactions occur only between those nodes that are chosen (e.g. in this case xuu, xv,
and x,, are 1). Note that these higher-order decision variables would have to be introduced only
for those clusters of sites that do, in fact, participate in higher-order interactions. This allows the
complexity of the ILP problem to grow naturally with the size of the system (i.e. the number of
variables and constraints grows linearly with the number of interactions in the system).
PSSM Constraint
To constrain CLASSY designs to favour a leucine-zipper fold, we derived heptad
position-specific amino-acid frequencies from the multi-species alignment of 432 bZIP leucine
zippers described above. These frequencies were then used to score all of the sequences in the
alignment (taking into account only a, d, e and g positions), from which a length-normalized
score distribution was derived. Based on this distribution, a cutoff value of 0.247 was imposed in
CLASSY such that all of the designed sequences had a PSSM score of at least 0.247. Although
this is a stringent cutoff, with 84% of native sequences scoring below it, the sequence space
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remaining is still large. For example, for a six-heptad design sequence, where a, d, e and g
positions are varied and 10 amino acids are allowed per position, the total sequence space is 1024
whereas after applying the PSSM cutoff of 0.247 it is still ~1018 (calculated by convolving score
distributions at individual positions to obtain the final distribution of scores and integrating it
from 0.247 up).
Choosing b, c and fPositions
Positions a, d, e and g are assumed to encode most of the interaction specificity of the
designed peptides (Vinson, et al. 2006, O'Shea, et al. 1992). Thus, we chose the identities of the
b, c and f positions such that they were appropriate for the already selected a, d, e, and g
positions, given what is observed in the multi-species dataset of 432 bZIP sequences referenced
above. Thus, for each b, c, and f position b1 we sought to optimize P(b, la,..., a,), where a,...an
are the identities of the selected a, d, e, and g positions. We expressed this quantity in terms of
probabilities we could measure from the dataset:
P(b1 lal,..., an) P(b, al,..., a) P(a1b,, a2 ..., an ). P(b,, a2 ,..., an)
P(aj,..., an ) P(ai,..., an )
P(ail1b,, a2,---, an 'p(a2 Jbi, a3 ,..., an).. P(an Jbi) P(b,)
P~al bi P~2 Jbi P ai,..., an )
P~a|b ) Pa2|, -..- P anjbj- P(bj
P(aj,..., an )
The last step assumes that the pre-selected amino-acid decoration at positions a, d, e, and g
represents well the natively observed decorations at these positions (i.e. probability P(ab 1)
measured in the adeg context of the designed peptide and the probability averaged over all native
contexts is the same). Quantity P(a,..., an) is hard to estimate, but it is constant with respect to
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b, c and f and is therefore not important. Conditional probabilities P(ak b,) can be easily
measured from the native bZIP dataset, and for each b, c and f position the amino acid that
optimizes the above probability can be found. Using this approach, we were able to obtain b, c, f
decorations of natural content and distribution. However, we found that infrequently this
procedure resulted in sequences with large charge and/or helix propensity (mostly due to the fact
that the pre-selected a, d, e, and g amino acids already had high values of charge or helix
propensity). Thus, we expressed the problem of finding the optimal b, c and f combination
according to the above equation as an ILP (by taking the logarithm of the probability it can be
decomposed into a sum of pre-computed probability logarithms) and incorporated constraints on
total charge, charge content (number of charged residues) and helix propensity. For each
property, the range of acceptable values was defined as p o-, where p and - are the mean
and standard deviation of the corresponding property in the native bZIP dataset. In a few
instances this resulted in no solutions (i.e. the selected a, d, e or g were already outside of the
range for one of the properties) and for these cases more liberal intervals were allowed (either
p ±1.5c- or p ± 20-). Finally, because we wanted to rely on UV absorbance for determining
concentration, we imposed the additional constraint that the b, c, f positions contain at least one
Y or W residue (unless there was one already present at a, d, e or g).
Uncovering Specificity-encoding Features
We analyzed the 8 designs determined to be most specific using the arrays to identify
specificity-encoding features. First, we compared each design-target complex with the
corresponding design-undesired heterocomplexes. For each such comparison, we computed the
contribution of each amino acid in the i-th position of the design sequence (aaj) to the overall
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stability and specificity. This was done by computing the interaction of aa, with the region of the
target peptide from i-7 to i+7 (one heptad N- and C-terminal to aaj) as well as the interaction of
aaj with the same region of the undesired partner. The first value corresponded to the stability
contribution of aa, and the difference between the two was the specificity contribution. To
further isolate specificity determinants, this difference was decomposed into contributions from
different positions on the target sequence and the corresponding positions on the undesired
partner sequence.
We performed a similar analysis to elucidate features encoding specificity against the
design-design homodimer, except the contribution of each amino acid aaj to specificity was
considered as the difference between interaction of aa with the residue opposing it in the target
sequence and its interaction with itself in the design homodimer. The same analysis was repeated
for pairs of amino acids at all position pairs (i andj) of the design sequence.
Dividing Human bZIPs into 20 Families
Human bZIPs were divided into 20 families based on the evolutionary analysis of
(Amoutzias, et al. 2007) with the exception of including CHOP and ZF as individual families,
and condensing OASIS and OASISb into a single family based on the similarity of their
interaction profiles (Newman and Keating. 2003). The phylogenetic tree of human bZIPs shown
in Figure B.S13 was made using only the leucine-zipper regions and was constructed with the
PHYLIP (http://evolution.genetics.washington.edu/phylip.html) package using the Neighbour-
Joining algorithm and the Jones-Taylor-Thornton (JTT) model of amino-acid replacements.
TreeDyn (http://www.treedyn.org/) was used to visualize and annotate the tree.
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How Many Unique anti-bZIP Profiles Are There?
Figure 3.3A shows that our CLASSY designs exhibit many novel interaction profiles
when binding human bZIPs, while the sequence diversity used to generate these profiles is rather
limited (Figure 3.3C). This suggests that there may be a very large number of different
interaction profiles, of which our 48 designs have revealed only a very small portion. But how
large is this number? To answer this question with high confidence we need either an extremely
large number of designs and measurements or an extremely accurate model. At present, neither is
available. However, if we have a good idea of a model's prediction accuracy and use this model
to calculate the number of unique profiles that exist, we can then estimate a lower bound on the
true number of profiles. Here, we used model HP/S/Cv for this purpose. Several steps were taken
to ensure that our estimates were always below the true number of profiles.
The interaction profile of a peptide was defined as a binary vector indicating whether the
peptide interacts (1) or does not interact (0) with each human bZIP. If two binary vectors are
equal, the profiles are equivalent. In reality, there is a lot of space between such vectors, because
interaction strength also plays a role in defining a profile. This is one way that we
underestimated the total number of possible profiles. We also defined these vectors at the family
level rather than the protein level - again, a significant underestimate of the real size of the
profile space. We considered 19 out of the 20 families (due to difficulties assessing model
performance on the ATF3 family), giving a total of 524,288 possible unique profiles. The
following procedure was followed:
Compute the total number of unique profiles predicted by HP/S/Cv. For each human bZIP coiled
coil Pi we defined a computational energy cutoff ci to optimally discriminate interactions and
non-interactions in the human bZIP interaction dataset (experimental interactions/non-
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interactions taken from (Fong, et al. 2004)). To increase prediction confidence, we introduced a
buffer parameter b, such that energy scores above c,+b were considered non-interactions, below
ci - b were considered interactions, and scores between c, - b and ci+b were not considered as
either (b was set to 3 kcal/mol by optimizing performance on the human bZIP interaction
dataset). This parameter increases prediction confidence but reduces the number of peptides that
can give rise to a profile, further reducing our final estimate. Next, we generated 1,000 random
binary profile vectors and ran CLASSY to find the most stable sequence consistent with each
profile (e.g. its interaction stability with each of the 40 bZIPs from the 19 considered families is
either below ci - b or above ci+b in accordance to the profile). The bZIP PSSM constraint was
applied. Out of these 1,000 cases, 5 produced a solution. Given that there are a total of 524,288
possible binary profiles, this translates into ~2,600 unique profiles that can be achieved in
design.
Estimate prediction rates. The rates of true positive (TP), true negative (TN), false positive (FP)
and false negative (FN) predictions were estimated from anti-bZIP*bZIP interaction data.
Performance is expected to be worse than for the human-human dataset for several reasons. First,
the process of design tends to exacerbate errors in an energy function. Second, because designed
sequences are different from native bZIPs in systematic ways, the ranges of HP/S/Cv scores for
anti-bZIP-bZIP and bZIP-bZIP interactions will also be different, making cutoffs derived from
the bZIP-bZIP dataset less applicable to anti-bZIP-bZIP interactions. Thus, although the
prediction rates for the human-human interactions were TP = 0.84, TN = 0.91, FP = 0.16, FN
0.09, they were worse for the anti-bZIP-bZIP interactions: TP = 0.39, TN= 0.94, FP = 0.61, FN
= 0.06. The drastic difference between the two performance rates is a result of over-training
optimal cutoffs to the case of human-human interactions, but since the most important goal here
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is not to over-estimate the performance rate, this approach is still valid. The performance
predicting relative stabilities of two complexes of anti-bZIP-bZIP is much better than this.
Given two predicted distinct profiles, find the probability that they are in fact the same. This
probability, ps, is a product of the probabilities that each individual element of the profile
(interaction or non-interaction with each human bZIP) is the same. Formally,
ps =(TN -TN + FN -FN)" -(TN -FP + FN -TP). (TP -FN + FP -TN) -(TP -TP + FP -FP)OO,
where oo, oz, zo, and zz are the number of corresponding profile elements that are both 1, 0 and
1, 1 and 0, or both 0, respectively. Probability ps was estimated to be 2.0 -104 by averaging over
1,000 pairs of randomly generated profiles.
Calculate the probability distribution of the true number ofprofiles. We predicted that there exist
~2,600 unique profiles. The first one we consider is certainly unique. The second one is
predicted to be unique, but it is actually unique with probability 1 - ps. The third one is also
predicted to be unique, but it is truly different from the first and the second with probability (1 -
ps)2. In general, if P(k, n) is the probability of having k unique profiles after considering n
predicted unique profiles, then we can give the recursive definition
P(k, n) = P(k, n - 1)- k -ps + P(k -1, n -1) -(1-ps)-. Using this we generated the probability
distribution of the true number of profiles after considering 2,600 profiles. This distribution had a
sharp peak around 1,900 profiles and quickly fell to essentially zero before and after that
(integral between 1,785 and 1950 is 0.9999). Based on this, there should exist at least -1,900
unique peptide-human bZIP interaction profiles, and probably there are many more.
A Picture of Multi-state Energy Phase Space
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Specificity-sweep calculations predict that designs selected solely for optimal binding to
the target are often not specific, and are especially prone to homodimerization (see Figure B.S
2A). Many specificity problems can be eliminated by sacrificing relatively small amounts of
stability (Figure B.S2C). However, it is not clear how severe the specificity constraint is and how
much it restricts the choice of sequences. We investigated this in a simplified case where
design-design homodimers are the only competing state. We constructed a 2D histogram of the
entire design sequence space for several design problems, looking at the distribution of
designetarget energies versus design-design energies. In such a histogram, each 2D bin
corresponds to energy ranges for the design-design and the design-target complexes and contains
the number of sequences that satisfy these ranges.
If each amino acid at each site made an independent contribution to the total energy, this
histogram could be built by convolving the 2D energy histograms of each individual site.
However, amino acids at different sites interact with each other. To address this, we used the fact
that amino acids more than a heptad apart do not interact in our CE energy expressions. As in the
case for independent site contributions, sites were considered one-by-one and their histograms
were convolved with the running total. However, at each step energy contributions from both
single-residue and pair-wise interactions with residues in the preceding heptad were
incorporated. In order to account for the pair-wise terms appropriately, individual histograms
were maintained for each unique sequence combination in the preceding heptad. To limit
memory usage, only 9 amino acids were considered at each site for this purpose. Note that
because positions b, c and f were not explicitly considered in our models, there were a total of 94
= 6,561 possible heptad sequences and 6,561 running total histograms needed to be kept at each
stage. In the last step these 6,561 histograms were added to produce the final 2D histogram.
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The results for ATF-2 and MafG are shown in Figure B.S12 (other bZIPs produced
similar results). The dashed lines show where the design-design and design-target energies are
equal. Clearly, most stable sequences are even more stable as homodimers (i.e. are below the
line; note log scale), indicating that destabilization of the design homodimer is an extremely
severe constraint that limits sequence space by many orders of magnitude.
Jun family constructs
The following peptides were used for the Jun family, which have more uniform length than those
previously constructed by Newman & Keating.
cJun
MSYYHHHHHHLESTSLYKKAGSGSRKLERIARLEEKVKTLKAQNSELASTANMLREQV
AQLKQKVMNHLE,
JunB
MSYYHHHHHHLESTSLYKKAGSGSRKLERIARLEDKVKTLKAENAGLSSTAGLLREQV
AQLKQKVMNHLE,
JunD
MSYYHHHHHHLESTSLYKKAGSGSGSRKLERISRLEEKVKTLKSQNTELASTASLLREQ
VAQLKQKVMNHLE
Data Analysis
Scanned images of slides were analyzed using the program Digital Genome
(Molecularware). For each probe the scan at the highest PMT voltage that did not show
saturation was used for analysis. The signal in the red channel from the Alexa Fluor 633
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hydrazide was used to identify the location of spots. The median signal and median background
for each spot was determined, and signal less background for each spot was calculated. Missed
spots and artifacts were manually flagged and removed from analysis; these represented less than
0.1% of all spots. For each pair of adjacent sub-arrays probed with the same labeled peptide, the
average of 8 measurements for each protein on the surface was calculated and defined as a.
These values are reported in Tables B.S3 - 5.
Two other quantities were used in analyses. Because a small number of probes showed
high background, a corrected fluorescence signal was defined as F = a - a, with ii the median
of all signals measured using a common probe. The maximum of this quantity for a given probe
was designated Fmax. The quantity -log(F/Fmax) was used in Figure 3.2, Figure 3.3A, and Figure
B.Sl and B.S14 to indicate relative array signal differences.
To distinguish signal from noise, and thus put an approximate lower bound on the signal
required as evidence for an interaction, we defined the quantity Sarray as
Sarra(a)= N(a- , where a is again the median of a, N is the number of unique
L (a, - )2 N,<a
i=1, a, <i
printed proteins, and Na<a is the number of proteins producing a below the median. N and Na<a
excluded other designed peptides on the surface when the solution probe was itself a designed
peptide. Saray is a Z-score-like quantity, where the distribution of signals below the median was
assumed to be primarily noise-driven and thus was used to correct stronger signals. Sarray values
are also provided in Tables B.S3 - 5.
For the purpose of estimating the number of designs that homodimerize, and how many
designs interacted with their target, the following criterion was used: A and B were judged to
give signal above background, and thus to interact, if they produced an Sarray score above 2.5
either when A was on the surface and B was the probe or when B was on the surface and A was
the probe. This cutoff was chosen based on reported homodimerization of bZIP families as well
as our solution measurements of stability (Newman and Keating. 2003, Acharya, et al. 2006b,
Vinson, et al. 2002).
Interaction-Profile Clustering
An interaction profile was defined using -log(F/Fma) scores derived from microarrays,
and profiles were clustered using Eucledian distance as the dissimilarity metric. Average linkage
clustering was performed using the linkage command in Matlab 6.5.
Circular Dichroism
Circular dichroism (CD) spectra were measured on AVIV 400 and 202 spectrometers in
12.5 mM potassium phosphate (pH 7.4)/150 mM KCl/0.25 mM EDTA/1M GuHCl/1 mM DTT.
All mixtures of peptides were incubated at room temperature for several hours before
measurement. Wavelength scans were performed at 40 pM total peptide concentration and
measured at 25 'C in a 1-mm cuvette. Scans were monitored from 280 nm to 195 nm in 1 nm
steps averaging for 5 seconds at each wavelength. Three scans for each sample were averaged.
Thermal unfolding curves were performed at 4 p.M total peptide concentration and measured in a
1-cm cuvette. Melting curves were determined by monitoring ellipticity at 222 nm with an
averaging time of 30 seconds, an equilibration time of 1.5 minutes, and a scan rate of 2 'C/min.
All samples were measured from 0 'C to 85 'C unless otherwise noted. All thermal denaturations
were reversible. Tm values were estimated by fitting thermal denaturation data to a monomer-
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dimer equilibrium, assuming no change in heat capacity upon folding. Specifically, we fit the
derivative of the CD signal with respect to temperature to the equation:
4epAH 1 1 +
d(signal). AH . r AH 1 1 R _T T_ _1
dT RT 2  R LTm T) AH [ 1I
8 -exp + 1
R Tm T_
Here A, AH, and Tm were fitting parameters, with AH and Tm corresponding to the change in
enthalpy upon folding and the apparent melting temperature, respectively. We fit the derivative
of the CD signal to reduce the reliance of the fit on pre- and post-transition baselines (John and
Weeks. 2000). For two-species mixtures AB, the difference between the melting curve of the AB
mix and the average of melting curves of A and B (SAB-A-B) was calculated and treated as the
signal for the purposes of fitting the above equation. No fitting was performed for mixtures
where SAB-A-B was positive at any point during the unfolding transition (i.e. the signal from the
average was stronger than the signal from the mixture), as it was not clear which species was
being melted. Those mixtures with SAB-A-B > 0 over the entire temperature range were assumed
to show no evidence of interaction. Fitting was performed using the non-linear least squares
method in Matlab 6.0. The 95% confidence intervals resulting from the fits are reported in Table
B.S2.
Comparing CD and Array-based Stability Ordering
Relative stability orders established by CD and microarray were compared
conservatively. The arrays were only used to judge relative stabilities when two interactions
involved the same solution probe interacting with partners on the same array surface. CD ranks
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were determined by visual inspection of thermal melts, with cases where the order was not
clearly obvious being assigned the same rank. Array ranks for interactions sharing a common
probe were established based on the Sarray measure, with ranks differing by only one unit in
normalized San-ay considered the same. All possible pair-wise comparisons of CD and array ranks
were made, a total of 41 comparisons, 35 of which gave the same order by CD and microarray.
Array Results were Highly Reproducible
The array measurements were highly reproducible over replicate experiments and a range
of concentrations, as shown in Figure B.S14. The complete array data (averaged background-
corrected signals as well as Sarray scores) are given in Tables B.S3-6. Proteins listed in columns
were fluorescently labelled and used in solution as probes against proteins on the surface, which
are listed in rows. All protein probes were at 160 nM unless otherwise noted. Duplicates are
labelled. Tables B.S3-5 contain values from experiments in rounds 1, 2, and 3 respectively.
Table B.S6 contains experimentally determined Sarray scores for 33 human proteins.
SUPPLEMENTARY DISCUSSION
Beyond bZIPs: Requirements for Applying CLASSY to Other Systems
There are a variety of reasons that we selected bZIP transcription factors for this study.
They comprise a biologically important class of proteins for which questions of interaction
specificity are central to function. But also, interaction specificity is probably better understood
for the bZIPs than for any other protein complex, and convenient properties of these proteins
facilitate modelling and measurement. To what extent can CLASSY be applied to other problems
in molecular recognition? To answer this it is important to distinguish between limitations that
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arise from CLASSY itself - of which there are few - and limitations that arise from our
understanding of specificity in other protein complexes. The systematic study of protein
interaction specificity is a new, expanding research area. There are already several complexes
amenable to study using CLASSY, and this number will increase with advances in experimental
screening technologies and computational modelling.
Below we outline three requirements that must be met to apply CLASSY to a specificity
design problem. For each, we comment on how the bZIPs satisfy the requirement and discuss
prospects for other complexes.
1. Application of CLASSY requires that sets of desired and competing states be defined.
To address interaction specificity explicitly, one must define the universe of relevant
complexes. For many problems, competing states of particular interest can be identified as those
that share structural and evolutionary similarity with the target. In our bZIP application, the
competitors were other bZIPs. These can be detected easily by sequence similarity. Many related
interaction specificity problems can be posed. In the design of peptides to activate specific
integrins, the competitors would be other integrins; in the design of specific PDZ domains the
competitors would be undesired protein C-terminal peptides; in the design of BH3 peptides that
bind specific Bcl-2 family members, the competitors would be other Bcl-2 proteins. Although
criterion 2 (below) may not yet be satisfied for these examples, at least one prior example of a
successful design calculation in each of these cases illustrates progress in modelling and
highlights the types of applications where CLASSY may prove fruitful (Yin, et al. 2007, Reina,
et al. 2002, Fu, et al. 2007). Similar examples can be constructed for any set of paralogous
interaction domains; zinc-finger and homeodomain transcription factors as well as SH2, SH3 and
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PDZ domains are discussed below.
2. A scoring function must provide information about the relative stabilities of the states under
consideration.
Specificity can be designed using CLASSY only if a model captures information about the
relative favourability of different states. CLASSY can use many types of scoring functions.
Physical/structure-based models and empirical/statistical models are equally compatible with the
requirements of the method. The only formal requirement is that the scoring function be
expressed as a linear function of sequence variables (not necessarily limited to amino-acid pair
terms). We have demonstrated that cluster expansion can accomplish this for complex structure-
based energy functions and for several different protein folds (Grigoryan, et al. 2006, Zhou, et al.
2005, Apgar, et al. 2009). Cluster expansion can in theory also be applied directly to large
experimental datasets, where available, to generate a predictive expression in the appropriate
computational form.
In designing anti-bZIPs, we took advantage of experiments that elucidated some of the
determinants of interaction specificity; we captured these in a hybrid structure-based/experiment-
based model, which was tested using available peptide array data (Grigoryan and Keating. 2006,
Newman and Keating. 2003). Specificity-scoring functions published for other protein domains
can now be tested using CLASSY. For example, models based on fitting residue interactions to
experimental data have been developed for PDZ domains and zinc fingers. Such scoring
functions typically have the functional form required for CLASSY (Stiffler, et al. 2007,
Wiedemann, et al. 2004, Kaplan, et al. 2005, Chen, et al. 2008). Scoring functions based on
structural modelling have the greatest potential to be general. RosettaDesign has been used for
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many applications, including the design of specific protein-protein interactions (Kortemme and
Baker. 2004, Kortemme, et al. 2004). Other structure-based specificity models have been tested
for PDZ (Reina, et al. 2002), SH2 (Sanchez, et al. 2008) and SH3 (Hou, et al. 2008, Hou, et al.
2006) domains. Structure-based models have also shown good performance for several
transcription factor families (Jamal Rahi, et al. 2008, Siggers and Honig. 2007, Paillard, et al.
2004, Morozov, et al. 2005). Physical structure-based models face significant challenges, in
particular capturing side-chain and backbone relaxation that can impact specificity. But as new
methods for modelling structural relaxation are developed (and several groups report progress in
this area (Das and Baker. 2008, Smith and Kortemme. 2008, Friedland, et al. 2008)), there are no
obvious barriers to employing them in conjunction with CLASSY. In fact, we recently
demonstrated that cluster expansion works well when applied to models that incorporate
backbone flexibility (Apgar, et al. 2009). Finally, structural approaches that use atom-based or
residue-based statistical potentials can give good predictions of binding energies and can capture
some interaction specificity trends (Zhou and Zhou. 2002, Aloy and Russell. 2002, Apgar, et al.
2008); such models may prove especially useful for negative design.
How good do the scoring functions need to be? Our bZIP scoring functions, while capable
of distinguishing strong interactions from non-interactions, do not provide quantitative
predictions of relative stability (they do not correlate strongly with experimental AAG estimates).
Models can likely be effective for use in CLASSY if they (1) accurately capture some key
specificity determinants and (2) are not under-defined. A model is under-defined if it has many
missing or inappropriate weights; these can allow the design optimization calculations to proceed
into non-sensible regions of sequence space. In our bZIP study, the experiments of Vinson and
colleagues provided valuable data contributing to (1), though these experiments did not
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comprehensively assess all possible specificity determinants (Acharya, et al. 2006a, Vinson, et al.
2006). To address (2), we used structural modelling to impose a physically realistic description
of all amino-acid interactions that were not defined by experiments. A similar combined
approach is likely to be appropriate for other domains. For example, for PDZ domains and zinc
fingers, a small set of weights derived from experiments seem to predict much of the observed
specificity (Wiedemann, et al. 2004, Chen, et al. 2008). But structural modelling may be required
to provide reasonable (even if not highly accurate) estimates for the many amino-acid
interactions that are not constrained by experiments. Also important for addressing (2) is the
ability of CLASSY to incorporate sequence property constraints (e.g. the PSSM constraint used
in this study), which can be used to ensure that only the sequence space that is reasonably well
described by the underlying model is considered in design.
Finally, energy gaps in CLASSY can be chosen according to the estimated accuracy of
the underlying energy function. Thus, if errors in predicted energies are known to be large, the
user can choose to impose large energy gaps as constraints, ensuring that any designs returned
are predicted to have a significant preference for the desired state over others (at the risk of
finding either no solutions or only poorly stable solutions).
In summary, while we do not yet know if breakthroughs in predicting specificity will come
primarily from improvements in modelling or from fitting to large experimental data sets, this
likely does not matter in terms of applying CLASSY. Designing specific PDZ/SH2/SH3 domains
or specific PDZ/SH2/SH3 ligands, or zinc-finger transcription factors with specialized binding
profiles, are already good candidate applications for testing this method more broadly.
3. An experimental assay appropriate for testing the specificity of the proteins under study is
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required.
It is impossible to know the quality of the scoring function, or the quality of CLASSY
designs, without experiments that report on interaction specificity. Assessing specificity profiles
generally involves testing many possible complexes. For the bZIPs, we took advantage of a
previously validated peptide microarray assay (Newman and Keating. 2003). Similar large data
sets exist for SH2, SH3, PTB, and PDZ domains, as well as for many transcription factors (Jones,
et al. 2006, Matys, et al. 2003, Spaller. 2006, Tonikian, et al. 2008, Noyes, et al. 2008, Berger, et
al. 2008). Exciting advances using SPOT arrays, protein microarrays, protein-binding DNA
arrays, phage-display/phage ELISA, protein complementation assays and plate-based
fluorescence assays expand the possibilities in this area, and suggest that many moderately sized
binary complexes will be amenable to analysis (Newman and Keating. 2003, Stiffler, et al. 2007,
Wiedemann, et al. 2004, Jones, et al. 2006, Tonikian, et al. 2008, Noyes, et al. 2008, Berger, et
al. 2008, Landgraf, et al. 2004, Tarassov, et al. 2008, Remy and Michnick. 2006).
CLASSY Introduces Negative Design Using Familiar bZIP Features
CLASSY designs employed a range of strategies to achieve specificity, but some trends
were evident. Designs optimized for stability alone often had a and d positions with medium-to-
large hydrophobic residues (Acharya, et al. 2006a), and CLASSY initially improved specificity
by maintaining these cores and modulating electrostatic g-e' interactions in early iterations of the
specificity sweeps (see Figure 3.1C for definitions of coiled-coil heptad positions; a prime
indicates a residue on the opposite helix). To achieve greater specificity (A), at a greater price in
stability, CLASSY introduced core substitutions such as pairing of Ile with Ala (e.g. to
destabilize homodimers using Ala-Ala pairs). The sequences selected for testing typically
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included additional elements, such as charged amino acids in core positions. Such interactions
imparted large amounts of specificity but were also predicted to be quite destabilizing. They
were chosen for analysis because we judged specificity to be relatively more important; generic
strategies such as ACID extensions could be used to improve stability if necessary (Ahn, et al.
1998).
Our 8 most specific designs exhibit canonical bZIP specificity determinants (Figure B.S
15A): there is a strong preference for Asn at an a position to be paired with Asn at the opposing
a', and electrostatic complementarity is exploited at g-e' positions (Grigoryan and Keating. 2006,
Vinson, et al. 2006). Interestingly, a less recognized complementarity between g-a' positions is
predicted to make a comparable, if not larger, contribution to specificity; this feature was
extensively used in our designs (Figure B. S 15A) (McClain, et al. 2002). A strong preference for
Leu-Leu over all other amino-acid pairs at d-d' positions was also exploited (Moitra, et al. 1997).
Finally, our model predicts that interactions between a and d' can contribute significantly to
specificity. In particular, a beta-branched residue at an a position strongly prefers a non-beta
branched residue at the next d position of the opposing strand. Similar effects have been noted in
anti-parallel coiled coils (Hadley, et al. 2008).
Off-target Interactions May Form via Structures That Were Not Modelled
In our computational modelling, we considered only parallel coiled-coil dimer structures
with a unique axial alignment of helices. For the designs that bound to their targets, it is likely
that the interaction occurred as modelled because the designs were restrained to have leucine
zipper-like sequences, frequently retained buried Asn and Lys residues to favour dimers over
other oligomers, and retained paired Asn residues at a-a' positions to favour particular parallel
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alignments (Oakley and Kim. 1998, Gonzalez, et al. 1996). These features were selected
automatically by CLASSY in most cases, and where they were not present in all candidate
designs, we imposed a bias for such solutions when choosing examples for experimental testing.
Further supporting the formation of dimers, interactions of designs with their targets were
observed to occur irrespective of which peptide was printed on the array and which was labelled
in solution, which is unlikely for some alternate stoichiometries.
When unexpected design-off-target interactions occurred, it is less clear what the
structures of those complexes were. In several instances, we suspect that the complex formed
was not one that was modelled as an undesired state. For example, the strong interaction between
anti-SMAF-2 and ATF-4 (Figure B.Sl) was predicted to be very unfavourable relative to anti-
SMAF-2-MafG (Figure B.S16A-B). However, because the SMAF family has an Asn in a
different heptad than most human bZIPs, the alignment used to model anti-SMAF-2 paired with
ATF-4 left two asparagines at a positions unpaired (see Figure B.S16A). Asn residues have a
strong preference to occur in pairs in coiled-coil dimers (Acharya, et al. 2006a), and it is unlikely
that the anti-SMAF-2-ATF-4 interaction would occur in this way. More likely, the complex
would adopt a shifted axial alignment (though this is also predicted to be unfavourable, Figure
B.S16C), an anti-parallel helix orientation, or some other structure. Anti-BACH2-2, which
showed strong homo-association on the array, illustrates another case where the complex formed
may not be the one that was modelled as an undesired state. Anti-BACH-2 homodimer was
predicted to be much less stable than anti-BACH-2*BACH1. However, although anti-BACH-2
has very strong anti-homodimerization features, they are heavily concentrated in the first two N-
terminal heptads (see Figure B.S17). It is likely that this portion of the homodimer simply does
not fold, and the rest of the sequence forms a stable association. Of course, if such problems can
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be anticipated, additional constraints can be incorporated into CLASSY, where alternative
alignments, coiled-coil lengths and orientations can be explicitly considered.
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SUPPLEMENTARY EXPERIMENTS
Figure B.Sl. Array measurements characterizing all 48 designs. Designs are in columns. Human
bZIPs on the arrays are in rows. Family names are in blue, with families separated by blue lines.
Shown as a heat map are interaction -log(F/Fmax) scores (see section Data analysis), with lower
scores (darker color) indicating stronger interactions. The "homodimer" row indicates the
interaction of each design in solution with itself on the array, relative to the strongest interaction
of that design with other partners on the array. The "relative stability" row indicates the
interaction of each surface-attached design with its target in solution, relative to the target's
strongest interaction (either the design or one of 33 human bZIPs on the same array). Green
boxes indicate intended targets.
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Figure B.S2. A global view of specificity sweeps with each human bZIP coiled coil as a target.
In each row, the protein indicated at left is the target. The first column contains the score of the
optimal designotarget complex, whereas each subsequent column contains the energy gaps
between the design-target complex and the corresponding design-competitor complex, including
the design homodimer in the second column. A positive energy gap corresponds to design-target
being more favorable than designecompetitor. The color bar gives the energy scale. (A), (B), (C)
and (D) correspond to designs from different stages of specificity sweeps. In (A) the design
producing the most stable complex for each target was used to compute energies (first iteration).
In (B) up to 1% of the stability score was sacrificed to gain specificity. In (C) up to 5% of
stability was sacrificed and in (D) the most specific designs were considered. In (E) and (F) the
specificity data are summarized as a function of decreasing stability. (E) shows the proportion of
anti-human designs for which the design-design homodimer has a gap of less than 6 kcal/mol,
and (F) shows the proportion of designs predicted to compete with a non-target-family human
bZIP by the same criterion. Energies were computed using model HP/S/Cv.
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Figure B.S3. Solution characterization of anti-ATF2 by CD. Format and presentation is the same
as in Fiigure 3.2B-E for anti-SMAF. The target protein is ATF-7 (which is in the same family as
ATF-2) (in A and B), the closest off-target competitor is p2l SNFT (in C), and the bZIP related
to the target by sequence is cJun (in D). Tm values are given in Table B.S2.
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Figure B.S4. Solution characterization of anti-ATF4 by CD. Format and presentation is the same
as in Figure 3.2B-E for anti-SMAF. The target protein is ATF-4 (in A and B), the closest off-
target competitor is Fos (in C), and the bZIP related to the target by sequence is ATF-3 (in D).
Tm values are given in TableB.S2.
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Figure B.S5. Solution characterization of anti-LMAF by CD.
same as in Figure 3.2B-E for anti-SMAF. The target protein is
off-target competitor is Fra2 (in C), and the bZIP related to the
D). Tm values are given in Table B.S2.
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Figure B.S6. Solution characterization of anti-JUN by CD. Format and presentation is the same
as in Figure 3.2B-E for anti-SMAF. The target protein is cJun (in A and B), the closest off-target
competitor is CHOP (in C), and the bZIP related to the target by sequence is ATF-7 (in D). Tm
values are given in Table B.S2.
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Figure B.S7. Solution characterization of anti-FOS by CD. Format and presentation is the same
as in Figure 3.2B-E for anti-SMAF. The target protein is Fos (in A and B), closest off-target
competitor is BACH1 (in C), and bZIP related to the target by sequence is ATF-3 (in D). Tm
values are given in Table B.S2.
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Figure B.S8. Solution characterization of anti-ZF by CD. Format and presentation is the same as
in Figure 3.2B-E for anti-SMAF. The target protein is ZF (in A and B), closest off-target
competitor is NFE2 (in C), and the bZIP related to the target by sequence is XBP-1 (in D). Tm
values are given in TableB.S2.
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Figure B.S9. Specificity sweep (A) and biased specificity sweep (B) diagrams for the design of a
peptide to bind the leucine-zipper region of ZF. Green dots correspond to the design-target
complex and red bars to the design-design complex. Blue bars in A) correspond to the energy of
the design-XBP-1 complex, which contrary to the prediction of the model showed evidence of
strong interaction on the microarray. As a way of addressing this issue, a biased specificity
sweep was conducted for ZF, where the gap between the energies of the design-ZF and
designeXBP-1 complexes was shifted by 19 kcal/mol. This is shown in (B) with blue bars
corresponding to the actual model-predicted designeXBP-1 energy, while the black bars are the
energies used in the biased specificity sweep. Whereas in the regular specificity sweep there is
no competition with the design-XBP-1 state, due to its incorrectly predicted high energy, in the
biased specificity sweep this competition is imposed. This procedure generated a successful,
highly specific design: anti-ZF.
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Figure B.S10. Adjusting the 9 a-position point ECI in model HP/S/Cv to optimally fit 100
stabilities experimentally measured by Vinson and co-workers2 2 . R for the final fit is 0.83.
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Figure B.S 11. The performance of cluster-expanded versions of models HP/S/Ca and HP/S/Cv
(panels A and B, respectively) on a randomly generated set of 10,000 sequences not present in
the training set. Root mean square deviations between CE-predicted and structure-based energies
are 2.4 and 2.6 kcal/mol for HP/S/Ca and HP/S/Cv, respectively. The cluster expansions contain
2,544 ECI for HP/S/Ca and 2,470 ECI for HP/S/Cv.
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Figure B.S 12. 2D energy histograms of two states - the design-target state and the design-design
homodimer state. Color represents the total number of possible sequences in each bin (bin sizes
are -1 kcal/mol). The targets are ATF-2 and MafG in (A) and (B), respectively. The line where
design-target and design-design scores are equal is shown. By optimizing only the design-target
energy, sequences with high homodimerization propensity will be obtained in these examples.
The specificity sweep procedure run with only one disfavoured state (design-design) locates the
top boundary of this phase space.
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Figure B.S13. Phylogentic tree constructed using the leucine-zipper regions of all human bZIP
proteins. Protein names are in black and family names are in blue. Green dots indicate the 33
proteins used in the experiments in this study. The scale refers to amino-acid replacements per
site.
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Figure B.S 14. Reproducibility of protein-microarray measurements of design interactions probed
in duplicate in (A) and at different concentrations in (B) (probe concentration in nM is shown as
part of the probe name in the top row and is 160 nM where not indicated). Data are displayed in
the same format as for Figure B.SL..
295
A) trs~lNO
L I~
udeired parbusiege
EI1K
b a L
'h
Figure B.S 15. Common specificity mechanisms in successful designed peptides. A) Specificity
features used for discriminating between designetarget and designeoff-target interactions. The
design is in black, the target in red and the undesired partner in gray. Amino acids listed with
single-letter codes are the residues comprising the specificity pattern. Slashes delineate
subgroups of residues, with corresponding subgroups delineated similarly at the interacting
position. CD designates hydrophobic residues Ile, Val or Leu and P stands for beta-branched
residues Ile or Val. In the last row, the a-d' interaction is between an a residue and the more C-
terminal d' residue on the opposite helix. B) Specificity features commonly used in designed
peptides to disfavor the design.design homodimer, using the same notation.
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Figure B.S16. Helical-wheel diagrams for anti-SMAF-2 complexes with ATF-4 and MafG. (A)
The anti-SMAF-2*ATF-4 complex is predicted to be much weaker than the anti-SMAF-2-MafG
complex shown in (B), in large part due to the misaligned asparagines at a positions in anti-
SMAF-2*ATF-4. (C) A different alignment of anti-SMAF-2-ATF-4, where the asparagines
match up, may be more favorable, although it is not predicted to be much stronger
computationally. Diagrams made with DrawCoil 1.0
(http://www.gevorggrigoryan.com/drawcoil/).
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Figure B.S17. Helical-wheel diagrams of the anti-BACH-2 homodimer complex, shown in (A),
and the anti-BACH-2*BACH1 complex shown in (B). The strong anti-homodimerization
features of anti-BACH-2 are concentrated at the N-terminus of the sequence, leaving open the
possibility that this portion simply does not fold, while the remainder of the coiled coil forms a
stable complex. Diagrams made with DrawCoil 1.0
(http://www.gevorggrigoryan.com/drawcoil/).
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Table B.Sl. All designed sequences tested. For each design, listed in columns are: the name of
the design, the name of the bZIP target for that design, the family of the target bZIP, the round of
design/testing in which this sequence was produced, the count of attempts to design a partner for
the given target, the energy function used and the designed sequence. Note that designs are
named after the family of the target rather than the individual protein. There were three rounds of
experiments. Attempts are different than rounds because not all targets were attempted in the
first (or second) rounds. An attempt involved testing one or two designs (in one case, three) for
each target considered in a set of experiments. When the first experimental attempt to identify a
specific design was unsuccessful, alternative solutions from the specificity sweep were selected
for testing in subsequent rounds (constituting further attempts). In a few cases, listed in the
footnotes, these additional designs were created with a modified procedure aimed at addressing
experimentally identified shortcomings of previous designs.
Design name Target Famil Rou Attem Method Design sequence
y nd pt
fgabcdefgabcdefgabcdefgabcdefgabcdefgabcdef
gabcdefgabc
anti-C/EBP-2 C/EBPa C/EB 2 1 HP/S/Ca FENVTHEFILATLENENAKLRRLEAKLERE
P LARLRNEVAWL
anti-C/EBP C/EBPa C/EB 3 2 HP/S/Cv AENQYVEDLIQYLEKENARLKKEVQRLV
P RELSYFRRRIAELA
anti-C/EBP-3 C/EBPa C/EB 3 2 HP/S/Cv AENQSVEDIIAKKEDENAHLKNEVKTLINE
P LETLRKKIEYLA
anti-C/EBPy C/EBPy C/EB 2 1 HP/S/Ca NDLDAYEREAEKLEKKNEVLRNRLAALE
Py NELATLRQEVASMKQELQS
anti-C/EBPy- C/EBPy C/EB 2 1 HP/S/Cv RDLQNVEREIQSLEKKNESLKKKIASLENE
2 Py  LATLKQEIAYFKRELAY
anti-CHOP CHOP CHO 3 1 HP/S/Cv DRLAVKENRVAVLKNENAKLRNIIANLKD
P RIAYFRRELAYLELEEEQLA
anti-CREB CREB CREB 2 1 HP/S/Cv QLVAQLRSKVEQLVNRNQALKNKLEYLR
QEIAETEQ
anti-CREB-2 CREB CREB 3 2 HP/S/Cv[1] NKVEQLKNKVEQLKNRNAALKNDLARLE
REIAYAEE
anti-CREB-3 CREB CREB 3 2 HP/S/Cv[1] QKVESLKQKIEELKQRKAQLKNDIANLEK
EIAYAET
anti-OASIS CREB3 OASI 2 1 HP/S/Cv QKVEQLKNKVEQKLKENESLENKVAELK
S NRNEYLKNKIENLINDITNLENDVAR
anti-OASIS-2 CREB3 OASI 2 1 HP/S/Cv QKVAELKNRVAVKLNRNEQLKNKVEELK
S NRNAYLKNELATLENEVARLENDVAE
anti-OASIS-3 CREB3 OASI 3 2 HP/S/Cv[5] QKVAQLKNRVAYKLKENAKLENIVARLE
S NDNANLEKDIANLEKDIANLERDVAR
anti-OASIS-4 CREB3 OASI 3 2 HP/S/Cv[5] QKVAQLKNIIAKKEDENAVLENLVAVLEN
S ENAYLEKELARLERDIARAERDVKV
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anti-ATF6 ATF-6 ATF6 3 1 HP/S/Cv EKIQELKRRLAYFRRENATLKNDNATLEN
ELASVEAENEALRK
anti-ZF-2 ZF ZF 2 1 HP/S/Cv QKIAYLRDRIAALKAENEALRAKNEALRS
KIEELKKEKEELRDKIAQKKDR
anti-ZF ZF ZF 3 2 HP/S/Cv[6] NLVAQLENEVASLENENETLKKKNLHKK
DLIAYLEKEIANLRKKIEE
anti-XBP1-2 XBP-1 XBP1 2 1 HP/S/Ca SKYDALRNKLEALKNRNAQLRKENEQLR
LEEAVLEVRNEVL
anti-XBP1 XBP-1 XBP1 2 1 HP/S/Cv QKIEYLKDKIAELKDRNAVKRSENAQLRQ
AVATLEQKNEEL
anti-E4BP4-2 E4BP4 E4BP 2 1 HP/S/Ca QKRQELKQRLAVLENDNARLKNDLAQLE
4 VEEAYIE
anti-E4BP4 E4BP4 E4BP 2 1 HP/S/Cv NKNNVKKNRLAVLENENATLRNELAWLR
4 LELAAME
anti-E4BP4-3 E4BP4 E4BP 3 2 HP/S/Cv[3] EKNQELKNRLAVLENDNAALRNDLARLE
4 REIAYME
anti-ATF2-2 ATF-2 ATF2 1 1 HP/S/Ca QKLQTLRDLLAVLENRNQELKQLRQHLK
DLLKYLEDELATLEKE
anti-ATF2-3 ATF-2 ATF2 2 2 HP/S/Cv STVEELLRAIQELEKRNAELKNRKEELKN
LVAHLRQELAAHKYE
anti-ATF2 ATF-2 ATF2 3 3 HP/S/Cv NTVKELKNYIQELEERNAELKNLKEHLKF
AKAELEFELAAHKFE
anti-ATF2-4 ATF-7 ATF2 3 3 HP/S/Cv QKVEELKNKIAELENRNAVKKNRVAHLK
QEIAYLKDELAAHEFE
anti-JUN cJun JUN 1 1 HP/S/Ca SIAATLENDLARLENENARLEKDIANLERD
LAKLEREEAYF
anti-FOS Fos FOS 1 1 HP/S/Ca NEKEELKSKKAELRNRIEQLKQKREQLKQ
KIANLRKEIEAYK
anti-ATF3 ATF-3 ATF3 1 1 HP/S/Ca ELTDELKNKKEALRKDNAALLNELASLEN
EIANLEKEIAYFK
anti-ATF3-2 ATF-3 ATF3 1 1 HP/S/Ca NETEQLINKKEQLKNDNAALEKDAASLEK
EIANLEKEIAYFK
anti-ATF3-3 ATF-3 ATF3 3 3 HP/S/Cv[7] NILASLENKKEELKKLNAHLLKEIENLEKE
IANLEKEIAYFK
anti-ATF4 ATF-4 ATF4 2 1 HP/S/Cv KRIAYLRKKIAALKKDNANLEKDIANLEN
EIERLIKEIKTLENEVASHEQ
anti-ATF4-2 ATF-4 ATF4 2 1 HP/S/Cv ARNAYLRKKIARLKKDNLQLERDEQNLE
KIIANLRDEIARLENEVASHEQ
anti-BATF p21 SNF BATF 2 1 HP/S/Ca NELESLENKKEELKNRNEELKQKREQLKQ
T KLAALRNKLDAYKNRL
anti-BATF-2 p21SNF BATF 3 2 HP/S/Cv NDIENLKDKIEELKQRKEELKQKIEYLKQK
T IEALRQKLAALKQRIA
anti-BATF-3 p21 SNF BATF 3 2 HP/S/Cv EKIEELKDKIAELRSRNAALRNKIEALKQK
T I I LEALRQKIEYLKDRIA
anti-PAR HLF PAR 3 1 HP/S/Cv NRLQELENKNEVLEKRKAELRNEVATLEQ
ELAAHRYELAAIEKEIA
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[1] The only strong off-target interaction for design anti-CREB, produced in round 2, was the
design-design homodimer. However, the specificity sweep produced no solutions that were
significantly more specific against the homodimer. Thus, in the next round we sought to remove
design homodimerization by considering only the homodimer as a competitor. In the resulting
designs anti-CREB-2 and anti-CREB-3, homodimerization was indeed no longer a problem, but
global specificity was reduced. This indicates that maintaining gaps to many states
simultaneously can be important.
[2] The two strong off-target competitors for anti-BACH in round 2 were Fos and NFE2. The
latter was deemed too close in sequence to effectively discriminate with our models. To improve
specificity against Fos, a biased specificity sweep was used with a gap offset of -10 kcal/mol for
Fos (making gaps with Fos more negative than they would be, which caused competition with
Fos to be more stringent). However, anti-BACH-3 still interacted with Fos more strongly than
with BACH-1.
[3] The initial two designs against E4BP4 were not very stable, and this was not predicted by the
models. HP/S/Cv predicted that the most stable design against E4BP4 had a Lys at the N-
terminal d position. To address this, we temporarily adjusted the ECI for Leu-Leu at d-d' in
HP/S/Cv to be more favorable by 2 kcal/mol and reran the specificity sweep procedure. Anti-
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anti-SMAF-2 MafG SMA 1 1 HP/S/Ca KEIEYLEKEIERLKDLREHLKQDNAAHRQ
F ELNALRLEEAKLEFILAHLLST
anti-SMAF-3 MafG SMA 1 1 HP/S/Ca KEIERLEKEIKTLINLLTTLRQDNAAHRKE
F AAALEKEEANLERDIQNLLRY
anti-SMAF MafG SMA 2 2 HP/S/Cv KEIANLEKEIASLEKKVAVLKQRNAAHKQ
F EVAALRKEIAYVEDEIQYVEDE
anti-LMAF-2 cMaf LMA 3 1 HP/S/Cv NKNETLKNINARLRNDVARLKNRIARLKD
F DIENVEDEIQYLE
anti-LMAF-3 cMaf LMA 3 1 HP/S/Cv LENAQIKKEIAQLRKEVAQLKQKIEELKN
F DNARVEREIQYLE
anti-LMAF cMaf LMA 3 1 HP/S/Ca KDIANLKKEIAHLKNDLQRLESIRERLKFD
F ILNHEQEEYALE
anti-NFE2 NFE2 NFE2 1 1 HP/S/Ca QKRQQLKQKLAALRRDIENLQDEIAYKED
EIANLKDKIEQLLS
anti-NFE2-2 NFE2 NFE2 3 2 HP/S/Cv QKIESLKDKLANKRDKIALLRSEVASFEKE
IAYLEKEIANLEN
anti-NFE2-3 NFE2 NFE2 3 2 HP/S/Cv[4] EKIEYLKDKLAHKRNEVAQLRKEVTHKV
DELTSLENEVAQLLK
anti-BACH-2 BACH1 BAC 2 1 HP/S/Ca QKREELKSRKAYLRKEIANLKKDILNLLD
H DLVAHEFELVTL
anti-BACH BACH1 BAC 2 1 HP/S/Cv QKIQYLKQRIAELRKKIANLRKDIANLEDD
H AAVKEDELVHL
anti-BACH-3 BACH1 BAC 3 2 HP/S/Cv[2] EKIEYLKDRIAELRSKIAALRNDLTHLKND
H KAHKENELAHLA
E4BP4-3 was picked from this list. Although this resulted in a more hydrophobic core, there was
no detectable increase in stability according to the microarray assay.
[4] The only strong off-target competitor for anti-NFE2 was ATF-4, so in this design we used a
biased specificity sweep approach with a gap offset of -3 kcal/mol for ATF-4 (making gaps with
ATF-4 more negative). However this design interacted with Fos, which had not previously been
a strong competitor.
[5] To eliminate the only significant competitor of anti-OASIS, p21SNFT, a biased specificity
sweep was run with a gap offset of -10 kcal/mol for p21 SNFT. This did indeed eliminate
p21 SNFT as a competitor, but MafG emerged as a new strong competitor.
[6] Because the only significant competitor for the first design, anti-ZF-2, was XBP-1, we
applied a biased specificity sweep approach with a gap offset of -10 kcal/mol for XBP-1. This
successfully removed XBP-1 as a competitor and resulted in a very specific and stable design.
[7] Significant competitors for designs against ATF-3 were Fos and ATF-4, whereas the models
considered JUN and ATF2 families more likely to interact. To bias the specificity sweep against
the relevant competitors, gap offsets of +8 and +2 kcal/mol for JUN and ATF2 families
respectively were imposed (making gaps with JUN and ATF2 family members less important in
the optimization).
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Table B.S2. Melting temperature (Tm) values estimated by fitting to CD-monitored melting
curves. Corresponding 95% confidence intervals are given in brackets (see section Circular
dichroism). Some measurements were made in duplicate to
measurements are marked with a number two in parentheses.
evaluate reproducibility; duplicate
bZIP-bZIP Tm (0 95% CI design-design Tm (0 95% CI
homodimer C) homodimers C)
S
CHOP 36.4 [35.8 anti-SMAF 11.6 [11.1
36.9] 12.1]
BACHI 8.4 [6.9 9.9] anti-ATF2 5.2 [1.7 8.7]
XBP-1 42 [41.7 anti-ATF4 48.6 [48 49.3]
42.3]
NFE2 multiple transitions anti-LMAF 3 [-3.4 9.3]
ZF 31.6 [31.3 anti-ZF 22.1 [21.7
31.8] 22.4]
MafB 19.8 [19.1 anti-JUN 7.3 [6.6 8.1]
20.6]
cMaf 43.1 [42.5 anti-FOS 27.2 [26.8
43.8] 27.6]
Fra2 <0 [-13.4
5.7]
p21SNFT 33 [32.6 design-bZIP Tm (0
33.4] heterodimers C)
ATF-4 7.9 [6.1 9.7] anti-ATF4:ATF-4 52.1 [51.4
52.8]
ATF-3 9.4 [6.4 12.3] anti-ATF2:ATF-7 41 [40.4
41.6]
ATF-3(2) 6.6 [4.3 9] anti-SMAF:MafG 37.9 [37 38.7]
Fos 10.6 [8.9 12.4] anti-JUN:cJun 24.2 [23.4
24.9]
Fos(2) 9 [8.1 9.9] anti-FOS:FOS 43.6 [42.7
44.4]
cJun 16.6 [16.0 anti-ZF:ZF 43 [42.7
17.3] 43.4]
cJun(2) 16.2 [15.7
16.8]
ATF-7 31.4 [31 31.8]
ATF-7(2) 31.7 [31.3
32.1]
MafG 30.2 [29.7
30.8]
MafG(2) 31.8 [31.5
1 _ 32.2]
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Table B.S3. Average background-corrected fluorescence values and Saray values from round 1 of
array measurements. Peptides on the surface are in rows, those in solution in columns. Duplicate
measurements are marked with a number two in parentheses. The anti-FOS peptide was tested at
concentrations ranging from 80 nM to 2000 nM, as indicated in the probe names.
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protein ATF-2 cJun Fos Fra2 ATF-3 ATF-4 p21SNF MafG
T
C/EBPa -1209.5 -220.3 290.7 -789.9 4573.1 16459.4 2169.7 -341.4
C/EBPP -2318.1 -543.4 -1387.9 -2406.9 7687.4 5320.2 2156.1 338.3
C/EBP6 -3235.8 -540.0 -1080.3 -978.3 7598.0 15172.1 2625.6 -244.6
C/EBPy 5155.8 345.5 733.2 261.6 21941.3 34208.8 5172.2 -7.9
CHOP 5110.1 996.5 5691.3 3996.1 24897.6 5879.3 18419.3 330.8
ATF-1 -1961.5 -947.1 -879.7 -860.9 -2213.3 -2296.8 -2072.6 -318.6
CREB -6256.7 -1354.7 -1370.9 -2093.1 -4312.5 -3194.2 -3906.8 -670.6
CREB-H -933.4 -830.6 -6.2 -351.2 -234.6 -91.3 -375.9 -284.4
CREB3 -820.6 -279.0 -1116.9 -1014.2 1396.7 -1809.6 438.1 -75.1
ATF-6 -3780.2 -1124.3 -980.4 -1252.0 -1825.8 -1502.1 -2020.6 -867.1
ZF -789.8 296.4 -359.9 -385.4 3404.8 5528.6 1020.3 862.2
XBP-1 -2048.6 -359.3 -726.9 -2537.3 445.3 -815.4 -1979.3 -294.4
E4BP4 -1942.6 -513.1 -932.1 -546.2 1080.1 -1776.0 305.7 116.0
ATF-2 6994.6 4898.9 5723.6 4635.6 20294.5 1121.1 5202.8 -266.1
ATF-7 9594.1 8099.6 6785.2 7509.6 22271.2 4419.6 7512.3 -452.8
cJun 14760.4 1997.3 27052.4 24950.8 24562.3 -319.9 11768.7 -334.2
JunB 4758.5 449.4 16150.8 16856.8 18105.6 -758.3 9728.8 17.1
JunD 9823.1 788.6 22888.9 22692.3 22719.3 -1331.8 11304.0 98.3
Fos 13984.2 35014.5 2120.9 1451.1 6142.6 7326.7 703.8 -854.8
Fra2 9788.4 19126.3 3892.8 608.9 9627.2 1022.6 266.4 -634.1
ATF-3 19928.4 12049.6 2674.5 6099.9 194.9 11042.8 13952.3 180.7
ATF-4 1728.8 -1060.4 8750.9 -223.4 21845.3 -1508.4 14458.4 -338.1
ATF-5 -4831.8 -1941.1 -2288.1 -1926.1 -2945.9 -3321.8 3954.8 -945.2
B-ATF 2149.7 13378.4 463.0 -713.3 8148.4 4415.8 2425.2 -675.4
p21SNFT 9068.7 12668.4 298.1 -20.7 23988.6 8109.1 5699.1 1393.3
HLF -2699.3 -188.0 -1099.3 -828.5 -627.9 -3384.4 121.6 -474.0
MafG -253.8 268.3 767.9 -532.1 3179.9 -193.2 2433.0 1387.9
cMaf -253.3 92.8 211.8 127.9 2222.3 1815.9 -1080.9 -39.1
MafB -733.8 -217.7 2278.7 1685.4 4347.4 -1942.6 -935.9 -471.9
NFE2 -2474.9 -544.6 -443.6 -1246.4 -890.6 -114.8 -1826.8 345.8
NFE2L1 98.8 -284.6 771.0 -13.0 -1682.8 3979.2 -769.6 38491.7
NFE2L3 -4486.5 -1628.7 -3240.7 -2830.6 -4049.0 -415.3 -3341.4 31185.9
BACH1 6185.9 456.6 1932.9 2078.1 -50.2 1253.1 895.5 18423.5
anti-ATF2-2 735.1 -410.0 -874.0 -1496.9 -753.9 -730.5 3897.1 -170.9
anti-ATF3 7223.3 1717.5 19632.5 15128.1 30646.4 16601.9 9409.2 3310.1
anti-ATF3-2 579.0 562.3 13724.4 7512.8 8260.4 838.6 936.2 532.1
anti-JUN 2505.5 6966.4 2211.1 511.4 6446.6 7163.3 2591.8 925.5
anti-FOS -177.0 2685.3 39044.8 22696.1 4548.8 -975.3 4052.0 1182.6
anti-SMAF- -2069.7 1877.4 1930.0 -1085.1 -447.6 21907.5 -1261.8 7926.6
2
anti-SMAF- -811.6 -280.1 -80.3 -743.6 -1135.0 -915.4 -801.5 -37.0
3 1
anti-NFE2 67.3 -304.7 6306.8 3092.9 479.4 10427.1 44.5 2958.3
304
protein NFE2 NFE2L1 BACH1 anti- anti-ATF3 anti- anti-JUN anti-
ATF2-2 ATF3-2 FOS
C/EBPa -1513.3 91.9 -206.9 -818.8 1158.0 277.4 -406.1 -599.1
C/EBPs -4574.9 -3091.3 -720.5 -2531.9 -310.7 367.1 -282.7 357.2
C/EBP6 -1143.5 -574.9 -1533.1 -565.9 955.0 350.7 -118.3 -616.6
C/EBPy -861.3 -716.8 82.1 8474.6 2587.9 390.4 615.8 2685.3
CHOP -979.9 -830.3 3777.6 14294.7 3111.1 437.6 2289.4 1452.8
ATF-1 -3053.8 -2446.8 1971.0 -2297.3 -687.1 410.1 1454.3 -923.4
CREB -5052.8 -2797.4 3077.3 -2383.3 -289.8 419.9 755.7 -991.0
CREB-H -708.1 -596.1 -209.9 3.3 -890.1 220.3 4.9 1466.1
CREB3 -816.0 -1099.2 -598.8 915.4 -1117.3 356.9 443.9 1224.9
ATF-6 -2016.0 -2267.0 -254.0 -991.8 -1229.4 302.4 -104.6 -896.9
ZF 2730.1 21547.8 2352.9 4059.1 973.3 336.9 -48.1 -372.2
XBP-1 -1705.0 -1383.3 696.1 -1392.5 -3462.4 334.6 -686.9 -903.9
E4BP4 -816.8 -1684.9 101.3 1511.1 -1434.5 306.0 531.5 -113.3
ATF-2 -2235.5 3164.0 4399.2 6767.6 486.4 322.3 -303.1 -86.7
ATF-7 724.4 7211.7 6091.9 13903.3 828.0 298.9 222.5 462.4
cJun -2589.8 -1940.9 42.4 532.4 805.9 284.5 4862.2 3658.3
JunB -218.6 -1815.1 -299.3 -457.1 -226.1 332.1 1163.0 1083.6
JunD -712.3 -1082.1 203.1 -587.7 258.5 272.1 2164.3 1754.9
Fos -1298.1 5426.5 2637.5 200.9 24395.9 4055.4 -196.8 35147.9
Fra2 -847.4 1584.0 2029.9 -857.9 6044.1 1450.1 -106.8 17465.9
ATF-3 -4021.9 -2556.2 647.3 -119.9 29694.3 968.5 1028.1 1567.6
ATF-4 -1788.3 27265.1 2516.6 8516.9 26002.3 594.9 1519.8 -546.8
ATF-5 -704.1 -996.6 1436.5 4261.2 -128.5 374.2 125.9 -1422.4
B-ATF -51.9 3341.1 4337.6 3925.6 1459.4 321.5 -214.2 818.5
p21SNFT -1526.1 -535.8 3288.4 11315.8 6627.7 489.4 249.2 2909.8
HLF -4778.1 -1520.3 21.0 -1036.3 -370.9 254.1 22.9 -633.5
MafG 11187.3 49004.5 25075.1 908.3 1654.0 567.8 594.9 1147.2
cMaf -899.0 3789.4 5396.6 -1087.3 -167.1 392.2 35.4 847.5
MafB -572.1 4157.4 11655.9 -968.2 -432.9 367.5 65.8 1440.7
NFE2 15668.0 -1367.0 759.1 -1075.2 433.8 316.7 -176.9 160.5
NFE2L1 -329.1 4830.4 -125.9 65.6 3530.9 388.6 268.8 -74.9
NFE2L3 13034.3 -3370.8 -1015.4 -1227.9 -1316.4 189.1 -1338.3 -1048.0
BACH1 -618.1 331.9 2580.4 -788.2 2616.3 373.6 705.9 6629.7
anti-ATF2- -2763.5 13087.5 -1592.5 6187.1
2
anti-ATF3 15014.4 44239.6 11233.2 -905.8
anti-ATF3- 306.4 8928.4 294.6 259.1
2
anti-JUN 673.9 15897.4 6819.8 804.3
anti-FOS -682.9 -6.0 17630.9 1828.7
anti-SMAF- 25607.3 42286.6 5227.0
2
anti-SMAF- 1143.1 11088.9 -95.0
3
anti-NFE2 32984.4 4472.4 7008.3
305
protein anti- anti- anti- anti- anti- anti- anti- anti-
SMAF-2 SMAF-3 NFE2 FOS80 FOS200 FOS500 FOS100 FOS200
0 0
C/EBPa -293.8 79.5 718.9 204.2 269.7 542.3 1006.1 765.1
C/EBP@ -400.9 -1884.7 -2306.9 326.9 292.4 394.1 1884.9 2025.0
C/EBP6 -131.1 -273.5 153.0 215.8 119.1 -173.7 -262.5 46.9
C/EBPy -112.2 1141.6 491.6 277.3 409.1 2203.7 6819.2 5537.9
CHOP -155.3 -139.3 380.4 284.7 316.7 1676.3 5432.5 3920.5
ATF-1 59.8 -1207.3 832.1 407.0 388.4 263.1 912.7 597.1
CREB -315.5 -2505.6 -2082.8 420.4 373.6 -534.3 -2069.0 -1908.0
CREB-H -112.5 217.1 50.6 197.1 217.1 1358.8 4158.9 3986.3
CREB3 37.9 212.3 39.1 346.1 329.9 927.3 4478.6 3427.3
ATF-6 -368.9 -995.1 -1413.6 289.1 199.1 -574.0 -907.5 -256.9
ZF 493.9 3841.1 -862.1 292.4 245.5 -124.1 -415.3 -415.5
XBP-1 -885.4 -970.1 -1292.3 300.0 296.3 464.1 1519.9 2019.6
E4BP4 -153.9 -485.7 -475.1 247.8 204.6 301.8 1727.7 1680.9
ATF-2 -332.3 433.0 5345.1 302.8 260.1 225.8 1281.9 1360.9
ATF-7 58.1 1554.9 3605.4 241.4 222.6 556.1 2134.9 2013.0
cJun 1305.1 560.6 5047.0 267.1 418.5 2437.4 6727.9 5978.1
JunB 888.6 206.7 1224.9 289.0 272.8 907.7 3161.1 2901.4
JunD 1268.3 390.4 2837.4 250.9 273.8 1210.7 4386.9 3817.1
Fos 2324.4 4563.1 15804.4 842.0 3725.9 23273.9 38005.9 25564.4
Fra2 239.9 609.2 13441.9 512.2 1444.0 11485.3 26424.6 17567.3
ATF-3 -197.5 1084.4 -518.9 381.8 408.1 1836.2 5583.1 4559.3
ATF-4 43709.7 5986.1 45654.4 362.3 249.4 -547.3 -1359.8 -1113.3
ATF-5 2216.7 1428.9 -2845.4 311.5 221.1 -957.7 -3448.1 -3212.2
B-ATF -117.8 371.0 359.6 231.8 253.8 1175.3 3755.0 3799.2
p21SNFT 26.2 -42.3 765.4 353.7 489.8 2748.9 7858.3 6502.9
HLF -408.0 -1247.6 -2333.3 224.8 145.4 -126.4 -459.4 -202.9
MafG 7202.8 11536.9 13977.4 274.2 234.8 1282.9 4000.7 3615.1
cMaf 283.4 2256.8 3369.4 334.1 336.7 1223.8 3534.1 2918.4
MafB 324.2 1583.5 1353.0 360.1 398.9 1641.6 5262.9 4428.6
NFE2 5185.0 10083.2 35514.2 268.6 247.3 628.6 2240.4 1950.7
NFE2L1 13690.0 4757.8 1653.6 270.4 226.1 105.8 1111.9 1050.1
NFE2L3 6394.8 -428.0 -1980.8 283.1 217.7 -588.6 -1904.6 -1727.6
BACH1 3044.0 4953.7 11213.1 341.3 614.3 5078.1 14230.9 10864.3
anti-ATF2-2
anti-ATF3
anti-ATF3-2
anti-JUN
anti-FOS 269.6 299.3 941.1 3211.7 2952.8
anti-SMAF- -273.9
2
anti-SMAF- 6627.9
3
anti-NFE2 21017.7
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Sarray values
protein ATF-2 cJun Fos Fra2 ATF-3 ATF-4 p21 SNF MafG
T
C/EBPa -0.4 -0.3 -0.2 -0.4 0.3 6.3 0.5 -0.6
C/EBP3 -0.8 -0.7 -1.2 -1.7 0.9 1.8 0.5 0.8
C/EBPS -1.2 -0.7 -1.0 -0.6 0.9 5.7 0.7 -0.4
C/EBPy 2.0 0.3 0.0 0.4 4.1 13.4 1.8 0.1
CHOP 2.0 1.0 2.8 3.3 4.7 2.0 7.4 0.8
ATF-1 -0.7 -1.1 -0.9 -0.5 -1.2 -1.3 -1.3 -0.6
CREB -2.3 -1.5 -1.2 -1.5 -1.7 -1.6 -2.1 -1.3
CREB-H -0.3 -1.0 -0.4 -0.1 -0.8 -0.4 -0.6 -0.5
CREB3 -0.2 -0.4 -1.0 -0.6 -0.4 -1.1 -0.2 -0.1
ATF-6 -1.4 -1.3 -1.0 -0.8 -1.2 -0.9 -1.3 -1.7
ZF -0.2 0.2 -0.6 -0.1 0.0 1.9 0.0 1.8
XBP-1 -0.7 -0.5 -0.8 -1.8 -0.7 -0.7 -1.3 -0.5
E4BP4 -0.7 -0.6 -0.9 -0.3 -0.5 -1.0 -0.3 0.3
ATF-2 2.7 5.1 2.8 3.8 3.7 0.1 1.8 -0.5
ATF-7 3.7 8.5 3.4 6.1 4.2 1.4 2.8 -0.9
cJun 5.7 2.0 14.6 19.8 4.7 -0.5 4.6 -0.6
JunB 1.9 0.4 8.6 13.4 3.2 -0.6 3.7 0.1
JunD 3.8 0.7 12.3 18.0 4.3 -0.9 4.4 0.3
Fos 5.4 37.1 0.8 1.3 0.6 2.6 -0.1 -1.7
Fra2 3.8 20.2 1.8 0.7 1.4 0.1 -0.3 -1.2
ATF-3 7.6 12.7 1.1 5.0 -0.7 4.1 5.5 0.4
ATF-4 0.7 -1.2 4.5 0.0 4.1 -0.9 5.7 -0.6
ATF-5 -1.8 -2.2 -1.7 -1.3 -1.4 -1.7 1.3 -1.9
B-ATF 0.9 14.1 -0.2 -0.4 1.0 1.4 0.6 -1.3
p21SNFT 3.5 13.4 -0.2 0.2 4.5 2.9 2.0 2.9
HLF -1.0 -0.3 -1.0 -0.5 -0.9 -1.7 -0.4 -0.9
MafG 0.0 0.2 0.0 -0.2 -0.1 -0.4 0.6 2.9
cMaf 0.0 0.0 -0.3 0.3 -0.3 0.4 -0.9 0.0
MafB -0.2 -0.3 0.9 1.5 0.2 -1.1 -0.8 -0.9
NFE2 -0.9 -0.7 -0.7 -0.8 -0.9 -0.4 -1.2 0.8
NFE2L1 0.1 -0.4 0.0 0.2 -1.1 1.3 -0.8 79.2
NFE2L3 -1.6 -1.8 -2.2 -2.0 -1.6 -0.5 -1.9 64.2
BACHI 2.4 0.4 0.7 1.8 -0.8 0.2 -0.1 38.0
anti-ATF2-2 0.3 -0.5 -0.9 -1.0 -0.9 -0.6 1.2 -0.3
anti-ATF3 2.8 1.7 10.5 12.1 6.0 6.3 3.6 6.9
anti-ATF3-2 0.3 0.5 7.2 6.1 1.1 0.0 0.0 1.2
anti-JUN 1.0 7.3 0.8 0.6 0.7 2.5 0.7 2.0
anti-FOS 0.0 2.8 21.3 18.0 0.3 -0.7 1.3 2.5
anti-SMAF-2 -0.7 1.9 0.7 -0.7 -0.8 8.4 -1.0 16.4
anti-SMAF-3 -0.2 -0.4 -0.5 -0.4 -1.0 -0.7 -0.8 0.0
anti-NFE2 0.1 -0.4 3.1 2.6 -0.6 3.8 -0.4 6.2
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protein NFE2 NFE2L1 BACH1 anti- anti- anti- anti-JUN anti-FOS
ATF2-2 ATF3 ATF3-2
C/EBPa -0.3 0.1 -0.9 -0.6 0.5 -0.9 -1.1 -1.0
C/EBPP -1.9 -1.6 -1.2 -1.9 -0.5 0.2 -0.9 -0.2
C/EBPS -0.2 -0.3 -1.7 -0.4 0.3 0.0 -0.5 -1.0
C/EBPy 0.0 -0.4 -0.8 6.6 1.4 0.5 0.8 1.6
CHOP -0.1 -0.4 1.3 11.1 1.8 1.0 3.9 0.6
ATF-1 -1.1 -1.3 0.3 -1.7 -0.8 0.7 2.4 -1.2
CREB -2.1 -1.5 0.9 -1.8 -0.5 0.8 1.1 -1.3
CREB-H 0.1 -0.3 -0.9 0.0 -0.9 -1.6 -0.3 0.6
CREB3 0.0 -0.6 -1.1 0.8 -1.1 0.0 0.5 0.5
ATF-6 -0.6 -1.2 -0.9 -0.7 -1.1 -0.6 -0.5 -1.2
ZF 1.8 11.4 0.5 3.2 0.3 -0.2 -0.4 -0.8
XBP-1 -0.4 -0.7 -0.4 -1.0 -2.7 -0.2 -1.6 -1.2
E4BP4 0.0 -0.9 -0.7 1.2 -1.3 -0.6 0.7 -0.6
ATF-2 -0.7 1.7 1.7 5.3 0.0 -0.4 -0.9 -0.6
ATF-7 0.8 3.8 2.6 10.8 0.3 -0.7 0.1 -0.1
cJun -0.9 -1.0 -0.8 0.5 0.2 -0.9 8.8 2.4
JunB 0.3 -1.0 -1.0 -0.3 -0.5 -0.3 1.8 0.3
JunD 0.1 -0.6 -0.7 -0.4 -0.1 -1.0 3.7 0.9
Fos -0.2 2.9 0.7 0.2 16.3 45.6 -0.7 27.0
Fra2 0.0 0.8 0.3 -0.6 3.8 13.5 -0.5 13.2
ATF-3 -1.6 -1.4 -0.4 0.0 19.9 7.6 1.6 0.7
ATF-4 -0.5 14.5 0.6 6.6 17.4 3.0 2.5 -0.9
ATF-5 0.1 -0.5 0.0 3.3 -0.4 0.3 -0.1 -1.6
B-ATF 0.4 1.8 1.6 3.1 0.7 -0.4 -0.7 0.1
p21SNFT -0.4 -0.3 1.0 8.8 4.2 1.7 0.1 1.8
HLF -2.0 -0.8 -0.8 -0.8 -0.6 -1.2 -0.3 -1.0
MafG 6.0 26.0 13.2 0.7 0.8 2.6 0.8 0.4
cMaf 0.0 2.0 2.2 -0.8 -0.4 0.5 -0.3 0.2
MafB 0.1 2.2 5.7 -0.7 -0.6 0.2 -0.2 0.6
NFE2 8.2 -0.7 -0.4 -0.8 0.0 -0.5 -0.7 -0.4
NFE2L1 0.2 2.6 -0.9 0.1 2.1 0.4 0.2 -0.6
NFE2L3 6.9 -1.8 -1.4 -0.9 -1.2 -2.0 -2.8 -1.3
BACHI 0.1 0.2 0.6 -0.6 1.5 0.2 1.0 4.7
anti-ATF2-2 -1.0 6.9 -1.7 4.8
anti-ATF3 7.9 23.5 5.5 -0.9
anti-ATF3-2 0.6 4.7 -0.6 -1.2
anti-JUN 0.7 8.4 3.0 1.2
anti-FOS 0.1 0.0 9.0 0.9
anti-SMAF- 13.2 22.4 2.1
2
anti-SMAF- 1.0 5.9 -0.9
3
anti-NFE2 16.8 2.4 3.1
308
protein anti- anti- anti- anti- anti- anti- anti- anti-
SMAF-2 SMAF-3 NFE2 FOS80 FOS200 FOS500 FOS100 FOS200
0 0
C/EBPa -0.9 -0.3 0.0 -1.9 -0.1 -0.2 -0.5 -0.6
C/EBPP -1.2 -1.8 -1.5 0.9 0.3 -0.4 -0.3 -0.2
C/EBPS -0.5 -0.5 -0.3 -1.7 -2.4 -1.0 -1.0 -0.9
C/EBPy -0.4 0.6 -0.1 -0.3 2.1 1.5 1.3 1.1
CHOP -0.6 -0.4 -0.2 -0.1 0.7 1.0 0.9 0.5
ATF-1 0.0 -1.3 0.0 2.7 1.8 -0.5 -0.6 -0.7
CREB -1.0 -2.3 -1.4 3.0 1.5 -1.4 -1.5 -1.6
CREB-H -0.4 -0.2 -0.3 -2.1 -0.9 0.6 0.5 0.6
CREB3 0.0 -0.2 -0.4 1.3 0.9 0.2 0.6 0.4
ATF-6 -1.1 -1.1 -1.1 0.0 -1.1 -1.4 -1.2 -1.0
ZF 1.2 2.7 -0.8 0.1 -0.4 -1.0 -1.0 -1.0
XBP-1 -2.5 -1.1 -1.0 0.2 0.4 -0.3 -0.4 -0.2
E4BP4 -0.6 -0.7 -0.6 -0.9 -1.1 -0.5 -0.3 -0.3
ATF-2 -1.0 0.0 2.3 0.3 -0.2 -0.6 -0.5 -0.4
ATF-7 0.0 0.9 1.4 -1.1 -0.8 -0.2 -0.2 -0.2
cJun 3.4 0.1 2.2 -0.5 2.2 1.8 1.3 1.3
JunB 2.3 -0.2 0.2 0.0 0.0 0.1 0.1 0.2
JunD 3.3 0.0 1.1 -0.9 0.0 0.5 0.5 0.5
Fos 6.2 3.3 7.6 12.5 52.9 24.0 11.4 8.4
Fra2 0.5 0.2 6.4 5.1 17.9 11.4 7.6 5.5
ATF-3 -0.7 0.5 -0.6 2.1 2.1 1.1 0.9 0.8
ATF-4 119.3 4.4 22.6 1.7 -0.4 -1.4 -1.3 -1.3
ATF-5 5.9 0.8 -1.8 0.5 -0.8 -1.8 -2.0 -2.1
B-ATF -0.5 0.0 -0.2 -1.3 -0.3 0.4 0.3 0.5
p21SNFT -0.1 -0.4 0.0 1.5 3.3 2.1 1.7 1.5
HLF -1.2 -1.3 -1.5 -1.5 -2.0 -1.0 -1.0 -1.0
MafG 19.5 8.8 6.7 -0.3 -0.6 0.5 0.4 0.4
cMaf 0.6 1.5 1.3 1.0 1.0 0.5 0.3 0.2
MafB 0.8 0.9 0.3 1.6 1.9 0.9 0.8 0.7
NFE2 14.0 7.6 17.5 -0.5 -0.4 -0.1 -0.1 -0.2
NFE2L1 37.3 3.4 0.5 -0.4 -0.7 -0.7 -0.5 -0.5
NFE2L3 17.3 -0.7 -1.4 -0.1 -0.9 -1.4 -1.5 -1.5
BACHI 8.2 3.6 5.3 1.2 5.2 4.6 3.7 3.1
anti-ATF2-2
anti-ATF3
anti-ATF3-2
anti-JUN
anti-FOS -0.4 0.4 0.2 0.2 0.2
anti-SMAF- -0.9
2
anti-SMAF- 4.9
3
anti-NFE2 10.2
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Table B.S4. Average background-corrected fluorescence values and Sary values) from round 2
of array measurements. Peptides on the surface are in rows, those in solution in columns.
Duplicate measurements are marked with a number two in parentheses. The anti-XBP1 peptide
was also tested at a concentration of 800 nM, as indicated in the probe name.
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protein C/EBPa C/EBPp C/EBP6 C/EBPy CHOP CREB CREB3 ATF-6
C/EBPa 14378.8 10132.1 19625.2 3902.0 20179.0 -633.1 -452.9 -540.1
C/EBP3 12039.9 3042.9 13983.8 3908.8 42048.5 -840.8 -1298.5 -1070.9
C/EBP6 15951.5 10389.3 15986.0 7234.7 16729.9 -239.9 255.3 -496.9
C/EBPy 13809.7 8788.3 24250.3 1623.4 22187.2 2080.9 1872.9 1414.9
CHOP 19799.0 31077.8 23783.9 14532.8 5784.9 2708.6 4397.6 1670.5
ATF-1 -840.7 -1925.9 -3695.5 -1632.7 -819.4 15719.9 -1393.8 -630.9
CREB -1528.8 -3224.4 -3356.7 -1296.3 -640.9 17969.9 -319.3 -4368.5
CREB-H 310.2 -347.4 -101.5 216.0 25.6 2800.9 3173.6 2037.7
CREB3 399.4 -1604.3 -821.1 138.4 102.9 2102.9 2519.8 269.0
ATF-6 -217.0 -1167.4 -1166.7 -669.8 -613.3 569.8 -208.3 14541.8
ZF 132.5 -958.8 -1345.8 -420.2 682.1 -730.3 -318.0 3118.7
XBP-1 668.6 48.5 -852.8 -180.8 -632.3 3970.9 271.3 26091.6
E4BP4 244.1 -1225.6 1344.1 737.1 835.3 15648.5 2934.3 2081.4
ATF-2 242.1 -447.0 -1214.4 2156.6 1323.1 1119.5 58.5 387.8
ATF-7 4336.8 3877.6 3626.4 5025.4 6198.5 2764.8 897.5 1302.3
cJun 1976.4 1017.8 2582.0 797.0 1445.8 3880.9 20.9 1615.4
JunB 641.5 -776.1 -285.5 -589.3 -139.1 2234.1 -575.7 1830.8
JunD 690.4 -818.8 1029.9 101.4 779.2 3247.6 -277.2 1564.9
Fos 4014.0 415.9 2099.0 885.0 3244.0 1392.1 -263.8 366.6
Fra2 1437.7 -28.4 627.0 436.3 1301.9 2829.6 -426.0 1812.5
ATF-3 3521.3 4105.6 6042.5 13256.1 9384.3 -557.1 311.8 -1090.1
ATF-4 41351.2 14860.3 45224.3 45710.6 29556.1 162.3 835.8 -1395.9
ATF-5 11769.3 1232.0 13935.9 43585.1 -930.4 -2876.8 -844.9 -3743.6
B-ATF 4622.4 5606.3 8968.8 7972.0 16112.8 4414.1 1948.8 2878.9
p21SNFT 6622.4 4153.6 13175.2 4778.7 25657.1 2509.4 4765.3 1481.5
TEF -581.9 -2005.1 -2087.2 -845.8 -327.3 -1793.1 -843.6 -3237.4
MafG 30.3 -714.3 307.3 -113.3 929.2 4842.8 -369.2 2885.7
cMaf 459.7 221.8 -674.3 -200.2 -729.1 2294.7 -119.3 1454.9
MafB 417.9 -1434.6 -2046.9 -944.7 -1315.3 2019.0 -1269.5 1752.3
NFE2 -606.8 -1494.0 -1943.2 -387.3 -570.9 736.8 -0.4 1107.4
NFE2L1 540.0 -611.9 807.6 -764.6 -1143.4 6114.6 -197.1 1019.3
NFE2L3 -535.8 -1643.8 -1520.6 -1795.9 -1347.8 -2402.1 -1392.2 -3045.3
BACHI 484.6 -190.1 -961.0 159.6 456.4 7972.2 377.3 3421.4
anti-XBP1-2 576.8 -482.4 -723.1 82.7 -277.3 3063.0 -157.6 6119.6
anti-XBP1 931.6 -701.3 -865.4 -532.0 -1009.9 3870.8 -203.9 6672.2
anti-BATF 1552.4 3090.8 1613.1 6935.3 25631.3 2435.3 1450.1 62.3
anti-SMAF 14.3 -448.7 -440.9 319.3 -406.3 5856.8 -150.9 1891.0
anti-E4BP4-2 752.3 -323.8 -141.9 73.1 -285.4 4925.5 -52.9 3899.9
anti-E4BP4 994.4 -111.4 -706.5 167.3 2327.4 4962.2 470.4 3062.4
anti-C/EBPy 3702.3 7158.3 16172.7 22417.9 16943.1 3989.9 2729.5 3093.9
anti-C/EBPy-2 15069.1 12318.4 40112.9 14940.6 13519.5 4375.3 5279.5 1591.3
anti-ATF4 10508.0 2319.8 22113.4 2202.3 3284.8 6850.2 16656.5 1201.3
anti-ATF4-2 12446.6 897.1 16506.4 1646.1 4607.8 2106.3 11698.6 809.5
anti-BACH-2 1721.8 -1163.9 -288.2 -742.6 -535.4 143.0 -758.2 -72.4
anti-BACH 4252.5 807.8 770.4 306.1 -525.6 6946.3 1033.5 1306.5
anti-ATF2-3 396.9 -284.6 2357.2 3461.2 4946.7 11952.9 3663.7 5248.6
anti-ZF-2 -610.4 -366.9 283.9 112.8 249.1 6619.8 2013.3 18946.3
anti-CREB -932.1 -991.4 -1724.9 1184.6 41.0 12012.5 1675.7 2727.9
anti-C/EBP-2 33587.8 21296.4 36955.0 27319.6 25905.8 2010.7 1682.1 2094.3
anti-OASIS 2627.1 6574.8 10764.7 6089.2 -325.4 5051.8 27429.9 1417.1
Anti-OASIS-2 1857.7 1113.3 1578.4 5850.9 1885.6 3453.4 15075.7 1725.9
C/EBPa -2414.9 660.8 -751.3 445.3 -31.9 2536.2 3711.4 34359.1
C/EBPp -1722.3 2157.9 -1934.4 -596.2 -559.8 -1107.8 4086.3 6426.5
C/EBP6 -4880.8 361.1 -415.8 -878.8 -443.6 -1296.7 7159.6 34679.4
C/EBPy -214.3 2398.1 3749.6 6527.0 355.6 640.1 22896.1 24108.8
CHOP 9281.3 2843.9 8722.0 7308.7 1574.7 3996.6 23808.6 11390.3
ATF-1 -2319.9 3468.7 5413.0 -1314.6 -319.8 -531.9 112.0 -4293.8
CREB -8696.3 1457.4 4003.8 -2087.8 -1269.1 -1561.0 -1440.7 -4408.7
CREB-H 1726.6 2271.0 3409.1 65.5 73.0 -334.1 1992.5 840.3
CREB3 1167.4 2201.3 876.5 -452.3 -583.4 -943.0 1259.4 -1027.1
ATF-6 1511.0 9836.3 -147.1 -886.0 -423.4 -479.1 354.5 -717.3
ZF 32236.8 22213.9 -437.1 704.9 261.0 -238.3 4145.3 8785.6
XBP-1 27480.3 31541.8 -161.8 221.9 66.7 -1327.7 3023.8 1618.1
E4BP4 1962.8 2244.8 40608.3 -361.0 -543.9 -811.4 4647.6 -3189.4
ATF-2 -555.1 3930.3 -561.5 4995.7 4631.9 3683.7 12381.9 1308.3
ATF-7 4956.8 2492.6 -37.1 7407.3 8615.6 6191.6 19157.9 9845.1
cJun 6370.2 2653.2 -744.8 13287.4 2943.1 28143.6 23634.2 703.5
JunB 4287.3 2020.8 -1211.3 4806.7 715.9 18676.8 19483.0 -3499.4
JunD 5962.6 1892.7 -1449.3 8136.4 828.8 22002.7 21914.4 -18.3
Fos 8015.2 996.9 -1.2 8113.9 29520.1 1778.4 3488.7 10138.6
Fra2 8316.2 3028.1 -1182.9 7411.4 17576.8 2955.3 5901.2 4285.1
ATF-3 6441.8 3085.6 888.3 10483.1 9526.3 1960.8 675.6 15171.7
ATF-4 27125.9 900.9 -851.6 1706.2 -483.2 5716.6 11746.7 -926.9
ATF-5 -1674.8 -1932.1 -835.9 -2308.8 -1581.6 -2499.8 -2249.5 -4026.6
B-ATF 7504.8 1769.3 2782.0 4070.7 16188.1 -582.0 8664.3 13362.1
p21SNFT 10062.6 2309.4 2341.2 7257.2 12525.1 374.5 19961.8 14456.7
TEF -2597.3 3076.5 -751.1 -1283.2 -934.8 -1822.0 123.3 -3493.4
MafG 6196.1 4109.8 113.4 588.8 1459.4 163.1 1756.7 1110.1
cMaf 2434.0 2664.9 11.3 1171.9 245.6 656.3 3638.8 5309.9
MafB 4784.0 3499.1 -522.7 833.6 22.9 1953.0 5563.9 -1037.3
NFE2 3751.2 914.6 -1195.4 316.3 -410.9 -1275.6 -692.5 -718.5
NFE2L1 27090.3 1167.9 -298.1 1388.1 -109.6 1058.5 363.6 6786.6
NFE2L3 -2936.2 -866.4 -787.3 -2125.3 -1338.3 -1975.7 -2200.8 -1621.5
BACHI 15754.4 4292.8 1411.6 5134.1 523.2 1516.8 1600.4 2707.9
anti-XBP1-2 15814.3 8919.3 -309.7 27.9 554.3 -193.4 2804.9 730.9
anti-XBP1 11306.4 5129.6 -1151.9 -652.3 990.0 -325.0 1342.6 1316.3
anti-BATF 28913.5 3469.6 -811.8 1959.2 -425.8 12467.3 5325.4 4115.8
anti-SMAF 4048.3 2717.3 -290.9 886.8 4516.6 1786.1 3155.2 1872.6
anti-E4BP4-2 2103.6 2188.9 1218.9 394.9 506.8 -648.4 3556.6 -672.4
anti-E4BP4 2764.3 2628.6 5120.1 54.1 450.8 415.0 2805.8 218.1
anti-C/EBPy 27028.4 2991.2 737.5 1480.3 2045.8 5762.1 12269.3 11299.2
anti-C/EBPy-2 12425.8 3463.8 1396.4 9184.3 5304.9 4767.3 6109.3 32502.9
anti-ATF4 24671.5 4353.9 3071.7 20937.1 9518.1 16634.8 20245.3 38930.5
anti-ATF4-2 7739.3 1445.9 -528.2 6264.4 1866.8 19898.6 17574.6 37258.2
anti-BACH-2 -1314.9 598.4 -1776.3 -838.9 -298.7 -244.9 1300.1 -3506.2
anti-BACH 863.4 2160.3 465.4 1621.6 19.2 14561.6 4288.1 930.2
anti-ATF2-3 28725.3 2959.3 4361.7 32284.5 2933.3 19785.3 16925.0 5705.9
anti-ZF-2 24889.6 23267.8 2000.4 2820.9 2112.4 2913.6 3294.3 8336.9
anti-CREB 479.3 2586.8 1745.8 -1018.0 328.2 1437.5 814.8 -1579.0
anti-C/EBP-2 18057.1 1833.5 -841.7 3313.6 546.9 9064.3 17207.1 44465.6
anti-OASIS 1277.9 2128.5 8390.2 -238.1 958.5 3741.5 13676.4 2058.8
anti-OASIS-2 4944.3 2320.0 3345.6 2668.4 1646.3 3004.5 16412.8 -527.3
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protein XBP-1 E4BP4 ATF-2 cJun Fos ATF-3 ATF-4
protein p21 SNFT TEF MafG cMaf NFE2 BACH1 anti-XBP1-2 anti-XBP1
C/EBPa 13324.3 445.9 -192.1 -290.8 -1825.0 -1600.7 132.8 238.3
C/EBPp 6601.3 -1122.6 -675.8 -128.6 -5212.5 -1075.1 384.8 460.9
C/EBPS 24971.1 244.4 -72.1 -3718.6 -1078.4 -2389.9 257.3 503.1
C/EBPy 18509.8 1652.1 -72.7 -13.1 -1967.1 56.1 421.9 520.3
CHOP 26243.4 4398.8 19.8 1568.9 -1860.4 6762.5 281.6 494.8
ATF-1 -11330.2 -928.5 -111.7 -793.5 -4380.5 2919.4 684.4 736.1
CREB -10522.6 -4101.9 -577.2 -1270.0 -6533.5 3999.6 259.1 482.2
CREB-H 3896.3 3423.8 -123.0 -351.1 -851.3 -426.2 466.6 536.6
CREB3 4114.5 -164.6 -184.4 83.8 -1348.8 -514.8 376.8 550.4
ATF-6 -5640.9 -60.1 -330.7 191.1 -3878.0 -90.1 696.0 609.6
ZF 1039.9 700.9 31.4 -209.6 1887.8 3316.3 3912.9 1391.6
XBP-1 -2073.5 2784.7 -173.4 -971.7 -3023.4 476.1 10564.9 2314.0
E4BP4 10000.5 2939.3 -319.8 -1818.8 -979.3 -74.4 477.6 510.0
ATF-2 24722.8 958.6 65.1 660.2 -2828.9 6905.6 69.3 735.9
ATF-7 29215.8 2030.9 -231.6 694.2 1295.8 9041.8 315.6 383.3
cJun 27603.6 2241.5 1.0 1493.8 -1682.4 1392.6 248.8 945.9
JunB 22546.1 1888.7 -96.3 -116.7 -1276.8 -44.5 274.8 729.2
JunD 29892.1 1232.4 -245.3 1303.6 -857.7 -214.9 481.0 515.9
Fos -404.2 2895.0 -281.6 2130.1 -2478.0 5113.0 177.6 690.6
Fra2 2168.2 2199.8 -359.5 1268.9 -1696.9 2183.1 557.7 791.6
ATF-3 31526.1 797.2 150.8 481.5 -6966.8 -493.4 616.3 746.8
ATF-4 27759.2 -3262.1 54.0 10884.5 -1981.8 3517.3 -28.6 595.3
ATF-5 15657.6 -4280.0 -89.4 -894.7 -556.2 775.4 110.4 355.3
B-ATF 19458.4 8601.8 -248.9 257.0 424.3 6754.7 307.3 468.6
p21SNFT 26991.1 4459.4 1263.4 855.8 -3043.9 4764.4 724.9 830.8
TEF -5321.8 3396.4 -419.1 -849.2 -5937.8 -398.2 60.4 514.6
MafG 16893.3 2031.6 1969.6 69.3 17719.7 44305.4 560.3 573.1
cMaf -191.3 1700.3 52.5 24096.8 -1070.4 9750.6 310.8 543.8
MafB -4965.8 2167.0 -153.5 27520.9 -1783.3 15627.7 606.1 657.8
NFE2 -5787.9 1823.6 380.2 -557.8 19093.1 448.7 572.1 656.1
NFE2L1 -1869.8 1249.7 38273.3 1542.1 708.1 21.9 339.8 395.8
NFE2L3 -15234.8 -3185.4 27391.5 -1131.9 12016.6 -1945.3 190.4 422.3
BACHI 5125.7 3448.2 13684.1 8474.9 -2608.5 3085.6 10529.3 1646.6
anti-XBP1-2 -1079.3 3235.8 -59.6 -423.9 -352.8 9744.2 276.7
anti-XBP1 -3135.4 3086.4 -221.3 -2219.3 -485.8 2714.4 406.4
anti-BATF 20417.3 9229.8 10298.6 -84.5 -1484.1 858.2
anti-SMAF 25246.4 2110.9 14168.2 2406.8 16335.1 5104.8
anti-E4BP4-2 -3405.6 4597.0 -701.6 -5.6 -1181.0 -733.8
anti-E4BP4 7575.1 8804.1 -23.4 43.4 -3.6 1532.9
anti-C/EBPy 24111.7 2821.7 305.2 -1611.9 -456.6 3704.6
anti-C/EBPy-2 24454.4 9770.1 413.5 32749.3 5732.5 5480.3
anti-ATF4 27373.3 2251.5 6694.0 5583.4 30084.7 24527.0
anti-ATF4-2 27211.6 542.3 -173.4 1428.1 10552.1 5146.4
anti-BACH-2 -11212.4 3.4 3.5 -551.8 -628.9 2207.5
anti-BACH 7472.1 2119.3 -200.9 6903.6 31129.8 33014.3
anti-ATF2-3 24496.7 1652.6 2296.5 52.4 -786.8 436.9
anti-ZF-2 10086.7 525.9 1476.9 886.3 3044.9 11656.3
anti-CREB 15076.1 3523.3 611.5 -219.1 -1507.3 3384.6
anti-C/EBP-2 28553.1 4660.8 -149.3 2873.7 2558.2 -156.1
anti-OASIS 21807.4 1829.9 3717.1 -494.7 -205.0 -479.9
anti-OASIS-2 20343.0 1975.1 2120.3 896.4 -2148.8 3221.1
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protein anti- anti- anti-E4BP4- anti- anti- anti- anti-ATF4 anti-BATF SMAF 2 E4BP4 C/EBPy C/EBPy-2 ATF4-2
C/EBPa -621.8 -378.9 351.2 118.4 1011.2 8545.8 2675.1 4290.0
C/EBPp -971.1 -1003.6 558.3 192.4 1258.9 8497.4 -2170.3 -1821.8
C/EBPS -1583.3 -588.2 556.9 -292.6 3168.4 21820.2 4396.6 2623.7
C/EBPy 1369.4 163.8 730.4 2936.7 23323.2 24328.1 1314.9 -388.9
CHOP 24028.7 278.6 1064.4 37604.3 21183.6 18430.5 1951.2 3609.8
ATF-1 -866.1 282.9 905.1 -118.7 -880.3 -1519.7 -695.3 -1609.2
CREB -3340.9 -339.4 581.1 -1504.4 -523.8 -1899.4 -1782.3 -1785.9
CREB-H 223.1 100.8 836.6 1076.1 -450.6 222.5 357.9 -83.7
CREB3 -785.2 -108.3 748.8 116.5 -590.8 702.8 8138.3 4481.9
ATF-6 -1388.6 -212.5 653.0 526.0 -1008.1 -696.6 -898.8 -984.5
ZF 1145.9 319.2 557.6 571.6 4653.5 1968.3 5086.2 1821.2
XBP-1 540.6 -227.3 646.1 360.1 -667.6 -1705.1 -1484.0 -429.2
E4BP4 -804.8 -618.3 855.1 5262.3 413.3 -352.1 -483.5 -1838.6
ATF-2 -829.7 -60.4 919.1 834.5 -229.2 4940.3 25340.7 4014.0
ATF-7 -191.9 1639.7 486.4 1233.8 560.5 8720.0 14443.4 7965.4
cJun -1152.4 18511.9 496.9 1578.9 1205.7 9882.3 14654.0 3451.2
JunB -1038.8 5859.3 591.0 496.4 -127.6 4819.8 13823.4 -658.9
JunD -1265.7 6489.1 453.8 452.6 139.0 4999.3 16156.4 1327.0
Fos 5770.8 3978.6 661.3 1347.4 8366.1 6282.0 29530.1 34437.4
Fra2 7879.5 1525.3 824.3 143.5 4514.6 13295.1 22081.8 10492.6
ATF-3 -387.4 1339.0 962.2 3528.4 6073.3 526.2 21316.4 22704.9
ATF-4 -587.6 746.6 748.1 282.1 8454.4 23207.6 39871.1 37368.8
ATF-5 -2197.9 -632.6 522.4 -1702.8 4543.3 1856.8 5264.9 1629.6
B-ATF 14011.9 650.6 645.8 7437.2 503.0 -468.7 6056.6 1613.9
p21SNFT 15853.1 8520.8 869.1 8896.9 2080.4 4893.9 7767.7 7312.8
TEF -2356.1 -457.4 714.1 2917.4 -401.9 -646.3 -1845.6 -2057.8
MafG 6080.5 42792.9 672.9 2946.1 -602.6 1030.6 13716.0 584.3
cMaf 3.3 1748.2 618.8 1370.9 -480.4 11262.8 699.6 565.5
MafB -568.6 847.7 729.1 754.2 -1544.9 4030.3 381.8 128.5
NFE2 -765.6 10067.1 575.1 114.3 -378.5 -313.4 25018.7 3268.6
NFE2L1 -1128.8 938.8 448.0 206.2 -894.1 -681.3 27209.3 1491.0
NFE2L3 -1978.8 -1158.5 476.7 -1657.2 -1318.4 -1392.6 7552.6 -1925.4
BACHI 11.8 3091.8 827.4 5133.9 1349.4 1077.1 7647.7 1427.4
anti-XBP1 -2
anti-XBP1
anti-BATF -1485.6
anti-SMAF 4741.2
anti-E4BP4-2 593.8
anti-E4BP4 12171.8
anti-C/EBPy 1559.8
anti-C/EBPy-2 10249.5
anti-ATF4 3540.6
anti-ATF4-2 4570.4
anti-BACH-2
anti-BACH
anti-ATF2-3
anti-ZF-2
anti-CREB
anti-C/EBP-2
anti-OASIS
anti-OASIS-2
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protein anti- anti- anti- anti-ZF-2 anti-CREB anti-C/EBP-BACH-2 BACH ATF2-3 2
C/EBPa 3026.8 819.7 -2789.2 -895.1 -100.6 22362.9
C/EBP3 -2525.7 -596.9 -1430.0 -1808.9 -449.8 11580.0
C/EBPS 4396.8 175.6 -293.8 -1413.6 -873.8 18934.1
C/EBPy 3661.0 806.5 22134.4 -111.1 3934.9 26889.6
CHOP -974.1 1041.7 41196.5 1515.1 3048.2 30991.9
ATF-1 -3360.4 642.3 946.4 -306.4 3148.6 -1469.4
CREB -5286.4 -261.1 6395.9 -3750.5 2830.2 -1195.2
CREB-H 457.4 1077.0 1467.7 1126.8 2010.1 -811.4
CREB3 -661.9 -535.3 4802.4 528.2 1683.2 -1491.6
ATF-6 -1529.3 -679.5 -533.5 3824.5 -637.5 -934.2
ZF -2627.5 -1016.6 30723.6 9987.6 -478.3 1161.9
XBP-1 -893.6 -1457.1 486.6 18013.8 20.0 -1757.4
E4BP4 -55.8 143.1 7336.0 1712.3 230.4 -2181.6
ATF-2 -941.4 2025.3 48886.9 1806.7 -378.4 -615.1
ATF-7 243.8 433.4 53617.9 3740.3 580.1 3845.8
cJun 575.9 -427.8 25474.4 5198.7 1563.1 -416.6
JunB -120.2 -583.4 12123.1 2123.8 168.8 -1490.4
JunD 586.1 -377.4 8849.9 2717.9 -664.9 -1019.7
Fos 3452.8 24319.0 49898.1 3532.8 5916.3 5173.0
Fra2 330.4 12409.4 53166.4 4148.0 4027.0 -1101.7
ATF-3 -4280.5 2880.0 50237.5 -324.6 605.3 4072.4
ATF-4 622.1 3715.4 917.6 4098.6 -320.8 36727.6
ATF-5 -1828.6 137.1 -4756.6 -5862.7 -359.6 3612.8
B-ATF 1873.9 4312.1 27785.4 1559.0 1262.4 3824.6
p21SNFT -1040.0 3808.8 48355.0 4508.4 7521.9 13473.9
TEF -3864.9 -1713.0 -2791.5 -2796.9 -1150.4 -1515.3
MafG 4747.2 755.0 31517.3 2968.3 4127.9 -854.8
cMaf -141.9 3569.3 1127.3 1845.4 -397.1 -130.3
MafB -618.8 3600.8 -1693.4 1369.1 -1146.1 -2332.8
NFE2 10477.2 30996.3 -3207.4 4143.6 -521.2 -1285.9
NFE2L1 6634.3 2780.9 -1364.1 3576.6 -127.1 1463.1
NFE2L3 -1925.3 201.1 -5328.6 -2656.3 -1138.1 -1718.4
BACHI 4769.8 15576.9 -693.9 5640.9 5151.3 -1300.2
anti-XBP1 -2
anti-XBP1
anti-BATF
anti-SMAF
anti-E4BP4-2
anti-E4BP4
anti-C/EBPy
anti-C/EBPy-2
anti-ATF4
anti-ATF4-2
anti-BACH-2 22601.3
anti-BACH 8223.3
anti-ATF2-3 18632.6
anti-ZF-2 5162.6
anti-CREB 16779.5
anti-C/EBP-2 -1467.1
anti-OASIS
anti-OASIS-2
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protein aSiS anti-OASIS-2 anti-C/EBPy(2) anti-SMAF(2) anti-XBP1800
C/EBPa -1009.8 -748.7 905.3 478.0 237.5
C/EBPP 951.6 -1294.3 308.6 55.1 319.2
C/EBP6 -4.6 -1457.8 2858.0 -5.4 250.5
C/EBPy 6182.5 6129.1 24063.3 2043.1 353.4
CHOP 1782.0 10525.9 20659.7 910.5 361.3
ATF-1 -1943.9 524.1 -1120.9 1019.6 702.9
CREB -319.8 -918.4 -956.4 419.1 649.9
CREB-H 2421.3 4961.9 -784.6 1199.8 407.9
CREB3 7748.9 10026.6 -1115.0 -113.9 398.7
ATF-6 -260.6 -374.9 -893.6 235.9 1157.8
ZF -579.4 820.8 4418.3 1278.1 3886.3
XBP-1 1126.6 3026.8 -574.4 814.8 6189.5
E4BP4 1063.3 497.4 -1688.9 226.6 409.8
ATF-2 -450.9 262.1 -539.6 1473.2 640.3
ATF-7 -956.2 3037.1 538.3 2280.6 373.7
cJun 1154.2 3427.1 513.6 22955.9 2842.2
JunB 67.4 3045.3 -814.7 7609.4 1651.4
JunD 191.6 1698.8 257.9 7231.5 1081.8
Fos 3890.1 17550.4 7112.3 4832.6 915.1
Fra2 801.3 13051.9 3398.8 1443.0 1139.6
ATF-3 6281.5 18198.6 5734.2 1915.7 521.9
ATF-4 943.7 796.4 6383.4 1328.9 294.3
ATF-5 -1073.9 -1726.5 3136.0 1060.6 71.9
B-ATF 1871.4 4359.3 562.5 1649.7 448.6
p21SNFT 10563.2 10585.2 1450.6 11300.8 1313.9
TEF -1023.8 -2560.5 -925.2 968.2 340.4
MafG 6805.5 11081.9 -324.3 42998.6 677.4
cMaf -213.1 802.3 -489.3 2598.1 425.9
MafB -2845.6 1042.4 -2180.1 1888.4 631.4
NFE2 467.0 -112.2 -538.4 12839.1 1034.5
NFE2L1 7.9 858.4 -1276.0 1119.5 389.6
NFE2L3 -1970.3 -2436.6 -1654.3 569.1 188.9
BACHI 394.6 4116.5 952.4 4105.9 4251.6
anti-XBP1 -2
anti-XBP1 455.1
anti-BATF
anti-SMAF 5382.6
anti-E4BP4-2
anti-E4BP4
anti-C/EBPy 1752.0
anti-C/EBPy-2
anti-ATF4
anti-ATF4-2
anti-BACH-2
anti-BACH
anti-ATF2-3
anti-ZF-2
anti-CREB
anti-C/EBP-2
anti-OASIS 269.4
anti-OASIS-2 
-101.6
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Sarray values.
protein C/EBPa C/EBPp C/EBPS C/EBPy CHOP CREB CREB3 ATF-6
C/EBPa 12.3 8.8 8.9 3.4 14.4 -1.3 -0.8 -0.8
C/EBP3 10.2 2.7 6.3 3.4 30.6 -1.4 -1.8 -1.0
C/EBPS 13.8 9.1 7.2 6.6 11.8 -1.1 0.0 -0.8
C/EBP7 11.8 7.7 11.1 1.2 15.9 -0.3 1.9 -0.1
CHOP 17.3 26.9 10.9 13.8 3.7 0.0 4.8 0.0
ATF-1 -1.6 -1.6 -2.1 -2.0 -1.2 4.9 -1.9 -0.9
CREB -2.3 -2.7 -2.0 -1.7 -1.1 5.7 -0.7 -2.3
CREB-H -0.6 -0.2 -0.4 -0.2 -0.6 0.0 3.3 0.2
CREB3 -0.5 -1.3 -0.8 -0.3 -0.5 -0.3 2.6 -0.5
ATF-6 -1.1 -0.9 -0.9 -1.1 -1.0 -0.8 -0.5 5.1
ZF -0.7 -0.7 -1.0 -0.8 -0.1 -1.3 -0.7 0.6
XBP-1 -0.2 0.1 -0.8 -0.6 -1.0 0.4 0.0 9.7
E4BP4 -0.6 -1.0 0.3 0.3 0.0 4.8 3.1 0.2
ATF-2 -0.6 -0.3 -0.9 1.7 0.4 -0.6 -0.2 -0.5
ATF-7 3.1 3.4 1.4 4.5 4.0 0.0 0.7 -0.1
cJun 1.0 1.0 0.9 0.4 0.5 0.4 -0.3 0.0
JunB -0.3 -0.6 -0.5 -1.0 -0.7 -0.2 -1.0 0.1
JunD -0.2 -0.6 0.1 -0.3 0.0 0.2 -0.6 0.0
Fos 2.8 0.5 0.6 0.4 1.8 -0.5 -0.6 -0.5
Fra2 0.5 0.1 -0.1 0.0 0.4 0.0 -0.8 0.1
ATF-3 2.4 3.6 2.5 12.5 6.4 -1.3 0.1 -1.0
ATF-4 37.0 12.9 21.0 44.2 21.3 -1.0 0.7 -1.2
ATF-5 9.9 1.2 6.2 42.2 -1.3 -2.1 -1.3 -2.1
B-ATF 3.4 4.9 3.9 7.4 11.4 0.6 1.9 0.5
p21SNFT 5.2 3.7 5.9 4.2 18.4 -0.1 5.2 0.0
TEF -1.4 -1.6 -1.4 -1.3 -0.8 -1.7 -1.3 -1.9
MafG -0.8 -0.5 -0.2 -0.5 0.1 0.8 -0.7 0.5
cMaf -0.4 0.3 -0.7 -0.6 -1.1 -0.2 -0.4 0.0
MafB -0.5 -1.1 -1.3 -1.3 -1.6 -0.3 -1.7 0.1
NFE2 -1.4 -1.2 -1.3 -0.8 -1.0 -0.8 -0.3 -0.2
NFE2L1 -0.4 -0.4 0.0 -1.2 -1.4 1.2 -0.5 -0.2
NFE2L3 -1.3 -1.3 -1.1 -2.2 -1.6 -2.0 -1.9 -1.8
BACHI -0.4 -0.1 -0.8 -0.3 -0.2 1.9 0.1 0.7
anti-XBP1-2 -0.3 -0.3 -0.7 -0.3 -0.8 0.1 -0.5 1.8
anti-XBP1 0.0 -0.5 -0.8 -0.9 -1.3 0.4 -0.5 2.0
anti-BATF 0.6 2.8 0.4 6.3 18.4 -0.1 1.4 -0.6
anti-SMAF -0.8 -0.3 -0.6 -0.1 -0.9 1.1 -0.5 0.1
anti-E4BP4-2 -0.2 -0.2 -0.4 -0.4 -0.8 0.8 -0.4 0.9
anti-E4BP4 0.1 0.0 -0.7 -0.3 1.1 0.8 0.2 0.6
anti-C/EBPy 2.5 6.3 7.3 21.5 12.0 0.4 2.8 0.6
anti-C/EBPy-2 13.0 10.7 18.6 14.2 9.4 0.6 5.8 0.0
anti-ATF4 8.8 2.1 10.1 1.7 1.9 1.5 18.8 -0.1
anti-ATF4-2 10.6 0.9 7.4 1.2 2.8 -0.3 13.1 -0.3
anti-BACH-2 0.7 -0.9 -0.5 -1.2 -1.0 -1.0 -1.2 -0.6
anti-BACH 3.0 0.8 0.0 -0.1 -1.0 1.6 0.9 -0.1
anti-ATF2-3 -0.5 -0.1 0.8 3.0 3.1 3.4 3.9 1.5
anti-ZF-2 -1.4 -0.2 -0.2 -0.3 -0.4 1.4 2.0 6.8
anti-CREB -1.7 -0.8 -1.2 0.7 -0.5 3.5 1.6 0.5
anti-C/EBP-2 29.9 18.5 17.1 26.3 18.6 -0.3 1.6 0.2
anti-OASIS 1.6 5.8 4.7 5.5 -0.8 0.8 31.2 -0.1
anti-OASIS-2 0.8 1.1 0.4 5.3 0.8 0.2 17.0 0.1
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protein ZF XBP- E4BP4 ATF- cJun Fos ATF- ATF-1 2 3 4
C/EBPa -1.3 -1.2 -0.8 -0.4 -0.5 0.5 -0.1 9.7
C/EBP -1.1 -0.2 -2.1 -0.9 -1.1 -1.1 0.0 1.4
C/EBPS -1.7 -1.4 -0.4 -1.1 -1.0 -1.2 0.9 9.8
C/EBPy -0.9 -0.1 4.2 2.9 -0.2 -0.4 5.7 6.6
CHOP 0.7 0.2 9.6 3.3 1.1 1.1 6.0 2.9
ATF-1 -1.3 0.6 6.0 -1.3 -0.8 -0.9 -1.2 -1.7
CREB -2.3 -0.7 4.4 -1.7 -1.8 -1.3 -1.7 -1.8
CREB-H -0.6 -0.1 3.8 -0.6 -0.4 -0.8 -0.6 -0.2
CREB3 -0.7 -0.2 1.0 -0.9 -1.1 -1.1 -0.9 -0.8
ATF-6 -0.6 4.8 -0.1 -1.1 -0.9 -0.9 -1.1 -0.7
ZF 4.7 12.9 -0.4 -0.3 -0.2 -0.7 0.0 2.1
XBP-1 3.9 19.1 -0.1 -0.5 -0.4 -1.2 -0.3 0.0
E4BP4 -0.5 -0.2 44.7 -0.8 -1.1 -1.0 0.2 -1.4
ATF-2 -0.9 0.9 -0.6 2.0 4.1 1.0 2.5 -0.1
ATF-7 0.0 0.0 0.0 3.3 8.1 2.1 4.6 2.4
cJun 0.2 0.1 -0.8 6.5 2.4 11.8 5.9 -0.3
JunB -0.1 -0.3 -1.3 1.9 0.2 7.6 4.7 -1.5
JunD 0.2 -0.4 -1.6 3.7 0.3 9.1 5.4 -0.5
Fos 0.5 -1.0 0.0 3.7 29.1 0.2 -0.2 2.5
Fra2 0.6 0.4 -1.3 3.3 17.1 0.7 0.6 0.8
ATF-3 0.3 0.4 1.0 5.0 9.0 0.2 -1.0 4.0
ATF-4 3.8 -1.0 -0.9 0.3 -1.0 1.9 2.3 -0.8
ATF-5 -1.1 -2.9 -0.9 -1.9 -2.1 -1.7 -1.9 -1.7
B-ATF 0.4 -0.5 3.1 1.6 15.7 -0.9 1.4 3.5
p21SNFT 0.9 -0.1 2.6 3.3 12.0 -0.5 4.8 3.8
TEF -1.3 0.4 -0.8 -1.3 -1.4 -1.4 -1.2 -1.5
MafG 0.2 1.1 0.2 -0.3 1.0 -0.6 -0.7 -0.2
cMaf -0.4 0.1 0.1 0.0 -0.3 -0.3 -0.1 1.1
MafB 0.0 0.7 -0.5 -0.2 -0.5 0.2 0.4 -0.8
NFE2 -0.2 -1.0 -1.3 -0.5 -0.9 -1.2 -1.5 -0.7
NFE2L1 3.8 -0.9 -0.3 0.1 -0.6 -0.2 -1.1 1.5
NFE2L3 -1.4 -2.2 -0.8 -1.8 -1.8 -1.5 -1.9 -1.0
BACHI 1.9 1.2 1.6 2.1 0.0 0.0 -0.8 0.3
anti-XBP1-2 1.9 4.2 -0.3 -0.6 0.0 -0.7 -0.4 -0.3
anti-XBP1 1.1 1.7 -1.2 -1.0 0.5 -0.8 -0.8 -0.1
anti-BATF 4.1 0.6 -0.9 0.4 -0.9 4.9 0.4 0.7
anti-SMAF -0.2 0.1 -0.3 -0.2 4.0 0.2 -0.3 0.1
anti-E4BP4-2 -0.5 -0.2 1.4 -0.4 0.0 -0.9 -0.2 -0.7
anti-E4BP4 -0.4 0.1 5.7 -0.6 -0.1 -0.5 -0.4 -0.4
anti-C/EBPy 3.8 0.3 0.9 0.2 1.5 1.9 2.5 2.9
anti-C/EBPy-2 1.3 0.6 1.6 4.3 4.8 1.5 0.6 9.1
anti-ATF4 3.4 1.2 3.4 10.6 9.0 6.7 4.9 11.0
anti-ATF4-2 0.5 -0.7 -0.5 2.7 1.4 8.2 4.1 10.5
anti-BACH-2 -1.1 -1.2 -1.9 -1.1 -0.8 -0.7 -0.8 -1.5
anti-BACH -0.7 -0.2 0.6 0.2 -0.5 5.8 0.1 -0.2
anti-ATF2-3 4.1 0.3 4.8 16.6 2.4 8.1 3.9 1.2
anti-ZF-2 3.4 13.6 2.2 0.9 1.6 0.7 -0.2 2.0
anti-CREB -0.8 0.1 2.0 -1.2 -0.2 0.0 -1.0 -0.9
anti-C/EBP-2 2.3 -0.4 -0.9 1.1 0.0 3.4 4.0 12.7
anti-OASIS -0.6 -0.2 9.3 -0.8 0.5 1.0 2.9 0.1
anti-OASIS-2 0.0 -0.1 3.7 0.8 1.1 0.7 3.7 -0.6
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protein p21SNFT TEF MafG cMaf NFE2 BACHI anti-XBP1-2 anti-XBP1
C/EBPa 0.0 -0.6 -0.5 -0.3 -0.3 -1.5 -1.6 -2.3
C/EBPP -0.4 -1.1 -2.3 -0.2 -1.7 -1.3 0.2 -0.7
C/EBPS 0.7 -0.7 0.0 -3.1 0.0 -1.8 -0.7 -0.3
C/EBPy 0.3 -0.1 0.0 -0.1 -0.4 -0.8 0.4 -0.2
CHOP 0.8 0.9 0.3 1.2 -0.3 1.8 -0.5 -0.4
ATF-1 -1.5 -1.1 -0.2 -0.7 -1.3 0.3 2.3 1.4
CREB -1.5 -2.2 -1.9 -1.1 -2.2 0.7 -0.7 -0.5
CREB-H -0.6 0.5 -0.2 -0.3 0.1 -1.0 0.8 -0.1
CREB3 -0.6 -0.8 -0.5 0.0 -0.1 -1.1 0.1 0.0
ATF-6 -1.2 -0.8 -1.0 0.1 -1.1 -0.9 2.4 0.5
ZF -0.8 -0.5 0.3 -0.2 1.2 0.4 25.0 6.4
XBP-1 -1.0 0.3 -0.4 -0.9 -0.8 -0.7 71.8 13.4
E4BP4 -0.2 0.3 -1.0 -1.6 0.0 -0.9 0.8 -0.3
ATF-2 0.7 -0.4 0.5 0.5 -0.7 1.8 -2.0 1.4
ATF-7 1.0 0.0 -0.6 0.5 1.0 2.7 -0.3 -1.2
cJun 0.9 0.1 0.2 1.2 -0.2 -0.3 -0.8 3.0
JunB 0.6 -0.1 -0.1 -0.2 -0.1 -0.9 -0.6 1.4
JunD 1.0 -0.3 -0.7 1.0 0.1 -0.9 0.9 -0.2
Fos -0.9 0.3 -0.8 1.7 -0.6 1.1 -1.3 1.1
Fra2 -0.7 0.1 -1.1 1.0 -0.3 0.0 1.4 1.8
ATF-3 1.1 -0.4 0.8 0.3 -2.4 -1.1 1.8 1.5
ATF-4 0.9 -1.9 0.4 9.0 -0.4 0.5 -2.7 0.4
ATF-5 0.1 -2.3 -0.1 -0.8 0.2 -0.6 -1.7 -1.4
B-ATF 0.4 2.4 -0.7 0.2 0.6 1.8 -0.4 -0.6
p21SNFT 0.8 0.9 5.0 0.7 -0.8 1.0 2.6 2.1
TEF -1.2 0.5 -1.4 -0.8 -2.0 -1.0 -2.1 -0.2
MafG 0.2 0.0 7.6 0.0 7.6 16.4 1.4 0.2
cMaf -0.8 -0.1 0.4 20.0 0.0 2.9 -0.3 0.0
MafB -1.1 0.1 -0.4 22.8 -0.3 5.2 1.7 0.8
NFE2 -1.2 -0.1 1.7 -0.5 8.2 -0.7 1.5 0.8
NFE2L1 -0.9 -0.3 144.0 1.2 0.7 -0.9 -0.1 -1.1
NFE2L3 -1.8 -1.9 103.1 -1.0 5.3 -1.6 -1.2 -0.9
BACHI -0.5 0.5 51.6 7.0 -0.6 0.3 71.5 8.3
anti-XBP1-2 -0.9 0.4 0.0 -0.4 0.3 2.9 -0.6
anti-XBP1 -1.0 0.4 -0.6 -1.9 0.2 0.2 -1.1
anti-BATF 0.4 2.6 38.9 -0.1 -0.2 -0.5
anti-SMAF 0.7 0.0 53.4 1.9 7.1 1.1
anti-E4BP4-2 -1.0 0.9 -2.4 -0.1 0.0 -1.1
anti-E4BP4 -0.4 2.5 0.1 0.0 0.4 -0.3
anti-C/EBPy 0.7 0.3 1.4 -1.4 0.3 0.6
anti-C/EBPy-2 0.7 2.8 1.8 27.2 2.8 1.3
anti-ATF4 0.9 0.1 25.4 4.6 12.7 8.7
anti-ATF4-2 0.9 -0.5 -0.4 1.1 4.7 1.1
anti-BACH-2 -1.5 -0.7 0.2 -0.5 0.2 0.0
anti-BACH -0.4 0.0 -0.5 5.7 13.1 12.0
anti-ATF2-3 0.7 -0.1 8.9 0.0 0.1 -0.7
anti-ZF-2 -0.2 -0.5 5.8 0.7 1.7 3.7
anti-CREB 0.1 0.5 2.5 -0.2 -0.2 0.5
anti-C/EBP-2 0.9 1.0 -0.3 2.3 1.5 -0.9
anti-OASIS 0.5 -0.1 14.2 -0.5 0.4 -1.0
anti-OASIS-2 0.4 0.0 8.2 0.7 -0.4 0.4
319
. anti- anti- anti- anti- anti- anti-C/EBPy- anti-
protein BATF SMAF E4BP4-2 E4BP4 /EBP 2 ATF4 anti-ATF4-2
y
C/EBPa 0.1 -1.0 -2.7 -0.5 0.5 1.8 -0.7 1.4
C/EBP -0.3 -1.7 -0.8 -0.4 0.7 1.8 -1.7 -1.7
C/EBPS -1.0 -1.2 -0.8 -0.9 2.3 6.1 -0.3 0.6
C/EBPy 2.3 -0.4 0.7 2.1 19.7 7.0 -1.0 -1.0
CHOP 27.0 -0.2 3.8 33.8 17.9 5.0 -0.8 1.1
ATF-1 -0.2 -0.2 2.3 -0.7 -1.2 -1.5 -1.4 -1.6
CREB -2.9 -0.9 -0.6 -2.0 -0.8 -1.6 -1.6 -1.7
CREB-H 1.0 -0.4 1.7 0.4 -0.8 -0.9 -1.2 -0.8
CREB3 -0.1 -0.7 0.9 -0.5 -0.9 -0.8 0.5 1.5
ATF-6 -0.8 -0.8 0.0 -0.1 -1.3 -1.2 -1.4 -1.3
ZF 2.0 -0.2 -0.8 -0.1 3.6 -0.3 -0.1 0.1
XBP-1 1.3 -0.8 0.0 -0.3 -1.0 -1.5 -1.6 -1.0
E4BP4 -0.1 -1.2 1.9 4.2 0.0 -1.1 -1.4 -1.7
ATF-2 -0.1 -0.6 2.5 0.2 -0.6 0.6 4.3 1.3
ATF-7 0.5 1.3 -1.5 0.5 0.1 1.9 1.9 3.3
cJun -0.5 20.1 -1.4 0.8 0.6 2.2 2.0 1.0
JunB -0.4 6.0 -0.5 -0.2 -0.5 0.6 1.8 -1.1
JunD -0.6 6.7 -1.8 -0.2 -0.3 0.7 2.3 -0.1
Fos 7.1 3.9 0.1 0.6 6.8 1.1 5.3 16.9
Fra2 9.4 1.2 1.6 -0.5 3.5 3.4 3.6 4.6
ATF-3 0.3 1.0 2.9 2.6 4.8 -0.8 3.5 10.9
ATF-4 0.1 0.3 0.9 -0.3 6.9 6.6 7.5 18.4
ATF-5 -1.6 -1.2 -1.2 -2.2 3.5 -0.4 -0.1 0.0
B-ATF 16.1 0.2 0.0 6.2 0.0 -1.1 0.1 0.0
p21SNFT 18.1 9.0 2.0 7.5 1.4 0.6 0.5 3.0
TEF -1.8 -1.1 0.6 2.1 -0.7 -1.2 -1.7 -1.9
MafG 7.4 47.2 0.2 2.1 -0.9 -0.6 1.8 -0.5
cMaf 0.8 1.4 -0.3 0.6 -0.8 2.7 -1.1 -0.5
MafB 0.1 0.4 0.7 0.1 -1.7 0.3 -1.2 -0.7
NFE2 -0.1 10.7 -0.7 -0.5 -0.7 -1.1 4.3 0.9
NFE2L1 -0.5 0.5 -1.8 -0.4 -1.2 -1.2 4.8 0.0
NFE2L3 -1.4 -1.8 -1.6 -2.1 -1.5 -1.4 0.4 -1.8
BACHI 0.8 2.9 1.6 4.1 0.8 -0.6 0.4 -0.1
anti-XBP1 -2
anti-XBP1
anti-BATF -0.9
anti-SMAF 4.7
anti-E4BP4-2 -0.5
anti-E4BP4 10.5
anti-C/EBPy 1.0
anti-C/EBPy-2 2.4
anti-ATF4 
-0.5
anti-ATF4-2 1.5
anti-BACH-2
anti-BACH
anti-ATF2-3
anti-ZF-2
anti-CREB
anti-C/EBP-2
anti-OASIS
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protein anti-BACH- anti- anti-ATF2- anti- anti-CREB anti-C/EBP-22 BACH 3 ZF-2
C/EBPa 1.3 0.0 -1.2 -0.8 -0.4 31.8
C/EBP3 -1.0 -1.0 -1.0 -1.1 -0.8 16.9
C/EBPS 1.8 -0.5 -0.9 -1.0 -1.3 27.1
C/EBPy 1.5 0.0 2.4 -0.6 4.5 38.0
CHOP -0.4 0.2 5.2 -0.1 3.4 43.7
ATF-1 -1.3 -0.1 -0.7 -0.6 3.6 -1.0
CREB -2.1 -0.8 0.1 -1.7 3.2 -0.7
CREB-H 0.2 0.2 -0.6 -0.2 2.2 -0.1
CREB3 -0.2 -1.0 -0.1 -0.4 1.8 -1.1
ATF-6 -0.6 -1.1 -0.9 0.6 -1.0 -0.3
ZF -1.0 -1.4 3.7 2.4 -0.8 2.6
XBP-1 -0.3 -1.7 -0.8 4.8 -0.2 -1.4
E4BP4 0.0 -0.5 0.3 0.0 0.0 -2.0
ATF-2 -0.4 0.9 6.4 0.0 -0.7 0.1
ATF-7 0.1 -0.3 7.1 0.6 0.5 6.3
cJun 0.3 -0.9 2.9 1.0 1.7 0.4
JunB 0.0 -1.0 1.0 0.1 0.0 -1.1
JunD 0.3 -0.9 0.5 0.3 -1.0 -0.4
Fos 1.5 17.9 6.5 0.5 6.9 8.1
Fra2 0.2 8.8 7.0 0.7 4.6 -0.5
ATF-3 -1.7 1.6 6.6 -0.6 0.5 6.6
ATF-4 0.3 2.2 -0.7 0.7 -0.6 51.6
ATF-5 -0.7 -0.5 -1.5 -2.3 -0.7 6.0
B-ATF 0.8 2.7 3.3 -0.1 1.3 6.2
p21SNFT -0.4 2.3 6.3 0.8 8.9 19.5
TEF -1.6 -1.9 -1.2 -1.4 -1.6 -1.1
MafG 2.0 0.0 3.8 0.3 4.8 -0.2
cMaf 0.0 2.1 -0.7 0.0 -0.7 0.8
MafB -0.2 2.1 -1.1 -0.1 -1.6 -2.2
NFE2 4.4 23.0 -1.3 0.7 -0.9 -0.8
NFE2L1 2.8 1.5 -1.0 0.5 -0.4 3.0
NFE2L3 -0.8 -0.4 -1.6 -1.3 -1.6 -1.4
BACHI 2.0 11.3 -0.9 1.1 6.0 -0.8
anti-XBP1 -2
anti-XBP1
anti-BATF
anti-SMAF
anti-E4BP4-2
anti-E4BP4
anti-C/EBPy
anti-C/EBPy-2
anti-ATF4
anti-ATF4-2
anti-BACH-2 9.4
anti-BACH 5.7
anti-ATF2-3 1.9
anti-ZF-2 1.0
anti-CREB 20.1
anti-C/EBP-2 -1.0
anti-OASIS
protein anti-OASIS anti-OASIS-2 anti-C/EBPy(2) anti-SMAF(2) anti-XBP1800
C/EBPa -1.0 -0.9 0.5 -1.0 -1.9
C/EBPp 0.5 -1.2 0.0 -1.5 -1.3
C/EBPS -0.3 -1.3 1.9 -1.6 -1.8
C/EBPy 4.4 2.8 17.4 0.8 -1.0
CHOP 1.1 5.3 14.9 -0.5 -1.0
ATF-1 -1.7 -0.2 -1.0 -0.4 1.6
CREB -0.5 -1.0 -0.9 -1.1 1.2
CREB-H 1.6 2.2 -0.8 -0.2 -0.6
CREB3 5.5 5.0 -1.0 -1.7 -0.7
ATF-6 -0.4 -0.7 -0.9 -1.3 5.0
ZF -0.7 -0.1 3.0 -0.1 25.4
XBP-1 0.6 1.1 -0.6 -0.7 42.6
E4BP4 0.5 -0.2 -1.4 -1.3 -0.6
ATF-2 -0.6 -0.4 -0.6 0.1 1.1
ATF-7 -1.0 1.1 0.2 1.0 -0.9
cJun 0.6 1.4 0.2 24.8 17.6
JunB -0.2 1.2 -0.8 7.1 8.7
JunD -0.1 0.4 0.0 6.7 4.4
Fos 2.6 9.1 5.0 4.0 3.2
Fra2 0.3 6.6 2.3 0.1 4.9
ATF-3 4.4 9.5 4.0 0.6 0.2
ATF-4 0.5 -0.1 4.5 -0.1 -1.5
ATF-5 -1.0 -1.5 2.1 -0.4 -3.1
B-ATF 1.1 1.9 0.2 0.3 -0.3
p21SNFT 7.6 5.3 0.9 11.4 6.2
TEF -1.0 -1.9 -0.9 -0.5 -1.1
MafG 4.8 5.6 -0.4 47.8 1.4
cMaf -0.4 -0.1 -0.6 1.4 -0.5
MafB -2.4 0.1 -1.8 0.6 1.1
NFE2 0.1 -0.6 -0.6 13.2 4.1
NFE2L1 -0.2 -0.1 -1.1 -0.3 -0.7
NFE2L3 -1.7 -1.9 -1.4 -0.9 -2.2
BACHI 0.0 1.7 0.5 3.1 28.1
anti-XBP1 -2
anti-XBP1 
-0.2
anti-BATF
anti-SMAF 4.6
anti-E4BP4-2
anti-E4BP4
anti-C/EBPy 1.1
anti-C/EBPy-2
anti-ATF4
anti-ATF4-2
anti-BACH-2
anti-BACH
anti-ATF2-3
anti-ZF-2
anti-CREB
anti-C/EBP-2
anti-OASIS 0.0
anti-OASIS-2 -0.6
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Table B.S5. Average background-corrected fluorescence values and Sarray values from round 3
of array measurements. Peptides on the surface are in rows, those in solution in columns.
Duplicate measurements are marked with a number two in parentheses.
protein C/EBPa C/EBPS C/EBPy CHOP CREB CREB3 ATF-6 ZF
C/EBPa 13209.9 14793.7 5578.6 20538.1 -3572.9 -348.5 -1109.8 -3046.3
C/EBP 13655.8 12534.1 8038.8 43556.6 -5424.4 -835.6 -2331.6 -934.4
C/EBPS 16058.1 12662.8 11335.4 19225.8 -3982.1 127.2 -1355.0 -3096.3
C/EBPy 12621.5 18023.1 3251.3 18315.5 -547.1 3900.8 -104.8 -729.8
CHOP 18136.8 17304.7 12237.4 6192.9 998.0 5479.4 194.9 2076.3
ATF-1 -785.0 -2284.6 -380.3 -1290.3 19529.9 -1428.0 -1519.2 -1797.7
CREB -2492.4 -3500.0 -1550.3 -1430.9 24165.9 283.8 -4971.3 -5890.9
CREB-H -428.6 -70.8 622.0 -337.6 1519.8 4298.0 632.3 189.1
CREB3 -49.9 421.8 358.1 -1656.3 -774.7 4662.0 -1059.0 656.1
ATF-6 -522.0 -1049.5 -572.3 -907.7 -1652.0 -889.6 15606.4 632.4
ZF -1218.1 -1837.4 -235.3 163.5 -3134.9 -928.9 1320.9 6024.5
XBP-1 417.8 -781.4 221.0 -727.7 1185.1 -101.2 23319.6 13396.5
E4BP4 -36.6 1346.3 1344.6 -108.0 16860.4 3140.1 669.8 1191.6
ATF-2 382.4 -603.7 4215.1 1217.9 -1842.3 -465.7 -477.2 103.3
ATF-7 4210.5 3216.8 7322.9 7111.1 -72.6 829.5 4.6 2472.9
cJun 1272.0 1988.3 1500.9 1819.6 1703.1 105.6 178.6 750.7
JunB -30.3 97.2 155.3 -296.2 -207.0 -676.0 459.6 1210.4
JunD 696.9 1078.4 714.2 388.4 1006.4 -587.1 163.5 1325.3
Fos 3548.1 1704.4 2049.2 4124.7 -819.8 -32.9 282.4 1736.5
Fra2 1460.7 615.3 1240.8 1409.2 401.1 -892.9 622.8 2158.4
ATF-3 4066.0 4646.3 15836.8 8668.4 -3591.8 644.9 -1484.1 -274.0
ATF-4 35862.3 33317.2 47227.6 34394.5 -3495.4 1130.4 -2093.1 17038.3
ATF-5 12591.1 10962.6 46411.8 -1321.4 -6165.7 -2218.4 -4080.1 -3706.3
B-ATF 4399.9 7027.9 10870.6 18098.6 2221.4 2149.7 1758.4 2508.6
p21SNFT 5924.9 10041.2 6911.2 24887.8 -188.7 5459.4 868.9 2257.5
HLF 74.8 595.2 638.8 4667.8 -171.4 -455.1 -495.7 630.0
MafG 476.8 1097.2 1218.4 968.3 2225.0 536.3 1270.0 3135.9
cMaf -296.7 -885.1 -0.5 -791.0 -1619.1 -863.1 341.9 595.3
MafB -161.8 -1295.9 -127.6 -1323.4 -765.9 -1335.6 513.1 2527.3
NFE2 -385.6 -1858.9 -141.2 -1908.1 -2632.1 -499.7 -371.4 -1048.1
NFE2L1 -132.1 201.7 -588.4 -1192.3 2935.9 -20.9 -967.8 8911.4
NFE2L3 -1097.4 -1365.4 -1335.9 -1704.3 -6599.8 -2039.2 -3744.5 -2930.1
BACHI -342.9 -978.6 528.6 601.6 7603.6 486.9 2064.3 3666.3
anti-CREB-2 3426.3 565.2 1771.2 -181.0 9291.7 2176.9 349.3 166.9
anti-CREB-3 -23.7 5.9 713.6 -1002.7 10743.3 3594.4 1934.2 17.1
anti-BACH-3 655.3 -18.3 673.1 -959.1 3107.1 508.0 325.8 487.3
anti-E4BP4-3 -126.6 407.3 1406.9 -109.4 3974.3 4394.6 2146.3 82.7
anti-C/EBP 20584.4 21468.8 21568.3 20689.9 -1976.8 2616.1 -301.9 142.7
anti-C/EBP-3 10762.1 10968.4 4878.9 15697.3 658.4 -316.8 919.1 192.8
anti-NFE2-2 -858.4 -1002.6 314.7 -1011.6 586.3 -1253.9 1557.9 -379.9
anti-NFE2-3 -379.0 -1652.0 -1036.6 -2910.3 -666.1 -1247.1 -131.9 -561.9
anti-OASIS-3 5571.9 12381.3 5384.7 -373.9 3533.3 19185.3 2236.6 1671.3
anti-OASIS-4 2210.6 4412.1 4143.6 2217.6 5246.9 15999.0 3511.4 1592.1
anti-ZF 364.5 -1154.4 432.4 -2419.6 47.3 -785.5 2591.8 20271.9
anti-ATF3-3 7028.8 6925.1 11063.5 4067.0 2507.4 2810.0 3335.0 8056.2
anti-ATF2 546.8 1840.7 8594.2 9824.8 18551.5 2679.1 2197.3 4015.5
anti-ATF2-4 -199.1 20.0 8047.6 855.6 1292.8 -566.8 494.0 326.2
anti-CHOP 13367.8 10774.3 18768.4 18869.4 911.3 1352.7 278.9 1138.9
anti-ATF6 334.4 -292.1 384.5 -406.9 1419.0 -530.4 14359.4 2530.7
anti-LMAF-2 5432.4 1871.6 2815.4 2752.5 8000.9 2074.6 -306.9 1250.2
anti-LMAF-3 -54.1 -561.8 307.2 -773.5 3296.1 138.3 1234.8 355.9
anti-LMAF 140.0 266.9 70.1 -413.1 2122.3 -70.0 1108.4 398.9
anti-PAR -311.4 -792.9 646.6 -212.9 657.4 -686.9 906.9 1589.5
anti-BATF-2 3976.1 3049.8 3833.1 1992.4 1257.1 8034.4 -925.1 -1142.6
anti-BATF-3 5996.0 6996.4 5492.1 5901.9 9897.6 14557.3 -249.8 1767.6
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protein XBP-1 E4BP4 ATF-2 ATF-7 cJun Fos ATF-3 ATF-4
C/EBPa 129.1 -162.4 -1032.3 1516.3 111.4 377.0 1029.7 14649.7
C/EBPb 1921.3 -283.2 -1335.3 2728.3 -258.2 499.3 2757.1 6848.3
C/EBPS -60.3 -576.0 -1908.1 -899.8 -47.8 -583.3 3976.4 15766.3
C/B2 1940.2 3345.4 5636.9 9823.9 1301.3 2071.9 17972.9 32061.8
CHOP 2038.8 8968.4 6154.9 13037.4 3220.8 7857.4 21974.4 6802.5
ATF-1 3430.6 5915.8 -1325.4 -1590.2 -275.8 -786.3 -4065.2 -987.7
CREB 934.3 5504.4 -3179.0 -1697.4 -1443.7 -289.8 -2972.5 -2644.9
CREB-H 2412.2 3255.1 -525.4 411.6 99.6 -398.8 -791.0 1050.1
CREB3 2225.7 1811.0 -1821.5 -1421.9 -351.6 -989.3 -1796.9 52.2
ATF-6 10367.0 147.6 -1838.1 -923.7 -803.8 -1048.4 -2662.3 -727.4
ZF 13890.1 -316.2 -286.3 396.6 1033.8 307.9 -50.1 6677.3
XBP-1 23973.1 768.0 -1654.5 -695.7 637.0 -543.3 -725.4 296.8
E4BP4 2769.9 35244.4 -1527.5 -699.9 -719.6 -555.3 -1720.9 -375.8
ATF-2 3979.3 -407.3 4629.9 9622.1 6359.8 6199.7 10201.1 1436.1
ATF-7 2308.2 156.3 9273.3 13070.9 12902.2 10117.0 16814.5 5917.4
cJun 2520.0 38.9 14318.4 23433.9 4173.0 35885.9 24256.0 548.1
JunB 2247.8 -605.8 5201.8 11126.3 996.7 20803.4 16463.1 106.5
JunD 1735.1 -276.8 7661.6 17368.8 1622.3 27824.8 21844.3 333.4
Fos 586.4 59.1 7564.2 12781.3 33395.6 3086.9 1165.1 7057.3
Fra2 2269.0 -201.4 6752.6 11611.6 20026.5 4411.1 5184.6 3243.9
ATF-3 911.3 332.7 14559.4 18778.8 12797.8 3479.4 -1830.5 9263.3
ATF-4 676.3 -217.9 2658.9 10813.5 111.3 11242.1 9813.9 -762.4
ATF-5 -2361.8 -612.6 -2975.8 -1683.4 -1713.1 -2562.1 -3205.2 -2369.6
B-ATF 2099.9 2208.6 4180.8 4389.8 19465.9 543.7 6528.3 6194.4
p21SNFT 1949.1 2566.6 7246.0 9490.8 14414.6 708.8 15836.9 7807.6
HLF 3818.4 1646.7 -1209.8 47.9 876.7 11.8 -797.8 1519.9
MafG 4014.9 1596.3 -182.9 2280.9 2626.5 555.7 466.8 1875.8
cMaf 2571.5 -312.8 -563.6 -658.4 497.4 738.3 -332.1 3776.1
MafB 2993.8 -202.3 -122.6 -1806.8 580.4 3470.3 99.9 -87.4
NFE2 759.2 -358.1 -1662.3 -1152.5 -420.2 -959.6 -2428.0 654.8
NFE2LI 990.2 -607.9 158.0 796.4 -328.9 1389.7 -1961.3 4173.1
NFE2L3 -1561.1 -868.3 -3042.9 -2222.9 -1553.4 -2322.6 -4125.4 110.8
BACHI 3163.0 1691.3 4289.5 5348.3 780.0 2171.4 -1058.2 2162.1
anti-CREB-2 2697.4 1096.6 424.2 369.3 1298.6 3561.6 1454.3 456.3
anti-CREB-3 2107.1 890.6 -411.8 -338.5 4204.9 39553.5 5507.6 1247.6
anti-BACH-3 3011.6 345.1 135.9 -574.3 -152.1 12210.6 1437.3 1599.3
anti-E4BP4-3 2913.9 2975.4 -821.6 -882.1 667.8 157.0 785.3 881.2
anti-C/EBP 2680.1 2505.1 3523.8 9706.1 2582.1 -167.0 890.1 4579.3
anti-C/EBP-3 1939.4 106.0 498.1 5439.1 2067.0 5125.0 6282.2 4427.3
anti-NFE2-2 3691.9 -800.8 -873.4 -854.8 6.5 2470.0 -548.5 895.7
anti-NFE2-3 1999.2 -319.8 -2642.0 -2155.8 -321.6 1304.5 -3494.1 2187.1
anti-OASIS-3 1480.3 9622.2 2064.1 4018.5 7855.2 7248.3 8315.4 3467.0
anti-OASIS-4 2889.8 5416.1 -631.7 787.9 1174.3 2349.5 7525.4 6100.8
anti-ZF 2833.9 -148.1 -1599.1 -1240.6 2008.1 779.7 -2762.3 1801.9
anti-ATF3-3 3412.1 486.1 3243.2 4351.4 9893.5 22313.4 13766.9 16658.9
anti-ATF2 1880.0 186.9 35112.0 32055.9 6294.3 3430.3 4126.7 4296.3
anti-ATF2-4 2497.2 -639.6 3705.6 15048.9 3613.6 10982.3 10693.9 1821.9
anti-CHOP 3383.2 4315.3 6226.3 9176.3 3639.3 14943.8 16488.3 12488.0
anti-ATF6 4569.6 97.4 -870.7 -627.5 411.1 -431.6 -265.1 809.5
anti-LMAF-2 2022.6 224.6 118.0 257.3 382.1 29369.4 2351.1 2312.7
anti-LMAF-3 2795.6 1805.9 1868.6 976.4 858.2 18032.8 1970.9 1227.8
anti-LMAF 1864.8 427.8 111.4 -590.3 -90.1 7380.7 103.3 1686.0
anti-PAR 2415.1 -292.3 -1249.0 761.1 2200.0 2456.1 6404.6 2066.4
anti-BATF-2 5106.8 309.9 2781.6 4860.6 4138.9 12061.0 2702.1 5525.0
anti-BATF-3 7117.7 8465.3 8727.6 7152.7 5984.1 15295.8 5413.6 866.4
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anti-CREB- anti-CREB-protein p21SNFT HLF MafG cMaf NFE2 BACHI 2 3
C/EBPa 5212.8 -256.6 -375.6 -1249.1 -1939.3 -1975.6 -100.6 -639.7
C/EBP 6411.1 434.1 -871.7 -1005.7 -6727.1 -2369.6 47.6 -197.4
C/EBP6 10373.5 1443.1 -667.3 -4241.4 -1143.3 -2251.8 -323.1 -316.8
C/EBPy 11231.8 3209.3 247.4 -673.4 -262.3 -350.6 698.2 34.8
CHOP 31993.1 36937.2 592.2 -237.7 725.1 3533.2 1177.2 127.9
ATF-1 -3789.8 -1021.8 -267.1 -1377.4 -4343.3 1982.5 544.4 226.9
CREB -4636.8 -4761.1 -655.8 -1624.0 -11555.7 1839.4 584.4 121.3
CREB-H 1012.3 420.5 -275.0 -422.8 118.9 -818.6 355.6 263.2
CREB3 -252.7 -979.5 -140.0 -698.0 230.1 -1547.2 337.7 -18.7
ATF-6 -2853.1 -370.9 -258.3 -673.0 -2123.3 -913.5 15.4 -358.4
ZF 2208.1 -995.4 240.8 -372.1 2886.3 780.3 139.8 -231.8
XBP-1 -2151.3 60.1 -228.0 -1510.3 -1632.3 -163.9 353.7 -570.3
E4BP4 2472.8 967.2 -362.7 -1237.8 222.3 -528.4 -167.1 -321.1
ATF-2 7411.9 737.2 -593.6 -514.6 -1567.8 3863.3 -146.4 -349.9
ATF-7 11721.5 1508.9 563.6 -38.8 3279.4 5888.4 270.3 -161.8
cJun 24109.8 5642.1 30.5 -95.1 -1656.6 -733.8 863.9 1241.2
JunB 25629.1 2137.8 -247.3 -1268.8 -1216.0 -1396.6 228.3 623.3
JunD 23364.3 2556.4 -169.9 644.7 189.4 -444.9 253.8 404.9
Fos -60.8 635.2 -350.8 1058.9 -1141.3 2665.6 2360.6 34629.8
Fra2 -1136.4 1150.3 -221.8 984.3 -382.9 898.6 1440.0 18814.9
ATF-3 22942.9 1429.4 -44.7 -56.6 -5603.0 -660.1 867.3 607.8
ATF-4 23444.8 8053.4 -304.1 8585.9 -75.6 660.1 38.1 -327.7
ATF-5 5509.9 603.0 -1266.3 -1964.4 1465.5 -877.6 -65.1 -552.5
B-ATF 6636.4 14240.4 -234.8 -487.6 1713.6 4512.3 330.9 -139.5
p21SNFT 8758.2 14211.5 1927.7 -407.8 -1488.6 3238.3 2173.4 279.4
HLF 3625.3 11523.4 -213.9 -876.1 -1612.4 -144.8 134.3 -419.3
MafG 6846.1 589.3 5846.6 -51.7 21970.8 29119.6 1777.0 782.9
cMaf -1601.7 -130.6 -321.6 16013.9 -196.1 4326.8 92.4 1256.2
MafB -2949.5 -622.6 -269.8 21421.3 1380.3 11118.8 78.8 1530.8
NFE2 -3446.4 -1088.9 1234.1 -1039.0 19406.9 -1453.3 414.6 586.6
NFF2L1 -2215.3 -711.1 38564.2 811.8 2517.2 -909.4 199.8 543.4
NFE2L3 -5146.1 -3135.1 43490.9 -1371.6 22893.8 -3604.4 -190.6 -139.3
BACHI 2420.9 2250.1 16170.7 3892.6 -2251.5 2300.1 2436.3 4184.1
anti-CREB-2 6702.6 53.0 1375.8 -375.8 3324.8 4956.1 1282.3
anti-CREB-3 1344.0 -218.8 1092.4 9720.4 8723.1 24989.0 851.9
anti-BACH-3 2733.1 -486.4 -412.9 1190.9 27545.9 10812.2
anti-E4BP4-3 -1046.2 1802.5 -627.3 -881.8 1405.9 452.1
anti-C/EBP 5508.0 13048.5 -467.4 -601.2 431.2 -1633.0
anti-C/EBP-3 5786.6 11024.0 -593.9 -1586.3 2412.1 -238.1
anti-NFE2-2 -2332.3 -63.0 -604.1 2531.4 1582.0 597.3
anti-NFE2-3 -3802.4 -1928.9 -510.9 -1200.9 10107.6 -234.4
anti-OASIS-3 2813.4 434.5 11150.1 169.4 6655.1 4290.9
anti-OASIS-4 7236.8 632.5 4753.7 -560.3 5339.3 -376.8
anti-ZF -2180.6 -1486.9 -89.6 -1228.1 29940.8 766.8
anti-ATF3-3 7977.9 1679.0 17906.1 1766.5 24377.7 8858.4
anti-ATF2 27165.6 7673.7 -52.3 508.0 965.2 172.4
anti-ATF2-4 13542.9 -483.7 -113.1 -362.5 1589.6 -873.4
anti-CHOP 34189.9 19272.0 26.8 385.8 4325.9 -262.6
anti-ATF6 -1630.1 -306.2 -172.7 -373.0 1762.9 174.2
anti-LMAF-2 20609.8 7392.1 -355.6 6390.9 7589.3 5216.8
anti-LMAF-3 324.8 1829.8 9261.1 29157.9 7536.3 6535.4
anti-LMAF 624.9 -373.6 2182.6 13285.5 4396.9 4952.5
anti-PAR -2122.5 364.9 -907.8 -1596.4 -315.1 -82.4
anti-BATF-2 5226.4 415.4 8680.0 3679.1 1333.0 6845.6 -
anti-BATF-3 11336.1 5908.9 12477.3 -1994.9 11289.7 10738.5
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protein anti-BACH anti-E4BP4 anti-C/EBP anti-C/EBP. anti-NFE2- anti-NFE2- anti- anti-
3 3 3 2 3 OASIS-3 OASIS-4
C/EBPa 2143.0 174.8 19483.5 4422.2 -355.2 154.6 173.8 241.5
C/EBPZ 245.4 304.5 20832.1 1479.4 -402.3 125.0 63.8 -2135.4
C/EBP6 139.9 84.4 27624.8 4766.2 -865.6 163.5 172.4 -697.9
CEB1y 1274.4 1639.6 28736.4 2177.7 180.6 248.3 517.2 1409.9
CHOP 2534.4 3108.3 25218.6 19179.5 1.9 417.3 455.3 6441.0
ATF-1 763.9 232.3 -1572.1 -221.4 -332.4 229.2 -98.1 -1156.4
CREB 106.3 -21.8 -2865.9 -568.4 -101.0 199.1 -115.4 -256.2
CREB-H 508.1 1785.8 -599.1 -326.8 -792.2 155.1 888.4 5117.4
CREB3 -20.6 1744.7 -360.0 -420.2 -511.9 224.5 1467.8 14325.4
ATF-6 -1299.8 498.3 -555.5 -316.5 -401.5 184.8 -95.3 4.4
ZF -170.4 786.3 59.3 -330.2 -26.6 272.4 192.4 -935.0
XBP-1 -1104.3 1056.8 -653.0 -321.8 -744.3 227.2 -14.8 3068.1
E4BP4 156.8 807.4 1630.3 -259.8 -955.6 139.9 375.6 2518.8
ATF-2 912.0 201.9 11515.4 104.6 -20.0 256.7 -43.1 -981.9
ATF-7 850.2 572.3 18691.0 1781.6 90.1 292.5 146.1 292.7
dun -340.8 556.6 12588.9 297.3 -588.3 134.4 1798.6 1136.4
JunB -427.9 703.1 8170.8 -399.3 -537.7 305.0 932.6 -2125.8
JunD -224.6 635.7 10636.1 -221.4 -215.6 522.9 1178.8 -1050.4
Fos 18745.0 1533.2 415.0 1192.4 2169.0 1059.9 637.1 2170.4
Fra2 8467.4 834.7 -122.7 -6.9 1296.9 643.9 -251.7 -1659.3
ATF-3 1744.6 1092.6 5388.7 1015.4 -103.4 386.7 1449.0 7954.6
ATF-4 1385.2 596.6 19941.3 1410.6 50.6 765.7 84.5 15012.3
ATF-5 -354.7 232.8 1098.2 -226.3 -1003.9 211.5 -475.1 -802.1
B-ATF 4697.1 713.5 7386.6 847.1 -426.7 214.4 -223.8 -71.4
p21SNFT 4964.8 976.1 15339.8 1843.2 -369.8 327.7 40.9 8407.6
HLF 141.9 589.1 6304.3 2294.4 -194.3 270.6 -187.0 -264.1
MafG 397.4 %3.6 146.1 -124.4 -405.6 355.4 2598.4 5215.3
cMaf 3008.6 184.3 453.6 -357.7 4059.5 169.9 -127.3 -591.6
MafB 3523.8 339.9 -2087.1 -462.3 194.8 330.0 -100.8 -1851.6
NFE2 25614.5 280.7 -386.0 -263.9 107.9 419.8 119.8 -520.1
NFE2L1 1860.9 268.2 -793.3 -647.3 309.1 349.0 187.6 546.3
NFE2L3 -220.4 -305.9 -2198.9 -406.8 -599.0 1.2 -388.6 -2437.3
BACHI 11790.9 1573.3 52.4 -54.1 1463.1 531.9 67.6 402.4
anti-CREB-2
anti-CREB-3
anti-BACH-3 4499.4
anti-E4BP4-3 1629.3
anti-C/EBP 5673.6
anti-C/EBP-3 -398.7
anti-NFE2-2 21301.4
anti-NFE2-3 923.5
anti-OASIS-3 -964.1
anti-OASIS-4 26870.5
anti-ZF
anti-ATF3-3
anti-ATF2
anti-ATF2-4
anti-CHOP
anti-ATF6
anti-LMAF-2
anti-LMAF-3
anti-LMAF
anti-PAR
anti-BATF-2
anti-BATF-3
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protein anti-ZF anti-ATF3- anti-ATF2 anti-ATF2- anti-CHOP anti-ATF6 anti- anti-3 4 LMAF-2 LMAF-3
C/EBPt -25.4 5394.8 -1254.0 -339.6 11954.4 104.4 -48.1 -786.5
C/EBP@ -467.5 5149.2 -627.7 -46.3 13913.9 162.6 -82.8 -1109.7
C/EBP6 -22.4 5497.4 -926.5 -470.6 11357.5 124.1 -106.1 -3455.9
C/EBPY 585.6 16082.0 1131.6 3701.4 18072.4 139.3 443.0 -448.8
CHOP 71.6 7075.2 3529.8 2911.8 20927.1 165.3 1998.6 329.6
ATF-1 -144.6 -798.6 387.5 -120.4 -817.9 165.4 -186.4 -436.8
CREB -53.6 -1185.9 562.3 -406.6 -1352.9 156.6 -458.7 -397.1
CREB-H 67.8 -1645.5 -268.6 -89.8 -764.1 159.9 53.9 -831.8
CREB3 -11.3 -1139.3 -705.1 -486.4 -1661.3 158.6 -212.1 -1038.1
ATF-6 517.4 -1231.6 -906.9 -398.4 -1868.9 1466.5 -345.4 -429.8
ZF 44044.8 9265.1 248.5 255.5 626.8 964.9 585.7 -285.3
XBP-1 1180.7 -211.6 -728.6 -493.7 -2719.2 2181.1 -755.8 -2185.7
E4BP4 -45.6 -1317.8 -852.9 -796.5 117.3 148.9 -220.6 278.8
ATF-2 -94.0 2287.5 15892.6 565.5 3454.3 218.6 -24.6 13479.1
ATF-7 157.8 3166.9 24424.9 8310.8 9652.8 171.7 383.5 5741.6
cJun 2224.6 17397.1 2563.4 4664.2 4618.9 239.3 -291.6 -52.5
JunB 753.6 8353.2 831.0 1838.9 1212.8 254.3 24.0 -872.8
JunD 902.7 11596.1 301.8 1392.8 1713.2 228.3 23.6 -119.5
Fos 569.6 35039.6 -535.3 5698.4 16116.5 183.7 16476.2 35641.2
Fra2 190.6 20464.5 -1010.9 4583.8 9976.9 204.6 8672.6 31956.7
ATF-3 91.7 21730.2 535.7 5781.0 20725.1 152.9 934.6 2967.8
ATF4 832.9 43681.9 341.0 -152.4 33308.7 198.9 -123.6 -19.4
ATF-5 19.8 -504.0 -479.8 -477.9 -2248.8 96.5 -588.4 -1210.1
B-ATF 87.6 1219.1 2301.8 13.3 18218.4 190.6 11858.0 412.4
p21SNFT 719.1 7028.4 7298.4 5691.6 33126.8 222.6 6614.2 1208.6
HLF 86.3 29.3 -471.7 -252.3 3446.3 240.3 615.4 -72.4
MafG 364.8 22641.6 -119.4 266.3 -475.6 211.1 660.3 17393.2
cMaf -62.5 1309.9 -490.1 2.0 -980.2 161.7 1045.0 25571.0
MafB 71.3 -726.8 -7.1 -317.6 32.0 246.3 786.3 20431.5
NFE2 4000.7 8994.6 -1355.6 -476.6 -2691.4 177.6 495.0 2026.1
NFE2L1 415.9 10572.8 -806.2 -609.9 -2601.3 135.9 33.4 638.0
NFE2L3 322.2 -2263.1 -347.4 -890.5 -1742.6 101.5 -558.1 -2065.5
BACHI 853.4 6761.4 -802.4 -193.9 -1099.7 833.6 445.3 5196.8
anti-CREB-2
anti-CREB-3
anti-BACH-3
anti-E4BP4-3
anti-C/EBP
anti-C/EBP-3
anti-NFE2-2
anti-NFE2-3
anti-OASIS-3
anti-OASIS-4
anti-ZF 7836.2
anti-ATF3-3 10722.9
anti-ATF2 -794.4
anti-ATF2-4 -243.1
anti-CHOP 9340.5
anti-ATF6 1966.1
anti-LMAF-2 3977.4
anti-LMAF-3 20934.9
anti-LMAF
anti-PAR
anti-BATF-2
anti-BATF-3
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protein anti- anti-PAR anti-BATF anti-BATF anti- anti- anti-ZF(2)
LMAF 2 3 ATF2(2) LMAF(2)
C/EBPa -871.9 -18.8 -1112.1 -2431.1 -843.2 -306.1 -94.1
C/EBPZ -977.6 122.6 -1571.9 -2797.9 -388.2 -644.4 -206.4
C/EBPS -1595.4 -70.9 -1296.8 -254.2 -774.6 -1321.4 -49.8
C/EBPy 359.0 350.3 2470.0 142.9 1287.6 622.3 602.6
CHOP 3041.4 1427.4 1917.8 5555.9 4240.5 2871.2 35.2
ATF-1 -458.1 154.3 -1142.9 -1438.6 297.2 -182.7 -22.4
CREB -237.5 97.6 -3065.3 -6040.4 668.7 -656.1 108.4
CREB-H -748.9 -10.4 17.9 1350.9 -418.4 -441.4 87.7
CREB3 -508.4 46.7 1320.1 1984.7 -310.1 -215.8 21.0
ATF-6 -838.7 70.3 -3596.8 -3331.4 -429.6 -904.7 388.8
ZF -705.8 319.1 -403.5 1838.1 -94.3 -44.3 33820.1
XBP-1 -2027.8 71.1 -2021.0 -525.6 -264.2 -1098.0 895.4
E4BP4 -694.5 -50.6 -2017.1 -654.3 -1404.6 -696.1 -11.6
ATF-2 1278.4 173.2 1509.4 2444.4 16847.8 2267.1 10.4
ATF-7 579.2 674.0 4919.4 4116.1 22662.7 1375.7 176.6
cJun -1184.4 517.8 4791.6 3539.0 2955.0 155.3 1858.1
JunB -558.5 261.1 6590.2 5778.6 828.8 -117.3 786.9
JunD 287.6 162.3 4922.3 4002.1 947.8 439.6 755.3
Fos 10262.9 633.7 10661.9 10178.0 198.3 11654.8 431.8
Fra2 15005.8 397.6 8319.8 8848.3 207.3 14514.8 221.7
ATF-3 1006.2 2399.6 4512.6 2635.9 434.3 1915.1 78.3
ATF-4 1262.4 356.3 6632.5 4305.6 613.6 1880.6 801.8
ATF-5 183.6 -15.1 -4658.7 -954.3 -268.9 296.9 -39.9
B-ATF 0.6 324.3 7148.6 8748.6 2440.4 1211.7 115.7
p21SNFT 2773.7 439.8 7081.5 6828.0 6479.3 3476.6 605.9
HLF -497.1 280.5 -2534.9 -122.2 71.4 -466.9 48.6
MafG 6120.6 -16.5 15293.9 12396.9 70.4 6918.6 359.3
cMaf 20835.4 196.3 2919.0 -1283.5 -317.1 15396.6 11.7
MafB 24035.4 169.3 4354.2 -568.1 -463.9 19611.3 61.8
NFE2 662.8 170.0 -123.0 1418.1 -774.6 1078.1 3372.8
NFE2L1 4858.1 139.3 -1771.3 1862.2 -432.9 5059.7 432.1
NFE2L3 -1532.1 43.9 -1858.4 -3154.9 -661.6 -946.6 158.2
BACHI 8826.7 232.6 3181.9 5344.6 -213.9 8569.6 640.4
anti-CREB-2
anti-CREB-3
anti-BACH-3
anti-E4BP4-3
anti-C/EBP
anti-C/EBP-3
anti-NFE2-2
anti-NFE2-3
anti-OASIS-3
anti-OASIS-4
anti-ZF 7694.6
anti-ATF3-3
anti-ATF2 -599.8
anti-ATF2-4
anti-CHOP
anti-ATF6
anti-LMAF-2
anti-LMAF-3
anti-LMAF 2455.9 2647.3
anti-PAR 
_ 538.2 _
anti-BATF-2 -2385.7 -
anti-BATF-3 1 -823.6
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Sarray values
protein C/EBPa C/EBP6 C/EBPy CHOP CREB CREB3 ATF-6 ZF
C/EBPa 12.7 8.5 3.0 13.0 -1.3 -0.5 -0.7 -1.7
C/EBPD 13.2 7.2 4.7 27.8 -1.8 -0.9 -1.4 -0.7
C/EBPS 15.6 7.3 7.0 12.1 -1.4 0.0 -0.9 -1.7
C/EBPy 12.2 10.5 1.3 11.6 -0.4 3.6 -0.2 -0.6
CHOP 17.7 10.0 7.6 3.7 0.0 5.1 -0.1 0.6
ATF-i -1.3 -1.7 -1.2 -1.1 5.4 -1.5 -1.0 -1.1
CREB -3.0 -2.5 -2.0 -1.2 6.8 0.1 -2.7 -3.0
CREB-H -0.9 -0.4 -0.5 -0.5 0.2 4.0 0.1 -0.2
CREB3 -0.5 -0.1 -0.7 -1.3 -0.5 4.3 -0.7 0.0
ATF-6 -1.0 -1.0 -1.3 -0.8 -0.7 -1.0 7.9 0.0
ZF -1.7 -1.5 -1.1 -0.1 -1.2 -1.0 0.5 2.5
XBP-1 -0.1 -0.8 -0.8 -0.7 0.1 -0.2 11.8 5.8
E4BP4 -0.5 0.5 0.0 -0.3 4.6 2.9 0.2 0.2
ATF-2 -0.1 -0.7 2.0 0.5 -0.8 -0.6 -0.4 -0.3
ATF-7 3.7 1.6 4.2 4.3 -0.3 0.7 -0.2 0.8
cJun 0.8 0.8 0.1 0.9 0.2 0.0 -0.1 0.0
JunB -0.5 -0.3 -0.8 -0.4 -0.3 -0.8 0.1 0.3
JunD 0.2 0.3 -0.4 0.0 0.0 -0.7 -0.1 0.3
Fos 3.1 0.7 0.5 2.4 -0.5 -0.2 0.0 0.5
Fra2 1.0 0.0 -0.1 0.7 -0.1 -1.0 0.1 0.7
ATF-3 3.6 2.4 10.2 5.3 -1.3 0.5 -0.9 -0.4
ATF-4 35.4 19.7 32.2 21.9 -1.3 1.0 -1.3 7.5
ATF-5 12.1 6.2 31.6 -1.1 -2.1 -2.2 -2.3 -2.0
B-ATE 3.9 3.9 6.7 11.4 0.4 1.9 0.7 0.8
p21SNFT 5.5 5.7 3.9 15.8 -0.3 5.1 0.3 0.7
HLf -0.4 0.0 -0.5 2.8 -0.3 -0.6 -0.4 0.0
MafG 0.0 0.3 -0.1 0.4 0.4 0.4 0.5 1.1
cMaf -0.8 -0.9 -0.9 -0.8 -0.7 -0.9 0.0 0.0
MafB -0.6 -1.1 -1.0 -1.1 -0.5 -1.4 0.1 0.9
NFE2 -0.9 -1.5 -1.0 -1.5 -1.0 -0.6 -0.4 -0.8
NFE2L1 -0.6 -0.2 -1.4 -1.0 0.6 -0.1 -0.7 3.8
NFE2L3 -1.6 -1.2 -1.9 -1.3 -2.2 -2.1 -2.1 -1.6
BACHI -0.8 -0.9 -0.6 0.1 1.9 0.3 0.9 1.4
anti-CREB-2 3.0 0.0 0.3 -0.4 2.4 1.9 0.0 -0.2
anti-CREB-3 -0.5 -0.4 -0.4 -0.9 2.9 3.3 0.8 -0.3
anti-BACH-3 0.2 -0.4 -0.5 -0.9 0.6 0.4 0.0 -0.1
anti-E4BP4-3 -0.6 -0.1 0.0 -0.3 0.9 4.1 0.9 -0.3
anti-C/EBP 20.1 12.6 14.2 13.1 -0.8 2.4 -0.3 -0.2
anti-C/EBP-3 10.3 6.2 2.5 9.9 -0.1 -0.4 0.3 -0.2
anti-NFE2-2 -1.3 -1.0 -0.7 -0.9 -0.1 -1.3 0.6 -0.5
anti-NFE2-3 -0.9 -1.4 -1.7 -2.1 -0.5 -1.3 -0.2 -0.6
anti-OASIS-3 5.1 7.1 2.8 -0.5 0.8 18.1 1.0 0.5
anti-OASIS-4 1.7 2.3 2.0 1.2 1.3 15.1 1.6 0.4
anti-ZF -0.1 -1.1 -0.6 -1.8 -0.3 -0.9 1.2 9.0
anti-ATF3-3 6.6 3.8 6.8 2.4 0.5 2.5 1.5 3.4
anti-ATF2 0.1 0.7 5.1 6.1 5.1 2.4 1.0 1.5
anti-ATF2-4 -0.7 -0.3 4.7 0.3 0.1 -0.7 0.1 -0.2
anti-CHOP 12.9 6.1 12.2 11.9 0.0 1.2 0.0 0.2
anti-ATF6 -0.1 -0.5 -0.7 -0.5 0.1 -0.6 7.2 0.9
anti-LMAF-2 5.0 0.8 1.0 1.5 2.1 1.8 -0.3 0.3
anti-LMAF-3 -0.5 -0.7 -0.7 -0.7 0.7 0.0 0.5 -0.1
anti-LMAF -0.3 -0.2 -0.9 -0.5 0.4 -0.2 0.4 -0.1
anti-PAR -0.8 -0.8 -0.5 -0.4 -0.1 -0.8 0.3 0.4
anti-BATF-2 3.5 1.5 1.7 1.0 0.1 7.5 -0.7 -0.8
anti-BATF-3 5.5 3.8 2.9 3.6 2.6 13.7 -0.3 0.5
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protein XBP-1 E4BP4 ATF-2 ATF-7 cJun Fos ATF-3 ATF-4
C/EBPa -1.4 -0.6 -0.7 0.4 -0.7 -0.7 -0.1 6.7
C/EBPB -0.3 -0.8 -0.8 1.1 -1.0 -1.1 0.4 2.6
C/EBP6 -1.5 -1.3 -1.2 -0.9 -0.8 -1.1 0.8 7.3
C/EBPy -0.3 5.5 3.2 5.0 0.2 -0.1 5.3 15.9
CHOP -0.2 15.4 3.5 6.8 1.7 2.1 6.5 2.6
ATF-1 0.6 10.0 -0.8 -1.3 -1.0 -1.2 -1.8 -1.5
CREB -0.9 9.3 -1.9 -1.4 -1.9 -1.0 -1.4 -2.4
CREB-H 0.0 5.4 -0.4 -0.7 -0.7 -1.0 -0.7 -0.4
CREB3 -0.1 2.8 -1.1 -1.2 -1.0 -1.2 -1.0 -1.0
ATF-6 4.9 -0.1 -1.1 -1.0 -1.4 -1.3 -1.3 -1.4
ZF 7.0 -0.9 -0.2 -0.2 0.0 -0.8 -0.5 2.5
XBP-1 13.2 1.0 -1.0 -0.8 -0.3 -1.1 -0.7 -0.8
E4BP4 0.2 61.4 -1.0 -0.8 -1.3 -1.1 -1.0 -1.2
ATF-2 1.0 -1.0 2.7 4.9 4.1 1.4 2.8 -0.2
ATF-7 -0.1 -0.1 5.4 6.9 9.1 2.9 4.9 2.1
cJun 0.1 -0.3 8.3 12.6 2.4 12.5 7.3 -0.7
JunB -0.1 -1.4 3.0 5.8 0.0 6.9 4.8 -0.9
JunD -0.4 -0.8 4.4 9.3 0.5 9.5 6.5 -0.8
Fos -1.1 -0.2 4.4 6.7 24.7 0.3 -0.1 2.7
Fra2 -0.1 -0.7 3.9 6.0 14.5 0.8 1.2 0.7
ATF-3 -0.9 0.3 8.5 10.0 9.0 0.4 -1.0 3.9
ATF-4 -1.1 -0.7 1.5 5.6 -0.7 3.3 2.7 -1.4
ATF-5 -2.9 -1.4 -1.8 -1.4 -2.1 -1.8 -1.5 -2.2
B-ATF -0.2 3.5 2.4 2.0 14.1 -0.7 1.6 2.3
p21SNFT -0.3 4.2 4.2 4.9 10.2 -0.6 4.6 3.1
HLF 0.9 2.6 -0.8 -0.4 -0.1 -0.9 -0.7 -0.2
MafG 1.0 2.5 -0.2 0.8 1.2 -0.7 -0.3 0.0
cMaf 0.1 -0.9 -0.4 -0.8 -0.4 -0.6 -0.6 1.0
MafB 0.4 -0.7 -0.1 -1.5 -0.3 0.4 -0.4 -1.0
NFE2 -1.0 -1.0 -1.0 -1.1 -1.1 -1.2 -1.2 -0.6
NFE2L1 -0.9 -1.4 0.0 0.0 -1.0 -0.4 -1.1 1.2
NFE2L3 -2.4 -1.9 -1.9 -1.7 -1.9 -1.7 -1.8 -0.9
BACHI 0.5 2.6 2.5 2.5 -0.2 -0.1 -0.8 0.2
anti-CREB-2 0.2 1.6 -0.3 -0.2 0.2 0.5 0.0 -0.7
anti-CREB-3 -0.2 1.2 -0.3 -0.6 2.4 13.9 1.3 -0.3
anti-BACH-3 0.4 0.3 0.0 -0.8 -0.9 3.7 0.0 -0.1
anti-E4BP4-3 0.3 4.9 -0.5 -0.9 -0.3 -0.8 -0.2 -0.5
anti-C/EBP 0.2 4.1 2.0 5.0 1.2 -0.9 -0.2 1.4
anti-C/EBP-3 -0.3 -0.1 0.2 2.6 0.8 1.0 1.5 1.3
anti-NFE2-2 0.8 -1.7 -0.6 -0.9 -0.8 0.0 -0.6 -0.5
anti-NFE2-3 -0.3 -0.9 -1.6 -1.7 -1.0 -0.4 -1.6 0.2
anti-OASIS-3 -0.6 16.5 1.1 1.8 5.2 1.8 2.2 0.8
anti-OASIS-4 0.3 9.2 -0.4 0.0 0.1 0.0 1.9 2.2
anti-ZF 0.3 -0.6 -1.0 -1.1 0.8 -0.6 -1.3 0.0
anti-ATF3-3 0.6 0.5 1.8 2.0 6.8 7.5 3.9 7.8
anti-ATF2 -0.3 0.0 20.5 17.5 4.0 0.4 0.9 1.3
anti-ATF2-4 0.1 -1.4 2.1 8.0 2.0 3.2 2.9 0.0
anti-CHOP 0.6 7.2 3.6 4.7 2.0 4.7 4.8 5.6
anti-ATF6 1.3 -0.2 -0.6 -0.8 -0.4 -1.0 -0.5 -0.6
anti-LMAF-2 -0.2 0.1 0.0 -0.3 -0.5 10.1 0.3 0.2
anti-LMAF-3 0.2 2.8 1.0 0.1 -0.1 5.9 0.2 -0.3
anti-LMAF -0.3 -1.1 0.0 -0.8 -0.8 1.9 -0.4 -0.1
anti-PAR 0.0 -0.8 -0.8 0.0 0.9 0.0 1.6 0.1
anti-BATF-2 1.7 0.2 1.6 2.3 2.4 3.6 0.4 1.9
anti-BATF-3 2.9 14.5 5.1 3.6 3.8 4.8 1.3 3.7
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331
protein p21SNFT HLF MafG cMaf NFE2 BACHI anti-CREB- anti-CREB-
_ _2 2
C/EBPa 0.3 -0.5 -0.5 -0.8 -0.8 -1.5 -1.2 -1.7
C/EBP 0.5 -0.1 -1.8 -0.6 -2.0 -1.7 -0.8 -0.7
C/EBP8 1.3 0.5 -1.3 -3.4 -0.6 -1.6 -1.9 -1.0
C/EBPy 1.4 1.5 1.1 -0.3 -0.4 -0.5 1.2 -0.2
CHOP 5.4 21.3 2.0 0.1 -0.2 1.9 2.7 0.0
ATF-1 -1.4 -1.0 -0.2 -0.9 -1.4 0.9 0.7 0.2
CREB -1.6 -3.1 -1.2 -1.1 -3.2 0.8 0.9 0.0
CREB-H -0.5 -0.1 -0.3 0.0 -0.3 -0.8 0.2 0.3
CREB3 -0.7 -0.9 0.1 -0.3 -0.3 -1.2 0.1 -0.3
ATF-6 -1.2 -0.6 -0.2 -0.3 -0.9 -0.8 -0.9 -1.1
ZF -0.3 -0.9 1.1 0.0 0.4 0.2 -0.5 -0.8
XBP-1 -1.1 -0.3 -0.1 -1.0 -0.7 -0.4 0.2 -1.5
E4BP4 -0.2 0.2 -0.5 -0.8 -0.3 -0.6 -1.4 -1.0
ATF-2 0.7 0.1 -1.1 -0.1 -0.7 2.1 -1.4 -1.0
ATF-7 1.5 0.5 1.9 0.3 0.5 3.3 -0.1 -0.6
cJun 3.9 3.0 0.5 0.2 -0.7 -0.7 1.7 2.4
JunB 4.2 0.9 -0.2 -0.8 -0.6 -1.1 -0.2 1.1
JunD 3.7 1.1 0.0 0.9 -0.3 -0.5 -0.1 0.6
Fos -0.7 0.0 -0.5 1.3 -0.6 1.3 6.3 75.3
Fra2 -0.9 0.3 -0.1 1.2 -0.4 0.3 3.5 40.8
ATF-3 3.7 0.5 0.3 0.3 -1.7 -0.7 1.7 1.1
ATF-4 3.7 4.4 -0.3 7.9 -0.3 0.1 -0.8 -1.0
ATF-5 0.4 0.0 -2.8 -1.4 0.0 -0.8 -1.1 -1.5
B-ATF 0.6 8.0 -0.2 -0.1 0.1 2.5 0.1 -0.6
p21SNFT 1.0 8.0 5.4 0.0 -0.7 1.7 5.7 0.3
HLF 0.0 6.4 -0.1 -0.4 -0.7 -0.4 -0.5 -1.2
MafG 0.6 0.0 15.5 0.3 5.1 17.4 4.5 1.4
cMaf -1.0 -0.4 -0.4 14.5 -0.4 2.4 -0.6 2.5
MafB -1.2 -0.7 -0.2 19.2 0.0 6.5 -0.7 3.1
NFE2 -1.3 -1.0 3.6 -0.6 4.5 -1.2 0.3 1.0
NFE2L1 -1.1 -0.8 99.5 1.0 0.3 -0.8 -0.3 0.9
NFE2L3 -1.7 -2.2 112.1 -0.9 5.3 -2.5 -1.5 -0.6
BACHI -0.2 1.0 42.0 3.8 -0.9 1.1 6.5 8.9
anti-CREB-2 0.6 -0.3 4.0 0.0 0.5 2.7 3.0
anti-CREB-3 -0.4 -0.5 3.2 8.9 1.8 14.9 1.6
anti-BACH-3 -0.2 -0.6 -0.6 1.4 6.5 6.3
anti-E4BP4-3 -0.9 0.7 -1.2 -0.4 0.0 0.0
anti-C/EBP 0.4 7.3 -0.8 -0.2 -0.2 -1.3
anti-C/EBP-3 0.4 6.1 -1.1 -1.1 0.3 -0.4
anti-NFE2-2 -1.1 -0.4 -1.1 2.6 0.1 0.1
anti-NFE2-3 -1.4 -1.5 -0.9 -0.7 2.2 -0.4
anti-OASIS-3 -0.2 -0.1 29.1 0.5 1.3 2.3
anti-OASIS-4 0.7 0.0 12.6 -0.2 1.0 -0.5
anti-ZF -1.1 -1.2 0.2 -0.8 7.1 0.2
anti-ATF3-3 0.8 0.6 46.4 1.9 5.7 5.1
anti-ATF2 4.5 4.1 0.3 0.8 -0.1 -0.2
anti-ATF2-4 1.9 -0.6 0.2 0.0 0.1 -0.8
anti-CHOP 5.8 10.9 0.5 0.7 0.7 -0.4
anti-ATF6 -1.0 -0.5 0.0 0.0 0.1 -0.2
anti-LMAF-2 3.2 4.0 -0.5 6.0 1.5 2.9
anti-LMAF-3 -0.6 0.7 24.2 26.1 1.5 3.7
anti-LMAF -0.6 -0.6 6.0 12.1 0.8 2.7
anti-PAR -1.1 -0.1 -1.9 -1.1 -0.4 -0.3
anti-BATF-2 0.3 -0.1 22.7 3.6 0.0 3.9
anti-BATF-3 1.5 3.1 32.5 -1.4 2.5 6.3
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protein anti-BACH anti-E4BP4- anti-C/EBP anti-C/EBP. anti-NFE2- anti-NFE2- anti- anti-
3 3 3 2 3 OASIS-3 OASIS-4
C/EBPa 1.2 -1.1 8.5 20.3 -0.3 -1.0 0.1 0.1
C/EBP -0.5 -0.7 9.1 7.3 -0.5 -1.3 -0.1 -1.6
C/EBPS -0.6 -1.3 12.3 21.8 -1.5 -0.9 0.1 -0.6
C/EBP7 0.4 2.4 12.8 10.4 0.9 -0.1 0.6 0.9
CHOP 1.6 5.9 11.1 85.3 0.5 1.4 0.5 4.5
ATF-1 0.0 -0.9 -1.4 -0.2 -0.3 -0.3 -0.3 -0.9
CREB -0.7 -1.5 -2.0 -1.7 0.2 -0.6 -0.3 -0.3
CREB-H -0.3 2.8 -0.9 -0.7 -1.4 -1.0 1.2 3.5
CREB3 -0.8 2.7 -0.8 -1.1 -0.7 -0.4 2.0 10.1
ATF-6 -2.0 -0.3 -0.9 -0.6 -0.5 -0.7 -0.3 -0.1
ZF -0.9 0.4 -0.6 -0.7 0.4 0.1 0.1 -0.7
XBP-1 -1.8 1.1 -0.9 -0.7 -1.2 -0.3 -0.2 2.1
E4BP4 -0.6 0.5 0.1 -0.4 -1.7 -1.2 0.4 1.7
ATF-2 0.1 -1.0 4.7 1.2 0.4 -0.1 -0.2 -0.8
ATF-7 0.0 -0.1 8.1 8.6 0.7 0.3 0.1 0.1
cJun -1.1 -0.1 5.2 2.1 -0.9 -1.2 2.5 0.7
JunB -1.2 0.2 3.2 -1.0 -0.8 0.4 1.2 -1.6
JunD -1.0 0.0 4.3 -0.2 0.0 2.4 1.6 -0.8
Fos 16.7 2.2 -0.4 6.0 5.5 7.5 0.8 1.4
Fra2 7.1 0.5 -0.7 0.7 3.5 3.6 -0.5 -1.3
ATF-3 0.9 1.1 1.9 5.2 0.2 1.2 2.0 5.5
ATF-4 0.5 0.0 8.7 7.0 0.6 4.7 0.0 10.5
ATF-5 -1.1 -0.9 -0.1 -0.2 -1.8 -0.5 -0.9 -0.7
B-ATF 3.6 0.2 2.8 4.5 -0.5 -0.5 -0.5 -0.1
p21SNFT 3.9 0.9 6.5 8.9 -0.4 0.6 -0.1 5.9
HLF -0.6 -0.1 2.3 10.9 0.0 0.1 -0.4 -0.3
MafG -0.4 0.8 -0.6 0.2 -0.5 0.9 3.7 3.6
cMaf 2.1 -1.0 -0.8 -0.8 9.8 -0.9 -0.3 -0.5
MafB 2.5 -0.7 -1.6 -1.3 0.9 0.6 -0.3 -1.4
NFE2 23.1 -0.8 -0.8 -0.4 0.7 1.5 0.0 -0.5
NFE2L1 1.0 -0.8 -1.0 -2.1 1.2 0.8 0.1 0.3
NFE2L3 -1.0 -2.2 -1.7 -1.0 -0.9 -2.5 -0.7 -1.8
BACHI 10.2 2.3 -0.6 0.5 3.8 2.5 -0.1 0.2
anti-CREB-2
anti-CREB-3
anti-BACH-3 3.4
anti-E4BP4-3 2.4
anti-C/EBP 2.0
anti-C/EBP-3 -1.0
anti-NFE2-2 49.6
anti-NFE2-3 6.2
anti-OASIS-3 -1.6
anti-OASIS-4 18.9
anti-ZF
anti-ATF3-3
anti-ATF2
anti-ATF2-4
anti-CHOP
anti-ATF6
anti-LMAF-2
anti-LMAF-3
anti-LMAF
anti-PAR
anti-BATF-2
anti-BATF-3
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protein anti-ZF anti-ATF3- anti-ATF2 anti-ATF2- anti-CHOP anti-ATF6 anti- anti-
3 4 IMAF-2 LMAF-3
C/EBPa -0.8 0.0 -1.8 -0.9 3.8 -1.7 -0.2 -0.6
C/EBP@ -2.7 -0.1 -0.6 0.2 4.5 -0.4 -0.3 -0.8
C/EBP8 -0.8 0.0 -1.2 -1.4 3.6 -1.3 -0.4 -2.7
C/EBPy 1.7 1.9 2.8 14.3 6.0 -0.9 1.1 -0.3
CHOP -0.4 0.3 7.4 11.3 7.1 -0.4 5.3 0.3
ATF-1 -1.3 -1.1 1.3 -0.1 -0.8 -0.3 -0.6 -0.3
CREB -0.9 -1.2 1.7 -1.1 -1.0 -0.6 -1.4 -0.3
CREB-H -0.4 -1.3 0.1 0.1 -0.8 -0.5 0.0 -0.6
CREB3 -0.8 -1.2 -0.8 -1.4 -1.1 -0.5 -0.7 -0.8
ATF-6 1.4 -1.2 -1.2 -1.1 -1.2 29.4 -1.1 -0.3
ZF 181.7 0.7 1.1 1.4 -0.3 17.9 1.5 -0.2
XBP-1 4.2 -1.0 -0.8 -1.5 -1.5 45.7 -2.2 -1.7
E4BP4 -0.9 -1.2 -1.1 -2.6 -0.5 -0.7 -0.7 0.2
ATF-2 -1.1 -0.6 31.3 2.5 0.7 0.9 -0.2 10.5
ATF-7 -0.1 -0.4 47.8 31.5 3.0 -0.2 0.9 4.5
cJun 8.5 2.1 5.6 17.9 1.1 1.3 -0.9 0.0
JunB 2.4 0.5 2.2 7.3 -0.1 1.7 -0.1 -0.7
JunD 3.0 1.1 1.2 5.6 0.1 1.1 -0.1 -0.1
Fos 1.6 5.2 -0.4 21.7 5.3 0.1 44.5 27.7
Fra2 0.1 2.7 -1.4 17.6 3.1 0.5 23.3 24.8
ATF-3 -0.3 2.9 1.6 22.0 7.0 -0.6 2.4 2.3
ATF-4 2.7 6.8 1.3 -0.2 11.6 0.4 -0.5 0.0
ATF-5 -0.6 -1.1 -0.3 -1.4 -1.3 -1.9 -1.7 -0.9
B-ATF -0.4 -0.7 5.0 0.4 6.1 0.2 32.0 0.3
p21SNFT 2.3 0.3 14.7 21.7 11.5 1.0 17.8 1.0
HLF -0.4 -1.0 -0.3 -0.6 0.7 1.4 1.5 0.0
MafG 0.8 3.0 0.4 1.4 -0.7 0.7 1.7 13.5
cMaf -1.0 -0.7 -0.4 0.4 -0.9 -0.4 2.7 19.9
MafB -0.4 -1.1 0.6 -0.8 -0.5 1.5 2.0 15.9
NFE2 15.8 0.6 -2.0 -1.4 -1.5 -0.1 1.2 1.6
NFE2L1 1.0 0.9 -1.0 -1.9 -1.5 -1.0 0.0 0.5
NFE2L3 0.6 -1.4 -0.1 -2.9 -1.2 -1.8 -1.6 -1.6
BACHI 2.8 0.2 -1.0 -0.3 -0.9 14.9 1.1 4.1
anti-CREB-2
anti-CREB-3
anti-BACH-3
anti-E4BP4-3
anti-C/EBP
anti-C/EBP-3
anti-NFE2-2
anti-NFE2-3
anti-OASIS-3
anti-OASIS-4
anti-ZF 31.7
anti-ATF3-3 0.9
anti-ATF2 -0.9
anti-ATF2-4 -0.5
anti-CHOP 2.9
anti-ATF6 40.8
anti-LMAF-2 10.6
anti-LMAF-3 16.3
anti-LMAF
anti-PAR
anti-BATF-2
anti-BATF-3
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protein anti- anti-PAR anti-BATF anti-BATF anti- anti- anti-ZF(2)
LMAF 2 3 ATF2(2) LMAF(2)
C/EBPa -0.9 -1.4 -0.7 -1.2 -1.7 -0.8 -1.5
C/EBP6 -1.0 -0.4 -0.9 -1.3 -0.7 -1.1 -2.1
C/EBPS -1.5 -1.7 -0.8 -0.5 -1.5 -1.7 -1.2
C/EBPy 0.1 1.3 0.3 -0.4 2.6 0.1 2.5
CHOP 2.4 9.0 0.1 1.1 8.4 2.1 -0.7
ATF-i -0.6 -0.1 -0.7 -0.9 0.6 -0.7 -1.1
CREB -0.4 -0.5 -1.3 -2.2 1.4 -1.1 -0.3
CREB-H -0.8 -1.3 -0.4 -0.1 -0.8 -0.9 -0.5
CREB3 -0.6 -0.9 0.0 0.1 -0.6 -0.7 -0.8
ATF-6 -0.9 -0.7 -1.4 -1.4 -0.8 -1.3 1.3
ZF -0.8 1.1 -0.5 0.1 -0.2 -0.5 190.4
XBP-1 -1.9 -0.7 -1.0 -0.6 -0.5 -1.5 4.1
E4BP4 -0.8 -1.6 -1.0 -0.7 -2.8 -1.1 -1.0
ATF-2 0.9 0.0 0.0 0.2 33.5 1.6 -0.9
ATF-7 0.3 3.6 1.0 0.7 45.0 0.8 0.1
cJun -1.2 2.5 1.0 0.5 5.9 -0.3 9.6
JunB -0.7 0.6 1.5 1.2 1.7 -0.6 3.5
JunD 0.0 -0.1 1.0 0.7 1.9 -0.1 3.3
Fos 8.4 3.3 2.6 2.4 0.4 10.1 1.5
Fra2 12.4 1.6 2.0 2.1 0.4 12.7 0.3
ATF-3 0.6 16.0 0.9 0.3 0.9 1.3 -0.5
ATF-4 0.9 1.3 1.5 0.8 1.2 1.2 3.6
ATF-5 0.0 -1.3 -1.7 -0.7 -0.5 -0.2 -1.2
B-ATF -0.2 1.1 1.6 2.0 4.9 0.6 -0.3
p21SNFT 2.1 1.9 1.6 1.5 12.9 2.7 2.5
HLE -0.6 0.8 -1.1 -0.5 0.2 -0.9 -0.7
MafG 4.9 -1.4 4.0 3.1 0.2 5.8 1.1
cMaf 17.3 0.2 0.4 -0.8 -0.6 13.5 -0.9
MafB 20.0 0.0 0.8 -0.6 -0.9 17.4 -0.6
NFE2 0.4 0.0 -0.4 -0.1 -1.5 0.5 18.1
NFE2LI 3.9 -0.2 -0.9 0.1 -0.8 4.1 1.5
NFE2L3 -1.5 -0.9 -0.9 -1.4 -1.3 -1.3 -0.1
BACHI 7.2 0.4 0.5 1.1 -0.4 7.3 2.7
anti-CREB-2
anti-CREB-3
anti-BACH-3
anti-F4BP4-3
anti-C/EBP
anti-C/EBP-3
anti-NFE2-2
anti-NFE2-3
anti-OASIS-3
anti-OASIS-4
anti-ZF 42.6
anti-ATF3-3
anti-ATF2 
-1.2
anti-ATF2-4
anti-CHOP
anti-ATF6
anti-LMAF-2
anti-LMAF-3
anti-LMAF 1.9 1.9
anti-PAR 2.6
anti-BATF-2 -1.1
anti-BATF-3 I 1 -0.7
336
Table B.S6. Calculated Sarray scores for the complete set of 33 human bZIP measurements.
Peptides on the surface are in rows, those in solution are in columns.
Protein C/EBPa C/EBPb C/EBPd C/EBPg CHOP ATF-1 CREB CREB- CREB3
C/EBPa 9.2 13.9 11.6 5.9 9.7 -1.1 -1.8 0.4 0.7
C/EBPb 4.3 6.6 3.6 4.7 17.1 -1.8 -2.1 0.1 -0.5
C/EBPd 10.7 17.3 10.3 8.5 9.9 -1.4 -2.3 -0.7 2.4
C/EBPg 5.1 12.1 11.5 1.0 8.6 -0.5 -0.1 -0.6 3.0
CHOP 14.7 34.5 16.1 20.1 2.5 0.8 0.5 1.7 6.8
ATF-1 -1.0 -1.6 -1.5 -1.2 -1.3 12.3 9.2 -2.2 -1.9
CREB -2.1 -2.6 -2.2 -1.9 -1.5 20.9 14.0 9.6 0.1
CREB-H -0.8 -1.3 -1.3 -0.5 -1.5 1.7 1.7 7.9 7.6
CREB3 0.3 -0.2 0.2 -0.4 -0.4 -1.1 -0.7 3.5 2.9
ATF-6 -1.6 -1.4 -1.3 -1.2 -1.5 -0.7 -0.6 -0.2 -1.9
ZF -1.3 -1.4 -2.2 -1.0 -1.7 -1.3 -1.4 0.0 -2.0
XBP-1 -3.4 -1.3 -2.9 -1.8 -2.6 1.1 1.4 -0.5 -2.3
E4BP4 -0.6 -0.2 -0.4 -0.6 -0.5 15.6 11.4 3.0 5.9
ATF-2 0.9 0.3 -0.8 3.6 0.8 -1.1 -0.7 -0.8 -0.5
ATF-7 2.4 3.7 0.8 5.2 3.0 -0.7 -0.4 -0.1 0.7
cJun -0.3 1.5 0.6 0.7 0.2 1.2 1.7 0.1 0.0
JunB 0.5 0.2 0.2 -0.7 0.0 -0.5 -0.3 -2.8 -1.4
JunD 0.0 0.3 0.4 0.0 -0.6 -0.2 -0.1 -0.7 -0.6
Fos 2.0 0.1 0.7 1.7 1.6 1.0 0.3 0.5 0.8
Fra2 -1.0 -1.6 -1.7 -1.4 0.0 0.5 0.7 -0.9 -1.2
ATF-3 1.8 6.8 1.2 14.0 5.9 -0.4 -1.0 0.6 1.7
ATF-4 23.4 12.6 13.1 23.2 10.4 -0.7 -1.0 1.2 1.1
ATF-5 4.2 0.3 3.1 23.2 -1.8 -2.8 -4.0 -1.6 -1.7
B-ATF 2.2 7.3 2.3 9.5 6.9 1.1 1.6 0.3 3.9
p21SNFT 1.7 5.7 4.1 4.6 9.6 -1.2 -0.3 1.2 6.9
HLF -0.4 0.1 -0.4 -0.9 1.0 -0.5 -0.9 0.2 -0.4
MafG -0.3 -0.5 -0.1 -0.4 0.2 0.9 1.2 -1.6 1.0
cMaf -1.0 -0.9 -1.9 -0.9 -1.4 0.2 0.4 -0.5 -1.4
MafB -2.7 -2.1 -2.5 -1.4 -2.3 0.1 0.5 -0.7 -2.5
NFE2 -1.2 -1.4 -1.8 -1.0 -1.2 -0.6 -0.9 -0.6 -0.3
NFE2L1 -1.2 -2.6 -0.9 -2.9 -2.8 2.0 2.3 -0.8 0.5
NFE2L3 -0.9 -2.7 -1.1 -1.3 -1.6 -3.0 -2.2 0.0 -1.2
BACH1 0.0 -0.6 -0.9 0.5 -0.3 6.4 5.6 -0.1 0.5
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Protein ATF-6 ZF XBP-1 E4BP4 ATF-2 ATF-7 cJun JunB
C/EBPa -0.8 -1.8 -1.3 0.5 -0.1 1.2 0.5 -0.6
C/EBPb -0.5 -1.6 0.8 -0.9 -0.4 1.6 -0.1 -0.2
C/EBPd -1.3 -3.1 -2.7 0.1 -1.4 -1.0 -0.4 -1.7
C/EBPg 0.4 -1.5 0.0 1.6 2.2 5.8 -0.1 0.1
CHOP 0.6 1.2 0.0 10.6 5.1 8.5 1.8 4.0
ATF-1 -0.7 -1.5 1.6 4.2 -1.3 -1.4 -0.6 -0.6
CREB -3.7 -4.5 1.0 4.1 -3.6 -1.9 -1.8 -2.2
CREB-H 0.8 -0.8 0.7 4.7 -0.4 -1.1 -0.6 -0.3
CREB3 -0.4 0.2 -0.3 0.2 -0.6 -1.3 -0.2 -1.1
ATF-6 12.3 0.9 13.0 -0.5 -1.6 -1.9 -1.7 -1.1
ZF 1.4 15.4 24.1 0.4 -1.2 -0.2 0.5 0.8
XBP-1 19.0 17.8 39.6 -1.1 -1.7 -1.6 -0.7 -0.2
E4BP4 0.7 -0.1 -0.1 39.8 -1.8 -1.8 -0.4 -0.5
ATF-2 -0.6 -0.3 1.5 -2.2 3.0 4.1 6.2 5.5
ATF-7 -0.1 1.0 0.0 -0.5 4.2 6.8 14.5 6.9
cJun -0.1 0.1 0.1 -0.1 12.4 17.4 4.2 1.4
JunB 0.2 0.4 -0.7 -1.1 3.5 6.2 0.4 -0.5
JunD 0.2 0.2 -0.3 -0.8 6.6 11.7 0.6 -0.3
Fos -0.4 1.8 -0.3 0.7 5.1 8.8 37.4 31.4
Fra2 0.5 0.3 0.4 -0.3 5.4 6.8 22.6 21.3
ATF-3 0.0 -0.7 2.0 0.9 7.8 12.3 10.8 12.2
ATF-4 -2.0 10.9 -1.0 -1.0 0.3 1.9 -1.1 -1.4
ATF-5 -2.8 -2.9 -2.3 -1.8 -2.6 -3.0 -3.4 -3.4
B-ATF 1.2 0.8 -0.3 3.0 2.4 1.6 20.2 26.8
p21SNFT 0.0 1.7 -0.2 3.0 4.1 5.5 17.4 18.7
HLF -1.1 0.1 0.0 0.9 -1.5 -1.7 -0.9 0.1
MafG -0.5 0.5 1.1 2.2 0.2 0.4 1.4 2.3
cMaf -0.1 -0.8 -1.0 -0.7 -0.4 -1.6 -0.4 0.8
MafB -0.1 0.8 0.7 -0.6 -0.6 -1.7 -0.9 0.5
NFE2 0.6 -0.3 -0.4 -0.7 -1.2 -2.0 -1.8 -1.6
NFE2L1 -0.6 19.8 -0.9 -2.5 0.0 0.5 -2.8 -1.3
NFE2L3 -2.8 -2.3 -2.1 -0.6 -2.3 -2.0 -2.2 -2.5
BACH1 2.9 3.8 2.9 1.2 2.7 2.1 0.1 1.1
338
Protein JunD Fos Fra2 ATF-3 ATF-4 ATF-5 B-ATF p21 SNFT
C/EBPa -0.2 0.7 -0.2 0.7 12.8 1.2 1.7 1.6
C/EBPb -0.5 -0.7 -0.1 1.3 4.9 0.1 3.4 1.3
C/EBPd -1.6 -0.2 0.0 1.6 16.5 0.7 3.4 4.1
C/EBPg 0.2 0.0 2.0 9.3 23.3 18.1 8.0 3.6
CHOP 3.5 8.8 11.7 11.5 11.0 -0.6 28.1 9.5
ATF-1 -1.0 -1.3 -1.0 -1.5 -1.4 -0.4 -0.6 -2.2
CREB -3.3 -2.3 -2.6 -2.8 -3.4 -2.3 -0.8 -3.4
CREB-H -1.0 -0.3 -0.7 -0.4 -1.3 0.3 -0.7 -0.8
CREB3 -0.4 -0.9 -1.4 0.2 0.2 0.0 -0.5 -0.1
ATF-6 -1.3 -1.9 -1.2 -1.7 -1.4 -0.4 -0.8 -2.4
ZF 0.5 -0.5 -0.4 -0.8 2.2 -0.6 -0.9 -1.0
XBP-1 -0.1 -1.3 -0.9 -1.9 -2.1 -1.4 -1.5 -2.5
E4BP4 -1.1 -1.8 -0.9 -0.4 -1.3 -1.5 -1.0 -0.1
ATF-2 6.2 5.3 8.5 5.6 0.4 -0.1 0.8 2.2
ATF-7 10.5 8.6 17.1 7.5 2.9 -1.2 0.5 2.8
cJun 1.3 44.9 76.8 13.1 -1.4 -0.8 25.9 6.9
JunB 0.0 29.1 38.0 6.4 -0.7 0.0 16.5 6.0
JunD -0.3 37.2 51.3 9.3 -1.4 -0.5 21.6 6.4
Fos 32.3 2.9 2.9 1.2 4.5 0.5 -0.5 -0.8
Fra2 23.7 3.6 1.2 2.3 0.1 -0.6 -2.0 -1.8
ATF-3 11.2 3.3 6.6 -0.2 6.1 -0.7 1.5 7.0
ATF-4 -1.6 5.4 1.0 3.9 -1.9 -0.5 2.9 2.9
ATF-5 -3.4 -3.1 -1.6 -2.5 -1.8 -1.6 0.3 0.7
B-ATF 26.7 -0.3 -2.0 2.0 3.0 2.2 -0.2 0.8
p21SNFT 16.5 0.2 0.4 7.5 3.9 1.0 1.1 2.2
HLF -1.1 -1.5 -1.2 -1.7 -0.4 -0.7 1.0 -0.5
MafG 1.8 1.3 -1.0 0.0 -0.1 0.6 -0.8 1.1
cMaf 0.2 0.2 -0.4 -0.6 3.5 -0.3 -0.9 -2.0
MafB 0.6 3.1 2.8 -0.6 -1.4 -1.0 -0.7 -2.0
NFE2 -1.7 -1.4 -1.1 -1.5 -0.6 -0.2 -1.8 -2.5
NFE2L1 -0.8 0.7 0.2 -1.7 4.2 0.2 -1.2 -1.4
NFE2L3 -2.6 -2.9 -2.0 -2.3 -1.0 -0.9 -0.8 -2.7
BACH1 1.4 1.8 1.0 -0.3 0.2 1.3 0.4 -0.1
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Protein HLF MafG cMaf MafB NFE2 NFE2L1 NFE2L3 BACH1
C/EBPa 0.0 -0.6 -0.4 -0.7 0.0 1.5 0.5 -0.7
C/EBPb -0.4 -0.2 -0.2 -0.3 -1.0 -1.2 -0.7 -1.7
C/EBPd -0.8 -0.4 -1.5 -2.2 -0.1 0.3 -0.1 -2.4
C/EBPg 0.2 0.0 -0.4 -0.2 -1.0 -1.2 0.6 -1.3
CHOP 23.8 1.3 -0.8 0.1 0.4 -0.5 -0.5 5.8
ATF-1 -1.4 -0.2 0.1 -0.3 -0.8 -0.8 -1.0 2.3
CREB -3.1 -2.0 -0.9 -2.0 -2.9 -1.5 -4.2 2.6
CREB-H -1.3 -0.2 -0.9 -0.6 0.4 -0.4 0.5 -1.9
CREB3 -0.3 -0.1 0.2 -0.1 0.4 -0.6 -0.1 -1.3
ATF-6 -1.6 -0.4 -2.1 -1.9 -1.2 -3.9 -2.5 -2.1
ZF -1.4 0.2 0.0 0.3 7.8 25.5 0.1 2.5
XBP-1 -1.8 -0.3 -1.3 -2.1 -2.4 -2.7 -0.9 -1.8
E4BP4 -0.5 0.4 -0.6 -0.3 -1.1 -1.8 0.0 0.1
ATF-2 0.6 0.1 0.7 1.1 -0.1 2.7 -0.6 6.3
ATF-7 0.6 0.4 0.0 0.2 3.9 6.5 0.9 9.2
cJun 2.7 -0.4 0.2 0.0 -2.4 -0.8 0.0 -0.3
JunB 1.1 -0.8 0.4 -0.1 -0.7 -1.6 -0.1 0.3
JunD 1.5 -0.2 -0.9 -0.3 -0.9 -0.7 -0.1 -0.6
Fos 1.2 0.4 1.4 6.3 -0.3 5.2 1.0 4.7
Fra2 0.4 0.2 -0.4 4.4 -1.1 1.1 -0.6 1.3
ATF-3 0.8 0.5 0.4 3.5 -0.7 -1.2 -2.0 -0.2
ATF-4 3.0 -0.3 5.6 0.5 0.6 17.6 5.5 0.1
ATF-5 -0.2 -3.2 -0.9 -2.2 1.5 0.5 -2.0 0.4
B-ATF 8.3 0.1 -2.2 0.2 0.6 4.1 1.7 5.1
p21SNFT 8.2 2.0 -0.5 0.7 -1.0 0.6 -0.5 2.5
HLF 1.9 -1.0 -1.1 -2.3 -0.3 -0.9 -0.4 -0.3
MafG -1.4 3.7 -0.5 0.4 21.3 36.1 71.6 41.6
cMaf -1.4 -0.1 16.3 13.3 -0.7 3.9 1.1 6.9
MafB -2.4 -0.6 15.7 8.2 -0.1 5.2 0.0 12.7
NFE2 -1.5 1.2 -0.7 -0.4 37.6 -0.4 22.3 -1.4
NFE2L1 -0.8 38.2 0.7 2.2 3.4 4.4 0.7 -0.7
NFE2L3 -2.3 46.4 -0.4 -1.2 33.0 -1.9 1.1 -2.4
BACH1 1.8 18.1 5.9 10.3 -0.5 0.8 0.2 3.9
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APPENDIX C
Supplementary Information for "A synthetic coiled-coil interactome
provides heterospecific modules for molecular engineering"
Reproduced with permission from:
Reinke AW, Grant RA, Keating AE. A synthetic coiled-coil interactome provides heterospecific
modules for molecular engineering. J Am Chem Soc. 2010 May 5;132(17):6025-31.
Collaborator notes:
Robert Grant helped in solving the two SYNZIP crystal structures.
SUPPLEMENTARY EXPERIMENTS
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SYNZIP peptides
SYNZIP1* NLVAQLENEVASLENENETLKKKNLHKKDLIAYLEKEIAJLRKKIEE
SVNZIP2* ARNAYLRKKIARLKKDNLQLERDEQNLEKIIANLRDEIARLENEVASHEQ
SYNZIP3* NEVTTLENDAAFIENENAYLEKEIARLRKEKAALRNRLAHKK
SYNZIP4* QKVAELKNRVAVKLNRNEQLKNKVEELKNRNAYLKNELATLENEVARLENDVAE
SYNZIPS* NTVKELKNYIQELEERNAELKNLKEHLKFAKAELEFELAAHKFE
SYNZIP6* QKVAQLKNRVAYKLKENAKLENIVARLENDNANLEKDIANLEKDIANLERDVAR
SYNZIP7* KEIEYLEKEIERLKDLREHLKQDNAAHRQELNALRLEEAKLEFILAHLLST
SYNZIP8* KEIANLEKEIASLEKKVAVLKQRNAAHKQEVAALRKEIAYVEDEIQYVEDE
SYNZIP9* QKVESLKQKIEELKQRKAQLKNOIANLEKEIAYAET
SYNZIP1O* NLLATLRSTAAVLENENHVLEKEKEKLRKEKEQLLNKLEAYK
SYNZIP11* ELTDELKNKKEALRKDNAALLNELASLENEIANLEKEIAVFK
SYNZIP12* NEDLVLENRLAALRNENAALENDLARLEKEIAYLEKEIEREK
SYNZIP13* QKVEELKNKIAELENRNAVKKNRVAHLKQEIAYLKDELAAHEFE
SYNZIP14* NDLDAYEREAEKLEKKNEVLRNRLAALENELATLRQEVASMKQELQS
SYNZIP15* FENVTHEFILATLENENAKLRRLEAKLERELARLRNEVAWL
SYNZIP16* NILASLENKKEELKKLNAHLLKEIENLEKEIANLEKEIAVFK
SYNZIP17* NEKEELKSKKAELRNRIEQLKQKREQLKQKIANLRKEIEAYK
SYNZIP18* S1AATLENDLARLENENARLEKDIANLERDLAKLEREEAYF
SYNZIP19* NELESLENKKEELKNRNEELKQKREQLKQKLAALRNKLDAYKNRL
SYNZIP2O* STVEELLRAIQELEKRNAELKNRKEELKNLVAHLRQELAAHKYE
SYNZIP21* NEVAQLENDVAVIENENAYLEKEIARLRKEIAALRDRLAHKK
SYNZIP22* KRIAYLRKKIAALKKDNANLEKDIANLENEIERLIKEIKTLENEVASHEQ
SYNZIP23* ALRAELKAKIALLRADNWALKRKAKDLRRLLRRLRNKAEELK
SYNZIP24 QKLQTLRDLLAVLENRNQELKQLRQHLKDLLKYLEDELATLEKF
SYNZIP25 NETEQLINKKEQLKNDNAALEKDAASLEKEIANLEKEIAYFK
SYNZIP26 EKIQELKRRLAYFRRENATLKNDNATLENELASVEAENEALRK
SYNZIP27 QKIQYLKQRIAELRKKIANLRKDIANLEJDAAVKEDELVHL
SYNZIP28 EKIEYLKDRIAELRSKIAALRNDLTHLKNDKAHKENELAHLA
SYNZIP29 NDIENLKDKIEELKQRKEELKQKIEYLKQKIEALRQKLAALKQRIA
SYNZIP30 EKIEELKDKIAELRSRNAALRNKIEALKQKLEALRQKIEYLKDRIA
SYNZIP31 AENQWVEDLIQYLEKENARLKKEVQRLVRELSYFRRRIAELA
SYNZIP32 AENQSVEDIIAKKEDENAHLKNEVKTLINELETLRKKIEYLA
SYNZIP33 RDLQNVEREIQSLEKKNESLKKKIASLENELATLKQEIAYFKRELAY
SYNZIP34 DRLAVKENRVAVLKNENAKLRNIIANLKDRIAVFRRELAYLELEEEQLA
SYNZIP35 NKVEQLKNKVEQLKNRNAALKNDLARLEREIAYAEE
SYNZIP36 EKNQELKNRLAVLENDNAALRNOLARLEREIAYMiE
SYNZIP37 KDIANLKKEIAHLKNDLQRLESIRERLKFDILNHEQEEYALE
SYNZIP38 NKNETLKNINARLRNDVARLKNRIARLKDDIENVEDEIQYLE
SYNZIP39 LENAQIKKEIAQLRKEVAQLKQKIEELKNDNARVEREIQYLE
SYNZIP40 QKRQQLKQKLAALRRDIENLQDEIAYKEDEIANLKDKIEQLLS
SYNZIP41 QKIESLKDKLANKRDKIALLRSEVASFEKEIAYLEKEIANLEN
SYNZIP42 EKIEVLKDKLAHKRNEVAQLRKEVTHKVDELTSLENEVAQLLK
SYNZIP43 QKVEQLKNKVEQKLKENESLENKVAELKNRNEYLKNKIENLINDIThLENDVAR
SYNZIP44 QKVAQLKNIIAKKEDENAVLENLVAVLENENAYLEKELARLERDIARAERDVKV
SYNZIP45 NRLQELENKNEVLEKRKAELRNEVATLEQEL.AAHRYELAAIEKEIA
SYNZIP46 KEIERLEKEIKTLINLLTTLRQDNAAHRKEAAALEKEEANLERDIQNLLRY
SYNZIP47 SKYDALRNKLEALKNRNAQLRKENEQLRLEEAVLEVRNEVL
SYNZIP48 QKIAYLRDRIAALKAENEALRAKNEALRSKIEELKKEKEELRDKIAQKKDR
Human peptides
BATF* QKADTLHLESEDLEKQNMALRKEIKQLTEELKVFTSVLNSHE
FOS* ELTDTLQAETDQLEDEKSALQTEIANLLKEKEKLEFILAAHR
ATF4* AEQEALTGECKELEKKNEALKERADSLAKEIQYLKDLIEEVRKARGKKRV
ATF3 EKTECLQKESEKLESVNAELKAQIEELKNEKQHLIYMLNLHR
BACHi DCIQNLESEIEKLQSEKESLLKERDHILSTLGETKQNLTGL
JUND ERISRLEEKVKTLKSQNTELASTASLLREQVAQLKQKVLSHV
NFE2L3 DIILNLEDDVCNLQAKKETLKREQAQCNCAINIMK KLHDL
BHeptad fgabcdefgabcdefgabcdefgabcdefgabcdefgabcdefgabcdefgabc
W eg aa e
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Figure C.S 1. Sequences and sequence features of the 55 peptides measured. (A) Multiple-sequence
alignment of the coiled-coil regions of the 55 peptides. Sequences start at an f position. Positions are
colored as follows: b, c, and f positions (black), g (orange), a (blue), d (green), and e (purple). Peptides
that form at least one hetero-specific interaction are indicated with an asterisk. (B) Sequence logo
constructed using a, d, e, and g positions of the first 5 heptads of each peptide. See (Grigoryan, et al.
2009) for details. Sequence logo created with http://weblogo.berkeley.edu/ (Crooks, et al. 2004).
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SYNZJP1
SYNZIP2
SYNZIP3
SYNZIP4
SYNZIP5
SYNZIP6
SYNZIP7
SYNZIPS
SYNZIP9
SYNZIP1O
SYNZIP11
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Figure C.S2. Array measurements for all 55 peptides. Peptides printed on the surface are listed in rows,
and fluorescently labeled peptides in solution are listed in columns. Color indicates the strength of the
array fluorescence signal, given as arrayscore values (see Methods) according to the color bar with 0
(black) indicating the strongest signal and >1 (white) indicating the weakest.
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0 0.2 0.4 0.6 0.8 1
arrayscore
experiment #1
Figure C.S3. Reproducibility of the array experiments. Five solution probes measured in separate
experiments are shown as a scatter plot. Arrayscore values >1 are set to 1. Blue, SYNZIP5 (R2.9)
Orange, SYNZIP6 (R2=.99). Teal, SYNZIP37 (R2=.91). Red, FOS (R2=.95). Green, A TF4 (R2=9)
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Figure C.S4. CD spectra for heterospecific pair SYNZIP6 + SYNZIP5. The mixture of SYNZIP5 with
SYNZIP6 (4 pM each peptide) is in green. SYNZIP6 alone (4 pM) is in blue, SYNZIP5 alone (4 pM) is
in red.
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Figure C.S5. CD-monitored thermal melts of peptide pairs that form orthogonal sets. (A) Isolated
peptides. ATF4-2 (green), SYNZIPl (blue), SYNZIP3 (purple), SYNZIP5 (teal), SYNZIP4 (red), and
SYNZIP6 (orange). (B) Interacting complexes: SYNZIP2 + SYNZIPl (green), SYNZIP4 + SYNZIP3
(red), SYNZIP6 + SYNZIP5 (blue). (C) Non-interactions for orthogonal pair [SYNZIP2:SYNZIP1,
SYNZIP6:SYNZIP5]: SYNZIP2 + SYNZIPS (red), SYNZIP2 + SYNZIP6 (blue), SYNZIP1 + SYNZIP5
(green) + SYNZIPl + SYNZIP6 (teal). (D) Non-interactions for orthogonal pair [SYNZIP2:SYNZIP1,
SYNZIP4:SYNZIP3]: SYNZIP2 + SYNZIP3 (red), SYNZIP2 + SYNZIP4 (blue), SYNZIP1 + SYNZIP3
(teal) + SYNZIPl + SYNZIP4 (green). Each individual peptide concentration was 4 pM, or 4 gM each (8
gM total peptide concentration) for mixtures.
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Figure C.S6. CD spectra characterizing an orthogonal set consisting of FOS:SYNZIP9 and
SYNZIP3:SYNZIP4. (A, B) Characterization of 'on' interactions. (C-F) Characterization of 'off
interactions. (A) FOS (blue), SYNZIP9 (red), mixture of FOS + SYNZIP9 (green), and the mathematical
average of the individual spectra (orange). (B) SYNZIP3 (blue), SYNZIP4 (red), mixture of SYNZIP3 +
SYNZIP4 (green), and the average of the individual spectra (orange). (C) SYNZIP3 (blue), SYNZIP9
(red), mixture of SYNZIP3 + SYNZIP9 (green), and the average of the individual spectra (orange). (D)
SYNZIP4 (blue), SYNZIP9 (red), mixture of SYNZIP4 + SYNZIP9 (green), and average of the
individual spectra (orange). (E) SYNZIP3 (blue), FOS (red), mixture of SYNZIP3 + FOS (green), and
average of the individual spectra (orange). (F) SYNZIP4 (blue), FOS (red), mixture of SYNZIP4 + FOS
(green), and average of the individual spectra (orange). Spectra were measured at 25 'C at peptide
concentrations of 40 pM or 20 pM of each peptide in mixtures (40 pM total peptide concentration).
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BFigure C.S7. Electron density maps of SYNZIP5:SYNZIP6 and SYNZIP2:SYNZIPl. (A) The fourth
heptad of SYNZIP5 (residues 23-29):SYNZIP6 (residues 37-43). (B) The fourth heptad of SYNZIP2
(residues 23-29):SYNZIP1(residues 23-29). These correspond to the heptads shown in Figure 3 G and H.
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Table C.S 1. Protein and DNA sequences used in this study.
Proteins used in
array assay.
Name Protein DNA[e] Source
SYNZIP1[a] SYYHHHHHHLESTSLY GGATCCAACCTGGTTGCGCAGCTCGAAAAC Grigoryan,
KKAGSGSNLVAQLEN GAAGTTGCGTCTCTGGAAAATGAGAACGAA et al. 2009
EVASLENENETLKKKN ACCCTGAAGAAAAAGAACCTGCACAAAAA
LHKKDLIAYLEKEIAN AGACCTGATCGCGTACCTGGAGAAAGAAAT
LRKKIEE CGCGAATCTGCGTAAGAAAATCGAAGAATG
ATAACTCGAG
SYNZIP2[a] SYYHHHHHHLESTSLY GGATCCGCGCGTAACGCGTATCTGCGTAAG Grigoryan,
KKAGSGSARNAYLRK AAAATCGCACGTCTGAAAAAAGACAACCTG et al. 2009
KIARLKKDNLQLERDE CAGCTGGAACGTGATGAACAGAACCTGGAA
QNLEKIIANLRDEIARL AAAATCATCGCGAACCTGCGTGACGAAATC
ENEVASHEQ GCGCGTCTCGAAAACGAAGTTGCGTCTCAC
GAACAGTGATAACTCGAG
SYNZIP3 [a] SYYHHHHHHLESTSLY GGATCCAACGAAGTTACCACTCTGGAGAAT This study
KKAGSGSNEVTTLEND GACGCTGCGTTCATCGAAAATGAAAACGCT
AAFIENENAYLEKEIAR TACCTGGAAAAAGAAATCGCGCGTCTGCGT
LRKEKAALRNRLAHK AAAGAAAAAGCGGCGCTGCGCAACCGTCTG
K GCGCACAAAAAATGATAACTCGAG
SYNZIP4[a] SYYHHHHHHLESTSLY GGATCCCAGAAAGTTGCGGAACTCAAAAAC Grigoryan,
KKAGSGSQKVAELKN CGTGTTGCGGTTAAACTGAATCGTAACGAA et al. 2009
RVAVKLNRNEQLKNK CAGCTGAAAAACAAAGTTGAAGAGCTGAA
VEELKNRNAYLKNEL GAACCGTAACGCTTACCTCAAGAACGAACT
ATLENEVARLENDVAE GGCGACCCTGGAGAACGAGGTTGCGCGTCT
GGAAAACGACGTTGCAGAATGATAACTCGA
G
SYNZIP5[a] SYYHHHHHHLESTSLY GGATCCAACACCGTTAAAGAACTGAAAAAC Grigoryan,
KKAGSGSNTVKELKN TACATCCAGGAGCTGGAAGAGCGTAACGCT et al. 2009
YIQELEERNAELKNLK GAACTCAAAAACCTGAAGGAACACCTGAAA
EHLKFAKAELEFELAA TTCGCAAAAGCGGAACTGGAATTCGAACTG
HKFE GCGGCTCACAAATTCGAGTGATAACTCGAG
SYNZIP6[a] SYYHHHHHHLESTSLY GGATCCCAAAAAGTTGCGCAGCTGAAAAAC Grigoryan,
KKAGSGSQKVAQLKN CGTGTTGCGTACAAACTGAAAGAAAACGCG et al. 2009
RVAYKLKENAKLENIV AAGCTGGAGAACATCGTGGCGCGTCTGGAA
ARLENDNANLEKDIAN AACGACAATGCGAACCTGGAGAAAGACATT
LEKDIANLERDVAR GCGAATCTCGAAAAGGACATCGCAAATCTG
GAACGTGACGTTGCGCGTTGATAACTCGAG
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SYNZIP7[a] SYYHHHHHHLESTSLY GGATCCAAAGAGATCGAATACCTGGAAAAA Grigoryan,
KKAGSGSKEIEYLEKEI GAAATTGAACGTCTGAAAGACCTGCGTGAA et al. 2009
ERLKDLREHLKQDNA CACCTGAAACAGGACAACGCGGCTCACCGT
AHRQELNALRLEEAKL CAGGAACTGAACGCGCTGCGTCTGGAAGAA
EFILAHLLST GCGAAACTGGAATTCATCCTGGCGCACCTG
CTGTCTACCTGATAACTCGAG
SYNZIP8[a] SYYHHHHHHLESTSLY GGATCCAAAGAGATCGCTAACCTGGAGAAA Grigoryan,
KKAGSGSKEIANLEKEI GAAATTGCGTCTCTGGAAAAAAAGGTTGCG et al. 2009
ASLEKKVAVLKQRNA GTTCTGAAACAGCGTAACGCTGCGCACAAA
AHKQEVAALRKEIAY CAGGAAGTTGCGGCTCTGCGTAAGGAAATC
VEDEIQYVEDE GCTTACGTGGAGGACGAAATCCAGTACGTT
GAAGACGAATGATAACTCGAG
SYNZIP9[a] SYYHHHHHHLESTSLY GGATCCCAGAAGGTTGAATCTCTGAAACAG Grigoryan,
KKAGSGSQKVESLKQ AAAATCGAAGAACTGAAGCAGCGTAAAGC et al. 2009
KIEELKQRKAQLKNDI GCAGCTGAAAAACGACATCGCGAACCTGGA
ANLEKEIAYAET AAAAGAAATCGCGTATGCGGAAACCTGATA
ACTCGAG
SYNZIP10[a] SYYHHHHHHLESTSLY GGATCCAACCTGCTGGCGACCCTGCGTTCT This study
KKAGSGSNLLATLRST ACCGCTGCGGTTCTGGAAAACGAAAACCAC
AAVLENENHVLEKEK GTACTGGAGAAGGAGAAAGAGAAACTGCG
EKLRKEKEQLLNKLEA CAAAGAAAAAGAACAGCTGCTGAACAAAC
YK TGGAAGCGTACAAATGATAACTCGAG
SYNZIP1 1 [a] SYYHHHHHHLESTSLY GGATCCGAACTGACCGATGAACTGAAAAAC Grigoryan,
KKAGSGSELTDELKNK AAAAAAGAAGCTCTGCGTAAAGACAACGCT et al. 2009
KEALRKDNAALLNEL GCGCTGCTGAACGAACTGGCGTCTCTGGAA
ASLENEIANLEKEIAYF AACGAAATTGCGAACCTGGAGAAAGAAATC
K GCGTACTTCAAATGATAACTCGAG
SYNZIP12[a] SYYHHHHHHLESTSLY GGATCCAATGAAGACCTGGTTCTGGAAAAC This study
KKAGSGSNEDLVLENR CGCCTTGCGGCGCTGCGTAACGAAAACGCT
LAALRNENAALENDL GCGCTTGAGAATGACCTGGCGCGTCTGGAG
ARLEKEIAYLEKEIERE AAAGAGATCGCGTACTTGGAGAAGGAAATC
K GAACGTGAAAAATGATAACTCGAG
SYNZIP13[a] SYYHHHHHHLESTSLY GGATCCCAGAAAGTTGAAGAACTGAAAAAC Grigoryan,
KKAGSGSQKVEELKN AAAATCGCGGAACTGGAAAACCGTAACGCG et al. 2009
KIAELENRNAVKKNRV GTTAAAAAGAACCGTGTTGCGCACCTGAAA
AHLKQEIAYLKDELAA CAGGAAATCGCTTATCTGAAAGACGAACTG
HEFE GCGGCTCACGAATTTGAATGATAACTCGAG
357
SYNZIP14[a] SYYHHHHHHLESTSLY GGATCCAACGACCTGGACGCGTACGAACGT Grigoryan,
KKAGSGSNDLDAYER GAAGCGGAAAAACTGGAAAAGAAAAACGA et al. 2009
EAEKLEKKNEVLRNRL AGTTCTGCGTAACCGTCTGGCGGCTCTCGA
AALENELATLRQEVAS AAACGAGCTGGCGACCCTGCGTCAGGAAGT
MKQELQS TGCGTCTATGAAACAGGAACTGCAATCTTG
ATAACTCGAG
SYNZIP15[a] SYYHHHHHHLESTSLY GGATCCTTTGAAAACGTTACCCACGAATTC Grigoryan,
KKAGSGSFENVTHEFI ATCCTGGCGACCCTGGAAAACGAAAACGCT et al. 2009
LATLENENAKLRRLEA AAACTGCGTCGTCTGGAAGCGAAACTGGAA
KLERELARLRNEVAW CGTGAACTGGCTCGTCTGCGTAACGAAGTT
L GCGTGGCTGTGATAACTCGAG
SYNZIP16[a] SYYHHHHHHLESTSLY GGATCCAACATCCTGGCGTCTCTCGAAAAC Grigoryan,
KKAGSGSNILASLENK AAAAAAGAAGAACTGAAAAAACTGAACGC et al. 2009
KEELKKLNAHLLKEIE GCACCTGCTGAAAGAAATCGAAAATCTGGA
NLEKEIANLEKEIAYFK GAAAGAGATCGCAAACCTGGAAAAGGAAA
TCGCGTACTTCAAATGATAACTCGAG
SYNZIP17[a] SYYHHHHHHLESTSLY GGATCCAACGAAAAAGAAGAACTGAAATC Grigoryan,
KKAGSGSNEKEELKSK CAAAAAAGCGGAACTGCGCAACCGTATCGA et al. 2009
KAELRNRIEQLKQKRE ACAGCTGAAACAGAAACGTGAACAACTGA
QLKQKIANLRKEIEAY AGCAGAAAATCGCGAACCTGCGTAAAGAA
K ATCGAAGCTTACAAATGATAACTCGAG
SYNZIP18[a] SYYHHHHHHLESTSLY GGATCCAGCATCGCGGCGACCCTGGAGAAC Grigoryan,
KKAGSGSSIAATLEND GATCTGGCGCGTCTGGAAAACGAAAACGCT et al. 2009
LARLENENARLEKDIA CGTCTCGAAAAAGACATCGCGAACCTGGAA
NLERDLAKLEREEAYF CGTGACCTGGCGAAACTGGAGCGTGAAGAA
GCGTACTTCTGATAACTCGAG
SYNZIP19[a] SYYHHHHHHLESTSLY GGATCCAACGAACTGGAATCTCTGGAGAAC Grigoryan,
KKAGSGSNELESLENK AAAAAAGAAGAACTGAAGAACCGTAACGA et al. 2009
KEELKNRNEELKQKRE AGAGCTGAAGCAGAAACGTGAACAGCTGA
QLKQKLAALRNKLDA AACAGAAACTGGCGGCTCTGCGTAACAAAC
YKNRL TGGACGCGTACAAAAACCGTCTGTGATAAC
TCGAG
SYNZIP20[a] SYYHHHHHHLESTSLY GGATCCAGCACTGTTGAAGAACTGCTGCGT Grigoryan,
KKAGSGSSTVEELLRA GCGATCCAGGAGCTGGAAAAACGTAACGCG et al. 2009
IQELEKRNAELKNRKE GAACTCAAAAACCGTAAAGAGGAACTGAA
ELKNLVAHLRQELAA AAATCTGGTTGCGCACCTGCGTCAAGAGCT
HKYE GGCAGCGCACAAATACGAATGATAACTCGA
G
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SYNZIP21 [a] SYYHHHHHHLESTSLY GGATCCAACGAAGTTGCGCAGCTGGAAAAC This study
KKAGSGSNEVAQLEN GACGTTGCGGTTATCGAAAATGAAAACGCG
DVAVIENENAYLEKEI TACCTGGAGAAGGAGATCGCGCGTCTGCGT
ARLRKEIAALRDRLAH AAAGAAATTGCGGCGCTGCGTGACCGTCTG
KK GCGCACAAAAAATGATAACTCGAG
SYNZIP22[a] SYYHHHHHHLESTSLY GGATCCAAACGTATCGCGTACCTGCGTAAG Grigoryan,
KKAGSGSKRIAYLRKK AAAATCGCGGCACTGAAAAAAGACAACGC et al. 2009
IAALKKDNANLEKDIA GAACCTCGAAAAAGATATCGCAAACCTGGA
NLENEIERLIKEIKTLE AAACGAAATCGAACGTCTGATCAAAGAAAT
NEVASHEQ CAAAACCCTGGAGAACGAAGTTGCGTCTCA
CGAACAGTGATAACTCGAG
SYNZIP23 [a] SYYHHHHHHLESTSLY GGATCCGCACTCCGTGCGGAACTGAAAGCG This study
KKAGSGSALRAELKA AAAATCGCGCTCCTGCGTGCTGACAACTGG
KIALLRADNWALKRK GCGCTGAAACGTAAAGCTAAAGACCTGCGT
AKDLRRLLRRLRNKAE CGTCTGCTGCGCCGTCTGCGTAACAAAGCG
ELK GAAGAGCTGAAATGATAACTCGAG
SYNZIP24[a] SYYHHHHHHLESTSLY GGATCCCAGAAACTGCAGACCCTGCGTGAT Grigoryan,
KKAGSGSQKLQTLRDL CTGCTGGCGGTTCTGGAGAACCGTAATCAG et al. 2009
LAVLENRNQELKQLR GAACTGAAACAGCTGCGTCAGCACCTGAAA
QHLKDLLKYLEDELAT GACCTGCTGAAATACCTGGAAGACGAACTG
LEKE GCGACCCTGGAAAAAGAATGATAACTCGAG
SYNZIP25[a] SYYHHHHHHLESTSLY GGATCCAACGAAACCGAACAGCTGATCAAC Grigoryan,
KKAGSGSNETEQLINK AAAAAAGAGCAGCTGAAAAACGACAACGC et al. 2009
KEQLKNDNAALEKDA AGCGCTCGAAAAAGATGCGGCGTCTCTGGA
ASLEKEIANLEKEIAYF AAAGGAAATCGCGAACCTGGAGAAAGAAA
K TTGCGTACTTCAAATGATAACTCGAG
SYNZIP26[a] SYYHHHHHHLESTSLY GGATCCGAAAAAATCCAGGAACTGAAACGT Grigoryan,
KKAGSGSEKIQELKRR CGTCTGGCGTACTTCCGTCGTGAAAACGCG et al. 2009
LAYFRRENATLKNDN ACCCTGAAAAACGACAACGCTACCCTGGAG
ATLENELASVEAENEA AACGAACTGGCGTCTGTTGAAGCGGAAAAC
LRK GAAGCGCTGCGTAAATGATAACTCGAG
SYNZIP27[a] SYYHHHHHHLESTSLY GGATCCCAGAAAATCCAGTACCTGAAACAG Grigoryan,
KKAGSGSQKIQYLKQR CGTATCGCGGAACTGCGTAAAAAGATTGCG et al. 2009
IAELRKKIANLRKDIAN AACCTGCGCAAAGACATCGCTAACCTGGAA
LEDDAAVKEDELVHL GATGACGCTGCGGTTAAAGAAGACGAACTG
GTTCACCTGTGATAACTCGAG
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SYNZIP28[a] SYYHHHHHHLESTSLY GGATCCGAAAAAATCGAATACCTGAAAGAC Grigoryan,
KKAGSGSEKIEYLKDR CGTATCGCGGAACTGCGTTCTAAAATCGCT et al. 2009
IAELRSKIAALRNDLTH GCGCTGCGTAACGACCTGACCCACCTGAAG
LKNDKAHKENELAHL AACGACAAAGCGCACAAAGAAAACGAACT
A GGCGCACCTGGCGTGATAACTCGAG
SYNZIP29[a] SYYHHHHHHLESTSLY GGATCCAACGACATCGAAAACCTGAAAGAC Grigoryan,
KKAGSGSNDIENLKDK AAGATCGAAGAACTCAAACAGCGTAAAGA et al. 2009
IEELKQRKEELKQKIEY AGAGCTGAAACAGAAAATCGAATACCTCAA
LKQKIEALRQKLAALK GCAGAAGATTGAAGCGCTGCGTCAGAAACT
QRIA GGCGGCTCTGAAGCAGCGTATCGCGTGATA
ACTCGAG
SYNZIP30[a] SYYHHHHHHLESTSLY GGATCCGAAAAAATCGAAGAACTGAAAGA Grigoryan,
KKAGSGSEKIEELKDKI CAAAATCGCGGAACTGCGTTCTCGTAACGC et al. 2009
AELRSRNAALRNKIEA TGCGCTGCGTAACAAAATTGAAGCGCTGAA
LKQKLEALRQKIEYLK ACAGAAACTGGAAGCTCTGCGTCAGAAGAT
DRIA CGAATACCTCAAAGACCGTATCGCGTGATA
ACTCGAG
SYNZIP3 1 [a] SYYHHHHHHLESTSLY GGATCCGCTGAAAACCAGTACGTTGAAGAC Grigoryan,
KKAGSGSAENQYVED CTGATCCAGTACCTGGAAAAAGAGAACGCT et al. 2009
LIQYLEKENARLKKEV CGTCTGAAAAAAGAAGTTCAGCGTCTGGTT
QRLVRELSYFRRRIAEL CGTGAACTGTCTTACTTCCGTCGTCGTATCG
A CGGAACTGGCGTGATAACTCGAG
SYNZIP32[a] SYYHHHHHHLESTSLY GGATCCGCTGAAAACCAGTCTGTTGAAGAC Grigoryan,
KKAGSGSAENQSVEDI ATCATCGCGAAAAAAGAAGATGAAAACGC et al. 2009
IAKKEDENAHLKNEVK GCACCTGAAAAACGAAGTTAAAACCCTGAT
TLINELETLRKKIEYLA CAACGAACTGGAAACTCTGCGTAAGAAAAT
CGAATACCTGGCGTGATAACTCGAG
SYNZIP33[a] SYYHHHHHHLESTSLY GGATCCCGTGACCTGCAGAACGTTGAACGT Grigoryan,
KKAGSGSRDLQNVER GAAATCCAGTCCCTGGAAAAGAAAAACGA et al. 2009
EIQSLEKKNESLKKKIA ATCTCTGAAGAAGAAAATCGCTTCTCTGGA
SLENELATLKQEIAYF GAACGAACTGGCGACCCTGAAACAGGAAAT
KRELAY CGCGTACTTCAAACGTGAGCTGGCTTACTG
ATAACTCGAG
SYNZIP34[a] SYYHHHHHHLESTSLY GGATCCGACCGTCTGGCGGTTAAAGAAAAC Grigoryan,
KKAGSGSDRLAVKEN CGTGTTGCGGTTCTGAAAAACGAAAACGCG et al. 2009
RVAVLKNENAKLRNII AAACTGCGTAACATCATCGCGAACCTGAAA
ANLKDRIAYFRRELAY GACCGTATCGCGTACTTCCGTCGTGAACTG
LELEEEQLA GCGTACCTGGAACTGGAAGAAGAACAGCTG
GCGTGATAACTCGAG
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SYNZIP35[a] SYYHHHHHHLESTSLY GGATCCAACAAGGTTGAGCAGCTCAAAAAC Grigoryan,
KKAGSGSNKVEQLKN AAAGTTGAACAGCTGAAAAACCGTAACGCT et al. 2009
KVEQLKNRNAALKND GCGCTGAAGAACGACCTGGCGCGTCTGGAA
LARLEREIAYAEE CGTGAAATCGCGTATGCGGAAGAATGATAA
CTCGAG
SYNZIP36[a] SYYHHHHHHLESTSLY GGATCCGAAAAAAACCAGGAACTGAAAAA Grigoryan,
KKAGSGSEKNQELKN CCGTCTGGCGGTTCTGGAAAACGACAACGC et al. 2009
RLAVLENDNAALRND TGCTCTGCGTAACGACCTGGCGCGTCTGGA
LARLEREIAYME ACGTGAAATCGCGTACATGGAATGATAACT
CGAG
SYNZIP37[a] SYYHHHHHHLESTSLY GGATCCAAAGACATCGCGAACCTCAAAAAA Grigoryan,
KKAGSGSKDIANLKKE GAAATCGCGCACCTGAAAAACGACCTGCAG et al. 2009
IAHLKNDLQRLESIRER CGTCTGGAATCTATCCGTGAACGTCTGAAA
LKFDILNHEQEEYALE TTCGACATTCTGAACCACGAACAGGAAGAA
TACGCACTGGAATGATAACTCGAG
SYNZIP38[a] SYYHHHHHHLESTSLY GGATCCAACAAAAACGAAACTCTGAAGAAC Grigoryan,
KKAGSGSNKNETLKNI ATCAACGCACGTCTGCGTAACGATGTTGCT et al. 2009
NARLRNDVARLKNRIA CGTCTCAAAAACCGTATCGCGCGTCTGAAA
RLKDDIENVEDEIQYL GACGACATCGAAAACGTTGAAGACGAAATC
E CAGTACCTGGAATGATAACTCGAG
SYNZIP39[a] SYYHHHHHHLESTSLY GGATCCCTGGAAAACGCTCAGATCAAAAAA Grigoryan,
KKAGSGSLENAQIKKE GAAATCGCTCAGCTGCGTAAAGAAGTTGCA et al. 2009
IAQLRKEVAQLKQKIE CAGCTGAAACAGAAAATCGAAGAACTGAA
ELKNDNARVEREIQYL AAACGATAACGCACGTGTTGAACGTGAAAT
E CCAGTACCTGGAATGATAACTCGAG
SYNZIP40[a] SYYHHHHHHLESTSLY GGATCCCAGAAACGTCAGCAACTGAAACAG Grigoryan,
KKAGSGSQKRQQLKQ AAACTGGCGGCTCTGCGTCGTGACATCGAA et al. 2009
KLAALRRDIENLQDEI AACCTGCAAGATGAAATCGCGTACAAAGAA
AYKEDEIANLKDKIEQ GACGAAATTGCGAACCTGAAAGACAAAATC
LLS GAACAGCTGCTGTCTTGATAACTCGAG
SYNZIP41 [a] SYYHHHHHHLESTSLY GGATCCCAGAAAATCGAATCTCTGAAAGAC Grigoryan,
KKAGSGSQKIESLKDK AAACTGGCGAACAAACGTGACAAAATCGCG et al. 2009
LANKRDKIALLRSEVA CTGCTGCGTTCTGAAGTTGCGTCTTTTGAAA
SFEKEIAYLEKEIANLE AAGAAATCGCATACCTGGAGAAAGAGATCG
N CAAACCTGGAAAACTGATAACTCGAG
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SYNZIP42[a] SYYHHHHHHLESTSLY GGATCCGAAAAAATCGAATACCTGAAAGAC Grigoryan,
KKAGSGSEKIEYLKDK AAACTGGCGCACAAACGTAACGAAGTTGCT et al. 2009
LAHKRNEVAQLRKEV CAGCTGCGTAAAGAAGTTACCCACAAAGTT
THKVDELTSLENEVAQ GACGAACTGACCTCTCTGGAAAACGAGGTT
LLK GCACAGCTGCTGAAATGATAACTCGAG
SYNZIP43 [a] SYYHHHHHHLESTSLY GGATCCCAGAAAGTGGAACAGCTGAAGAA Grigoryan,
KKAGSGSQKVEQLKN CAAGGTTGAACAGAAACTGAAAGAGAACG et al. 2009
KVEQKLKENESLENKV AGTCTCTGGAGAACAAAGTTGCGGAGCTGA
AELKNRNEYLKNKIEN AAAACCGTAACGAGTACCTCAAAAACAAAA
LINDITNLENDVAR TCGAGAACCTGATCAACGACATCACCAACC
TGGAAAACGACGTTGCGCGTTGATAACTCG
AG
SYNZIP44[a] SYYHHHHHHLESTSLY GGATCCCAGAAAGTTGCGCAGCTGAAAAAC Grigoryan,
KKAGSGSQKVAQLKNI ATCATCGCGAAAAAAGAAGATGAGAACGCT et al. 2009
IAKKEDENAVLENLVA GTTCTGGAAAACCTGGTTGCGGTGCTGGAG
VLENENAYLEKELARL AACGAAAACGCGTACCTCGAAAAGGAACTG
ERDIARAERDVKV GCGCGTCTGGAACGCGACATCGCGCGTGCG
GAACGTGATGTTAAAGTTTGATAACTCGAG
SYNZIP45[a] SYYHHHHHHLESTSLY GGATCCAACCGTCTGCAGGAACTGGAAAAC Grigoryan,
KKAGSGSNRLQELENK AAAAACGAGGTTCTGGAGAAACGTAAAGC et al. 2009
NEVLEKRKAELRNEV GGAACTGCGCAACGAAGTTGCGACCCTGGA
ATLEQELAAHRYELAA ACAGGAGCTGGCTGCGCACCGTTACGAACT
IEKEIA GGCGGCGATCGAAAAAGAAATCGCATGATA
ACTCGAG
SYNZIP46[a] SYYHHHHHHLESTSLY GGATCCAAAGAAATCGAACGTCTGGAAAAA Grigoryan,
KKAGSGSKEIERLEKEI GAGATCAAAACCCTGATCAACCTCCTGACC et al. 2009
KTLINLLTTLRQDNAA ACCCTGCGTCAGGACAACGCGGCACACCGT
HRKEAAALEKEEANLE AAAGAAGCAGCGGCACTGGAGAAAGAAGA
RDIQNLLRY AGCGAACCTGGAACGTGACATCCAGAACCT
GCTGCGTTACTGATAACTCGAG
SYNZIP47[a] SYYHHHHHHLESTSLY GGATCCAGCAAATACGACGCGCTGCGTAAC Grigoryan,
KKAGSGSSKYDALRN AAACTGGAAGCGCTGAAAAACCGTAACGCG et al. 2009
KLEALKNRNAQLRKE CAGCTCCGTAAAGAAAACGAACAGCTGCGT
NEQLRLEEAVLEVRNE CTGGAAGAAGCGGTTCTGGAGGTTCGTAAC
VL GAAGTTCTGTGATAACTCGAG
SYNZIP48[a] SYYHHHHHHLESTSLY GGATCCCAGAAAATTGCGTACCTGCGTGAT Grigoryan,
KKAGSGSQKIAYLRDR CGTATCGCGGCACTGAAAGCTGAAAACGAA et al. 2009
IAALKAENEALRAKNE GCTCTGCGTGCGAAAAATGAAGCGCTGCGT
ALRSKIEELKKEKEELR TCTAAAATCGAGGAACTGAAGAAAGAAAA
DKIAQKKDR AGAAGAACTGCGCGACAAAATCGCTCAGAA
AAAAGACCGTTGATAACTCGAG
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BATF[b] SYYHHHHHHLESTSLYKKAGSGSQKADTLHLESEDLEKQNAALRKEIKQ Newman,
LTEELKYFTSVLNSHELE et al. 2003
FOS[b] SYYHHHHHHLESTSLYKKAGSEFFRRERNKMAAAKCRNRRRELTDTLQ Newman,
AETDQLEDEKSALQTEIANLLKEKEKLEFILAAHRPACKIPDDLGFPEEMS et al. 2003
LE
ATF4[b] SYYHHHHHHLESTSLYKKAGSEFNKTAATRYRQKKRAEQEALTGECKEL Newman,
EKKNEALKERADSLAKEIQYLKDLIEEVRKARGKKRVP et al. 2003
ATF3[b] SYYHHHHHHLESTSLYKKAGSGSCPEEDERKKRRRERNKIAAAKCRNKK Newman,
KEKTECLQKESEKLESVNAELKAQIEELKNEKQHLIYMLNLHRPTCIVRA et al. 2003
QNGRTPEDLE
BACH1[b] SYYHHHHHHLESTSLYKKAGSEFGCRKRKLDCIQNLESEIEKLQSEKESL Newman,
LKERDHILSTLGETKQNLTGLCQKVCKEAALSQEQNLE et al. 2003
JUND[b] SYYHHHHHHLESTSLYKKAGSGSERISRLEEKVKTLKSQNTELASTASLL Newman,
REQVAQLKQKVLSHVLE et al. 2003
NFE2L3[b] SYYHHHHHHLESTSLYKKAGSEFGDIRRRGKNKVAAQNCRKRKLDIILN Newman,
LEDDVCNLQAKKETLKREQAQCNKAINIMKQKLHDLYHDIFSRLRDDQG et al. 2003
RPVLE
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Proteins used in circular dichroism and
crystallography studies.
SYNZIPl [c] GSNLVAQLENEVASLENENETLKKKNLHKKDLIAYLEKEIANLRKKIEE This study
SYNZIP2[c] GSARNAYLRKKIARLKKDNLQLERDEQNLEKIIANLRDEIARLENEVASH This study
EQ
SYNZIP3 [c] GSNEVTTLENDAAFIENENAYLEKEIARLRKEKAALRNRLAHKK This study
SYNZIP4[c] GSQKVAELKNRVAVKLNRNEQLKNKVEELKNRNAYLKNELATLENEVA This study
RLENDVAE
SYNZIP5[c] GSNTVKELKNYIQELEERNAELKNLKEHLKFAKAELEFELAAHKFE This study
SYNZIP6[c] GSQKVAQLKNRVAYKLKENAKLENIVARLENDNANLEKDIANLEKDIAN This study
LERDVAR
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SYNZIP9[c] GSQKVESLKQKIEELKQRKAQLKNDIANLEKEIAYAET This study
FOS LZ[c] GSELTDTLQAETDQLE GGATCCGAACTGACCGACACTCTGCAGGCG This study
DEKSALQTEIANLLKE GAAACCGACCAGCTCGAAGATGAAAAATCT
KEKLEFILAAHR GCGCTGCAGACCGAAATCGCGAACCTGCTG
AAAGAAAAAGAGAAACTGGAATTCATCCTG
GCTGCTCACCGTTGATAACTCGAG
SYNZIP4(1-42)[c] GSQKVAELKNRVAVKLNRNEQLKNKVEELKNRNAYLKNELATLE This study
SYNZIP4(15-54)[c] GSNRNEQLKNKVEELKNRNAYLKNELATLENEVARLENDVAE This study
Proteins used in pull-down assays.
SYNZIP1(1-47)[d] GSCGSNLVAQLENEVASLENENETLKKKNLHKKDLIAYLEKEIANLRKKI This study
EE
SYNZIP2(1-47)[d] GSCGSARNAYLRKKIARLKKDNLQLERDEQNLEKIIANLRDEIARLENEV This study
AS
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SYNZIP3(1-40)[d] GSCGSNEVTTLENDAAF This study
IENENAYLEKEIARLRKEKAALRNRLAH
SYNZIP4(15-54)[d] GSCGSNRNEQLKNKVEELKNRNAYLKNELATLENEVARLENDVAE This study
SYNZIP5(1-40)[d] GSCGSNTVKELKNYIQELEERNAELKNLKEHLKFAKAELEFELAA This study
SYNZIP6(15-54)[d] GSCGSKENAYLENIVARLENDNANLEKDIANLEKDIANLERDVAR This study
[a] SYNZIP protein constructs used for array measurments have the following linker at the N-Terminus including the
BamHI site: SYYHHHHHHLESTSLYKKAGSGS
[b] The coiled-coil region of the human sequences is in green. Additional human protein sequence is in
red. Cloning sequence is in black.
[c] Constructs used for circular dichroism and crystallography studies include a GS at the N-Terminus
after cleavage by TEV.
[d] Constructs used in pull-down assays include a GS at the N-Terminus after cleavage by TEV and a cysteine
followed by a short GS linker.
[e] DNA sequence is of the insert and includes BamHI and XhoI sites that were used for cloning. DNA sequence for
proteins used in array studies is the same for the proteins used in other assays unless otherwise indicated.
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Table C.S2. Average background-corrected fluorescence values from the array experiment.
Peptides in solution are in columns and those on the surface are in rows. Duplicates are indicated
with a number 2 in parentheses.
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Protein SYNZIPI SYNZIP2 SYNZIP3 SYNZIP4 SYNZIP5 SYNZIP6 SYNZIP7 SYNZIP8 SYNZIP9 SYNZIP1O
SYNZIP1 2727.0 47850.8 605.9 1205.6 22.9 199.5 4675.4 299.5 38.0 -30.5
SYNZIP2 49531.5 4907.1 1023.0 1079.1 224.6 491.0 3565.9 3800.1 1065.6 -103.4
SYNZIP3 -484.4 1852.9 -583.3 34221.4 7000.9 99.4 -113.8 1257.0 467.9 -591.9
SYNZIP4 -314.8 2693.8 36766.9 -52.5 -8.3 15580.8 210.1 1145.5 -220.3 2395.4
SYNZIP5 85.3 7669.4 9659.6 2677.5 -176.3 35912.5 118.0 4261.3 1387.8 712.8
SYNZIP6 -898.5 8038.1 1564.0 40661.4 37774.0 -90.5 -143.1 720.1 3008.5 4376.5
SYNZIP7 3491.8 6240.3 -319.3 285.4 -309.1 -559.8 281.8 2372.4 -118.8 135.4
SYNZIP8 -26.3 7685.3 1528.5 1877.3 452.3 -27.0 3148.9 1916.0 3176.3 5871.5
SYNZIP9 -178.8 3007.3 1339.8 -612.9 854.6 1983.5 58.5 4728.9 653.9 4627.0
SYNZIP1O 310.3 5178.4 211.6 12234.0 1521.5 4070.0 1541.6 17712.1 7305.1 -601.0
SYNZIP11 6169.8 4973.8 5287.0 10656.3 7699.0 497.4 1255.1 1310.3 5522.8 766.3
SYNZIP12 359.0 5306.0 4520.8 9755.4 13703.5 288.4 295.3 911.6 4612.0 2802.9
SYNZIP13 -345.9 32090.0 10973.8 -2270.0 360.9 1113.0 -74.5 167.9 -653.5 12047.6
SYNZIP14 308.1 37913.3 7528.3 5078.0 686.9 3957.0 194.5 1646.5 1597.3 -41.9
SYNZIP15 608.5 409.9 2844.3 -1704.5 -328.4 516.0 -207.8 -233.0 -1521.0 -1778.5
SYNZIP16 1200.8 14994.5 5220.3 4013.3 17575.6 199.6 538.1 1751.4 3404.1 2502.8
SYNZIP17 26.8 9431.3 14422.1 1381.8 759.1 5368.6 300.9 4604.0 136.1 1475.5
SYNZIP18 -424.4 2586.3 -4.3 23264.6 12069.0 -291.6 -150.5 1529.4 9335.6 -397.8
SYNZIP19 5755.8 45176.9 2068.1 2440.9 -115.9 20840.0 680.1 11074.8 2522.1 -532.1
SYNZIP20 2040.5 49162.4 6805.8 3834.1 -348.5 19414.9 3515.0 2430.6 2857.6 6797.8
SYNZIP21 -563.0 6872.3 2657.1 30320.8 25120.1 -154.9 4659.9 4335.9 1424.1 13937.8
SYNZIP22 20784.0 19647.1 3614.3 2006.1 17091.3 392.4 6791.8 11137.5 1996.0 27744.9
SYNZIP23 4067.9 20087.8 2195.3 13143.9 491.8 24128.6 2195.0 50967.8 16428.9 242.6
SYNZIP24 -757.1 46231.9 -287.0 -2798.0 -794.3 649.1 -352.4 3943.9 -546.4 -624.5
SYNZIP25 1703.0 -228.9 -495.8 4192.5 4468.4 -290.3 -310.8 -304.9 244.8 -391.4
SYNZIP26 243.3 157.0 -176.8 348.1 -292.8 2291.9 32.6 734.3 -365.4 -740.6
SYNZIP27 389.1 5852.0 855.1 5952.4 2178.8 1826.3 1518.3 3726.3 988.3 313.0
SYNZIP28 -451.6 6751.8 14.1 2456.4 331.0 2174.5 822.1 2946.0 482.8 -569.5
Protein SYNZIP11 SYNZIP12 SYNZIP13 SYNZIP14 SYNZIP15 SYNZIP16 SYNZIP17 SYNZIP18 SYNZIP19 SYNZIP20
SYNZIP1 3129.4 208.9 674.0 460.6 1026.0 2663.5 1067.3 -239.8 5059.6 4305.8
SYNZIP2 602.4 1427.1 17562.1 42445.5 -2040.4 16600.4 5490.0 306.0 24005.9 33929.3
SYNZIP3 4448.8 6912.4 14412.8 6351.1 6177.4 11614.3 15054.1 -255.3 1281.9 16144.0
SYNZIP4 489.6 3136.9 -167.4 2033.0 -1616.4 6396.4 501.5 12474.3 1452.5 8718.3
SYNZIP5 12771.6 22853.4 2599.4 2408.9 -638.5 33866.9 5001.6 19688.1 -356.3 953.3
SYNZIP6 1258.3 2618.0 4032.5 8001.0 4907.5 1410.1 19399.5 -173.1 44070.8 33644.3
SYNZIP7 -227.5 -838.5 179.0 -841.0 -2143.1 -879.5 115.0 -773.4 377.1 5980.6
SYNZIP8 -138.4 -43.6 -283.1 -37.1 -307.6 2545.9 2857.4 233.4 4890.4 3113.5
SYNZIP9 1250.9 2207.6 -836.0 1389.6 1595.3 5740.9 1029.8 5380.9 2561.5 6657.9
SYNZIP1O 2878.3 3540.0 22523.8 4706.6 -1154.4 16454.4 4745.5 1651.8 -286.4 17169.3
SYNZIP 1l 2033.9 122.8 3307.6 8680.3 4114.5 2228.9 10994.0 934.3 23409.5 30053.0
SYNZIP12 99.1 -367.3 21923.0 21412.9 6919.6 3774.3 15590.8 1723.0 24047.9 22937.9
SYNZIP13 270.8 14448.4 -785.0 1039.0 35569.3 12968.1 -1576.9 10401.1 -1291.1 -849.0
SYNZIP14 4518.1 21521.9 2938.5 3194.6 20648.3 16603.8 22442.5 10510.9 2516.8 3112.0
SYNZIP15 1994.3 4332.4 36848.6 13204.5 -1832.3 11318.8 14731.9 537.6 1312.0 834.8
SYNZIP16 564.0 1005.4 8469.8 7710.0 5484.4 9851.5 12009.5 2442.3 15363.3 30927.3
SYNZIP17 4598.0 9530.8 382.3 12973.0 31507.6 16546.9 2430.9 29468.9 51.5 4942.6
SYNZIP18 2356.9 2288.9 17480.3 10362.9 2825.4 10579.0 34443.3 195.0 34738.6 19722.3
SYNZIP19 15415.9 25068.0 955.0 470.0 -974.5 38380.9 2777.3 45298.1 -969.0 -607.1
SYNZIP20 41208.5 43431.4 628.3 641.1 1738.3 39021.5 5128.9 43702.4 -806.3 5974.6
SYNZIP21 19684.5 9979.8 20943.3 15840.0 27662.0 24776.9 22328.3 3974.3 36175.3 22019.4
SYNZIP22 4447.5 6560.8 13293.5 44903.9 22642.0 17881.1 8033.3 5696.3 39174.6 29506.9
SYNZIP23 16873.3 34517.6 4931.1 23576.8 26741.0 48678.0 12428.3 37390.1 -662.5 14160.9
SYNZIP24 1719.3 8750.4 -639.8 -1220.8 325.4 21574.3 -1315.0 2602.5 -1666.1 -2221.8
SYNZIP25 -351.8 -629.1 1032.6 510.9 -2561.6 -1163.6 1746.8 -606.8 12561.6 20570.9
SYNZIP26 1319.8 150.6 1725.4 -95.6 -402.1 1.4 -368.6 12.6 1905.4 3065.8
SYNZIP27 5058.0 2295.8 501.8 5619.5 15248.9 9462.1 3089.6 1459.4 629.0 6337.5
SYNZIP28 4881.4 945.3 -94.9 2150.8 8602.9 11086.9 1900.8 744.0 -1211.1 -564.6
Protein SYNZIP21 SYNZIP22 SYNZIP23 SYNZIP24 SYNZIP25 SYNZIP26 SYNZIP27 SYNZIP28 SYNZIP29 SYNZIP30
SYNZIP1 1348.8 13166.0 11992.6 2089.1 571.4 741.9 985.3 392.4 2686.8 5131.9
SYNZIP2 7554.8 5972.3 20889.4 31406.8 114.3 581.1 8668.3 18089.3 8859.1 5370.0
SYNZIP3 9319.3 1659.8 10970.8 2170.9 -27.9 243.9 170.6 12.0 1133.0 1757.5
SYNZIP4 38542.3 4748.5 33133.0 -997.5 -209.3 799.6 6243.8 2106.1 2143.0 6827.6
SYNZIP5 33212.9 21966.1 3954.5 1907.4 2968.6 738.9 19386.3 7975.8 6678.5 7283.1
SYNZIP6 526.5 -1250.0 41241.5 16534.5 68.4 165.6 5514.3 8949.3 13667.1 14659.5
SYNZIP7 9034.1 3329.9 2323.5 -861.0 -217.1 552.9 5001.4 3690.3 2588.6 5274.6
SYNZIP8 8510.0 3386.6 32177.9 8915.8 -123.4 407.9 7415.3 9124.1 5094.0 6270.1
SYNZIP9 4588.6 -214.6 29461.3 644.4 207.8 558.1 6560.5 7202.9 2679.0 224.3
SYNZIP1O 28564.3 22701.6 2167.0 465.4 455.0 686.0 4247.4 239.1 10781.9 7398.9
SYNZIP11 32459.1 3536.0 34355.9 12299.8 584.3 2561.1 22745.5 36794.6 23519.8 21946.9
SYNZIP12 16377.6 3419.5 33987.9 15220.6 -41.3 862.1 14693.3 13717.1 12273.5 13080.4
SYNZIP13 24996.9 9577.1 9489.6 -210.5 -160.8 558.8 -1246.1 -706.8 3881.1 2904.6
SYNZIP14 26253.5 21724.0 36041.9 -114.0 204.3 970.6 11060.1 6766.0 8380.4 11584.4
SYNZIP15 35396.0 7230.5 17382.3 5704.0 217.5 963.3 26415.9 19114.1 9017.8 8936.1
SYNZIP16 27027.5 7271.8 42243.6 21729.1 -83.8 602.9 15216.6 20446.1 9539.0 10450.5
SYNZIP17 35158.8 1022.4 22352.0 3058.1 403.5 750.9 5285.8 7445.3 2337.8 1693.5
SYNZIP18 9645.8 1627.8 33912.3 10686.9 -1031.1 533.1 14059.4 9643.9 12798.0 16171.6
SYNZIP19 49971.5 31356.6 1179.3 -182.4 2028.3 958.3 2979.1 34.9 5165.9 6621.8
SYNZIP20 36110.6 15364.5 18270.1 1188.9 8618.6 1781.6 15086.0 -648.8 1156.8 2391.3
SYNZIP21 5635.0 3822.4 38270.0 21588.3 572.8 632.1 220.3 766.9 2907.3 2997.3
SYNZIP22 16302.6 1366.0 33168.3 22768.5 631.6 961.1 7654.8 18178.3 8721.3 11848.6
SYNZIP23 46508.3 18793.4 -635.3 9376.5 1206.6 2496.4 126.5 -1312.8 3667.1 2347.3
SYNZIP24 42194.3 8413.8 420.8 10344.3 70.1 -32.1 3985.3 -221.5 -11.9 -343.6
SYNZIP25 1140.3 -993.6 7693.1 2440.8 -70.5 377.1 4227.5 7108.3 15053.8 13857.0
SYNZIP26 3487.4 -1153.1 9555.6 -571.5 3731.3 1079.4 -2087.3 -1663.6 700.4 895.3
SYNZIP27 1197.6 -120.0 1155.8 5261.0 373.0 946.3 15214.5 11332.9 2437.9 1684.1
SYNZIP28 715.1 -157.5 -1390.5 1587.6 245.6 530.3 10344.4 4448.1 931.0 521.3
Protein SYNZIP31 SYNZIP32 SYNZIP33 SYNZIP34 SYNZIP35 SYNZIP36 SYNZIP37 SYNZIP38 SYNZIP39 SYNZIP40
SYNZIP1 1478.4 38.5 305.8 549.5 446.1 412.6 710.5 541.3 429.3 1523.1
SYNZIP2 16270.3 385.6 38042.5 2768.0 -40.9 139.0 16860.3 790.3 1660.4 1912.6
SYNZIP3 9286.6 889.3 2402.3 9764.8 13850.0 3096.6 701.9 2401.1 617.8 -132.6
SYNZIP4 10758.4 41.5 5789.6 764.1 575.1 341.0 1183.6 1496.0 1091.1 3005.9
SYNZIP5 35487.3 30555.3 5312.8 3299.5 1725.6 1474.9 1406.3 740.4 4688.1 30876.8
SYNZIP6 15801.4 623.9 7950.1 2593.4 6735.6 2904.6 1100.0 1450.6 -392.0 1167.9
SYNZIP7 41.9 -370.3 2247.3 424.5 91.8 89.1 1726.8 1522.6 1153.4 11141.5
SYNZIP8 1217.8 -82.0 3136.1 809.5 421.9 116.9 915.5 2925.8 3316.3 10745.1
SYNZIP9 2950.8 200.9 1236.5 -117.5 327.1 285.8 24072.8 442.3 1522.3 2002.4
SYNZIP1O 12440.5 664.8 14952.5 4863.1 7532.4 810.1 1806.0 1580.3 9100.6 2918.8
SYNZIP11 8404.6 -173.1 31036.3 9121.3 1905.4 620.5 4844.1 12993.5 10133.6 3213.0
SYNZIP12 22124.5 2328.1 36988.6 6454.5 4732.9 958.4 1956.9 4639.9 961.5 5161.3
SYNZIP13 2772.3 81.5 2221.1 16.8 -181.4 -50.1 166.6 -13.9 -2.0 4561.0
SYNZIP14 18649.3 916.3 24270.0 22491.3 2464.9 2040.5 5534.3 3229.3 1917.9 11333.5
SYNZIP15 48837.4 13359.5 43436.3 36460.3 638.5 336.8 3790.0 1328.9 -287.4 1684.6
SYNZIP16 7936.6 484.0 34066.0 7310.6 1855.4 407.3 9738.0 3304.0 4137.0 14315.5
SYNZIP17 9065.3 360.9 7464.9 724.3 655.8 1238.0 33626.5 624.4 4377.6 1317.4
SYNZIP18 16593.4 401.9 10363.3 9376.3 19906.8 3726.4 5216.5 3350.5 551.9 12116.0
SYNZIP19 16170.0 1115.5 43399.3 11110.5 2646.0 1352.3 7652.1 2448.3 6755.6 32438.9
SYNZIP20 15291.3 2172.9 9773.4 4216.1 4062.1 7885.3 -383.3 307.0 456.4 9689.3
SYNZIP21 19554.9 6103.4 13281.3 8181.8 9571.6 5215.9 1600.0 1910.0 170.8 698.3
SYNZIP22 15375.9 1028.1 31330.0 5762.5 7432.1 511.8 6781.0 5398.8 2886.9 5431.8
SYNZIP23 47534.9 4024.0 20924.1 22911.3 11860.4 25743.9 357.3 854.0 2202.8 11532.5
SYNZIP24 25124.9 6517.9 1311.6 3093.5 -520.3 -458.9 1583.4 1664.0 533.4 17240.6
SYNZIP25 1985.3 -32.4 26088.8 -31.4 -6.0 9.0 347.9 945.5 438.0 492.9
SYNZIP26 918.8 -265.9 590.9 214.9 333.3 890.4 100.1 88.1 -298.3 -239.6
SYNZIP27 5682.9 676.1 2856.3 1714.9 922.8 888.3 21756.1 1749.4 4126.5 6724.8
SYNZIP28 1914.5 61.8 2431.0 530.3 -86.6 522.9 12196.5 631.3 4580.3 6693.4
Protein SYNZIP41 SYNZIP42 SYNZIP43 SYNZIP44 SYNZIP45 SYNZIP46 SYNZIP47 SYNZIP48 BATF FOS
SYNZIPl 999.1 432.6 134.0 23.9 620.8 14386.0 575.9 14520.0 -75.8 1417.4
SYNZIP2 671.6 648.6 7749.1 -270.6 2049.0 2085.1 244.0 7664.8 1308.0 17359.6
SYNZIP3 164.9 359.8 8791.1 -106.8 370.3 28.4 950.0 -123.6 447.8 -556.3
SYNZIP4 2911.1 488.1 6217.1 37336.0 70.3 4227.3 195.1 2593.9 890.6 4944.8
SYNZIP5 667.4 616.0 9197.4 7318.1 370.4 960.0 333.4 8558.8 6890.5 3569.3
SYNZIP6 -194.9 506.3 17352.1 5085.8 2047.1 -227.0 144.9 1530.6 44.8 5079.8
SYNZIP7 302.9 368.8 5864.4 -716.6 311.6 1454.4 255.9 3570.8 -529.0 2602.3
SYNZIP8 1110.5 536.4 -190.0 -44.8 1177.3 2348.9 567.0 2013.9 819.6 2767.0
SYNZIP9 7895.5 688.4 -627.6 1500.6 531.6 2978.1 -632.4 169.9 214.5 34170.9
SYNZIP1O 1378.1 738.0 4152.5 1352.3 598.3 2150.9 1645.6 5208.0 1003.9 1562.6
SYNZIP11 4424.5 1424.5 2567.8 813.3 3601.9 2973.3 1379.1 8323.0 2010.9 15830.4
SYNZIP12 1610.9 1178.6 8583.1 -1728.1 3103.0 799.8 914.5 5387.5 3180.3 9262.3
SYNZIP13 1019.4 452.1 -1177.1 -100.3 -145.0 480.4 59.5 351.1 73.6 7393.3
SYNZIP14 2611.1 759.3 3923.6 3037.9 668.8 1356.4 442.1 19711.0 1634.6 6924.8
SYNZIP15 -313.1 224.6 17729.9 -1455.6 -297.4 1080.5 649.8 15768.8 5377.8 8950.4
SYNZIP16 22046.6 942.6 1694.3 1519.6 5918.5 1485.0 1025.6 5514.1 1104.9 11950.5
SYNZIP17 13695.9 551.6 0.5 10334.5 1269.3 7741.8 198.1 -279.5 1423.4 31131.5
SYNZIP18 -254.0 671.3 18844.9 883.4 2713.9 309.4 1966.6 6394.5 -55.3 2034.0
SYNZIP19 3142.4 542.1 533.8 6987.9 457.4 2429.1 106.0 9506.1 20530.6 11655.9
SYNZIP20 2605.5 439.9 -142.4 3469.3 271.4 1832.6 1090.3 5166.9 5052.0 17962.3
SYNZIP21 351.0 566.8 2579.8 699.3 900.5 1037.3 7398.3 3473.3 2297.3 4793.9
SYNZIP22 14364.3 7311.9 6067.9 1502.6 10906.8 6275.9 979.0 2258.1 6420.5 18413.1
SYNZIP23 262.4 459.0 20967.5 25367.3 722.1 5010.5 1245.4 4291.0 41325.6 25403.4
SYNZIP24 -121.4 301.3 -906.8 -1086.9 -153.4 1198.9 -424.0 478.1 1389.4 -557.1
SYNZIP25 193.6 621.8 -339.6 -1308.8 992.1 -852.4 673.0 4632.4 125.4 14939.0
SYNZIP26 -115.8 323.6 -114.8 359.5 -178.8 -19.0 531.8 9262.0 721.9 1261.9
SYNZIP27 24764.8 982.3 271.4 2822.1 3689.9 5945.8 258.4 224.3 1233.4 11190.9
SYNZIP28 6882.5 577.9 -385.6 1292.8 947.5 6163.0 -24.6 -361.5 796.6 7196.6
Protein ATF4 ATF3 BACHI JUND NFE2L3 SYNZIP5(2) SYN37(2) SYNZIP6(2) ATF4(2) FOS(2)
SYNZIP1 3053.8 1420.0 1577.6 3627.1 2925.1 290.4 380.3 163.9 1997.3 1168.5
SYNZIP2 28082.8 18064.8 1266.9 7929.5 1109.6 1068.3 7298.6 763.0 22237.3 18017.8
SYNZIP3 5823.0 3581.0 134.5 28656.3 -86.9 11407.4 -180.0 418.0 4817.3 -658.3
SYNZIP4 3458.6 17232.4 696.4 5558.6 681.0 4.5 278.5 14845.0 3406.3 6151.4
SYNZIP5 6154.3 7063.1 146.1 11543.6 147.0 -121.6 -26.6 40014.4 5716.6 4467.9
SYNZIP6 4243.6 12134.8 2673.8 16589.0 -258.6 50451.1 -107.1 -112.6 3719.8 4670.8
SYNZIP7 32347.3 360.5 4649.4 6636.9 27047.4 -185.5 201.1 -246.8 30001.6 3755.4
SYNZIP8 1243.1 2317.9 2708.6 6235.3 1894.3 1311.3 -7.4 125.3 1264.1 2566.5
SYNZIP9 1541.8 6073.8 24587.6 5738.9 3399.1 1439.0 19199.0 2013.0 1329.5 31369.4
SYNZIP1O 5436.6 4179.5 -150.5 12891.0 470.9 2624.5 702.9 4658.4 5082.5 2021.8
SYNZIP11 17929.4 26643.8 10092.0 16369.5 4545.5 11578.1 2212.0 533.5 15494.5 18153.5
SYNZIP12 12482.6 40057.8 4713.6 11054.3 828.3 17760.9 447.9 850.5 10379.1 10370.5
SYNZIP13 1628.3 11177.0 -271.5 1128.6 576.6 659.3 -230.9 1800.0 1851.0 6599.4
SYNZIP14 9191.0 9794.9 2727.0 8261.8 303.5 1466.0 2471.6 5248.0 5608.0 7193.1
SYNZIP15 35747.3 14239.9 -629.9 1597.1 342.9 -426.4 1037.8 393.6 26273.6 8321.8
SYNZIP16 20306.6 10669.4 10058.1 16018.1 4126.0 23360.8 5900.3 253.3 16289.1 14487.6
SYNZIP17 951.1 3487.1 20467.5 4762.5 351.8 1223.6 23343.1 5787.1 1121.8 31600.1
SYNZIP18 8274.4 5824.8 4007.5 19155.4 956.1 17117.4 2225.8 109.9 5166.6 1663.5
SYNZIP19 4515.0 7485.1 259.4 265.0 388.0 -200.1 3888.1 19731.6 4373.4 11508.9
SYNZIP20 4251.1 15726.5 -88.9 3124.3 1787.9 -52.0 -718.1 20718.6 3381.3 19099.0
SYNZIP21 3314.1 32347.4 1111.0 27319.5 1097.1 31805.6 -131.3 651.1 3480.8 4989.3
SYNZIP22 46531.6 16363.6 15474.1 26119.5 28539.3 20949.0 2210.4 -128.5 37329.8 19989.5
SYNZIP23 3541.8 19932.6 7074.4 2978.0 2526.4 688.6 -243.1 24579.4 3239.4 25406.4
SYNZIP24 1939.9 365.5 -1420.4 -284.6 171.9 -707.0 308.3 771.3 2117.4 -651.6
SYNZIP25 3907.1 7493.3 357.8 3463.0 246.9 7360.1 -180.4 -351.0 3354.0 14167.5
SYNZIP26 1364.1 743.8 1003.0 1360.8 300.1 848.8 -158.8 58.5 1260.4 407.6
SYNZIP27 3004.3 3749.1 20822.9 1764.3 1659.9 3435.1 15729.6 2018.0 2248.6 12173.0
SYNZIP28 1807.1 2316.8 10386.3 -42.0 1139.0 716.5 6897.8 2023.4 1833.1 8138.3
Protein SYNZIP1 SYNZIP2 SYNZIP3 SYNZIP4 SYNZIP5 SYNZIP6 SYNZIP7 SYNZIP8 SYNZIP9 SYNZIP10
SYNZIP29 1896.9 30870.3 1920.8 1975.0 3266.1 9225.5 3999.0 12211.0 1676.0 7345.8
SYNZIP30 4521.9 24828.0 2650.0 13367.0 3763.5 15017.8 8682.0 19723.5 661.9 %20.9
SYNZIP31 -227.6 4698.1 192.9 -476.5 3162.6 92.5 -91.4 -141.6 -156.5 490.9
SYNZIP32 -1281.1 1743.4 -1031.4 -4299.9 6521.3 9.4 -152.8 -259.0 -593.0 -526.4
SYNZIP33 -354.9 25369.3 1083.9 334.6 316.5 845.6 1766.4 2265.9 317.0 4585.0
SYNZIP34 119.5 4531.6 3470.8 1309.3 514.3 513.4 3.1 350.1 -146.4 612.9
SYNZIP35 427.6 1246.8 16456.8 1286.9 655.4 3118.8 255.4 588.0 87.4 2182.1
SYNZIP36 -71.9 -324.3 311.9 -1904.9 -132.8 772.3 -62.1 92.0 -371.0 -196.8
SYNZIP37 -141.6 8759.5 -522.0 220.9 -456.3 -663.6 544.5 148.5 8519.1 -415.4
SYNZIP38 57.0 404.9 1296.6 2669.0 37.5 103.9 983.8 1996.6 -247.9 -24.6
SYNZIP39 -191.0 3869.1 847.9 2954.3 365.9 -3.8 1788.6 3831.8 916.3 1073.1
SYNZIP40 137.4 2158.0 -158.0 2992.3 10116.6 237.3 8195.4 8907.0 -131.9 -811.6
SYNZIP41 -1118.5 1083.1 -182.9 2248.1 -303.8 -229.0 415.6 544.5 2035.4 -991.5
SYNZIP42 35.9 788.4 408.6 -90.4 -124.8 102.8 26.9 300.4 34.1 -209.5
SYNZIP43 -934.0 15741.5 10102.1 4654.3 2996.9 4873.8 4742.4 68.0 -238.5 1651.9
SYNZIP44 -190.0 441.8 -258.4 38735.1 3533.3 1397.5 -129.6 -180.3 3271.5 306.5
SYNZIP45 -175.6 4051.9 672.5 707.8 -535.0 1052.4 67.8 1818.8 430.4 -403.3
SYNZIP46 2115.8 -620.0 -932.8 -914.3 -506.4 -383.4 -100.4 -75.9 -126.0 -163.3
SYNZIP47 27.9 -97.6 306.1 -1210.6 -298.8 1398.6 -277.5 590.9 -366.6 -503.8
SYNZIP48 5590.1 10726.9 904.1 1250.6 2799.6 1541.6 4291.0 7820.9 -245.5 5330.5
BATF 169.0 4108.0 289.5 3800.6 1982.6 122.5 483.4 640.1 273.4 188.6
FOS 355.9 25811.1 438.1 4373.0 353.0 823.4 1809.4 1107.1 31699.6 -516.1
ATF4 341.3 45201.3 3634.5 1430.3 703.5 443.0 36041.1 476.3 -387.3 481.1
ATF3 -158.8 17343.6 891.5 8663.8 369.3 1460.9 363.5 598.0 670.9 220.3
BACH1 452.4 2642.6 -1.4 4098.1 39.0 366.8 2991.0 1942.3 8760.5 -308.9
JUND 271.3 2510.0 12860.5 2623.4 832.3 3651.6 795.6 3186.0 878.1 1003.8
NFE2L3 134.3 -858.3 -336.5 -580.9 -133.3 83.8 4285.5 165.0 327.6 -171.6
Protein SYNZIPIl SYNZIP12 SYNZIP13 SYNZIP14 SYNZIP15 SYNZIP16 SYNZIP17 SYNZIP18 SYNZIP19 SYNZIP20
SYNZIP29 20577.6 14436.9 3188.5 10125.3 14839.0 25111.4 3769.8 16366.8 581.5 6595.0
SYNZIP30 21824.9 15677.3 5439.3 15343.8 29943.3 23308.1 3590.8 23744.4 6878.9 6579.3
SYNZIP31 248.3 3610.6 -657.3 2890.5 17842.8 2402.3 -785.0 1358.6 803.9 5209.0
SYNZIP32 -227.8 279.5 -1209.8 323.4 11618.3 162.5 -1720.1 -391.9 1243.3 1323.3
SYNZIP33 12673.0 22749.5 307.3 22381.8 27053.1 24659.4 5735.1 4350.4 13702.9 7584.0
SYNZIP34 3235.9 2524.3 748.4 20234.4 40815.0 8797.0 927.9 3038.1 2890.9 4347.8
SYNZIP35 976.8 -495.8 374.3 1183.8 1481.4 3338.9 2659.6 10191.5 3651.4 7530.1
SYNZIP36 -139.6 128.4 -523.4 -231.8 -996.9 -405.0 16.4 490.8 506.0 2182.9
SYNZIP37 44.3 -426.4 14.1 39.5 627.4 8424.4 15728.6 366.5 3770.3 -1960.5
SYNZIP38 3164.3 -37.1 181.9 7925.3 2440.6 4952.9 879.8 -34.9 1560.0 -555.3
SYNZIP39 3212.0 266.1 -453.1 1242.1 762.1 6160.0 3434.4 19.1 4787.5 1473.9
SYNZIP40 692.9 236.8 648.8 7773.0 1464.0 18851.3 301.8 2569.1 13835.0 7316.4
SYNZIP41 54.0 128.3 -254.6 -831.8 -1632.6 15347.4 6736.6 -357.0 1778.9 960.4
SYNZIP42 150.6 -51.1 161.8 -673.9 -871.5 1826.1 831.5 -423.5 -838.6 -548.3
SYNZIP43 132.8 3818.1 -337.1 2192.5 26601.9 2690.3 -751.5 6669.6 -707.1 511.5
SYNZIP44 813.3 -423.1 1070.5 4856.4 -544.8 2946.3 11164.0 38.1 9649.9 7054.6
SYNZIP45 1308.8 1357.0 -60.5 -119.1 -2049.0 10866.9 1885.8 742.6 464.6 -100.4
SYNZIP46 -700.5 -987.5 -701.1 -1094.1 -5031.0 -1059.5 -806.0 -777.1 -261.9 -160.6
SYNZIP47 765.3 20.1 487.1 -302.0 -592.0 -337.3 -1327.6 -42.8 -591.4 1623.8
SYNZIP48 7251.1 5793.0 184.0 6076.4 10075.8 4610.3 -1247.5 6124.1 3850.3 3134.5
BATF 1846.9 673.9 539.3 883.0 5957.1 2534.0 3008.6 -212.5 16793.1 7000.8
FOS 6157.9 1934.0 2685.0 6466.4 5057.4 28581.8 37108.3 117.8 6972.8 25938.1
ATF4 10480.9 6243.9 520.3 8382.4 49513.4 41931.1 346.1 1062.1 294.1 838.9
ATF3 6402.1 19974.8 4257.4 4087.5 4948.4 12070.3 2376.5 214.0 1093.4 13519.4
BACHI 1788.8 -636.5 615.5 2117.1 -2430.8 7640.8 10141.1 -480.0 543.8 -1276.6
JUND 506.9 -1547.8 1265.4 -289.3 -458.3 14361.9 2505.5 1165.8 -1055.6 2079.0
NFE2L3 30.8 -417.5 98.1 -792.1 -804.4 -560.6 -524.0 -538.9 -1534.5 -1125.4
Protein SYNZIP21 SYNZIP22 SYNZIP23 SYNZIP24 SYNZIP25 SYNZIP26 SYNZIP27 SYNZIP28 SYNZIP29 SYNZIP30
SYNZIP29 10481.0 9108.3 12240.8 5028.9 14431.5 424.0 8083.5 6141.9 416.4 640.5
SYNZIP30 14194.4 10006.6 16090.4 10835.1 12132.4 778.3 1441.4 229.9 426.5 1630.0
SYNZIP31 9598.8 435.6 23329.6 16403.5 -92.0 177.1 419.5 669.8 798.0 375.9
SYNZIP32 7954.6 -1280.0 4434.9 9960.4 -93.5 964.4 4821.9 3274.6 2862.3 1435.4
SYNZIP33 14104.1 9135.1 14%3.9 5618.4 7911.0 331.9 5119.9 10270.8 3513.1 1894.1
SYNZIP34 10535.1 2697.3 28266.9 8234.6 227.5 743.0 2034.1 658.4 2390.8 3495.5
SYNZIP35 17653.9 1099.1 26860.6 923.0 151.3 874.5 2715.4 -240.6 2466.9 7036.1
SYNZIP36 1569.8 -1066.0 11293.4 -1201.4 34.8 388.1 791.3 173.5 1053.4 2300.5
SYNZIP37 987.4 -1737.9 -893.8 1978.5 61.4 596.8 32892.1 18435.0 4601.3 1977.9
SYNZIP38 2810.9 -388.9 2498.4 11068.4 171.5 %7.3 6707.0 6157.9 2708.8 2190.4
SYNZIP39 1328.0 -109.0 5792.3 3799.4 -305.5 572.8 9844.3 12439.9 3262.1 4044.1
SYNZIP40 -276.5 -659.1 8391.6 26446.1 138.4 849.1 10091.6 17681.6 2758.9 1056.0
SYNZIP41 -130.5 2339.1 -1279.1 555.0 68.0 315.4 30882.3 13176.8 4472.8 2349.4
SYNZIP42 -69.4 6331.9 -171.4 652.4 192.3 986.4 4210.1 237.4 5146.6 2024.4
SYNZIP43 11665.8 2572.1 34636.5 12303.6 112.9 339.0 -1211.5 -1321.0 1187.5 2325.8
SYNZIP44 1918.0 23.6 28527.5 2598.5 548.8 574.6 11327.6 10547.1 7743.5 8754.5
SYNZIP45 1837.8 3990.3 1%6.3 -392.3 -268.3 754.8 12878.0 5165.8 2977.6 5765.9
SYNZIP46 -1490.8 -2292.1 -1062.4 -545.8 -196.1 63.4 2680.3 3731.4 1810.3 1776.8
SYNZIP47 9564.6 -1087.5 871.3 -1214.1 4208.8 255.1 -2068.1 -636.1 338.0 352.6
SYNZIP48 5566.9 686.1 2989.5 483.4 3965.9 12198.8 -2002.1 -1452.5 -217.1 -60.0
BATF 3581.4 3339.6 38364.0 5683.3 187.6 757.3 7114.9 8121.6 5987.0 6497.4
FOS 7486.6 12546.8 26601.6 534.0 1413.4 1068.9 24859.9 19649.8 8339.8 5178.5
ATF4 4479.1 30585.9 7694.1 11346.5 288.0 777.4 3533.3 1365.6 8279.6 6124.8
ATF3 29434.8 7975.8 24547.0 1577.0 106.0 1185.8 2495.0 1887.5 3678.9 4279.8
BACHI 919.4 3805.9 6787.6 -99.0 1584.8 1866.3 30298.1 22918.8 4367.1 4725.8
JUND 29895.6 10619.0 7296.3 697.5 20.4 1306.9 -1786.1 -1311.0 4660.0 4605.3
NFE2L3 -1093.9 3456.1 -1738.8 -185.5 186.8 -105.9 -491.3 -1419.5 269.5 603.3
Protein SYNZIP31 SYNZIP32 SYNZIP33 SYNZIP34 SYNZIP35 SYNZIP36 SYNZIP37 SYNZIP38 SYNZIP39 SYNZIP40
SYNZIP29 6525.9 4252.6 12063.4 3571.1 103.4 758.8 15566.4 4197.3 4578.9 9246.5
SYNZIP30 11833.9 3705.1 12311.5 6951.1 7601.3 7576.1 5188.4 2818.1 5833.5 6277.9
SYNZIP31 12845.8 820.8 5088.3 22225.5 96.0 848.0 1488.0 474.9 -209.1 247.1
SYNZIP32 5780.6 303.6 1929.5 21185.6 -404.6 249.9 764.9 1464.5 2267.8 -236.5
SYNZIP33 13516.8 2042.8 18294.6 21285.5 947.5 2015.9 2558.4 1247.9 3484.6 4232.4
SYNZIP34 41747.5 36836.0 39042.9 10390.4 274.5 734.3 3025.0 1614.3 925.4 1853.9
SYNZIP35 4433.4 -63.1 2486.9 677.1 1358.8 677.0 1555.6 1583.3 1357.1 3599.3
SYNZIP36 2821.9 171.8 1090.0 587.6 174.5 843.1 572.0 471.3 65.6 -103.4
SYNZIP37 1434.0 39.3 596.3 1546.3 406.4 75.0 2358.9 2354.4 4380.6 4384.5
SYNZIP38 4101.5 -46.3 4548.4 3334.1 746.9 452.9 9506.3 3193.1 2086.8 3038.4
SYNZIP39 1774.6 219.6 2998.3 1040.9 1274.8 333.0 8809.6 2277.1 9723.1 3486.0
SYNZIP40 1426.0 -143.1 3572.3 243.3 2184.6 173.8 7521.8 2104.4 1557.4 14896.5
SYNZIP41 794.1 -38.5 2688.3 321.5 2607.5 169.4 1699.9 1982.1 1782.6 3529.0
SYNZIP42 1770.0 -530.9 1984.8 322.3 290.3 316.6 1136.0 540.1 592.0 19532.3
SYNZIP43 9910.3 179.6 4927.8 366.6 416.1 701.1 984.9 246.9 -91.4 1951.3
SYNZIP44 16103.5 1072.0 5818.9 2281.1 7600.0 4859.6 716.0 1479.3 96.1 2382.0
SYNZIP45 4293.4 149.9 7143.4 1168.0 87.4 290.3 1092.3 3241.4 2472.4 3650.8
SYNZIP46 -1576.0 -56.1 -1184.9 -1889.4 -99.8 -168.1 249.0 230.6 193.0 -247.8
SYNZIP47 576.3 51.8 -43.1 -216.5 -200.0 64.3 356.9 369.0 -1236.5 -264.6
SYNZIP48 2622.1 178.0 6620.4 639.5 1486.1 3665.0 768.4 806.0 709.6 1509.9
BATF 13330.5 1540.5 3127.1 17304.9 584.5 582.6 1721.9 10870.4 1694.4 1011.4
FOS 1853.4 816.4 5876.9 10360.4 2255.4 724.9 7880.9 13262.1 12213.9 5632.3
ATF4 32811.0 1242.9 27808.3 28253.0 260.4 569.8 1829.8 349.1 528.4 21756.3
ATF3 9108.1 1161.8 3026.9 14628.5 1130.9 994.0 2252.9 2349.8 3975.0 1357.8
BACHI 2206.8 -234.6 1996.3 1235.1 3108.3 801.1 10083.3 2518.9 6443.4' 6296.5
JUND 18241.6 300.0 8043.9 2521.3 224.5 403.5 -13.3 292.3 418.4 1418.8
NFE2L3 624.8 -494.8 821.6 -249.6 229.9 349.5 126.9 -152.3 -109.3 326.8
Protein SYNZIP41 SYNZIP42 SYNZIP43 SYNZIP44 SYNZIP45 SYNZIP46 SYNZIP47 SYNZIP48 BATF FOS
SYNZIP29 13843.0 4461.0 1072.9 10681.0 4194.5 12912.9 99.0 -131.4 5111.3 9189.1
SYNZIP30 12834.6 1001.4 5983.5 16354.3 5876.8 23510.6 808.1 859.1 7876.8 12206.1
SYNZIP31 -221.9 296.0 1153.4 1996.8 230.1 9.0 102.8 -633.5 2210.5 -26.0
SYNZIP32 -987.5 395.0 -1065.3 -552.4 228.3 319.1 116.1 -60.9 1737.3 4674.1
SYNZIP33 3187.5 954.3 2582.5 860.8 5600.1 959.5 147.5 3504.8 1597.6 4427.9
SYNZIP34 1148.8 491.9 547.8 535.1 378.3 1169.3 228.6 693.1 13095.3 8182.8
SYNZIP35 5301.6 545.3 708.5 3017.9 142.1 465.9 299.5 1453.1 295.9 3024.1
SYNZIP36 418.4 461.4 662.1 1624.4 75.5 -98.6 52.8 959.3 -0.9 638.8
SYNZIP37 849.1 551.0 -685.5 -691.4 601.5 1419.5 483.1 -43.3 -23.9 4497.6
SYNZIP38 23897.9 650.6 -91.5 -75.6 2717.3 692.5 -26.8 484.8 9668.5 18673.1
SYNZIP39 2346.8 596.3 25.5 -97.0 951.8 5209.3 325.9 762.0 227.5 10208.5
SYNZIP40 3498.4 6775.5 -4647.8 -1083.8 831.5 2152.0 430.8 38.3 -121.4 3875.4
SYNZIP41 13639.9 1222.6 -454.9 -401.9 787.5 -185.9 -12.8 -303.8 -158.8 1074.6
SYNZIP42 4762.6 695.3 0.5 -99.3 80.4 -108.0 140.0 85.9 -292.1 2172.3
SYNZIP43 822.1 420.8 -811.3 30243.9 352.3 6761.5 63.3 -58.3 706.6 3319.3
SYNZIP44 -230.1 335.6 33033.3 9029.1 512.1 1088.6 2209.6 1393.5 202.0 1035.5
SYNZIP45 490.5 526.3 1257.0 -192.4 709.8 328.3 70.5 819.4 68.3 3057.6
SYNZIP46 -522.3 227.5 436.6 -2569.1 338.4 1545.9 10.5 5615.1 -214.1 -678.8
SYNZIP47 -222.6 273.6 -104.3 398.9 -310.8 -296.8 128.0 8248.0 332.4 746.9
SYNZIP48 -348.5 458.6 -195.3 2779.8 1187.4 12065.8 21439.1 2571.6 1855.4 2462.5
BATF 715.1 480.8 1645.9 -484.8 421.5 664.3 346.8 949.0 671.9 1091.0
FOS 1418.5 973.3 -145.6 -163.3 614.9 3601.5 661.8 383.3 183.0 2417.6
ATF4 125.1 926.0 941.5 3857.8 412.1 2929.0 258.3 2005.5 5058.0 5382.0
ATF3 908.3 512.9 2961.4 1974.9 1449.8 370.6 678.5 -242.5 1625.8 3603.0
BACHI 1611.0 930.0 -0.4 -1432.5 1162.5 3202.6 11239.8 1899.9 966.4 2435.1
JUND -31.4 601.3 -140.1 -861.4 225.8 345.0 303.1 1184.3 17584.1 22293.1
NFE2L3 -994.8 291.3 -21.9 -611.5 0.8 265.9 55.8 -742.8 -260.3 -1926.1
Protein ATF4 ATF3 BACHI JUND NFE2L3 SYNZIP5(2) SYN37(2) SYNZIP6(2) ATF4(2) FOS(2)
SYNZIP29 8674.4 4866.3 11467.6 9058.4 5495.8 4790.6 14756.8 9066.6 6620.0 11400.4
SYNZIP30 12458.9 7376.4 17800.8 11935.9 9128.6 6310.1 2989.5 15460.1 10116.8 13449.4
SYNZIP31 6120.8 2839.4 206.8 3165.5 13.1 3248.3 223.0 44.8 4529.0 364.6
SYNZIP32 5014.3 7568.0 66.9 6813.9 632.1 9805.4 63.9 -606.8 4410.9 12184.0
SYNZIP33 18008.4 4339.4 4169.5 8353.5 8524.8 824.9 817.8 978.0 13227.0 4968.4
SYNZIP34 17674.8 19232.9 675.0 5185.3 1235.3 717.4 1362.0 505.0 14255.3 9653.9
SYNZIP35 1989.5 2626.6 5027.8 2326.6 1194.5 935.6 728.3 3840.1 1924.3 3736.6
SYNZIP36 1753.6 3381.1 1060.8 1372.9 507.9 -205.5 -58.3 1580.8 1919.3 863.5
SYNZIP37 1973.4 1903.8 4773.3 2179.6 1959.8 -202.5 439.5 176.4 2504.4 4514.6
SYNZIP38 2727.0 4894.4 4388.8 1231.8 772.3 275.1 3456.8 -287.0 2642.4 19993.1
SYNZIP39 2422.0 3492.3 7314.3 4994.8 77.8 907.6 4679.5 366.8 958.0 12813.9
SYNZIP40 13239.0 -896.0 7118.1 2705.5 1785.1 12696.8 2756.1 -333.6 10121.5 6037.3
SYNZIP41 669.0 536.8 948.8 424.5 459.6 -156.8 -288.1 -115.5 1025.1 1602.4
SYNZIP42 4351.1 746.3 338.3 358.0 813.3 95.1 455.0 17.4 3206.3 2475.9
SYNZIP43 2988.9 9388.4 -141.5 1247.6 221.0 3747.8 145.0 5225.3 2600.9 3998.1
SYNZIP44 5835.3 8621.6 403.6 5087.1 71.4 5305.9 -94.8 798.0 5829.6 1247.5
SYNZIP45 3345.9 7287.3 1439.1 4763.0 199.6 77.6 239.0 1796.3 1648.9 4256.1
SYNZIP46 -419.8 -462.6 355.1 1211.5 833.6 -538.0 -79.3 -553.3 400.1 -244.4
SYNZIP47 686.8 660.0 4774.5 453.3 -300.0 211.8 -673.0 122.0 521.9 77.4
SYNZIP48 5761.4 2081.0 10982.6 1879.3 1272.8 4041.9 115.4 1665.5 4930.1 2420.0
BATF 8019.1 7824.9 4464.8 35898.8 1824.6 2706.3 768.1 -666.8 7322.9 2072.8
FOS 6565.6 3277.9 2061.5 26790.8 676.1 660.6 2984.5 876.5 5317.8 3855.9
ATF4 881.5 15257.6 2381.3 1593.0 8034.4 1142.5 1138.3 119.3 683.9 6049.3
ATF3 9937.0 1793.8 491.5 20496.4 -409.3 1160.8 1131.5 1854.1 6762.9 3957.6
BACHI 3553.5 472.5 3295.6 7532.3 524.0 170.1 5262.9 283.0 3410.0 4463.4
JUND 987.4 25712.8 -84.5 2800.8 25.6 1688.8 87.5 2166.8 1413.1 22039.5
NFE2L3 1456.4 -1875.4 -295.3 -1931.3 382.1 -293.5 272.5 -146.8 1664.4 -1536.9
Table C.S3. List of the proteins composing each of the subnetworks identified.
2 nodes Motif A B
pairs A-B SYNZIP5 SYNZIP6
pairs A-B SYNZIP20 SYNZIP1 1
pairs A-B SYNZIP20 SYNZIP16
pairs A-B SYNZIP20 SYNZIP2
pairs A-B SYNZIP13 SYNZIP15
pairs A-B SYNZIP16 SYNZIP23
pairs A-B SYNZIP12 SYNZIP23
pairs A-B SYNZIP22 SYNZIP19
pairs A-B SYNZIP22 SYNZIP14
pairs A-B SYNZIP22 SYNZIP10
pairs A-B SYNZIP22 ATF4
pairs A-B SYNZIP2 SYNZIP14 -
pairs A-B SYNZIP2 SYNZIP1
pairs A-B SYNZIP19 SYNZIP18
pairs A-B SYNZIP19 SYNZIP21
pairs A-B SYNZIP15 ATF4
pairs A-B SYNZIP9 FOS
pairs A-B SYNZIP17 SYNZIP18
pairs A-B SYNZIP17 FOS
pairs A-B SYNZIP18 SYNZIP23
pairs A-B SYNZIP23 SYNZIP21
pairs A-B SYNZIP23 SYNZIP6
pairs A-B SYNZIP23 SYNZIP8
pairs A-B SYNZIP23 BATF
pairs A-B SYNZIP21 SYNZIP4
pairs A-B SYNZIP3 SYNZIP4
pairs A-B SYNZIP7 ATF4
3 nodes Motif A B C
line A-B-C SYNZIP5 SYNZIP6 SYNZIP5
line A-B-C SYNZIP1 1 SYNZIP20 SYNZIP16
line A-B-C SYNZIP1 1 SYNZIP20 SYNZIP2
line A-B-C SYNZIP20 SYNZIP2 SYNZIP14
line A-B-C SYNZIP20 SYNZIP2 SYNZIP1
line A-B-C SYNZIP13 SYNZIP15 ATF4
line A-B-C SYNZIP16 SYNZIP23 SYNZIP16
line A-B-C SYNZIP16 SYNZIP23 SYNZIP16
line A-B-C SYNZIP16 SYNZIP23 SYNZIP6
line A-B-C SYNZIP16 SYNZIP23 SYNZIP8
line A-B-C SYNZIP16 SYNZIP23 BATF
line A-B-C SYNZIP12 SYNZIP23 SYNZIP12
line A-B-C SYNZIP12 SYNZIP23 SYNZIP6
line A-B-C SYNZIP12 SYNZIP23 SYNZIP8
line A-B-C SYNZIP12 SYNZIP23 BATF
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line A-B-C SYNZIP19 SYNZIP22 SYNZIP14
line A-B-C SYNZIP19 SYNZIP22 SYNZIP10
line A-B-C SYNZIP19 SYNZIP22 ATF4
line A-B-C SYNZIP14 SYNZIP22 SYNZIP10
line A-B-C SYNZIP10 SYNZIP22 ATF4
line A-B-C SYNZIP14 SYNZIP2 SYNZIP1
line A-B-C SYNZIP19 SYNZIP18 SYNZIP19
line A-B-C SYNZIP19 SYNZIP18 SYNZIP23
line A-B-C SYNZIP18 SYNZIP19 SYNZIP21
line A-B-C SYNZIP19 SYNZIP21 SYNZIP19
line A-B-C SYNZIP19 SYNZIP21 SYNZIP4
line A-B-C SYNZIP15 ATF4 SYNZIP15
line A-B-C SYNZIP9 FOS SYNZIP9
line A-B-C SYNZIP18 SYNZIP17 FOS
line A-B-C SYNZIP18 SYNZIP23 SYNZIP21
line A-B-C SYNZIP18 SYNZIP23 SYNZIP6
line A-B-C SYNZIP18 SYNZIP23 SYNZIP8
line A-B-C SYNZIP18 SYNZIP23 BATF
line A-B-C SYNZIP21 SYNZIP23 SYNZIP6
line A-B-C SYNZIP21 SYNZIP23 SYNZIP8
line A-B-C SYNZIP21 SYNZIP23 BATF
line A-B-C SYNZIP6 SYNZIP23 SYNZIP8
line A-B-C SYNZIP6 SYNZIP23 BATF
line A-B-C SYNZIP8 SYNZIP23 BATF
line A-B-C SYNZIP21 SYNZIP4 SYNZIP21
4 nodes Motif A B C D
2 pairs A-B,C-D SYNZIP5 SYNZIP6 SYNZIP13 SYNZIP1
5
2 pairs A-B,C-D SYNZIP5 SYNZIP6 SYNZIP1 SYNZIP2
2 pairs A-B,C-D SYNZIP5 SYNZIP6 ATF4 SYNZIP1
5
2 pairs A-B,C-D SYNZIP5 SYNZIP6 FOS SYNZIP9
2 pairs A-B,C-D SYNZIP5 SYNZIP6 SYNZIP7 ATF4
2 pairs A-B,C-D SYNZIP20 SYNZIP 11 SYNZIP15 SYNZIP1
3
2 pairs A-B,C-D SYNZIP22 SYNZIP19 SYNZIP3 SYNZIP4
2 pairs A-B,C-D SYNZIP22 ATF4 SYNZIP3 SYNZIP4
2 pairs A-B,C-D SYNZIP2 SYNZIP1 SYNZIP21 SYNZIP4
2 pairs A-B,C-D SYNZIP2 SYNZIP1 SYNZIP3 SYNZIP4
2 pairs A-B,C-D SYNZIP15 ATF4 SYNZIP3 SYNZIP4
2 pairs A-B,C-D SYNZIP9 FOS SYNZIP21 SYNZIP4
2 pairs A-B,C-D SYNZIP9 FOS SYNZIP3 SYNZIP4
2 pairs A-B,C-D SYNZIP9 FOS SYNZIP7 ATF4
2 pairs A-B,C-D SYNZIP17 FOS SYNZIP7 ATF4
2 pairs A-B,C-D SYNZIP23 SYNZIP6 SYNZIP7 ATF4
2 pairs A-B,C-D SYNZIP23 SYNZIP8 SYNZIP7 ATF4
2 pairs A-B,C-D SYNZIP3 SYNZIP4 SYNZIP7 ATF4
hub A-B,A-C,A-D SYNZIP2 SYNZIP1 SYNZIP20 SYNZIP1
1 4
hub A-B,A-C,A-D SYNZIP23 SYNZIP16 SYNZIP12 SYNZIP1
8
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hub A-B,A-C,A-D SYNZIP23 SYNZIP6 SYNZIP12 SYNZIP1
6
hub A-B,A-C,A-D SYNZIP23 SYNZIP8 SYNZIP12 SYNZIP1
6
hub A-B,A-C,A-D SYNZIP23 BATF SYNZIP12 SYNZIP1
6
hub A-B,A-C,A-D SYNZIP23 SYNZIP6 SYNZIP18 SYNZIP1
6
hub A-B,A-C,A-D SYNZIP23 SYNZIP8 SYNZIP18 SYNZIP1
6
hub A-B,A-C,A-D SYNZIP23 BATF SYNZIP18 SYNZIP1
6
hub A-B,A-C,A-D SYNZIP23 SYNZIP8 SYNZIP16 SYNZIP6
hub A-B,A-C,A-D SYNZIP23 BATF SYNZIP16 SYNZIP6
hub A-B,A-C,A-D SYNZIP23 BATF SYNZIP16 SYNZIP8
hub A-B,A-C,A-D SYNZIP23 SYNZIP6 SYNZIP18 SYNZIP1
2
hub A-B,A-C,A-D SYNZIP23 SYNZIP8 SYNZIP18 SYNZIP1
2
hub A-B,A-C,A-D SYNZIP23 BATF SYNZIP18 SYNZIP1
2
hub A-B,A-C,A-D SYNZIP23 SYNZIP8 SYNZIP12 SYNZIP6
hub A-B,A-C,A-D SYNZIP23 BATF SYNZIP12 SYNZIP6
hub A-B,A-C,A-D SYNZIP23 BATF SYNZIP12 SYNZIP8
hub A-B,A-C,A-D SYNZIP22 SYNZIP1O SYNZIP19 SYNZIP1
4
hub A-B,A-C,A-D SYNZIP22 ATF4 SYNZIP19 SYNZIP1
0
hub A-B,A-C,A-D SYNZIP23 SYNZIP6 SYNZIP18 SYNZIP2
1
hub A-B,A-C,A-D SYNZIP23 SYNZIP8 SYNZIP18 SYNZIP2
1
hub A-B,A-C,A-D SYNZIP23 BATF SYNZIP18 SYNZIP2
1
hub A-B,A-C,A-D SYNZIP23 SYNZIP8 SYNZIP18 SYNZIP6
hub A-B,A-C,A-D SYNZIP23 BATF SYNZIP18 SYNZIP6
hub A-B,A-C,A-D SYNZIP23 BATF SYNZIP18 SYNZIP8
hub A-B,A-C,A-D SYNZIP23 SYNZIP8 SYNZIP21 SYNZIP6
hub A-B,A-C,A-D SYNZIP23 BATF SYNZIP21 SYNZIP6
hub A-B,A-C,A-D SYNZIP23 BATF SYNZIP21 SYNZIP8
hub A-B,A-C,A-D SYNZIP23 BATF SYNZIP6 SYNZIP8
line A-B-C-D SYNZIP5 SYNZIP6 SYNZIP23 SYNZIP8
line A-B-C-D SYNZIP13 SYNZIP15 ATF4 SYNZIP7
line A-B-C-D SYNZIP19 SYNZIP21 SYNZIP4 SYNZIP3
box A-B-C-D-A SYNZIP21 SYNZIP23 SYNZIP18 SYNZIP1
9
5 nodes Motif A B C D E
pair+line A-B,C-D-E SYNZIP5 SYNZIP6 SYNZIP13 SYNZIP1 ATF4
5
pair+line A-B,C-D-E SYNZIP5 SYNZIP6 SYNZIP15 ATF4 SYNZIP7
pair+line A-B,C-D-E SYNZIP7 ATF4 SYNZIP5 SYNZIP6 SYNZIP23
pair+line A-B,C-D-E SYNZIP3 SYNZIP4 SYNZIP19 SYNZIP2 ATF4
2
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pair+line A-B,C-D-E SYNZIP2 SYNZIP1 SYNZIP21 SYNZIP4 SYNZIP3
pair+line A-B,C-D-E SYNZIP3 SYNZIP4 SYNZIP15 ATF4 SYNZIP7
pair+line A-B,C-D-E SYNZIP7 ATF4 SYNZIP9 FOS SYNZIP17
pair+line A-B,C-D-E SYNZIP9 FOS SYNZIP21 SYNZIP4 SYNZIP3
pair+line A-B,C-D-E SYNZIP7 ATF4 SYNZIP8 SYNZIP2 SYNZIP6
3
hub A-B,A-C,A-D,A-E SYNZIP23 SYNZIP12 SYNZIP18 SYNZIP1 SYNZIP6
6
hub A-B,A-C,A-D,A-E SYNZIP23 SYNZIP12 SYNZIP18 SYNZIP1 SYNZIP8
6
hub A-B,A-C,A-D,A-E SYNZIP23 SYNZIP12 SYNZIP18 SYNZIP1 BATF
6
hub A-B,A-C,A-D,A-E SYNZIP23 SYNZIP12 SYNZIP16 SYNZIP6 SYNZIP8
hub A-BA-C,A-D,A-E SYNZIP23 SYNZIP12 SYNZIP16 SYNZIP6 BATF
hub A-B,A-C,A-D,A-E SYNZIP23 SYNZIP12 SYNZIP16 SYNZIP8 BATF
hub A-B,A-CA-D,A-E SYNZIP23 SYNZIP18 SYNZIP16 SYNZIP6 SYNZIP8
hub A-B,A-C,A-D,A-E SYNZIP23 SYNZIP18 SYNZIP16 SYNZIP6 BATF
hub A-B,A-C,A-D,A-E SYNZIP23 SYNZIP18 SYNZIP16 SYNZIP8 BATF
hub A-B,A-C,A-D,A-E SYNZIP23 SYNZIP16 SYNZIP6 SYNZIP8 BATF
hub A-B,A-C,A-D,A-E SYNZIP23 SYNZIP18 SYNZIP12 SYNZIP6 SYNZIP8
hub A-B,A-C,A-D,A-E SYNZIP23 SYNZIP18 SYNZIP12 SYNZIP6 BATF
hub A-B,A-CA-D,A-E SYNZIP23 SYNZIP18 SYNZIP12 SYNZIP8 BATF
hub A-B,A-C,A-D,A-E SYNZIP23 SYNZIP12 SYNZIP6 SYNZIP8 BATF
hub A-B,A-C,A-D,A-E SYNZIP23 SYNZIP18 SYNZIP21 SYNZIP6 SYNZIP8
hub A-B,A-C,A-DA-E SYNZIP23 SYNZIP18 SYNZIP21 SYNZIP6 BATF
hub A-B,A-C,A-D,A-E SYNZIP23 SYNZIP18 SYNZIP21 SYNZIP8 BATF
hub A-B,A-C,A-D,A-E SYNZIP23 SYNZIP18 SYNZIP6 SYNZIP8 BATF
hub A-B,A-C,A-D,A-E SYNZIP23 SYNZIP21 SYNZIP6 SYNZIP8 BATF
6 nodes Motif A B C D E F
line + A-B-C-D, E-F SYNZIP5 SYNZIP6 SYNZIP23 SYNZIP8 ATF4 SYNZIP7
pair
line + A-B-C-D, E-F SYNZIP13 SYNZIP15 ATF4 SYNZIP7 SYNZIP5 SYNZIP6
pair
3 pairs A-B,C-D,E-F SYNZIP9 FOS ATF4 SYNZIP7 SYNZIP5 SYNZIP6
3 pairs A-B,C-D,E-F SYNZIP9 FOS ATF4 SYNZIP7 SYNZIP4 SYNZIP3
hub A-B,A-C,A-D,A-E,A- SYNZIP23 SYNZIP16 BATF SYNZIP8 SYNZIP6 SYNZIP1
F 8
hub A-B,A-C,A-D,A-E,A- SYNZIP23 SYNZIP16 BATF SYNZIP8 SYNZIP6 SYNZIP1
_F 2
hub A-B,A-C,A-D,A-E,A- SYNZIP23 SYNZIP16 BATF SYNZIP8 SYNZIP18 SYNZIP1
F 2
hub A-B,A-C,A-D,A-E,A- SYNZIP23 SYNZIP16 BATF SYNZIP6 SYNZIP18 SYNZIP1
F _2
hub A-B,A-C,A-D,A-E,A- SYNZIP23 SYNZIP16 SYNZIP8 SYNZIP6 SYNZIP18 SYNZIP1
F 2
hub A-B,A-C,A-D,A-E,A- SYNZIP23 SYNZIP12 BATF SYNZIP8 SYNZIP6 SYNZIP1
F 8
hub A-B,A-C,A-D,A-E,A- SYNZIP23 SYNZIP18 BATF SYNZIP8 SYNZIP6 SYNZIP2
IF I
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Table C.S4. Crystallographic data collection and refinement statistics.
Protein SYNZIP6: SYNZIPl:
Data Set SYNZIP5 SYNZIP2
Space Group P 63 P 31
Cell dimensions
a, b, c(A) 82.7, 82.7, 150.6 49.9, 49.9, 113.2
a, p, y(,) 90, 90, 120 90, 90, 120
X (A) 0.97927 1.5418
Resolution (A) 50 - 2.46 50 - 1.75
Rsym (%)ab 10.9 (54.8) 3.8 (29.4)
#ref 21204 31354
Completeness (%)a 99.7 (99.3) 98.2 (90.7)
Redundancya 5.8 (5.4) 4.6 (2.8)
# dimers/ASU 4 3
Twin law h,-h-k,-l -k,-h,-l
Twin fraction 0.324 0.392
Rwork/Rfree(%)c 21.2/25.8 19.0/22.8
aValues in parentheses refers to data in the highest resolution shell
b = Xh j Ij(h) - <I(h)>| / Eh~j <I(h)>, where Ij(h) is the jth reflection of index h and <I(h)> is
the average intensity of all observations of I(h)
CRwork = Xh |Fobs(h) - Fcaic(h) I / Xh IFobs(h)|, calculated over the 95% of the data in the working
set. Rfree equivalent to Rwork except calculated over the 5% of the data assigned to the test set
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Barr virus protein BZLF1
Reproduced with permission of Elsevier B.V. from
Chen, T. S., Reinke, A. W. & Keating, A. E. Design of peptide inhibitors that bind
the bZIP domain of Epstein-Barr virus protein BZLF1. JMol Biol 408, 304-20
Collaborator notes
Aaron Reinke performed the electrophoretic mobility shift assay
386
ABSTRACT
Designing proteins or peptides that bind native protein targets can aid the development of
novel reagents and/or therapeutics. Rational design also tests our understanding of the principles
underlying protein recognition. This article describes several strategies used to design peptides
that bind to the basic region leucine zipper (bZIP) domain of the viral transcription factor BZLF 1,
which is encoded by the Epstein-Barr virus. BZLF 1 regulates the transition of the Epstein-Barr
virus from a latent state to a lytic state. It shares some properties in common with the more
studied human bZIP transcription factors, but also includes novel structural elements that pose
interesting challenges to inhibitor design. In designing peptides that bind to BZLF 1 by forming a
coiled-coil structure, we considered both affinity for BZLF 1 and undesired self-association,
which can weaken the effectiveness of an inhibitor. Several designed peptides exhibited different
degrees of target-binding affinity and self-association. Rationally engineered molecules were
more potent inhibitors of DNA binding than a control peptide corresponding to the native BZLF 1
dimerization region itself. The most potent inhibitors included both positive and negative design
elements and exploited interaction with the coiled-coil and basic DNA-binding regions of
BZLF1.
INTRODUCTION
The basic-region leucine-zipper (bZIP) transcription factors are a large class of proteins
conserved in eukaryotes and several viruses that regulate a wide range of biological processes.
The structure of bZIP-DNA complexes is very simple: a helical and positively charged DNA-
binding region is contiguous with a coiled coil that mediates protein homo- or hetero-
dimerization (O'Shea, et al. 1991). The bZIP coiled-coil helices wrap around one another in a
parallel orientation with "knobs-into-holes" side-chain packing geometry, and a 7-amino-acid
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heptad repeat characterizes the structure, in which each residue can be assigned a register
position labeled a through g (Figure D. 1). High-affinity binding of bZIP transcription factors to
DNA requires protein dimerization.
Given the many important biological roles of the bZIPs, molecules that selectively disrupt
bZIP-DNA interactions could be valuable reagents and even potential therapeutics. Several
strategies have been reported for identifying inhibitors. Small molecules have been discovered
via high-throughput screening, (Rishi, et al. 2005)and peptides that bind to the coiled-coil
regions of the bZIPs and disrupt dimer formation have been selected from targeted combinatorial
libraries (Mason, et al. 2009, Mason, et al. 2007, Mason, et al. 2006).A particularly effective
strategy for blocking bZIP-DNA interactions was developed by Vinson and co-workers, who
created a series of dominant-negative peptide inhibitors by replacing the basic regions of certain
bZIP proteins with a sequence enriched in negatively charged residues (the "acidic extension"),
giving so-called A-ZIPs (Acharya, et al. 2006b, Ahn, et al. 1998, Olive, et al. 1997, Krylov, et al.
1995). The A-ZIPs bind tightly and selectively to bZIPs and have been used to study the effects
of inhibiting dimerization and hence DNA binding in both cell culture and animal models (Oh, et
al. 2007, Gerdes, et al. 2006).
Current understanding of bZIP coiled-coil interactions has also enabled the computational
design of synthetic peptides to block bZIP dimerization. Significant effort has been dedicated to
elucidating sequence determinants governing the interactions of bZIP coiled coils, and to
developing predictive computational models that capture these. Several types of residue-pair
interactions that are important for specificity have been characterized in detail over the past 20
years, and models derived from physics-based calculations, machine learning, and
experimentally measured coupling energies have been developed to explain and predict bZIP
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coiled-coil interactions (Mason, et al. 2006, Grigoryan and Keating. 2006, Fong, et al. 2004,
Krylov, et al. 1994, Acharya, et al. 2006a, Steinkruger, et al. 2010). Using such binding models,
Grigoryan et al. recently designed a series of peptides that bind to targets in 19 out of 20 human
bZIP families (Grigoryan, et al. 2009).
An interesting issue in the study of bZIP interactions is specificity. Given the similarities
among sequences, and the many bZIPs in most eukaryotes, a large number of homo- and
heterodimers can potentially form. Interactions among human bZIPs have been shown to be
highly selective when assayed in vitro,(Vinson, et al. 2006, Newman and Keating. 2003) but it
can be difficult to achieve specificity in designed bZIP-like peptides. In particular, peptides
engineered to bind to bZIP coiled-coil regions have been shown to self-associate strongly and
also interact with undesired partners, (Mason, et al. 2007, Grigoryan, et al. 2009) In this work we
address considerations of both affinity and anti-homodimer specificity in the design of peptide
inhibitors for a viral bZIP protein, BZLF1.
BZLF 1 (Zta, ZEBRA, EB 1) is encoded by the Epstein-Barr virus (EBV) and triggers the
virus's latent to lytic switch by functioning as a transcription factor and regulator of DNA
replication. (Countryman, et al. 1987, Schepers, et al. 1993, Feederle, et al. 2000, Liu and Speck.
2003)Infection by EBV has been linked to several human malignancies such as Hodgkin's
disease and Burkitt's lymphoma (Young and Rickinson. 2004). The basic region of BZLF 1 is
highly homologous to that of human bZIPs and is responsible for direct contact with DNA; a
coiled-coil region immediately C-terminal to the basic helix mediates dimerization. However, a
recent crystal structure and other biochemical studies have revealed several unique features of
BZLF 1 (Figure D. 1 a) (Petosa, et al. 2006, Schelcher, et al. 2007). The coiled-coil region at the
dimerization interface is only 4 heptads long, whereas the coiled-coil regions of human bZIPs
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typically contain at least 5 heptads. Furthermore, only one of the four BZLF 1 coiled-coil heptads
includes a leucine residue at the d position; this residue occurs with much higher frequency in
human bZIP sequences (hence the name "leucine zipper"). The stability of the BZLF1
homodimer is significantly enhanced by a unique C-terminal (CT) region that folds back on the
coiled coil to form additional contacts; (Schelcher, et al. 2007)the CT region is only partially
observed in the crystal structure. Prior work using peptide arrays showed that BZLF1 constructs
corresponding to the coiled coil or the coiled coil plus the CT region homo-associate in
preference to binding any of 33 representative human bZIP proteins (Reinke, et al. 2010b).
It has been shown that a peptide corresponding to the coiled-coil region of BZLF 1, lacking
the DNA binding residues, inhibits BZLF 1 binding to DNA at high micromolar concentrations
(Hicks, et al. 2003). In this work, we sought new peptides that would mimic the coiled-coil
interface of the native structure yet provide more potent inhibition of DNA binding. As a design
target, BZLF1 is both simpler and more complex than human and viral bZIPs that have been the
subjects of previous computational design studies (Grigoryan, et al. 2009, Reinke, et al. 201 Ob).
It is simpler because of its unique structural features, which make coiled-coil inhibitors designed
to target it unlikely to interact broadly with other bZIP proteins. However, it is more complex
because the CT region and unusually tight helix packing make the interface unlike the
dimerization domains of better-understood bZIPs (Petosa, et al. 2006). Here we explore the
extent to which previously applied design strategies can be used successfully in the context of
BZLF 1. Throughout our analyses, we explicitly addressed two design criteria: affinity for
BZLF1 and design self-association, which is an undesirable trait for an inhibitor. The best
inhibitor incorporated both elements and included modifications of BZLF 1 in both the coiled-
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coil and DNA-binding regions. As assessed using DNA-binding gel-shift assays, this designed
peptide was much more potent than one corresponding to the native dimerization domain.
RESULTS
Computational design ofapeptide to bind the N-terminal part of the BZLFJ coiled coil
Our goal was to identify variants of the BZLF 1 dimerization domain that would function as
more effective dominant negative inhibitors of DNA binding. As described in the Introduction,
BZLF 1 possesses several unique features as a bZIP design target. These include the
unconventional, short coiled-coil segment and the CT region. The CT can be divided into the
proximal CT (residues 222 - 231) and the less structured distal CT (residues 232 - 246), as
shown in Figure D.lb. We began by re-designing the N-terminal two and a half heptads of the
BZLF1 coiled coil (residues 191 -209, Fig 2.2b), because we anticipated that this segment
would provide the greatest opportunity to improve affinity and heterodimer specificity over the
native sequence. Residues 210 - 221 also form part of the coiled-coil structure, but additionally
engage in non-coiled-coil hydrophobic contacts with the proximal CT as observed in the crystal
structure (Figure D. 1 a). Thus, in order to maintain this stabilizing interaction, these residues were
not changed in the design.
Both the desired design-target heterodimer and the undesired design homodimer were
modeled as parallel, blunt ended coiled coils. We used the CLASSY protein-design algorithm to
choose residues at 10 sites in the design, optimizing the predicted affinity of the design-target
complex (Grigoryan, et al. 2009). The scoring function used was based on a hybrid model that
included both physics-based and experimentally derived terms and is described further in the
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Methods. The optimal-affinity design, which we call BDc (BZLF 1 design against the coiled-coil
region, shown in Figure D.2c), was predicted to be hetero-specific. In design energy units the
predicted stabilities were as follows: BZLF1 homodimer: -29 kcal/mol, BDc homodimer: -32
kcal/mol, BZLF1/BDcc heterodimer: -44 kcal/mol. Although the score for the design self-
interaction was close to that for native BZLF 1 coiled-coil homodimerization, the score for the
design-target interaction was significantly better. Thus, although CLASSY can be used to
improve specificity against undesired states as well as affinity for a target, (Grigoryan, et al.
2009) this was predicted not to be necessary in this case.
I'.,' I.-,'(a) C-terminal (b)
region X231 (residues 191 to 231)
CC
(210-221) cc CC Proximal CT
CC 191 221 231(191-209) basic X24 (residues 191 to 245)
basic \ region cc ProximaiCT DistalCT
region
191 221 231 24
BZLF1 JUN/FOS
basic region coiled coil (CC)
bcdef gabodef gmbcdef gabcdef gabodef gabcdef gabode
BZLF1: LEIKRYKNRVASRKCR AKFKQ LLQRYRE VAAMKSS ENDRLRL LLKQM
175 191 221
FOS: RRIRRERNEMAA CR NRRE LTDTLQA ETDQLED EKSAILOT EIANLLK EKEKLEF ILAAHR
JUN: AERXRIAASKCR RKLE RIARLEE KVMTLKA mISELAS TMIRE QVAQLKQ KVIWH
CEBPA: YRVRRERNNIAVRKSR DKAKO RNVETQQ KVzLTS DINlLRK RVE6LSR ELDTLRG IFR
Figure D.1 Sequence and structure of the BZLF1 bZIP domain.
(a) Crystal structure of BZLF1 bound to DNA26 (PDB ID 2C9L, left) compared to human
JUN/FOS bound to DNA (Glover and Harrison. 1995) (PDB ID 1FOS, right). The basic region is
blue, the coiled coil is green, and the C-terminal (CT) region is red. At the bottom are sequence
alignments for the basic and coiled-coil regions of BZLF1 and representative human bZIPs.
Leucines at d positions in the coiled coils are underlined. (b) Scheme of constructs used in this
study. The "231" construct includes the coiled coil (CC) and the proximal C-terminal (CT)
region; the "245" construct includes the coiled coil (CC) and the full-length C-terminal (CT)
region.
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Figure D.2 Designed inhibitors.
(a) Structural models representing two types of design-BZLF 1 complexes tested in this work. At
left, the "231" constructs, and at right, the "245" constructs. "X" is a placeholder for the name of
a design, e.g. BDec. Color is as in Figure D.la except that the designed region is shown in orange.
The dashed boxes in the "245" complex indicate that part of the distal CT (237-245) is not
resolved in the crystal structure. (b) Helical wheel diagram for the BZLF 1 homodimer. (c-e)
Helical wheel diagrams for the designs. On the left are design-target heterodimers and on the
right are design homodimers. Design residues are highlighted in bold and with a grey
background. Potential electrostatic interactions are indicated in blue if attractive and red if
repulsive. (c) Design BDc,, (d) Design BDIED, (e) Design BDEEI. In all helical wheel diagrams,
only residues from b position 191 (Ala) tofposition 209 (Ser) are shown (this region is orange in
Figure D.2a), with the helix proceeding from N-to-C terminus into the page. Diagrams generated
using DrawCoil 1.0 (http://www.gevorggrigoryan.com/drawcoil/).
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(a)
BZLF1 / X23
The BDc solution populated most a and d positions (coiled-coil "core" positions) with Ile
and Leu respectively, which are very common in conventional bZIP sequences (Figure D.2c). A
single d-position Glu residue at the extreme N terminus of the coiled coil is uncharacteristic of
bZIP sequences, but was predicted to interact favorably with an e-position Lys on BZLF 1. The
five designed e and g positions (coiled-coil "edge" positions) were all populated with glutamate
for improved electrostatic interactions with the target, where three residues in this region are
positively charged. Interestingly, predicted charged interactions involved both edge-to-edge (e.g.
g to e') and core-to-edge (d to e') residues in the BZLF 1 target, as was previously observed for
anti-human bZIP designs (Grigoryan, et al. 2009). Although core sites occupied by Ile and Leu
favor design self-interaction, the charged residues at e and g are predicted to disfavor it. Charge
repulsion is a commonly observed negative design element in many native and model coiled
coils (O'Shea, et al. 1993, Vinson, et al. 2002, Woolfson. 2005, Grigoryan and Keating. 2008).
The anti-BZLF1 peptide was cloned in the context of residues 191- 231 of BZLF1. This
construct, BDM, includes the entire coiled-coil domain and the proximal CT (Figure D.lb, D.2a,
Table D. 1), potentially retaining native interactions observed in the X-ray structure between the
C-terminal part of the coiled coil and the CT region. Because the residues optimized in the
design calculations are more than 8 A away from residue 1231 in the modeled structure (Figure
D.2a), the proximal CT excluded from the calculations was not expected to significantly
influence the results. Potential interactions between the designed residues and the distal CT,
which are not evident in the crystal structure but are suggested by prior studies (Schelcher, et al.
2007), are addressed in experiments described below.
We used circular dichroism (CD) spectroscopy to study the interaction properties of BDC.
Thermal denaturation experiments showed that the BD1 homo-oligomer is destabilized
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compared to the target homodimer in the same sequence context (BZLF 1", residues 191 to 231);
Tm values were 38 'C vs. 43 'C (Figure D.3a and Table D.1). The hetero-complex between BD"
and BZLF 1" (Tm of 53 'C, Table D.2) was significantly stabilized compared to the BZLF 1231
homodimer. We conclude that the BD2 design is very hetero-specific, consistent with
expectations based on the design algorithm. The agreement indicates success of the automated
CLASSY approach even on a target with a sequence quite different from the human bZIPs.
Designs with weaker self-association
The BDc design achieved hetero-specificity mostly by improving design-target affinity
compared to the native BZLF 1 complex. We also sought solutions that achieved hetero-
specificity against the same target (the N-terminal part of the BZLF 1 coiled coil) by weakening
design self-interaction. Toward this end, we tested a negative design strategy that placed charged
residues at a core d position and the adjacent e position such that they would create a local
cluster of 4 negative charges in the modeled design coiled-coil homodimer. There are 3 close
inter-chain pair contacts in such a cluster (2 d-e' interactions and one d-d' interaction). We
observed variations of this strategy in design solutions obtained using the CLASSY algorithm
when optimizing affinity for the target under increasingly stringent constraints limiting the
stability of the design homodimer.
We picked two sets of amino-acid changes, (K207E, S208D) and (Y200E, R201E), each
corresponding to the (d, e ') negative design strategy described above. We also included one
stabilizing design element present in the BD solution, A2041 (substituting Ile for Ala at an a
position), to compensate for a potential loss in stability due to the introduction of charge in the
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core. The resulting two designs were cloned, expressed and purified, again in the context of
BZLF1 residues 191 to 231 (2041, 207E, 208D, referred to as BD , and 200E, 201E, 2041,
referred to as BD , Fig 2.2d-e).
Table D.1 Sequencesa and melting temperatures (*C)b for BZLF1 and design constructs.
basic/acid coiled coil proximal CT distal CT
191 221 231 245 Tm
c gabcdef abcdef~M 
m
BZLF1"' #EELLQHYRE ENDRLRL CPSLDVDSII 43
A-BZLF1231  QRAEELARENEELEKEA MIMELLKYRE ENDRLRL CPSLDVDSII 33
B-BZLF1"1  LEIKRYKNRVASRKCR g|MNLLQHYRE ENDRLRL CPSLDVDSII 31
BZLF1245  AMELLQHYRE il]MIENDRLRL CPSLDVDSII PRTPDVLHEDLLNF 71
A-BZLF1245  QRAEELARENEELEKEA EiiELLKYRE ENDRLRL CPSLDVDSII PRTPDVLHEDLLNF 43
B-BZLF1245  LEIKRYKNRVASRKCR El XLLQHYRE ] ENDRLRL CPSLDVDSII PRTPDVLHEDLLNF 67
BD AlqMEIQHLEE ENDRLRL CPSLDVDSII 38
BD1c4 AXEEIQHLEE ENDRLRL CPSLDVDSII PRTPDVLHEDLLNF 40
A-BD QRAEELARENEELEKEA |ELLKLEE ENDRLRL CPSLDVDSII PRTPDVLHEDLLNF 40
BDJ |1IMLLQHYRE ENDRLRL CPSLDVDSII N/Ac
BD" 25AXLLQHYRE ENDRLRL CPSLDVDSII PRTPDVLHEDLLNF 26
A-BD QRAEELARENEELEKEA liJiliELLKYRE 
_MENDRLRLM CPSLDVDSII PRTPDVLHEDLLNF N/Ac
BD 2 1  01M LLQHEEE ENDRLRLLLKQM CPSLDVDSII N/Ac
a The sequences SHHHHHHGESKEYKKGSGS, or GYHHHHHHGSY (the latter for constructs
with the acidic extension, A-) should be placed at each N terminus to obtain the full sequences of
the recombinant proteins listed in the table. Sites with amino acids different from those of the
native sequence (either introduced in the design or as part of the acidic extension) are underlined.
Different regions of the sequence (basic region/acidic extension, coiled coil, proximal CT and
distal CT) are separated by space. As explained in the text, the acidic extension overlaps the 9 N-
terminal residues of the coiled coil. Coiled-coil heptads are indicated using shading.b Total protein concentration was 4 pM.
c N/A indicates either lack of cooperative folding or that the observed melting curve indicated the
presence of more than one species.
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(*C) for different BZLF1/design hetero-interactions.
Target
BZLF 1231
B-BZLF 1245
B-BZLF 1231
JUN
Design
BD~ct
BDC
BDIc
BD2C
A-BD2s
A-BZLF 124
A-BZLF 1231
BD~c
Tma
53
N/Ac
66
N/Ac
>80
74
ATm
12 (43/38)
N/Ac
12 (67/40)
N/Ac
> 26 (67/40)
19 (67/43)
58 26 (31/33)
41 10 (23/40)
a Total protein concentration was 4 pM.
b ATm was obtained by taking the Tm for the hetero-complex and subtracting from it the average
of the Tm values for each individual species (listed in parentheses for easy comparison, Tm for the
target is shown first, followed by that of the design) when applicable.
cN/A indicates either lack of cooperative folding or that the observed melting curve indicated the
presence of more than one species.
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Table D.2 Melting temperatures
(a) (d)0 0
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0 20 40 60 80 0 20 40 60 80(b) 0 Temperature (OC) (e) 0, Temperature (c)
5D-5000 --
-10000 ..------- -o- 3BD- BD
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Figure D.3 Melting curves for targets, designs and complexes monitored by mean residue
ellipticity at 222 nm.
Four curves are shown in each panel: the target at 4 tM (open triangles), the design at 4 jiM
(open circles), a mixture of the target and the design at 2 pM each (closed squares), and the
numerical average of the individual melting curves for the target and the design (short dashed
lines). The target is BZLF1 231 for panels (a) - (c) and B-BZLF1 245 for panels (d) - (f), as
21231 231 245 245described in text, and the designs are: (a) BD23, (b) BDIED, (c) BDE, (d) BDcc, (e) BDIED,() 245
and (f) A-BDcc.
Thermal denaturation experiments monitored by CD showed that both designed peptides,
BD21, and BD 2I, had relatively weak helical signals even at very low temperatures (Figure D.3b,
c), illustrating the effectiveness of the negative design strategy. We compared the melting curve
for the mixture of each design and BZLF 1231 with the numerical average of the individual melting
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curves for each species (Figure D.3b, c). The difference between the two curves below -22 'C
reflects interaction between the designed peptides and BZLF 12", and confirms that the designed
peptides bind the target more strongly than they interact with themselves. However, an
interaction is evident only at low temperatures, indicating that the stability of the design-target
complex is lower than the BZLF 1231 target homodimer. Therefore, these 2 designed peptides
represent a specificity profile distinct from that of BD2; one that achieves greater destabilization
against design self-interaction at the expense of the stability of the design-target interaction.
BDcc and BZLF] form a heterodimer
We modeled all coiled-coil interactions as parallel, symmetric dimers. Although the
oligomerization states of coiled coils can be sensitive to very few amino-acid changes, (Harbury,
et al. 1993, Taylor and Keating. 2005) in BZLF1 the presence of the CT region is expected to
strongly favor the parallel dimer geometry observed in the crystal structure for BZLF 1. The
designed heterodimer also includes an Asn-Asn interaction at a-a', which has been shown to
strongly favor dimers, and multiple charged residues at the e and g positions that are also more
prevalent in dimers (Mason and Arndt. 2004). Nevertheless, we performed analytical
ultracentrifugation (AUC) experiments to study the interaction between BD" and BZLF 12.
Global analysis of sedimentation equilibrium runs performed at multiple concentrations and rotor
speeds showed that the best-fit molecular weight for both BD" and the
1:1 mixture of BD" with BZLF 12" corresponded to that expected for a dimer (representative
data are shown along with the global fit in Figure D.4). For BD" with BZLF 12", the fitted
molecular weight was 104% of that expected for the heterodimer, with a fitted RMS of 0.027
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fringes. RMS values obtained by fixing an exact dimer or trimer weight were 0.029 or 0.090
fringes, respectively. For BD", the fitted molecular weight is 102% of that expected for the
homodimer, with a fitted RMS of 0.021 fringes. RMS values obtained by fixing a dimer or a
trimer weight were 0.021 or 0.10 fringes, respectively. The AUC data thus confirm the validity
of modeling these interactions as dimers.
1 5 2 5
1 25
2 231 2 231
. 0.5 BDCC + BZLF1 ,1.5 BDcC
00
q) -0. 005
0 0
-1.54-0.5
-2
-.0. 05
S-0.0 
-0.05
5.95 6 605 6.1 5,95 6 6.05 61
radius (cm) radius (cm)
Figure D.4 Representative analytical ultracentrifugation data for BD + BZLF1P' (left)
and BD (right).
The fits shown were obtained with data collected at 2 concentrations and 3 different centrifuge
speeds. At the bottom are the residuals to the fit.
Testing designs in the full-length BZLF] dimerization domain
The designs described above targeted the BZLF 1 coiled coil and were tested in the context of
BZLF 1231. However, inhibitors of protein function must bind to the full-length protein. One
difficulty with designing against the entire BZLF1 dimerization domain (residues 191 - 245) is
that the crystal structure shows only the proximal and part of the distal CT region (up to residue
236), with the remaining part of the distal CT region contributing no electron density (Petosa, et
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al. 2006). Nevertheless, the distal CT region (Figure D. Ib) has been shown to contribute
positively to BZLF 1 dimer stability despite possibly being less structured (Schelcher, et al. 2007).
We tested whether our design procedures, which considered only the structured coiled coil,
could provide molecules that bind the full-length BZLF 1 dimerization domain. For this purpose,
a BZLF1 construct that included both the DNA binding basic region and the full-length
dimerization domain (termed B-BZLF 12", residues 175-245, Table D.1) was used instead of
BZLF 1"' as the target. The designed mutations in BD.c. and BD"' were made in the context of
the full-length BZLF 1 dimerization domain without the basic region (residues 191-245) to create
two new design constructs, BDcc and BDI (Figure D.2a, Table D. 1); the distal CT was included
in the design constructs to exploit its potentially favorable interaction with the target.
The distal CT dramatically stabilized the BZLF 1 homodimer (compare BZLF l"' and
BZLF 12" Tm values of 43 'C and 71 'C, respectively), consistent with prior reports (Schelcher, et
al. 2007). In contrast, self-association of the BDec design was not significantly stabilized by the
distal CT (Table D.1). When BD24. and B-BZLF12 4s were mixed, there was clear evidence of
interaction (Figure D.3d, Table D.2). However, the hetero-interaction between BDcc and B-
BZLF 12" did not appear to be stronger than the self-association of the target B-BZLF 12" (Table
D. 1, D.2), which contrasts with the behavior of the shorter constructs, BD.c. and BZLF 1231
(Figure D.3a, Table D.2). Differences in relative stabilities for the shorter and longer constructs
suggest that residues in the design do not interact as favorably as the native residues with the
distal CT.
In contrast to BD2 ' analysis of BD... showed that both the design self-interaction and the
design-target interaction were stabilized by the distal CT (compare Figure D.3b with Figure
D.3e). As a result, BD 5 was heterospecific at low temperature. Compared to BD2 c, BD245TED cc, ED
401
showed weaker self-association but also displayed weaker affinity for B-BZLF 12". Together, the
results show that the effect of the distal CT is not negligible and depends on sequence in the
coiled-coil region. The impact of the distal CT on the specificity profiles for different designs is
considered further in the Discussion.
Specificity of BDcc against human bZIPs
Specificity against human bZIP proteins was not addressed explicitly in our design
procedure because we reasoned that the CT region, which is unique to BZLF 1, would likely
stabilize interaction with BZLF1 but not with human proteins. To assess this, we selected a few
human bZIPs and evaluated their interactions with BDec using CD spectroscopy. To identify
those human bZIP proteins most likely to associate with BDcc, we calculated interaction scores
with 36 representative human bZIP coiled coils using the scoring function employed in the
CLASSY algorithm, which has been shown to be useful for evaluating bZIP coiled-coil
associations (Figure D.5a) (Grigoryan and Keating. 2006). Interestingly, BDc was predicted to
interact more favorably with BZLF1 than with any of the human bZIPs, even though the scoring
scheme used did not consider interactions involving the CT region. We chose 5 of the top 10
scoring complexes for experimental testing, selecting representative proteins that spanned 5
families and included JUN, the closest predicted competitor. We used constructs for the human
proteins that included the basic region and the coiled coil (Figure D.5b-f). Analysis of melting
curves for each human bZIP and each 1:1 mixture with BD24 showed that only JUN interacted
with BD". The BDc"/JUN complex, however, was significantly weaker than that between BD2
and B-BZLF1245 (Tm values of 41C vs. 66'C, Table D.2). Thus, BDc is not a promiscuous
design and binds preferentially to its target, BZLF 1.
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Figure D.5 Specificity of design against human bZIPs
(a) Predicted scores for BDee interacting with BZLF1 or human bZIP peptides. (b-f) Melting
curves for selected human bZIP peptides, BD24 or 1:1 mixtures of the two, monitored by mean
residue ellipticity at 222 nm. Four curves are shown in each panel: the human bZIP at 4gM (open
triangles), BD24 at 4 pM (open circles), a mixture of the human protein and BD24 at 2p.M each
(closed squares), and the numerical average of the individual melting curves for the human bZIP
and the design (short dashed lines). The human bZIPs are: (b) JUN, (c) ATF2, (d) CEBPG, (e)
CREBZF, and (f) NFIL3.
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Enhancing design performance with an N-terminal acidic extension
Vinson and colleagues have shown that replacing the basic region of several native bZIPs
with a designed sequence enriched in glutamates can provide potent dominant-negative
inhibitors of bZIP dimerization and DNA binding (Acharya, et al. 2006b, Ahn, et al. 1998, Olive,
et al. 1997). They also showed that such an acidic extension improved the affinity of a peptide
rationally designed to heterodimerize with human bZIP CEBPA (Krylov, et al. 1995). Because
the basic region of BZLF 1 is highly similar to that of human bZIPs (Figure D. 1 a), we reasoned
that incorporating an acidic extension into the N-terminus of our BD. design might enhance its
affinity for BZFL 1.
Three acidic extension variants developed by Vinson et al. differ in 2 positions that could
interact with the BZLF 1 basic region, if the interaction occurred with a coiled-coil-like geometry
as has been hypothesized for other systems (Acharya, et al. 2006b). We chose to use the "A"-
extension, which introduced the possibility of an attractive Glu-Arg g-e' interaction and a Leu-
Leu core-core a-a' interaction. Following prior work in the Vinson laboratory, (Olive, et al. 1997)
we constructed A-BD (sequence in Table D.1). The modification added 17 residues at the N-
terminus and replaced 6 out of 9 of the most N-terminal residues of the designed region (Table
D.1). Interestingly, A-BDE showed much greater helicity than BD and BD , indicating that
either some of the N-terminal 26 residues and/or the distal C-terminal region are likely helical in
this context (Figure D.3f). The Tm for A-BD. was similar to those for BD2 and BD2 (Table
D.1), whereas interaction with B-BZLF 1245 was significantly stabilized compared to the BD./B-
BZLF12" interaction as expected (Figure D.3f). The heterocomplex melted at > 80 'C (Table
D.2). Together these observations indicate that changes made in A-BD did not stabilize the
design homodimer, but further enhanced its interaction with B-BZLF 1245, as desired for inhibitor
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design.
For comparison, we constructed several other peptides with acidic extensions and assessed
their self-association (Table D.1). This modification dramatically destabilized BZLF 1245 by 28 'C
(71 'C for BZLF 12" vs. 43 C for A-BZLF 1245). A-BZLF 1231 was also destabilized, but by only 10
'C (430 C for BZLF123 1 vs. 33 'C for A-BZLF1 231 ). BD25 was destabilized by an amount that
could not be quantified because A-BD2 did not exhibit a cooperative melt. A-BZLF 1245 was
tested for interaction with B-BZLF 1245 and formed a heterocomplex with Tm of 74 'C (compared
to the Tm for B-BZLF 1245 self-interaction, 67 'C, Tables D.1, D.2). The Tm for the heterocomplex
between A-BZLF123 ' and B-BZLF123' was 58 'C (compared to the Tm for B-BZLF12 31 self-
interaction, 31 'C). These results are consistent with an interaction between the acidic extension
and the basic region stabilizing the heterocomplexes, and also with an unfavorable interaction
between the distal CT and the acidic extension, which is considered further in the Discussion.
Inhibiting DNA binding by BZLF1
We used an electrophoretic mobility shift assay (EMSA) to assess inhibition of B-BZLF 1245
binding to DNA by different designed peptides (Figure D.6). The dimerization domain of BZLF 1
lacking the basic region, BZLF 1245, was included for comparison purposes. All peptides tested
showed concentration-dependent inhibition. BD245 , A-BZLF124 and A-BD2 were more effective
than BZLF 1245. Design BD14 was also an effective inhibitor. The most potent inhibitor was A-
BDE, which completely inhibited B-BZLF12 5 binding to DNA at equi-molar concentration.
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(a)
BZLF124
(b)
A-BZLF1 2
(e)
245A-BDcc- 245BDIED
Figure D.6 Peptide inhibition of B-BZLF1245 binding to DNA.
Representative gel-shift images were shown for: (a) BZLF 1245, (b) A-BZLF 1245, (c) BDc4, (d)
A-BDc~c, (e) BDIED. The first two lanes for each gel include DNA only (first lane) and B-
BZLF124swith DNA (second lane). Inhibitor peptides were added in increasing concentrations
from 10 nM to above 2 pM (left to right, 2-fold dilutions). Conditions are described in Materials
and Methods in more detail, and were slightly different for panel (a)-(d) vs. panel (e).
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DISCUSSION
In this study, we employed different design strategies to create inhibitor peptides targeting the
viral bZIP protein BZLF 1. We sought peptides that achieved hetero-specificity through enhanced
affinity for the target and/or reduced self-interaction. Below we discuss our different design
approaches and the experimental behaviors of our designed peptides.
Applying CLASSY to BZLF1
As demonstrated earlier, (Grigoryan, et al. 2009) CLASSY is an algorithm that can be applied
to design bZIP-like coiled coils. It was developed in conjunction with a specialized scoring
function that includes computed structure-based terms, helix propensities, and experimentally
determined coupling energies. The scoring function was validated on a large-scale dataset of
human bZIP coiled-coil interactions (Grigoryan and Keating. 2006) and supported the successful
design of numerous bZIP-binding peptides. It is not known to what extent the bZIP scoring
function can be applied in design problems involving coiled-coil targets with features not
observed in typical human bZIPs. Here, we explored whether the BZLF1 dimerization domain
could be treated as a standard bZIP target for CLASSY design.
To treat BZLF 1 as a coiled coil, we designed against the N-terminal part of the sequence and
did experimental tests using constructs that did not include the distal CT (the "23 1 " constructs,
Fig 1 b, 2a), much of which is not observed in the X-ray structure. The BZLF 1 coiled-coil region
is rather short (4 heptads), has only one Leu at position d among these heptads, and includes a
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region with very narrow inter-helical distance (-4 A Ca-Ca distance at a-position residue 204).
These variations might be expected to compromise performance of the scoring function, as
coiled-coil context is known to influence the contributions of residues and residue pairs to
stability (Steinkruger, et al. 2010, Moitra, et al. 1997, Lu and Hodges. 2004). Thus, methods
validated using human bZIPs might not generalize broadly to all coiled-coil dimers. However,
we found that design BD" incorporated elements very commonly employed in published anti-
human bZIP designs (see below), and that these gave good experimental performance in this less
canonical example. Success might be attributed to the fact that introducing more canonical
residues at interfacial sites on one helix (the design) makes the design-target heterodimer more
similar to the human bZIPs, e.g. the heterodimer likely has a more typical helix-helix separation.
Features contributing to the stability and specificity of the designs
Analysis of the designed sequences suggests that stability and specificity were achieved using
different combinations of core, edge and core-edge interactions. For example, in the BD" design,
the a and d heptad positions were populated with hydrophobic Ile and Leu, respectively, (e.g.
Y200L, A2041, K207L), which are expected to be exceptionally stabilizing in the design.
homodimer (Acharya, et al. 2002). Therefore, a strategy that used only these mutations to
stabilize the design-target interaction would likely stabilize the design self-interaction even more,
and fail to achieve heterospecificity. Negative design elements that likely compensate for over-
stabilization of the design self-interaction come from interfacial e and g positions occupied by
negatively charged amino acids. These negative charges make favorable interactions with
positively charged residues in the target (e.g. 201R, 207K), consistent with improving the
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stability of the design-target interaction. However, they also introduce repulsive g-e' or e-g'
interactions in the design homodimer (e.g. 196E-201E (g-e '), 203E-208E (g-e'), 201E-203E (e-
g')). Similar examples of using a highly hydrophobic core to achieve stability while modulating
specificity using interfacial charge have been observed in many prior coiled-coil designs
(Woolfson. 2005). One less familiar feature in the BD2 design is the presence of an N-terminal
glutamate at a d position. Two glutamate residues at d and d' in a homodimer are destabilizing in
coiled coils, (Tripet, et al. 2000) but this residue potentially interacts favorably with an e ' lysine
in BZLF 1, via a core-to-edge type interaction that has previously been noted in CLASSY-derived
designs and other studies (Steinkruger, et al. 2010, Grigoryan, et al. 2009, Havranek and Harbury.
2003, Reinke, et al. 2010a, Barth, et al. 2008).
Designs BD 21 and BD 21 relied much more on core-to-edge interactions, which were placed
close to the middle of the coiled coil in these designs. In contrast to g-e' interactions, no coupling
energies have been measured for negatively charged residues at d-d' or d-e' sites. CLASSY
performed poorly in predicting the relative stabilities of complexes involving BD2 and BD23,,
most likely because experimental data describing such charged core-core and core-edge
interactions were not available to guide the development of the scoring function (Grigoryan and
Keating. 2006, Grigoryan, et al. 2009). Nevertheless, a cluster of 4 negatively charged residues in
the design homodimer proved very effective as a negative design element; BD2 and BD 23 did
not appreciably self-associate. Affinity for the target was also compromised, however.
Substitution of alanine with isoleucine at a position 204 was introduced to compensate for some
of the lost stability of the heterodimer, showing how a different combination of stabilizing and
destabilizing elements can generate a hetero-specific design that inhibits DNA binding (Figure
D.6).
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Substitution of isoleucine for alanine at a position 204 is found in all 3 designs. In the native
structure, alanine at this position fits well in the tight space between unusually close helices (-4
A Ca-Ca distance between residue 204 on the two chains). Isoleucine cannot be built into this
site in the crystal structure without severe clashes. Nonetheless, the larger Ile was accommodated
in all three designs, and an alanine to isoleucine mutation is stabilizing in the context of
BZLF 12" (an increase of Tm by 9 'C under the conditions of Table D.1, data not shown). These
data suggest a change in the backbone structure upon making this substitution. Local
rearrangement of the design-BZLF 1 complex to a more typical backbone structure probably
helps explain why the CLASSY bZIP scoring function worked well. To achieve good predictive
ability for a wider range of backbone structures, backbone flexibility could be treated explicitly
(Barth, et al. 2008, Mandell and Kortemme. 2009).
The influence of the distal CT region
Previous studies revealed that the distal CT, although unresolved in the BZLF 1 crystal
structure, might interact with the N-terminal part of the BZLF 1 coiled-coil region, thereby
stabilizing the dimer (Schelcher, et al. 2007). We confirmed a stabilizing role for this region
(Table D. 1, comparing BZLF 1231 and BZLF 12"). Interestingly, this effect depends on the
sequence in the coiled-coil region (Table D. 1, D.2). The distal CT does not stabilize the BDc
design self-interaction, and it enhances the stability of the BD"-target interaction only modestly.
On the other hand, the distal CT significantly increased the stability of the BD" design self-
interaction, as well as the stability of the BD" -target interaction. There are more sequence
changes in the BDc design, and the number of negative charges introduced is larger than in the
BDIED design. As discussed below, the influence of the distal CT is also sensitive to the acidic
410
extension included in some designs. Although the structure of the interaction between the distal
CT and the N-terminal part of the coiled coil in the native protein is not known, repulsive
electrostatics, or unfavorable desolvation of charges in the coiled-coil region are plausible
mechanisms for disfavoring this interaction in the BDc design.
Specificity against human bZIPs
We did not consider specificity against human bZIPs in our design procedure. However, we
showed that the design BDcc is not promiscuous in binding human bZIP proteins. Computational
analysis predicted that the coiled-coil region of BDec would interact with the BZLF 1 coiled coil
moderately more favorably than with any other human bZIP coiled coil (but with a few close
competitors). This is interesting, given the fairly canonical coiled-coil sequence features of BDec-
The requirement to satisfy hydrogen bonding for Asn 204 at the a position in BDcc, and the
charge complementarity between the e and g positions of BDc and BZLF 1 helices but not most
human proteins, contributed to the predicted binding preference.
Thermal stability studies confirmed that BD" does not bind strongly to selected human
bZIPs identified in the computational analysis. In addition to selectivity derived from the coiled-
coil region (which was predicted to be modest), the CT region likely confers additional
specificity. Interactions with BD2 and B-BZLF1245 could benefit from native-like contacts
between the CT region and the coiled coil domain, which are not conserved in complexes with
human proteins. Thus, the interaction specificity of BD2 is likely encoded in both its coiled-coil
domain and the CT region.
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Improving inhibitor potency using an N-terminal acidic extension
The Vinson group has demonstrated that dominant-negative inhibitors of bZIP dimerization
and DNA binding can be created by replacing the basic region of native or modified native bZIPs
with an acidic sequence (Acharya, et al. 2006b). In this study, we used this strategy to improve
the potency of our designed peptides. The resulting A-BD peptide maintained specificity,
showing little change in the Tm for the design self-association. The small change in homodimer
stability probably results from destabilization by the negative charges in the extension, countered
by a stabilizing leucine residue introduced at d position 193 (this residue is Glu in BDcc) (Olive,
et al. 1997). A-BD. formed a more stable complex with the target B-BZLF 2 " than did BD245
(an increase of Tm > 14 'C at 4 pM, Table D.2). This indicates that the acidic extension, which
targets the basic region of bZIPs, can be used in conjunction with computational design methods
targeting the coiled coil. Given that the Vinson laboratory has demonstrated that the coiled-coil
region of A-ZIPs governs interaction specificity, while the acidic extension provides much
enhanced affinity, this is an appealing strategy for expanding the design of tight-binding and
selective bZIP inhibitors (Acharya, et al. 2006b, Ahn, et al. 1998, Olive, et al. 1997, Krylov, et al.
1995, Grigoryan, et al. 2009).
Interestingly, modifying BZLF 1 with an acidic extension did not stabilize interaction of A-
BZLF 1245 with B-BZLF 1245 as much as expected (Tm of 74. C compared to 67 'C for the B-
BZLF1 24 ' homodimer, Table D.1, D.2). In contrast, interaction of the shorter construct A-
BZLF1231 with B-BZLF123 ' was stabilized to a much greater extent (Tm of 58 'C compared to 31
'C for the B-BZLF 123' homodimer). Furthermore, the destabilizing effect of the acidic extension
on design homodimer stability is quite different in BZLF 1241 vs. BZLF 1231 (decreasing Tm values
by 28 'C vs. 10 'C, Table D. 1). These observations are consistent with a model where the distal
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CT interacts unfavorably with the acid extension, much as it appears to interact unfavorably with
negative charges in the N-terminal part of the BDc design. Although not addressed in the
present study, the performance of A-BZLF 1245 as an inhibitor could potentially be improved by
redesigning the acidic extension so that interference from the distal CT is minimized, although
this is difficult in the absence of structural information about this part of the protein.
Analysis of inhibitor potency
To test the designed peptides as inhibitors of BZLF 1 DNA binding, we used an in vitro
EMSA assay to monitor the population of B-BZLF 1245 bound to DNA in the presence of different
peptides (Figure D.6). It is unsurprising that A-BDc", which formed the most thermo-stable
complex with B-BZLF 124 and exhibited the largest difference in homodimer vs. heterodimer
stability, was the most potent inhibitor. The improved performance of BDcc and A-BZLF 124
relative to the native peptide, BZLF 1245, could be rationalized by their improved affinity and/or
anti-homodimer specificity (see below). BD14 inhibited DNA binding effectively and we
estimate its potency is similar to that of BZLF 1245, although these two peptides could not be
compared using identical assay conditions (see Materials and Methods). The effectiveness of
BD24 resulted from a combination of reduced affinity but improved anti-homodimer specificity.
To explore more generally how affinity and specificity each influence potency, we
constructed a simple computational model with the following assumptions: 1) the target bZIP, the
DNA, and the designed peptide were the only components present, 2) the target bZIP homodimer
was the only species that could bind DNA (i.e. complete cooperative binding), 3) non-specific
DNA binding was neglected. Some of the assumptions made may not apply to all of our
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experiments. We computed concentration dependent inhibition of DNA binding for a series of
designs covering a spectrum of affinities and specificities. Affinity was described by the ratio
between the dissociation constant of the target bZIP homodimer and that of the design-target
heterodimer (KdT2/ KdDT, D: design, T: target, see Materials and Methods), and specificity was
described by the ratio between the dissociation constant for the design homodimer and that of the
design-target heterodimer (KdD2 / KdDT). The efficacy of different inhibitors is illustrated in a heat
map in Figure D.7 that indicates the improvement in ICso over a reference for which K D2 - Kd DT
- KT 2 The reference inhibitor with affinity and specificity of 1 was included to reflect the
behavior of the dimerization domain of the target bZIP. We explored two scenarios that led to
different inhibition landscapes: one where modeled dissociation constants for the target bZIP
complex and bZIP-DNA interactions were lower than the target bZIP concentration (Figure
D.7a), and another where they were higher (Figure D.7b)
The results in Figure D.7 support intuition about the importance of both affinity and
specificity. Lines of constant color running across the plots in Figure D.7 show that equivalent
potency can be achieved using different combinations of affinity and specificity. Clearly, neither
affinity nor preference for hetero vs. homodimerization correlates directly with design
performance. For the purposes of discussion, we label 3 regions on the plots: Haffinity:Lspec
indicates inhibitors with high affinity for the target but limited anti-homodimer specificity,
Laffinity:Hspec indicates inhibitors with affinity for the target that is comparable to or weaker than
the reference inhibitor, but with weaker self-association, and Hamnnity:Hspec inhibitors have both
tighter target-binding affinity and weaker self-association than the reference. Among our designs,
and to the extent that approximate stabilities assessed by thermal denaturation under CD
conditions can be extrapolated to the gel-shift assay, BD" and BD"5 are both Lafflnity:Hspec
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inhibitors that use anti-homodimer specificity to improve inhibitor potency. A-BD maintains
anti-homodimer specificity but gains additional affinity via the acidic extension, making it a
Haffinity:Hspec inhibitor.
The model in Figure D.7 is useful for broadly guiding the computational design of specific
inhibitors, so we conclude with a few general observations. First, heterospecificity is important,
but not sufficient, for good performance. A design is hetero-specific if the ratio KdT2.KdD2/(KdDT) 2
is larger than 1. In the figure, this region is below the dashed line and all inhibitors with potency
better than the reference lie in this region. Maintaining hetero-specificity for high affinity designs
imposes a bound on design homodimer stability. This is relevant for parallel dimeric coiled-coil
targets, because amino-acid changes that enhance interaction with the target often stabilize the
design self-interaction even more (Acharya, et al. 2002). Second, the relative importance of
improving affinity vs. specificity depends on the target and assay conditions. For panel a,
improved hetero-specificity implies enhanced design performance regardless of whether affinity
or specificity is the main contributor. On the other hand, if the target bZIP concentration is lower,
as in panel b, improving specificity alone is no longer sufficient, and affinity must be optimized;
very potent designs in panel b can only be achieved by optimizing along the path toward
HamnityHspec. Finally, the overall diagonal trends for constant-IC50 regions in both panels
emphasize that improving either affinity or specificity can potentially lead to success, depending
on the specific conditions and requirements for an application. Designs belonging to the
HaffinityHspec class are the most effective. However, such designs might not exist, or could be hard
to identify for a particular problem. In such cases, one could consider optimizing primarily
affinity or specificity, depending on which is easier to achieve. Although not used extensively for
this purpose here, the CLASSY algorithm is well suited for identifying designs with different
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affinity vs. specificity trade-offs (Grigoryan, et al. 2009).
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Figure D.7 Inhibition of DNA binding as a function of the affinity and anti-homodimer
specificity of the inhibitor.
A description of the model is given in Methods. The ratio of the IC 50 for a design to the IC50 for a
reference inhibitor with affinity equal to the wild-type protein is used as an indicator of design
potency (scale at right). This ratio is plotted as a function of the affinity and specificity of the
inhibitor. In (a), the Kd values for target dimerization and DNA binding are 10-fold lower than
the bZIP concentration. In (b) the Kd values for both associations are 10-fold higher than the
bZIP concentration. Labeling on the graph (HaLs: HafinityLspec, LaHs: Laffinityfspec and HaHs:
HaffinityLspec) is described in Discussion. The dashed line represents designs with zero hetero-
specificity. The reference inhibitor is indicated with a star.
CONCLUSION: IMPLICATIONS FOR PROTEIN DESIGN
This study addresses three topics relevant to the design of peptides that inhibit native protein-
protein interactions. First is the issue of specificity, which arises in many protein design
problems and is acute for coiled-coil targets where self-association of the design can compete
with target inhibition. Using BZLF 1 as a target, we characterized peptides that balance affinity
and specificity in different ways. This adds to the small number of examples where affinity and
specificity have both been treated as design considerations (Grigoryan, et al. 2009, Havranek and
Harbury. 2003, Barth, et al. 2008, Kortemme, et al. 2004, Ali, et al. 2005, Bolon, et al. 2005,
Sammond, et al. 2010, Karanicolas and Kuhlman. 2009). Second, we explored a design problem
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where features of the target that are not well described in an existing structure (the BZLF 1 distal
CT) nevertheless influence complex stability. We showed that different designs responded
differently to the introduction of the distal CT. This argues for developing methods that broadly
survey design solution space and discovering a large set of potentially good designs, rather than
identifying only "the best" design according to some imperfect criteria. This can be
accomplished in various ways, e.g. by exploring a range of tradeoffs between stability and
specificity, or exploring a variety of related structural templates as design scaffolds (Grigoryan,
et al. 2009, Fu, et al. 2007). Testing diverse solutions maximizes the chance of finding a design
that interacts well with poorly characterized features of the target. Finally, our best design
exploited a modular strategy where optimization of the coiled-coil dimerization interface was
coupled with a more generic strategy developed previously for stabilizing inhibitor-bZIP
complexes. Modularity is likely to be a key strategy for the design of ever more complex
molecular parts.
MATERIALS AND METHODS
Cloning, protein expression and purification
Synthetic genes encoding native or redesigned BZLF 1 sequence, residues 175 or 191 to 245
(B-BZLF 14, BZLF l", BD22, BDE), were constructed by gene synthesis. Primers were
designed using DNAWorks, (Hoover and Lubkowski. 2002) and a two-step PCR procedure was
used for annealing and amplification. Genes encoding the native or redesigned sequence in the
context of residues 191 to 231 were made in a single-step PCR reaction using the longer
constructs as templates. The genes were cloned via BamHI/XhoI restriction sites into a modified
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version of a pDEST1 7 vector that encodes an N-terminal 6xHis tag and a GESKEYKKGSGS
linker that improves the solubility of the recombinant protein (Reinke, et al. 201 Ob). To facilitate
cloning of genes encoding the acidic extension, a pET 1 6b vector (Novagen) was modified to
encode an N-terminal 6xHis tag, followed by a GSY linker and the acidic extension sequence.
Genes encoding BZLF12 ", BZLF12 5 and the designs BDC and BD," were subsequently cloned
into the modified vector using AflI/XhoI restriction sites to make A-BZLF 1231, A-BZLF 12", A-
BD2 and A-BD 1. Recombinant proteins were expressed in E. coli RP3098 cells. Cultures were
grown at 37 *C to an OD of ~0.4-0.9, and expression was induced by addition of 1 mM IPTG.
Purification was performed under denaturing conditions (6M GdnHCl) using an Ni-NTA affinity
column followed by reverse-phase HPLC. Human bZIP constructs containing the basic region
and the coiled-coil domain were described previously (Reinke, et al. 201 Ob).
Computational protein design using CLASSY
The sequence BDec was designed using the CLASSY algorithm as previously reported
(Grigoryan, et al. 2009). In brief, the algorithm solves for the sequence predicted to interact most
favorably with a target sequence (here, chosen to be the N-terminal part of the BZLF 1 leucine
zipper, residues 191 to 209) using integer linear programming. It is possible to impose
constraints on the gap between the energy of interaction with the target and the energy of
undesired states such as the design homodimer. No such constraint was applied in the design of
BDec, which was predicted to favor the design-target interaction over design homodimerization
without it. The scoring function used was HP/S/Cv. This function was derived by combining
molecular mechanics calculations and experimentally determined coupling energies for many
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core a-a' interactions .The Leu-Leu core d-d' interaction was modeled with an empirical value
of -2 kcal/mol". The HP/S/Cv structure-based energy function was transformed into a sequence-
based expression using cluster expansion, and modified using empirical data, as described by
Grigoryan et al (Grigoryan and Keating. 2006, Acharya, et al. 2006a, Grigoryan, et al. 2009).
Predicting interactions between BDcc and human bZIPs
BZLF1 was aligned with 36 human bZIPs using the conserved basic region, and interaction
scores for residues 191-221 of BDc with the correspondingly aligned 31 residues of each human
bZIP were computed using the HP/S/Cv model as described above.
Circular dichroism spectroscopy
Circular dichroism experiments were performed and analyzed, and Tm values fitted as
described previously (Grigoryan, et al. 2009). Thermal melts from 0 0C to 85 *C were mostly
reversible, regaining >95% of signal or giving closely similar Tm values for the reverse melt
(except for samples containing NFIL3, which precipitated upon heating to 85 *C). Melting
temperatures were estimated by fitting the data to a two-state equilibrium (unfolded/folded),
assuming no heat capacity changes upon folding. A detailed description of the equation was
described previously (Grigoryan, et al. 2009). In cases where high-temperature unfolding
precluded accurate fitting of unfolded baselines, the Tm was either defined as the mid-point of the
unfolding transition after manually picking the baseline (for the 1:1 mixture of B-BZLF 1" and
A-BZLF 1"), or a lower bound on the Tm value was estimated (for the 1:1 mixture of B-BZLF 1245
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and A-BDK). The protein concentrations are given in the figure legends. All measurements were
performed in PBS buffer containing 12.5 mM potassium phosphate (pH 7.4), 150 mM KCl, 0.25
mM EDTA and 1 mM DTT. Samples were heated to 65 0C for 5 minutes before measurement to
equilibrate peptide mixtures, and then cooled to and equilibrated at the starting temperature.
Analytical ultracentrifugation
Protein samples were dialyzed against the reference buffer (12.5 mM sodium phosphate, 150
mM NaCl, 1mM DTT, 0.25 mM EDTA, pH 7.4) three times (including once overnight) before
measurements. Sedimentation equilibrium runs were performed with a Beckman XL-I analytical
ultracentrifuge using interference optics. Two concentrations for each protein sample were
prepared (50 and 100 pM), and runs at 3 different speeds (28,000, 35,000 and 48,000 rpm) were
carried out at 20 0C. Each run was ~ 20 h, and equilibrium was confirmed by negligible
differences between the sample distribution in the cell over sequential scans. Data were analyzed
globally with the program HeteroAnalysis (Cole and Lary. 2006), using a calculated (Laue, et al.
1992) partial specific volume of 0.7275 ml/g (for the BD"/BZLF123 mixture) or 0.7245 ml/g
(for BD") and a solution density of 1.005 g/ml.
Electrophoretic mobility shift assay (EMSA)
Gel shift assays were performed as described previously (Reinke, et al. 201 Ob). Briefly, 10
nM B-BZLF 1245 was prepared either alone or mixed with each inhibitor at 9 concentrations
ranging from 10 nM to 2560 nM in 2-fold dilutions. Gel-shift buffer ((150 mM KCl, 25 mM
TRIS pH 8.0, 0.5 mM EDTA, 2.5 mM DTT, 1 mg/ml BSA, 10% (v/v) glycerol, 0.1 pg/ml
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competitor DNA (Poly (I) -Poly (C) (Sigma))) was then added and incubated for 10 minutes at 42
'C. Closely similar results were obtained when incubating samples for 20 minutes at 42 'C. The
competitor BDE was not stable upon heating and was incubated for 2 hours at 18-22 'C.
Radiolabeled annealed AP-l site ,CGCTTGATGACTCAGCCGGAA (IDT), at a final
concentration of 0.7 nM was added and incubated for 15 minutes at 18-22 'C. Complexes were
separated on NOVEX DNA retardation gels (Invitrogen). Dried gels were imaged using a
phosphorimaging screen and a Typhoon 9400 imager. ImageQuant software (Amersham
Biosciences) was used to quantify band intensities.
Simulating the impact of affinity and specificity on designed peptide behaviors
The simulation treated the following species: The target bZIP monomer (T), the target bZIP
homodimer (T2 ), the design monomer (D), the design homodimer (D2), the design-target bZIP
heterodimer (DT), free DNA (DNA) and the complex formed between the target bZIP
homodimer and DNA (T2DNA). Species are linked by the following reactions:
[T] 2 KT 22T T2 [T2=Kd
2D <_ D2 [D] 2  4 2[D2]
D + T DT [D][T] - KDT[DT] 'd
[T2][DNA] T DNAT2+ DNAC T2DNA =K2[T2 DNA] d
[T] + [DT] + 2[T2] + 2[T2DNA] = [T]totai
[D] + [DT] + 2[D2] = [D]totai
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[DNA] + [T2 DNA] = [DNA]totai
Affinity is defined as KdT2 / Kd DT, and a value > 1 indicates the design-target bZIP heterodimer
is more stable than the target bZIP homodimer (improved affinity). Specificity is defined as KdD2
/ KdDT, and a value > 1 indicates the design-target bZIP heterodimer is more stable than design
homodimer (improved specificity). A design with affinity and specificity equal to 1 was used as a
reference. The IC50 value was defined as the design concentration [D]total at which 50% less DNA
is bound relative to zero design concentration. The total target bZIP concentration [T]totai was
fixed at 10 nM, and the total DNA concentration [DNA]tta at 0.7 nM. Different combinations of
KdT2 and KdT2DNA values were explored (10~9, 10-8, and 10~7 M for each), including when both are
lower than [T]totai (10-9 M/10-9 M, Figure D.7a) and when both are higher than [T]totai (10~7 M/I0~7
M, Figure D.7b). For each combination of fixed KdT2 and KdT2DNA, the IC50 values for a range of
designs with different affinities (0.1 to 10) and specificities (0.1 to 100) were calculated. The
ratio IC50 desin/ICo50ref with a value < 1 implying greater potency than the reference, was plotted
as a heat map. The dashed lines on the plots in Figure D.7 indicate points where the product of
affinity and specificity ((KT2 * KdD2)/(KdDT * KDT)) equals 1. All designs below the dashed line
are hetero-specific. The simulation was carried out and heat maps were generated using Matlab
(MathWorks).
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